<HTML><HEAD><TITLE>Gene Ontology Results</TITLE></HEAD><BODY>
<H1>Gene Ontology Enrichment Results</H1>
<A HREF="homerResults.html">Homer <i>de novo</i> Motif Enrichment Results</A><BR/>
<A HREF="knownResults.html">Known Motif Enrichment Results</A><BR/>
<H4>Text file version of complete results (i.e. open with Excel)
<UL>
<LI><A HREF="biological_process.txt">biological process</A>: Functional groupings of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="molecular_function.txt">molecular function</A>: Mechanistic actions of proteins (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="cellular_component.txt">cellular component</A>: Protein localization (<A HREF="http://www.geneontology.org">Gene Ontology</A>)</LI>
<LI><A HREF="chromosome.txt">chromosome location</A>: Genes with similar chromosome localization (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="kegg.txt">KEGG pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.genome.jp/kegg/pathway.html">KEGG</A>)</LI>
<LI><A HREF="interactions.txt">protein interactions</A>: "Proteins interacting with a common protein (BIND, EcoCyc, HPRD)" (<A HREF="http://www.ncbi.nlm.nih.gov/gene">NCBI Gene</A>)</LI>
<LI><A HREF="interpro.txt">interpro domains</A>: Proteins with similar domains and features (<A HREF="http://www.ebi.ac.uk/interpro/">Interpro</A>)</LI>
<LI><A HREF="pfam.txt">pfam domains</A>: Proteins with similar domains and features (<A HREF="http://www.sanger.ac.uk/Software/Pfam/">Pfam</A>)</LI>
<LI><A HREF="smart.txt">smart domains</A>: Proteins with similar domains and features (<A HREF="http://smart.embl-heidelberg.de/">SMART</A>)</LI>
<LI><A HREF="gene3d.txt">gene3d domains</A>: Proteins with similar domains and features (<A HREF="http://cathwww.biochem.ucl.ac.uk:8080/Gene3D">Gene3D</A>)</LI>
<LI><A HREF="prosite.txt">prosite domains</A>: Proteins with similar domains and features (<A HREF="http://ca.expasy.org/prosite/">Prosite</A>)</LI>
<LI><A HREF="prints.txt">prints domains</A>: Proteins with similar domains and features (<A HREF="http://www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/">PRINTS</A>)</LI>
<LI><A HREF="msigdb.txt">MSigDB lists</A>: "Genes sets for pathways, factor/miRNA target predictions, expression patterns, etc." (<A HREF="http://www.broadinstitute.org/gsea/msigdb/index.jsp">MSigDB</A>)</LI>
<LI><A HREF="biocyc.txt">BIOCYC pathways</A>: Groups of proteins in the same pathways (<A HREF="http://biocyc.org/">BIOCYC</A>)</LI>
<LI><A HREF="cosmic.txt">COSMIC cancer mutations</A>: Genes mutated in similar cancers (<A HREF="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/">COSMIC</A>)</LI>
<LI><A HREF="gwas.txt">GWAS genes</A>: Genes mutated in similar diseases (<A HREF="http://www.genome.gov/26525384">GWAS Catalog</A>)</LI>
<LI><A HREF="lipidmaps.txt">Lipid Maps pathways</A>: Groups of proteins in the same lipid pathways (<A HREF="http://www.ncbi.nlm.nih.gov/biosystems/">Lipid Maps/Biosystems</A>)</LI>
<LI><A HREF="pathwayInteractionDB.txt">Pathway Interaction DB</A>: Groups of proteins in the same pathways (<A HREF="http://pid.nci.nih.gov/">Pathway Interaction Database</A>)</LI>
<LI><A HREF="reactome.txt">REACTOME pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.reactome.org/PathwayBrowser/">REACTOME</A>)</LI>
<LI><A HREF="smpdb.txt">SMPDB pathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.smpdb.ca/">SMPDB</A>)</LI>
<LI><A HREF="wikipathways.txt">WikiPathways</A>: Groups of proteins in the same pathways (<A HREF="http://www.wikipathways.org/index.php/Special:BrowsePathwaysPage">Wikipathways</A>)</LI>
</UL>
<H2>Enriched Categories</H2>
<TABLE border="1" cellpading="0" cellspacing="0">
<TR><TH>P-value</TH><TD>ln(P)</TD><TD>Term</TD><TD>GO Tree</TD><TD>GO ID</TD><TD># of Genes in Term</TD><TD># of Target Genes in Term</TD><TD># of Total Genes</TD><TD># of Target Genes</TD><TD>Common Genes</TD></TR>
<TR><TD>1.256e-12</TD><TD>-27.40</TD><TD>BENPORATH_EED_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_EED_TARGETS</TD><TD>997</TD><TD>20</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,PAX9,HS3ST3B1,ZIC4,GRIA2,GABRB2,CXCL14,GPC5,EYA4,NPTX2,IL7,HEY1,BMPR1B,PAPPA,PCDH17,RNF128,ALX1,SPAG6,MTSS1,FOXA2</TD></TR>
<TR><TD>2.898e-10</TD><TD>-21.96</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_WITH_H3K27ME3</TD><TD>1045</TD><TD>18</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,GRIA2,ZIC4,HS3ST3B1,PAX9,CXCL14,GABRB2,EPHA3,GPC5,IL7,EYA4,HEY1,SATB2,PCDH17,PAPPA,FOXA2,SPAG6,RNF128</TD></TR>
<TR><TD>1.171e-09</TD><TD>-20.57</TD><TD>BENPORATH_PRC2_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_PRC2_TARGETS</TD><TD>610</TD><TD>14</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,ZIC1,HS3ST3B1,PAX9,HEY1,GRIA2,ZIC4,CXCL14,PCDH17,PAPPA,RNF128,FOXA2,SPAG6,GPC5</TD></TR>
<TR><TD>6.298e-09</TD><TD>-18.88</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>MSigDB lists</TD><TD>BENPORATH_SUZ12_TARGETS</TD><TD>963</TD><TD>16</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,PAPPA,FOXA2,SPAG6,RNF128,ALX1,IL7,HEY1,CXCL14,GPC5,PCDH11X,ZIC1,GRIA2,ZIC4,HS3ST3B1,PAX9</TD></TR>
<TR><TD>2.622e-08</TD><TD>-17.46</TD><TD>AACTTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AACTTT_UNKNOWN</TD><TD>1745</TD><TD>20</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,PAX9,PLAG1,HS3ST3B1,ZIC4,SLC6A15,CPEB2,KYNU,MEIS2,PCDH11X,ZFHX4,EYA4,PEX5L,STAC,NPTX2,FST,LSR,RNF128,MTSS1,FOXA2</TD></TR>
<TR><TD>9.242e-08</TD><TD>-16.20</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>1009</TD><TD>15</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,IL7,STAC,ZIC1,NPTX2,FST,HS3ST3B1,PLAG1,SATB2,PCDH17,CXCL14,PAPPA,CDKN2A,GPC5,EPHA3</TD></TR>
<TR><TD>1.120e-06</TD><TD>-13.70</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>3694</TD><TD>26</TD><TD>17255</TD><TD>49</TD>
<TD>GRIA2,PCDH11X,RNF128,GALNT13,ZFHX4,CRB1,SPAG6,MTSS1,STAC,PLEKHM3,GPC5,KYNU,PCDH17,SATB2,MEIS2,PAPPA,FST,CDKN2A,ZIC4,CLDN1,ALX1,IL7,CLVS2,PEX5L,EPHA3,SLC6A15</TD></TR>
<TR><TD>1.168e-06</TD><TD>-13.66</TD><TD>PBX1_02</TD><TD>MSigDB lists</TD><TD>PBX1_02</TD><TD>119</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,MTSS1,ZIC4,IL7,MEIS2,ZIC1</TD></TR>
<TR><TD>2.837e-06</TD><TD>-12.77</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>7347</TD><TD>37</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH17,CPEB2,LSR,ZIC1,ALX1,IL7,SLC6A15,DCDC2,GRIA2,PCDH11X,RNF128,ZFHX4,PLEKHM3,EDA2R,KYNU,SATB2,PAX9,MEIS2,PAPPA,ZIC4,CDKN2A,HS3ST3B1,EYA4,PEX5L,CLVS2,PCDH20,EPHA3,FOXA2,GABRB2,NPTX2,RBM11,GALNT13,CRB1,SPAG6,MTSS1,STAC,GPC5</TD></TR>
<TR><TD>3.192e-06</TD><TD>-12.65</TD><TD>PAX4_02</TD><TD>MSigDB lists</TD><TD>PAX4_02</TD><TD>221</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,MEIS2,KYNU,ZIC1,ZFHX4,RNF128,ZIC4</TD></TR>
<TR><TD>7.182e-06</TD><TD>-11.84</TD><TD>AP1_Q2</TD><TD>MSigDB lists</TD><TD>AP1_Q2</TD><TD>250</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZIC1,PAPPA,USP2,ZIC4,PAX9,RNF128</TD></TR>
<TR><TD>1.253e-05</TD><TD>-11.29</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>2154</TD><TD>18</TD><TD>17255</TD><TD>49</TD>
<TD>CLVS2,IL7,BMPR1B,EPHA3,DCDC2,PCDH17,SATB2,PAPPA,CDKN2A,STAC,MTSS1,GPC5,KYNU,PCDH11X,GRIA2,GALNT13,CRB1,ZFHX4</TD></TR>
<TR><TD>1.253e-05</TD><TD>-11.29</TD><TD>Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>Burkitt_lymphoma</TD><TD>2154</TD><TD>18</TD><TD>17255</TD><TD>49</TD>
<TD>MTSS1,STAC,GPC5,KYNU,GRIA2,PCDH11X,GALNT13,ZFHX4,CRB1,IL7,CLVS2,BMPR1B,EPHA3,DCDC2,PCDH17,SATB2,PAPPA,CDKN2A</TD></TR>
<TR><TD>1.449e-05</TD><TD>-11.14</TD><TD>GSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_24H_UP</TD><TD>MSigDB lists</TD><TD>GSE41176_UNSTIM_VS_ANTI_IGM_STIM_BCELL_24H_UP</TD><TD>184</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,ENPP5,DCDC2,SLC6A15,PCDH17,NPTX2</TD></TR>
<TR><TD>1.786e-05</TD><TD>-10.93</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_large_B_cell_lymphoma</TD><TD>4254</TD><TD>26</TD><TD>17255</TD><TD>49</TD>
<TD>SATB2,PCDH17,MEIS2,PAPPA,FST,ZIC4,CDKN2A,CLDN1,ALX1,CLVS2,IL7,PEX5L,SLC6A15,EPHA3,GRIA2,PCDH11X,RNF128,GALNT13,ZFHX4,CRB1,SPAG6,MTSS1,STAC,GPC5,PLEKHM3,KYNU</TD></TR>
<TR><TD>2.701e-05</TD><TD>-10.52</TD><TD>oesophagus-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma</TD><TD>4348</TD><TD>26</TD><TD>17255</TD><TD>49</TD>
<TD>LSR,ZIC1,ZIC4,CDKN2A,EYA4,PCDH17,SATB2,AZGP1,IDO2,EPHA3,NPTX2,DCDC2,ALX1,PEX5L,CLVS2,PCDH20,GALNT13,ZFHX4,CRB1,USP2,GRIA2,PCDH11X,RNF128,PLAG1,KYNU,STAC</TD></TR>
<TR><TD>2.819e-05</TD><TD>-10.48</TD><TD>FAC1_01</TD><TD>MSigDB lists</TD><TD>FAC1_01</TD><TD>207</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,ZIC1,EYA4,ZIC4,FOXA2,HEY1</TD></TR>
<TR><TD>2.897e-05</TD><TD>-10.45</TD><TD>TAATAAT_MIR126</TD><TD>MSigDB lists</TD><TD>TAATAAT_MIR126</TD><TD>208</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>HS3ST3B1,PLAG1,ZFHX4,GRIA2,ZIC4,ZIC1</TD></TR>
<TR><TD>3.143e-05</TD><TD>-10.37</TD><TD>RNA polymerase II regulatory region sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000977</TD><TD>783</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>ALX1,PAX9,ZIC4,FOXA2,ZFHX4,MEIS2,ZIC1,SATB2,PLAG1,HEY1</TD></TR>
<TR><TD>3.354e-05</TD><TD>-10.30</TD><TD>RNA polymerase II regulatory region DNA binding</TD><TD>molecular function</TD><TD>GO:0001012</TD><TD>789</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>HEY1,SATB2,PLAG1,ZIC4,PAX9,FOXA2,ZIC1,MEIS2,ZFHX4,ALX1</TD></TR>
<TR><TD>3.435e-05</TD><TD>-10.28</TD><TD>ACTGTGA_MIR27A_MIR27B</TD><TD>MSigDB lists</TD><TD>ACTGTGA_MIR27A_MIR27B</TD><TD>439</TD><TD>8</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,NPTX2,PLAG1,SATB2,PCDH17,MEIS2,PAPPA,ZFHX4</TD></TR>
<TR><TD>3.488e-05</TD><TD>-10.26</TD><TD>CIZ_01</TD><TD>MSigDB lists</TD><TD>CIZ_01</TD><TD>215</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,PCDH11X,ZIC4,MEIS2,ZIC1,PAPPA</TD></TR>
<TR><TD>5.171e-05</TD><TD>-9.87</TD><TD>human chr8q21.13</TD><TD>chromosome location</TD><TD>human chr8q21.13</TD><TD>37</TD><TD>3</TD><TD>26169</TD><TD>51</TD>
<TD>ZFHX4,IL7,HEY1</TD></TR>
<TR><TD>5.234e-05</TD><TD>-9.86</TD><TD>developmental process</TD><TD>biological process</TD><TD>GO:0032502</TD><TD>5697</TD><TD>30</TD><TD>18054</TD><TD>51</TD>
<TD>NPTX2,CLDN1,BMPR1B,SPAG6,PAX9,RBM11,MTSS1,LSR,IL7,FOXA2,PLEKHM3,KYNU,GABRB2,CRB1,SATB2,DCDC2,ZIC1,CDKN2A,MEIS2,EPHA3,FST,CXCL14,ALX1,ZIC4,EYA4,USP2,PLAG1,EDA2R,PCDH17,HEY1</TD></TR>
<TR><TD>5.313e-05</TD><TD>-9.84</TD><TD>transcription regulatory region sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000976</TD><TD>833</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>SATB2,PLAG1,HEY1,ALX1,PAX9,ZIC4,FOXA2,ZFHX4,ZIC1,MEIS2</TD></TR>
<TR><TD>6.431e-05</TD><TD>-9.65</TD><TD>CTTTGA_LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGA_LEF1_Q2</TD><TD>1122</TD><TD>12</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,FST,ZIC4,HEY1,PLAG1,MEIS2,KYNU,USP2,GABRB2,GPC5,FOXA2,ENPP5</TD></TR>
<TR><TD>6.727e-05</TD><TD>-9.61</TD><TD>stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable</TD><TD>969</TD><TD>11</TD><TD>17255</TD><TD>49</TD>
<TD>DCDC2,SLC6A15,GPC5,MTSS1,STAC,ZFHX4,CDKN2A,CRB1,ZIC4,PAPPA,SATB2</TD></TR>
<TR><TD>6.727e-05</TD><TD>-9.61</TD><TD>mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable</TD><TD>COSMIC cancer mutations</TD><TD>mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable</TD><TD>969</TD><TD>11</TD><TD>17255</TD><TD>49</TD>
<TD>SATB2,PAPPA,CRB1,ZIC4,CDKN2A,ZFHX4,STAC,MTSS1,GPC5,SLC6A15,DCDC2</TD></TR>
<TR><TD>7.320e-05</TD><TD>-9.52</TD><TD>Znf_ZIC</TD><TD>interpro domains</TD><TD>IPR041643</TD><TD>5</TD><TD>2</TD><TD>18616</TD><TD>51</TD>
<TD>ZIC4,ZIC1</TD></TR>
<TR><TD>7.740e-05</TD><TD>-9.47</TD><TD>zf_ZIC</TD><TD>pfam domains</TD><TD>PF18366</TD><TD>5</TD><TD>2</TD><TD>17385</TD><TD>49</TD>
<TD>ZIC4,ZIC1</TD></TR>
<TR><TD>7.781e-05</TD><TD>-9.46</TD><TD>tryptophan catabolic process to kynurenine</TD><TD>biological process</TD><TD>GO:0019441</TD><TD>5</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>7.860e-05</TD><TD>-9.45</TD><TD>astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>astrocytoma_Grade_III</TD><TD>1567</TD><TD>14</TD><TD>17255</TD><TD>49</TD>
<TD>PEX5L,ALX1,MTSS1,KYNU,GPC5,PLEKHM3,EPHA3,PAPPA,PCDH11X,CRB1,ZIC4,CDKN2A,ZFHX4,GALNT13</TD></TR>
<TR><TD>8.659e-05</TD><TD>-9.35</TD><TD>sequence-specific double-stranded DNA binding</TD><TD>molecular function</TD><TD>GO:1990837</TD><TD>883</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>ZIC4,PAX9,ZFHX4,MEIS2,ZIC1,FOXA2,ALX1,HEY1,SATB2,PLAG1</TD></TR>
<TR><TD>9.191e-05</TD><TD>-9.29</TD><TD>AP1_Q4</TD><TD>MSigDB lists</TD><TD>AP1_Q4</TD><TD>256</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,HS3ST3B1,ZIC4,USP2,ZIC1,PAPPA</TD></TR>
<TR><TD>1.058e-04</TD><TD>-9.15</TD><TD>EVI1_05</TD><TD>MSigDB lists</TD><TD>EVI1_05</TD><TD>163</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,PLAG1,MEIS2,IL7,USP2</TD></TR>
<TR><TD>1.152e-04</TD><TD>-9.07</TD><TD>CATGTAA_MIR496</TD><TD>MSigDB lists</TD><TD>CATGTAA_MIR496</TD><TD>166</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,MEIS2,EPHA3,GRIA2,SATB2</TD></TR>
<TR><TD>1.165e-04</TD><TD>-9.06</TD><TD>'de novo' NAD biosynthetic process</TD><TD>biological process</TD><TD>GO:0034627</TD><TD>6</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.165e-04</TD><TD>-9.06</TD><TD>'de novo' NAD biosynthetic process from tryptophan</TD><TD>biological process</TD><TD>GO:0034354</TD><TD>6</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.204e-04</TD><TD>-9.02</TD><TD>oesophagus-lower_third-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-lower_third-carcinoma-squamous_cell_carcinoma</TD><TD>3577</TD><TD>22</TD><TD>17255</TD><TD>49</TD>
<TD>GALNT13,ZFHX4,PCDH11X,GRIA2,EDA2R,GPC5,SPAG6,ZIC1,CDKN2A,ZIC4,EYA4,HS3ST3B1,PCDH17,SATB2,PAPPA,ENPP5,MEIS2,AZGP1,EPHA3,IDO2,PEX5L,PCDH20</TD></TR>
<TR><TD>1.332e-04</TD><TD>-8.92</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-diffuse_adenocarcinoma</TD><TD>4447</TD><TD>25</TD><TD>17255</TD><TD>49</TD>
<TD>LSR,ZIC1,ZIC4,EYA4,CDKN2A,PAX9,SATB2,PCDH17,PAPPA,FST,MEIS2,EPHA3,DCDC2,FOXA2,CLDN1,PEX5L,PCDH20,ALX1,GALNT13,CRB1,ZFHX4,PCDH11X,GRIA2,STAC,SPAG6</TD></TR>
<TR><TD>1.332e-04</TD><TD>-8.92</TD><TD>diffuse_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>diffuse_adenocarcinoma</TD><TD>4447</TD><TD>25</TD><TD>17255</TD><TD>49</TD>
<TD>FOXA2,DCDC2,EPHA3,ALX1,PEX5L,PCDH20,CLDN1,EYA4,ZIC4,CDKN2A,LSR,ZIC1,MEIS2,PAPPA,FST,PCDH17,SATB2,PAX9,SPAG6,STAC,ZFHX4,CRB1,GALNT13,GRIA2,PCDH11X</TD></TR>
<TR><TD>1.361e-04</TD><TD>-8.90</TD><TD>follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>follicular_lymphoma</TD><TD>1239</TD><TD>12</TD><TD>17255</TD><TD>49</TD>
<TD>SPAG6,GABRB2,GPC5,PAPPA,PCDH11X,SATB2,GRIA2,CDKN2A,HS3ST3B1,ZIC4,ZFHX4,GALNT13</TD></TR>
<TR><TD>1.387e-04</TD><TD>-8.88</TD><TD>central_nervous_system-brain-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-astrocytoma_Grade_III</TD><TD>1442</TD><TD>13</TD><TD>17255</TD><TD>49</TD>
<TD>MTSS1,ALX1,PEX5L,EPHA3,GPC5,PLEKHM3,KYNU,PCDH11X,PAPPA,GALNT13,ZFHX4,CRB1,CDKN2A</TD></TR>
<TR><TD>1.443e-04</TD><TD>-8.84</TD><TD>anatomical structure development</TD><TD>biological process</TD><TD>GO:0048856</TD><TD>5354</TD><TD>28</TD><TD>18054</TD><TD>51</TD>
<TD>USP2,ZIC4,ALX1,EYA4,HEY1,PCDH17,PLAG1,EDA2R,ZIC1,DCDC2,CXCL14,EPHA3,FST,MEIS2,GABRB2,CRB1,PLEKHM3,SATB2,NPTX2,SPAG6,PAX9,BMPR1B,FOXA2,LSR,RBM11,MTSS1,IL7,CLDN1</TD></TR>
<TR><TD>1.451e-04</TD><TD>-8.84</TD><TD>lung-carcinoma-small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-small_cell_carcinoma</TD><TD>10086</TD><TD>41</TD><TD>17255</TD><TD>49</TD>
<TD>HEY1,ZFHX4,PLCH1,RNF128,PLAG1,GRIA2,USP2,PCDH11X,KYNU,PLEKHM3,EDA2R,LSR,ZIC1,PCDH17,CXCL14,DCDC2,ALX1,IL7,CRB1,GALNT13,RBM11,SCGB3A2,GPC5,MTSS1,SPAG6,STAC,EYA4,CDKN2A,ZIC4,MEIS2,PAPPA,FST,SATB2,PAX9,FOXA2,EPHA3,BMPR1B,PCDH20,PEX5L,CLVS2,CLDN1</TD></TR>
<TR><TD>1.473e-04</TD><TD>-8.82</TD><TD>small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>small_cell_carcinoma</TD><TD>10091</TD><TD>41</TD><TD>17255</TD><TD>49</TD>
<TD>FOXA2,EPHA3,BMPR1B,PEX5L,CLVS2,PCDH20,CLDN1,EYA4,CDKN2A,ZIC4,FST,PAPPA,MEIS2,PAX9,SATB2,GPC5,SCGB3A2,STAC,SPAG6,MTSS1,CRB1,GALNT13,RBM11,DCDC2,IL7,ALX1,LSR,ZIC1,CXCL14,PCDH17,KYNU,EDA2R,PLEKHM3,HEY1,ZFHX4,PLAG1,RNF128,PLCH1,PCDH11X,GRIA2,USP2</TD></TR>
<TR><TD>1.478e-04</TD><TD>-8.82</TD><TD>lower_third</TD><TD>COSMIC cancer mutations</TD><TD>lower_third</TD><TD>8105</TD><TD>36</TD><TD>17255</TD><TD>49</TD>
<TD>GPC5,STAC,MTSS1,SPAG6,GALNT13,CRB1,RBM11,IDO2,EPHA3,GABRB2,CLDN1,CLVS2,PEX5L,PCDH20,EYA4,CDKN2A,ZIC4,HS3ST3B1,SATB2,PAPPA,ENPP5,MEIS2,AZGP1,EDA2R,HEY1,ZFHX4,PCDH11X,GRIA2,RNF128,SLC6A15,DCDC2,ALX1,ZIC1,LSR,CPEB2,PCDH17</TD></TR>
<TR><TD>1.563e-04</TD><TD>-8.76</TD><TD>pancreas-carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoid-endocrine_tumour</TD><TD>7396</TD><TD>34</TD><TD>17255</TD><TD>49</TD>
<TD>GRIA2,USP2,PCDH11X,RNF128,ZFHX4,PLEKHM3,KYNU,PCDH17,CXCL14,LSR,ZIC1,IL7,SLC6A15,DCDC2,GALNT13,CRB1,MTSS1,SPAG6,STAC,SCGB3A2,GPC5,SATB2,PAX9,AZGP1,MEIS2,PAPPA,HS3ST3B1,CLDN1,PEX5L,CLVS2,EPHA3,BMPR1B,GABRB2,NPTX2</TD></TR>
<TR><TD>1.571e-04</TD><TD>-8.76</TD><TD>transcription regulatory region DNA binding</TD><TD>molecular function</TD><TD>GO:0044212</TD><TD>949</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>ALX1,FOXA2,ZFHX4,ZIC1,MEIS2,ZIC4,PAX9,PLAG1,SATB2,HEY1</TD></TR>
<TR><TD>1.576e-04</TD><TD>-8.76</TD><TD>TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P</TD><TD>MSigDB lists</TD><TD>TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P</TD><TD>546</TD><TD>8</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,MEIS2,STAC,PLAG1,SATB2,CPEB2,GRIA2,PCDH20</TD></TR>
<TR><TD>1.584e-04</TD><TD>-8.75</TD><TD>regulatory region nucleic acid binding</TD><TD>molecular function</TD><TD>GO:0001067</TD><TD>950</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>ZFHX4,MEIS2,ZIC1,FOXA2,PAX9,ZIC4,ALX1,HEY1,PLAG1,SATB2</TD></TR>
<TR><TD>1.777e-04</TD><TD>-8.64</TD><TD>lung-left_upper_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-left_upper_lobe-carcinoma-adenocarcinoma</TD><TD>567</TD><TD>8</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH11X,PAPPA,ZIC1,ZFHX4,CDKN2A,ZIC4,SLC6A15,PLEKHM3</TD></TR>
<TR><TD>1.806e-04</TD><TD>-8.62</TD><TD>oesophagus-lower_third-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-lower_third-carcinoma-adenocarcinoma</TD><TD>6408</TD><TD>31</TD><TD>17255</TD><TD>49</TD>
<TD>GPC5,MTSS1,STAC,GALNT13,ZFHX4,HEY1,CRB1,GRIA2,PCDH11X,RNF128,RBM11,EPHA3,SLC6A15,GABRB2,DCDC2,CLDN1,ALX1,PEX5L,PCDH20,CLVS2,LSR,ZIC4,CDKN2A,EYA4,PCDH17,SATB2,CPEB2,MEIS2,AZGP1,ENPP5,PAPPA</TD></TR>
<TR><TD>1.819e-04</TD><TD>-8.61</TD><TD>GSE7460_TREG_VS_TCONV_ACT_WITH_TGFB_UP</TD><TD>MSigDB lists</TD><TD>GSE7460_TREG_VS_TCONV_ACT_WITH_TGFB_UP</TD><TD>183</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>CLVS2,PCDH11X,CDKN2A,MEIS2,IL7</TD></TR>
<TR><TD>1.821e-04</TD><TD>-8.61</TD><TD>left_upper_lobe</TD><TD>COSMIC cancer mutations</TD><TD>left_upper_lobe</TD><TD>569</TD><TD>8</TD><TD>17255</TD><TD>49</TD>
<TD>PLEKHM3,SLC6A15,ZIC4,CDKN2A,ZFHX4,ZIC1,PAPPA,PCDH11X</TD></TR>
<TR><TD>1.836e-04</TD><TD>-8.60</TD><TD>GO_GLYCOPROTEIN_BINDING</TD><TD>MSigDB lists</TD><TD>GO_GLYCOPROTEIN_BINDING</TD><TD>98</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,BMPR1B,FST,GPC5</TD></TR>
<TR><TD>1.897e-04</TD><TD>-8.57</TD><TD>WTGAAAT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WTGAAAT_UNKNOWN</TD><TD>561</TD><TD>8</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,PAX9,ZIC1,FST,NPTX2,ZFHX4,PAPPA,USP2</TD></TR>
<TR><TD>1.920e-04</TD><TD>-8.56</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm</TD><TD>7461</TD><TD>34</TD><TD>17255</TD><TD>49</TD>
<TD>IL7,ALX1,DCDC2,SLC6A15,PCDH17,LSR,ZIC1,KYNU,PLEKHM3,RNF128,PLCH1,PCDH11X,ZFHX4,PEX5L,PCDH20,CLVS2,CLDN1,NPTX2,BMPR1B,EPHA3,PAPPA,AZGP1,MEIS2,PAX9,SATB2,HS3ST3B1,CDKN2A,STAC,MTSS1,SPAG6,GPC5,RBM11,CRB1,GALNT13</TD></TR>
<TR><TD>1.991e-04</TD><TD>-8.52</TD><TD>double-stranded DNA binding</TD><TD>molecular function</TD><TD>GO:0003690</TD><TD>977</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>SATB2,PLAG1,HEY1,ALX1,ZIC4,PAX9,FOXA2,ZFHX4,MEIS2,ZIC1</TD></TR>
<TR><TD>2.011e-04</TD><TD>-8.51</TD><TD>GSE36392_TYPE_2_MYELOID_VS_MAC_IL25_TREATED_LUNG_UP</TD><TD>MSigDB lists</TD><TD>GSE36392_TYPE_2_MYELOID_VS_MAC_IL25_TREATED_LUNG_UP</TD><TD>187</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>FST,PCDH11X,HS3ST3B1,PCDH20,GRIA2</TD></TR>
<TR><TD>2.062e-04</TD><TD>-8.49</TD><TD>GSE19825_NAIVE_VS_IL2RALOW_DAY3_EFF_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE19825_NAIVE_VS_IL2RALOW_DAY3_EFF_CD8_TCELL_UP</TD><TD>188</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,FOXA2,CRB1,PLAG1,AZGP1</TD></TR>
<TR><TD>2.166e-04</TD><TD>-8.44</TD><TD>ATACTGT_MIR144</TD><TD>MSigDB lists</TD><TD>ATACTGT_MIR144</TD><TD>190</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,ZIC4,CPEB2,PAPPA,MEIS2</TD></TR>
<TR><TD>2.188e-04</TD><TD>-8.43</TD><TD>bone-chondrosarcoma-conventional</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-conventional</TD><TD>8</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,HEY1</TD></TR>
<TR><TD>2.394e-04</TD><TD>-8.34</TD><TD>FXR_Q3</TD><TD>MSigDB lists</TD><TD>FXR_Q3</TD><TD>105</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,NPTX2,ZIC1,MEIS2</TD></TR>
<TR><TD>2.419e-04</TD><TD>-8.33</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_B</TD><TD>MSigDB lists</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_B</TD><TD>42</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,EYA4,CDKN2A</TD></TR>
<TR><TD>2.469e-04</TD><TD>-8.31</TD><TD>carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>carcinoid-endocrine_tumour</TD><TD>7903</TD><TD>35</TD><TD>17255</TD><TD>49</TD>
<TD>IL7,SLC6A15,DCDC2,CXCL14,PCDH17,LSR,ZIC1,PLEKHM3,KYNU,PCDH11X,GRIA2,USP2,RNF128,ZFHX4,CLDN1,CLVS2,PEX5L,BMPR1B,EPHA3,GABRB2,NPTX2,PAX9,SATB2,PAPPA,MEIS2,AZGP1,CDKN2A,HS3ST3B1,STAC,MTSS1,SPAG6,GPC5,SCGB3A2,GALNT13,CRB1</TD></TR>
<TR><TD>2.480e-04</TD><TD>-8.30</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma</TD><TD>1970</TD><TD>15</TD><TD>17255</TD><TD>49</TD>
<TD>NPTX2,EPHA3,BMPR1B,SLC6A15,ENPP5,PLAG1,PAPPA,PLCH1,PAX9,PCDH11X,GRIA2,SATB2,ZIC4,CDKN2A,ZFHX4</TD></TR>
<TR><TD>2.492e-04</TD><TD>-8.30</TD><TD>autonomic_ganglia-neuroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-neuroblastoma</TD><TD>4032</TD><TD>23</TD><TD>17255</TD><TD>49</TD>
<TD>EPHA3,NPTX2,GABRB2,DCDC2,CLVS2,LSR,ZIC1,CDKN2A,ZIC4,CPEB2,AZGP1,FST,PAPPA,KYNU,GALNT13,ZFHX4,CRB1,GRIA2,PCDH11X,RNF128,PLCH1,PLAG1,RBM11</TD></TR>
<TR><TD>2.495e-04</TD><TD>-8.30</TD><TD>peritoneum-appendix-other-pseudomyxoma_peritonei</TD><TD>COSMIC cancer mutations</TD><TD>peritoneum-appendix-other-pseudomyxoma_peritonei</TD><TD>596</TD><TD>8</TD><TD>17255</TD><TD>49</TD>
<TD>EDA2R,CLVS2,STAC,ZFHX4,CDKN2A,EYA4,MEIS2,PCDH17</TD></TR>
<TR><TD>2.495e-04</TD><TD>-8.30</TD><TD>pseudomyxoma_peritonei</TD><TD>COSMIC cancer mutations</TD><TD>pseudomyxoma_peritonei</TD><TD>596</TD><TD>8</TD><TD>17255</TD><TD>49</TD>
<TD>CLVS2,STAC,EDA2R,MEIS2,PCDH17,ZFHX4,EYA4,CDKN2A</TD></TR>
<TR><TD>2.502e-04</TD><TD>-8.29</TD><TD>neuroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>neuroblastoma</TD><TD>4033</TD><TD>23</TD><TD>17255</TD><TD>49</TD>
<TD>EPHA3,GABRB2,NPTX2,DCDC2,CLVS2,LSR,ZIC1,CDKN2A,ZIC4,CPEB2,AZGP1,FST,PAPPA,KYNU,GALNT13,ZFHX4,CRB1,GRIA2,PCDH11X,RNF128,PLCH1,PLAG1,RBM11</TD></TR>
<TR><TD>2.508e-04</TD><TD>-8.29</TD><TD>larynx</TD><TD>COSMIC cancer mutations</TD><TD>larynx</TD><TD>1972</TD><TD>15</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1,PAPPA,ENPP5,PLAG1,SATB2,GRIA2,PCDH11X,PAX9,ZFHX4,CDKN2A,ZIC4,NPTX2,SLC6A15,BMPR1B,EPHA3</TD></TR>
<TR><TD>2.524e-04</TD><TD>-8.28</TD><TD>appendix</TD><TD>COSMIC cancer mutations</TD><TD>appendix</TD><TD>597</TD><TD>8</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH17,MEIS2,CDKN2A,EYA4,ZFHX4,STAC,CLVS2,EDA2R</TD></TR>
<TR><TD>2.553e-04</TD><TD>-8.27</TD><TD>peritoneum</TD><TD>COSMIC cancer mutations</TD><TD>peritoneum</TD><TD>598</TD><TD>8</TD><TD>17255</TD><TD>49</TD>
<TD>ZFHX4,CDKN2A,EYA4,MEIS2,PCDH17,EDA2R,CLVS2,STAC</TD></TR>
<TR><TD>2.570e-04</TD><TD>-8.27</TD><TD>ONDER_CDH1_TARGETS_2_DN</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_2_DN</TD><TD>440</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,MTSS1,RNF128,LSR,CLDN1,FST,STAC</TD></TR>
<TR><TD>2.730e-04</TD><TD>-8.21</TD><TD>cellular developmental process</TD><TD>biological process</TD><TD>GO:0048869</TD><TD>3769</TD><TD>22</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1,PLAG1,EDA2R,ALX1,FST,EPHA3,CDKN2A,DCDC2,ZIC1,SATB2,PLEKHM3,GABRB2,CRB1,CLDN1,LSR,FOXA2,MTSS1,RBM11,IL7,BMPR1B,SPAG6,NPTX2</TD></TR>
<TR><TD>2.746e-04</TD><TD>-8.20</TD><TD>OCT1_02</TD><TD>MSigDB lists</TD><TD>OCT1_02</TD><TD>200</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,ZIC4,NPTX2,ZIC1,CXCL14</TD></TR>
<TR><TD>2.776e-04</TD><TD>-8.19</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>acute_myeloid_leukaemia_therapy_related</TD><TD>1546</TD><TD>13</TD><TD>17255</TD><TD>49</TD>
<TD>MTSS1,PEX5L,CLVS2,GPC5,PCDH17,SATB2,PCDH11X,MEIS2,RNF128,PAPPA,GALNT13,ZFHX4,CRB1</TD></TR>
<TR><TD>2.776e-04</TD><TD>-8.19</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related</TD><TD>1546</TD><TD>13</TD><TD>17255</TD><TD>49</TD>
<TD>PEX5L,CLVS2,MTSS1,GPC5,MEIS2,RNF128,PAPPA,PCDH17,SATB2,PCDH11X,ZFHX4,CRB1,GALNT13</TD></TR>
<TR><TD>2.808e-04</TD><TD>-8.18</TD><TD>bone-chondrosarcoma-mesenchymal</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-mesenchymal</TD><TD>9</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,HEY1</TD></TR>
<TR><TD>2.854e-04</TD><TD>-8.16</TD><TD>autonomic_ganglia</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia</TD><TD>4067</TD><TD>23</TD><TD>17255</TD><TD>49</TD>
<TD>DCDC2,NPTX2,GABRB2,EPHA3,CLVS2,CDKN2A,ZIC4,ZIC1,LSR,PAPPA,FST,AZGP1,CPEB2,KYNU,CRB1,ZFHX4,GALNT13,RBM11,PLAG1,RNF128,PLCH1,PCDH11X,GRIA2</TD></TR>
<TR><TD>2.918e-04</TD><TD>-8.14</TD><TD>REACTOME_TRYPTOPHAN_CATABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_TRYPTOPHAN_CATABOLISM</TD><TD>9</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.979e-04</TD><TD>-8.12</TD><TD>soft_tissue-blood_vessel-angiosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-blood_vessel-angiosarcoma</TD><TD>2238</TD><TD>16</TD><TD>17255</TD><TD>49</TD>
<TD>GALNT13,PCDH11X,EDA2R,GPC5,KYNU,ZIC1,EYA4,CDKN2A,HS3ST3B1,SATB2,PCDH17,PAPPA,MEIS2,EPHA3,DCDC2,PCDH20</TD></TR>
<TR><TD>2.979e-04</TD><TD>-8.12</TD><TD>angiosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>angiosarcoma</TD><TD>2238</TD><TD>16</TD><TD>17255</TD><TD>49</TD>
<TD>DCDC2,EPHA3,PCDH20,EYA4,CDKN2A,HS3ST3B1,ZIC1,PAPPA,MEIS2,PCDH17,SATB2,KYNU,EDA2R,GPC5,GALNT13,PCDH11X</TD></TR>
<TR><TD>3.162e-04</TD><TD>-8.06</TD><TD>multicellular organism development</TD><TD>biological process</TD><TD>GO:0007275</TD><TD>4967</TD><TD>26</TD><TD>18054</TD><TD>51</TD>
<TD>DCDC2,ZIC1,CXCL14,EPHA3,FST,MEIS2,USP2,ZIC4,ALX1,EYA4,HEY1,PCDH17,EDA2R,PLAG1,NPTX2,PAX9,BMPR1B,IL7,RBM11,MTSS1,FOXA2,LSR,CLDN1,GABRB2,CRB1,SATB2</TD></TR>
<TR><TD>3.284e-04</TD><TD>-8.02</TD><TD>blood_vessel</TD><TD>COSMIC cancer mutations</TD><TD>blood_vessel</TD><TD>2257</TD><TD>16</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH11X,GALNT13,KYNU,EDA2R,GPC5,PAPPA,MEIS2,PCDH17,SATB2,EYA4,CDKN2A,HS3ST3B1,ZIC1,PCDH20,DCDC2,EPHA3</TD></TR>
<TR><TD>3.389e-04</TD><TD>-7.99</TD><TD>GSE6259_FLT3L_INDUCED_DEC205_POS_DC_VS_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE6259_FLT3L_INDUCED_DEC205_POS_DC_VS_CD4_TCELL_DN</TD><TD>115</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,NPTX2,RBM11,SLC6A15</TD></TR>
<TR><TD>3.470e-04</TD><TD>-7.97</TD><TD>indole-containing compound catabolic process</TD><TD>biological process</TD><TD>GO:0042436</TD><TD>10</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.470e-04</TD><TD>-7.97</TD><TD>indolalkylamine catabolic process</TD><TD>biological process</TD><TD>GO:0046218</TD><TD>10</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.470e-04</TD><TD>-7.97</TD><TD>tryptophan catabolic process</TD><TD>biological process</TD><TD>GO:0006569</TD><TD>10</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.504e-04</TD><TD>-7.96</TD><TD>bone-chondrosarcoma-dedifferentiated</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-dedifferentiated</TD><TD>10</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>3.504e-04</TD><TD>-7.96</TD><TD>mesenchymal</TD><TD>COSMIC cancer mutations</TD><TD>mesenchymal</TD><TD>10</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,HEY1</TD></TR>
<TR><TD>3.564e-04</TD><TD>-7.94</TD><TD>oesophagus-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-carcinoma-squamous_cell_carcinoma</TD><TD>6620</TD><TD>31</TD><TD>17255</TD><TD>49</TD>
<TD>EDA2R,GPC5,SPAG6,HEY1,ZFHX4,CRB1,GALNT13,PLCH1,PLAG1,RBM11,GRIA2,PCDH11X,GABRB2,FOXA2,EPHA3,BMPR1B,ALX1,PCDH20,CLVS2,PEX5L,IL7,EYA4,ZIC4,CDKN2A,LSR,ZIC1,AZGP1,MEIS2,PAPPA,FST,PCDH17</TD></TR>
<TR><TD>3.821e-04</TD><TD>-7.87</TD><TD>GO_POSITIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>967</TD><TD>10</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,SATB2,PAX9,HEY1,PLAG1,BMPR1B,MEIS2,ALX1,FOXA2,CDKN2A</TD></TR>
<TR><TD>4.165e-04</TD><TD>-7.78</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia</TD><TD>3882</TD><TD>22</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH17,SATB2,PAX9,CPEB2,MEIS2,PAPPA,CDKN2A,IL7,CLVS2,PEX5L,EPHA3,BMPR1B,DCDC2,GRIA2,USP2,PCDH11X,RBM11,GALNT13,ZFHX4,CRB1,GPC5,KYNU</TD></TR>
<TR><TD>4.165e-04</TD><TD>-7.78</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>acute_lymphoblastic_B_cell_leukaemia</TD><TD>3882</TD><TD>22</TD><TD>17255</TD><TD>49</TD>
<TD>CLVS2,PEX5L,IL7,DCDC2,BMPR1B,EPHA3,PAPPA,MEIS2,CPEB2,PAX9,PCDH17,SATB2,CDKN2A,KYNU,GPC5,RBM11,PCDH11X,USP2,GRIA2,CRB1,ZFHX4,GALNT13</TD></TR>
<TR><TD>4.234e-04</TD><TD>-7.77</TD><TD>kynurenine metabolic process</TD><TD>biological process</TD><TD>GO:0070189</TD><TD>11</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.254e-04</TD><TD>-7.76</TD><TD>HNF6_Q6</TD><TD>MSigDB lists</TD><TD>HNF6_Q6</TD><TD>220</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,PCDH17,ZIC4,PAX9,PLAG1</TD></TR>
<TR><TD>4.254e-04</TD><TD>-7.76</TD><TD>TCF4_Q5</TD><TD>MSigDB lists</TD><TD>TCF4_Q5</TD><TD>220</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,ENPP5,ZIC1,FST,GABRB2</TD></TR>
<TR><TD>4.273e-04</TD><TD>-7.76</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma</TD><TD>1001</TD><TD>10</TD><TD>17255</TD><TD>49</TD>
<TD>HS3ST3B1,CDKN2A,ZFHX4,GALNT13,PCDH11X,SATB2,GRIA2,GABRB2,GPC5,SPAG6</TD></TR>
<TR><TD>4.434e-04</TD><TD>-7.72</TD><TD>FOXO4_01</TD><TD>MSigDB lists</TD><TD>FOXO4_01</TD><TD>222</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,SATB2,CRB1,FST,MEIS2</TD></TR>
<TR><TD>4.441e-04</TD><TD>-7.72</TD><TD>GO_TRYPTOPHAN_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_TRYPTOPHAN_METABOLIC_PROCESS</TD><TD>11</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.526e-04</TD><TD>-7.70</TD><TD>AP3_Q6</TD><TD>MSigDB lists</TD><TD>AP3_Q6</TD><TD>223</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,RBM11,PAPPA,MEIS2,CXCL14</TD></TR>
<TR><TD>4.794e-04</TD><TD>-7.64</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HOELZEL_NF1_TARGETS_UP</TD><TD>126</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>HS3ST3B1,HEY1,PCDH17,PAPPA</TD></TR>
<TR><TD>5.071e-04</TD><TD>-7.59</TD><TD>tryptophan metabolic process</TD><TD>biological process</TD><TD>GO:0006568</TD><TD>12</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>5.083e-04</TD><TD>-7.58</TD><TD>Tryptophan catabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-71240</TD><TD>13</TD><TD>2</TD><TD>10287</TD><TD>27</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>5.111e-04</TD><TD>-7.58</TD><TD>tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-5651</TD><TD>7</TD><TD>2</TD><TD>902</TD><TD>5</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>5.145e-04</TD><TD>-7.57</TD><TD>CAGGTG_E12_Q6</TD><TD>MSigDB lists</TD><TD>CAGGTG_E12_Q6</TD><TD>2298</TD><TD>16</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,MEIS2,ENPP5,PLAG1,PAX9,ZIC4,USP2,BMPR1B,PCDH17,RNF128,MTSS1,EYA4,IL7,NPTX2,FST,LSR</TD></TR>
<TR><TD>5.172e-04</TD><TD>-7.57</TD><TD>GO_ORGAN_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_ORGAN_MORPHOGENESIS</TD><TD>822</TD><TD>9</TD><TD>17275</TD><TD>50</TD>
<TD>ALX1,BMPR1B,PLAG1,SATB2,PAX9,CRB1,HEY1,IL7,ZIC1</TD></TR>
<TR><TD>5.210e-04</TD><TD>-7.56</TD><TD>FOXM1_01</TD><TD>MSigDB lists</TD><TD>FOXM1_01</TD><TD>230</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>NPTX2,MEIS2,PCDH17,MTSS1,PLAG1</TD></TR>
<TR><TD>5.314e-04</TD><TD>-7.54</TD><TD>GATA4_Q3</TD><TD>MSigDB lists</TD><TD>GATA4_Q3</TD><TD>231</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,FST,MEIS2,ZIC4,PLAG1</TD></TR>
<TR><TD>5.319e-04</TD><TD>-7.54</TD><TD>PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_UP</TD><TD>MSigDB lists</TD><TD>PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_UP</TD><TD>12</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>FST,CLDN1</TD></TR>
<TR><TD>5.526e-04</TD><TD>-7.50</TD><TD>CDX2_Q5</TD><TD>MSigDB lists</TD><TD>CDX2_Q5</TD><TD>233</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,PAPPA,ZIC4,FOXA2,PLAG1</TD></TR>
<TR><TD>5.552e-04</TD><TD>-7.50</TD><TD>AACWWCAANK_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AACWWCAANK_UNKNOWN</TD><TD>131</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,GABRB2,PLAG1,ZFHX4</TD></TR>
<TR><TD>5.566e-04</TD><TD>-7.49</TD><TD>cell differentiation</TD><TD>biological process</TD><TD>GO:0030154</TD><TD>3675</TD><TD>21</TD><TD>18054</TD><TD>51</TD>
<TD>PLAG1,HEY1,EDA2R,ALX1,FST,EPHA3,DCDC2,ZIC1,SATB2,PLEKHM3,GABRB2,CRB1,CLDN1,SPAG6,BMPR1B,FOXA2,IL7,MTSS1,LSR,RBM11,NPTX2</TD></TR>
<TR><TD>5.744e-04</TD><TD>-7.46</TD><TD>TST1_01</TD><TD>MSigDB lists</TD><TD>TST1_01</TD><TD>235</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,PCDH17,ZIC4,HEY1,ZFHX4</TD></TR>
<TR><TD>5.971e-04</TD><TD>-7.42</TD><TD>lung-right_lower_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-right_lower_lobe-carcinoma-adenocarcinoma</TD><TD>5798</TD><TD>28</TD><TD>17255</TD><TD>49</TD>
<TD>EYA4,ZIC4,ZIC1,FST,ENPP5,PAPPA,MEIS2,CXCL14,SATB2,PCDH17,GABRB2,NPTX2,SLC6A15,IDO2,EPHA3,PCDH20,CLVS2,PEX5L,ALX1,CRB1,ZFHX4,GALNT13,PLAG1,PCDH11X,KYNU,GPC5,SPAG6,MTSS1</TD></TR>
<TR><TD>5.971e-04</TD><TD>-7.42</TD><TD>right_lower_lobe</TD><TD>COSMIC cancer mutations</TD><TD>right_lower_lobe</TD><TD>5798</TD><TD>28</TD><TD>17255</TD><TD>49</TD>
<TD>PLAG1,PCDH11X,CRB1,ZFHX4,GALNT13,SPAG6,MTSS1,KYNU,GPC5,FST,ENPP5,PAPPA,MEIS2,CXCL14,SATB2,PCDH17,ZIC4,EYA4,ZIC1,PCDH20,CLVS2,PEX5L,ALX1,GABRB2,NPTX2,IDO2,SLC6A15,EPHA3</TD></TR>
<TR><TD>6.084e-04</TD><TD>-7.40</TD><TD>TCF11_01</TD><TD>MSigDB lists</TD><TD>TCF11_01</TD><TD>238</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PEX5L,RNF128,SATB2,ZFHX4,ZIC4</TD></TR>
<TR><TD>6.158e-04</TD><TD>-7.39</TD><TD>right_upper_lobe</TD><TD>COSMIC cancer mutations</TD><TD>right_upper_lobe</TD><TD>10584</TD><TD>41</TD><TD>17255</TD><TD>49</TD>
<TD>KYNU,EDA2R,PLEKHM3,RNF128,PLCH1,PLAG1,GRIA2,USP2,PCDH11X,ZFHX4,ALX1,IL7,SLC6A15,PCDH17,CPEB2,ZIC1,SPAG6,MTSS1,STAC,GPC5,CRB1,GALNT13,PCDH20,PEX5L,CLVS2,CLDN1,NPTX2,FOXA2,GABRB2,BMPR1B,IDO2,EPHA3,AZGP1,MEIS2,FST,PAPPA,SATB2,PAX9,CDKN2A,EYA4,ZIC4</TD></TR>
<TR><TD>6.158e-04</TD><TD>-7.39</TD><TD>lung-right_upper_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-right_upper_lobe-carcinoma-adenocarcinoma</TD><TD>10584</TD><TD>41</TD><TD>17255</TD><TD>49</TD>
<TD>ZFHX4,PCDH11X,USP2,GRIA2,PLAG1,PLCH1,RNF128,EDA2R,PLEKHM3,KYNU,ZIC1,CPEB2,PCDH17,SLC6A15,IL7,ALX1,GALNT13,CRB1,GPC5,STAC,SPAG6,MTSS1,EYA4,ZIC4,CDKN2A,PAX9,SATB2,FST,PAPPA,MEIS2,AZGP1,EPHA3,BMPR1B,IDO2,GABRB2,NPTX2,FOXA2,CLDN1,CLVS2,PCDH20,PEX5L</TD></TR>
<TR><TD>6.201e-04</TD><TD>-7.39</TD><TD>ZID_01</TD><TD>MSigDB lists</TD><TD>ZID_01</TD><TD>239</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,PLAG1,ZIC1,MEIS2,PAPPA</TD></TR>
<TR><TD>6.234e-04</TD><TD>-7.38</TD><TD>human chr3q24</TD><TD>chromosome location</TD><TD>human chr3q24</TD><TD>19</TD><TD>2</TD><TD>26169</TD><TD>51</TD>
<TD>ZIC1,ZIC4</TD></TR>
<TR><TD>6.358e-04</TD><TD>-7.36</TD><TD>sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0043565</TD><TD>1130</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>ZFHX4,MEIS2,ZIC1,FOXA2,PAX9,ZIC4,ALX1,HEY1,PLAG1,SATB2</TD></TR>
<TR><TD>6.533e-04</TD><TD>-7.33</TD><TD>SMID_BREAST_CANCER_LUMINAL_B_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_LUMINAL_B_DN</TD><TD>514</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,SLC6A15,PLCH1,CDKN2A,NPTX2,KYNU,ZIC1</TD></TR>
<TR><TD>6.684e-04</TD><TD>-7.31</TD><TD>GATA_C</TD><TD>MSigDB lists</TD><TD>GATA_C</TD><TD>243</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,PCDH11X,ZIC4,ZIC1,IL7</TD></TR>
<TR><TD>6.730e-04</TD><TD>-7.30</TD><TD>plasma membrane part</TD><TD>cellular component</TD><TD>GO:0044459</TD><TD>2794</TD><TD>17</TD><TD>18985</TD><TD>51</TD>
<TD>EDA2R,BMPR1B,EPHA3,PCDH20,CLDN1,GPC5,HS3ST3B1,PCDH17,STAC,NPTX2,GABRB2,SLC6A15,CRB1,ARHGAP45,PCDH11X,AZGP1,GRIA2</TD></TR>
<TR><TD>6.799e-04</TD><TD>-7.29</TD><TD>tryptophan degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_TRYPTOPHAN-DEGRADATION-1</TD><TD>8</TD><TD>2</TD><TD>902</TD><TD>5</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>7.034e-04</TD><TD>-7.26</TD><TD>conventional</TD><TD>COSMIC cancer mutations</TD><TD>conventional</TD><TD>14</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,HEY1</TD></TR>
<TR><TD>7.133e-04</TD><TD>-7.25</TD><TD>GO_SINGLE_ORGANISM_BEHAVIOR</TD><TD>MSigDB lists</TD><TD>GO_SINGLE_ORGANISM_BEHAVIOR</TD><TD>375</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,MEIS2,NPTX2,ZIC1,PCDH17,USP2</TD></TR>
<TR><TD>7.405e-04</TD><TD>-7.21</TD><TD>TTGTTT_FOXO4_01</TD><TD>MSigDB lists</TD><TD>TTGTTT_FOXO4_01</TD><TD>1901</TD><TD>14</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,PAPPA,MEIS2,PCDH17,USP2,ZIC4,HEY1,SATB2,PLAG1,FST,ZIC1,NPTX2,SCGB3A2,PEX5L</TD></TR>
<TR><TD>7.461e-04</TD><TD>-7.20</TD><TD>AFP1_Q6</TD><TD>MSigDB lists</TD><TD>AFP1_Q6</TD><TD>249</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZIC1,SATB2,ZFHX4,ZIC4</TD></TR>
<TR><TD>7.461e-04</TD><TD>-7.20</TD><TD>AREB6_01</TD><TD>MSigDB lists</TD><TD>AREB6_01</TD><TD>249</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,IL7,USP2,ZIC4,PLAG1</TD></TR>
<TR><TD>7.473e-04</TD><TD>-7.20</TD><TD>cell-cell adhesion via plasma-membrane adhesion molecules</TD><TD>biological process</TD><TD>GO:0098742</TD><TD>255</TD><TD>5</TD><TD>18054</TD><TD>51</TD>
<TD>PCDH11X,CRB1,PCDH17,PCDH20,CLDN1</TD></TR>
<TR><TD>8.273e-04</TD><TD>-7.10</TD><TD>upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma</TD><TD>1508</TD><TD>12</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1,PCDH17,PAX9,ZFHX4,CDKN2A,CRB1,ZIC1,PCDH20,PEX5L,EPHA3,GPC5,PLEKHM3</TD></TR>
<TR><TD>8.390e-04</TD><TD>-7.08</TD><TD>human chr12q21.31</TD><TD>chromosome location</TD><TD>human chr12q21.31</TD><TD>22</TD><TD>2</TD><TD>26169</TD><TD>51</TD>
<TD>ALX1,SLC6A15</TD></TR>
<TR><TD>8.395e-04</TD><TD>-7.08</TD><TD>GO_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION</TD><TD>64</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,FOXA2,ALX1</TD></TR>
<TR><TD>8.416e-04</TD><TD>-7.08</TD><TD>FARMER_BREAST_CANCER_CLUSTER_3</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_CLUSTER_3</TD><TD>15</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,CLDN1</TD></TR>
<TR><TD>8.451e-04</TD><TD>-7.08</TD><TD>AP1FJ_Q2</TD><TD>MSigDB lists</TD><TD>AP1FJ_Q2</TD><TD>256</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,MEIS2,PAPPA,PAX9,HS3ST3B1</TD></TR>
<TR><TD>8.549e-04</TD><TD>-7.06</TD><TD>system development</TD><TD>biological process</TD><TD>GO:0048731</TD><TD>4365</TD><TD>23</TD><TD>18054</TD><TD>51</TD>
<TD>GABRB2,CRB1,SATB2,NPTX2,PAX9,BMPR1B,FOXA2,LSR,IL7,MTSS1,CLDN1,USP2,ZIC4,ALX1,HEY1,PLAG1,PCDH17,ZIC1,DCDC2,CXCL14,EPHA3,MEIS2,FST</TD></TR>
<TR><TD>9.218e-04</TD><TD>-6.99</TD><TD>humerus</TD><TD>COSMIC cancer mutations</TD><TD>humerus</TD><TD>556</TD><TD>7</TD><TD>17255</TD><TD>49</TD>
<TD>GPC5,KYNU,CDKN2A,EYA4,ZFHX4,PCDH11X,MTSS1</TD></TR>
<TR><TD>9.453e-04</TD><TD>-6.96</TD><TD>GTGACTT_MIR224</TD><TD>MSigDB lists</TD><TD>GTGACTT_MIR224</TD><TD>151</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,CPEB2,ZFHX4,PLAG1</TD></TR>
<TR><TD>9.600e-04</TD><TD>-6.95</TD><TD>GO_INDOLALKYLAMINE_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_INDOLALKYLAMINE_METABOLIC_PROCESS</TD><TD>16</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>9.988e-04</TD><TD>-6.91</TD><TD>metal ion binding</TD><TD>molecular function</TD><TD>GO:0046872</TD><TD>4137</TD><TD>21</TD><TD>17306</TD><TD>46</TD>
<TD>GALNT13,PCDH11X,NPTX2,PLEKHM3,EYA4,PCDH17,PAPPA,ENPP5,STAC,IDO2,ZIC1,BMPR1B,ZIC4,CRB1,PLAG1,PCDH20,PLCH1,USP2,RNF128,ZFHX4,ARHGAP45</TD></TR>
<TR><TD>1.009e-03</TD><TD>-6.90</TD><TD>DNA-binding transcription activator activity, RNA polymerase II-specific</TD><TD>molecular function</TD><TD>GO:0001228</TD><TD>438</TD><TD>6</TD><TD>17306</TD><TD>46</TD>
<TD>MEIS2,ZIC1,PAX9,PLAG1,ALX1,SATB2</TD></TR>
<TR><TD>1.020e-03</TD><TD>-6.89</TD><TD>TGATTTRY_GFI1_01</TD><TD>MSigDB lists</TD><TD>TGATTTRY_GFI1_01</TD><TD>267</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>CRB1,ZFHX4,ZIC4,MEIS2,ZIC1</TD></TR>
<TR><TD>1.021e-03</TD><TD>-6.89</TD><TD>DNA-binding transcription activator activity</TD><TD>molecular function</TD><TD>GO:0001216</TD><TD>439</TD><TD>6</TD><TD>17306</TD><TD>46</TD>
<TD>PAX9,MEIS2,ZIC1,SATB2,PLAG1,ALX1</TD></TR>
<TR><TD>1.036e-03</TD><TD>-6.87</TD><TD>indolalkylamine metabolic process</TD><TD>biological process</TD><TD>GO:0006586</TD><TD>17</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.036e-03</TD><TD>-6.87</TD><TD>lung-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-squamous_cell_carcinoma</TD><TD>15000</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>EDA2R,PLEKHM3,KYNU,ZFHX4,HEY1,USP2,GRIA2,PCDH11X,RNF128,PLCH1,PLAG1,SLC6A15,DCDC2,ALX1,IL7,ZIC1,LSR,PCDH17,CPEB2,CXCL14,SCGB3A2,GPC5,MTSS1,SPAG6,STAC,GALNT13,CRB1,RBM11,EPHA3,IDO2,BMPR1B,GABRB2,FOXA2,NPTX2,CLDN1,PEX5L,PCDH20,CLVS2,CDKN2A,HS3ST3B1,ZIC4,EYA4,SATB2,PAX9,MEIS2,AZGP1,PAPPA,FST,ENPP5</TD></TR>
<TR><TD>1.068e-03</TD><TD>-6.84</TD><TD>TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497</TD><TD>MSigDB lists</TD><TD>TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497</TD><TD>559</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2,MTSS1,PLAG1,SATB2,PCDH17,PAPPA,ZIC1</TD></TR>
<TR><TD>1.086e-03</TD><TD>-6.83</TD><TD>MAHADEVAN_IMATINIB_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>MAHADEVAN_IMATINIB_RESISTANCE_UP</TD><TD>17</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,KYNU</TD></TR>
<TR><TD>1.090e-03</TD><TD>-6.82</TD><TD>CTCAAGA_MIR526B</TD><TD>MSigDB lists</TD><TD>CTCAAGA_MIR526B</TD><TD>70</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2,ZFHX4,PCDH17</TD></TR>
<TR><TD>1.092e-03</TD><TD>-6.82</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SERVITJA_ISLET_HNF1A_TARGETS_UP</TD><TD>157</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>FST,MEIS2,SLC6A15,ZFHX4</TD></TR>
<TR><TD>1.104e-03</TD><TD>-6.81</TD><TD>CTTTGTA_MIR524</TD><TD>MSigDB lists</TD><TD>CTTTGTA_MIR524</TD><TD>408</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,ZIC1,MTSS1,CPEB2,GRIA2,EPHA3</TD></TR>
<TR><TD>1.110e-03</TD><TD>-6.80</TD><TD>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>3583</TD><TD>20</TD><TD>17255</TD><TD>49</TD>
<TD>GALNT13,ZFHX4,CRB1,GRIA2,PCDH11X,GPC5,KYNU,EYA4,CDKN2A,SATB2,PCDH17,MEIS2,PAPPA,BMPR1B,EPHA3,SLC6A15,GABRB2,CLDN1,ALX1,PCDH20</TD></TR>
<TR><TD>1.110e-03</TD><TD>-6.80</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</TD><TD>3583</TD><TD>20</TD><TD>17255</TD><TD>49</TD>
<TD>PAPPA,MEIS2,SATB2,PCDH17,CDKN2A,EYA4,PCDH20,ALX1,CLDN1,GABRB2,BMPR1B,SLC6A15,EPHA3,PCDH11X,GRIA2,CRB1,ZFHX4,GALNT13,KYNU,GPC5</TD></TR>
<TR><TD>1.111e-03</TD><TD>-6.80</TD><TD>intestinal_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>intestinal_adenocarcinoma</TD><TD>7350</TD><TD>32</TD><TD>17255</TD><TD>49</TD>
<TD>EPHA3,NPTX2,GABRB2,PEX5L,PCDH20,CDKN2A,EYA4,ZIC4,HS3ST3B1,PAX9,SATB2,ENPP5,PAPPA,FST,AZGP1,MEIS2,MTSS1,GALNT13,CRB1,RBM11,SLC6A15,DCDC2,ALX1,LSR,PCDH17,EDA2R,ZFHX4,PCDH11X,GRIA2,PLAG1,PLCH1,RNF128</TD></TR>
<TR><TD>1.111e-03</TD><TD>-6.80</TD><TD>stomach-carcinoma-intestinal_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-intestinal_adenocarcinoma</TD><TD>7350</TD><TD>32</TD><TD>17255</TD><TD>49</TD>
<TD>DCDC2,SLC6A15,ALX1,LSR,PCDH17,EDA2R,ZFHX4,PLAG1,PLCH1,RNF128,PCDH11X,GRIA2,GABRB2,NPTX2,EPHA3,PCDH20,PEX5L,EYA4,CDKN2A,HS3ST3B1,ZIC4,PAPPA,ENPP5,FST,MEIS2,AZGP1,PAX9,SATB2,MTSS1,CRB1,GALNT13,RBM11</TD></TR>
<TR><TD>1.126e-03</TD><TD>-6.79</TD><TD>DURAND_STROMA_S_UP</TD><TD>MSigDB lists</TD><TD>DURAND_STROMA_S_UP</TD><TD>273</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,GALNT13,CLDN1,PAPPA,EYA4</TD></TR>
<TR><TD>1.213e-03</TD><TD>-6.71</TD><TD>Homeobox-like_sf</TD><TD>interpro domains</TD><TD>IPR009057</TD><TD>293</TD><TD>5</TD><TD>18616</TD><TD>51</TD>
<TD>ZFHX4,ALX1,PAX9,SATB2,MEIS2</TD></TR>
<TR><TD>1.219e-03</TD><TD>-6.71</TD><TD>chr3q24</TD><TD>MSigDB lists</TD><TD>chr3q24</TD><TD>18</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,ZIC1</TD></TR>
<TR><TD>1.219e-03</TD><TD>-6.71</TD><TD>GO_HEPARAN_SULFATE_PROTEOGLYCAN_BINDING</TD><TD>MSigDB lists</TD><TD>GO_HEPARAN_SULFATE_PROTEOGLYCAN_BINDING</TD><TD>18</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>FST,GPC5</TD></TR>
<TR><TD>1.252e-03</TD><TD>-6.68</TD><TD>pattern specification process</TD><TD>biological process</TD><TD>GO:0007389</TD><TD>428</TD><TD>6</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,BMPR1B,HEY1,FOXA2,ZIC1,ALX1</TD></TR>
<TR><TD>1.259e-03</TD><TD>-6.68</TD><TD>animal organ morphogenesis</TD><TD>biological process</TD><TD>GO:0009887</TD><TD>953</TD><TD>9</TD><TD>18054</TD><TD>51</TD>
<TD>CRB1,ALX1,PLAG1,HEY1,SATB2,ZIC1,IL7,PAX9,BMPR1B</TD></TR>
<TR><TD>1.284e-03</TD><TD>-6.66</TD><TD>VERHAAK_GLIOBLASTOMA_PRONEURAL</TD><TD>MSigDB lists</TD><TD>VERHAAK_GLIOBLASTOMA_PRONEURAL</TD><TD>164</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2,MTSS1,PCDH11X,CRB1</TD></TR>
<TR><TD>1.284e-03</TD><TD>-6.66</TD><TD>GSE26030_UNSTIM_VS_RESTIM_TH17_DAY15_POST_POLARIZATION_UP</TD><TD>MSigDB lists</TD><TD>GSE26030_UNSTIM_VS_RESTIM_TH17_DAY15_POST_POLARIZATION_UP</TD><TD>164</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,PLAG1,KYNU,BMPR1B</TD></TR>
<TR><TD>1.300e-03</TD><TD>-6.65</TD><TD>GTGCCAA_MIR96</TD><TD>MSigDB lists</TD><TD>GTGCCAA_MIR96</TD><TD>282</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,NPTX2,EPHA3,MTSS1,ZFHX4</TD></TR>
<TR><TD>1.327e-03</TD><TD>-6.63</TD><TD>NAD de novo biosynthesis</TD><TD>BIOCYC pathways</TD><TD>HUMAN_NADSYN-PWY</TD><TD>11</TD><TD>2</TD><TD>902</TD><TD>5</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.327e-03</TD><TD>-6.63</TD><TD>L-kynurenine degradation</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY-6309</TD><TD>11</TD><TD>2</TD><TD>902</TD><TD>5</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.342e-03</TD><TD>-6.61</TD><TD>GSE21546_UNSTIM_VS_ANTI_CD3_STIM_ELK1_KO_DP_THYMOCYTES_UP</TD><TD>MSigDB lists</TD><TD>GSE21546_UNSTIM_VS_ANTI_CD3_STIM_ELK1_KO_DP_THYMOCYTES_UP</TD><TD>166</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>DCDC2,CLVS2,PAX9,USP2</TD></TR>
<TR><TD>1.347e-03</TD><TD>-6.61</TD><TD>cation binding</TD><TD>molecular function</TD><TD>GO:0043169</TD><TD>4228</TD><TD>21</TD><TD>17306</TD><TD>46</TD>
<TD>RNF128,USP2,ARHGAP45,ZFHX4,PCDH20,CRB1,PLAG1,PLCH1,ENPP5,PAPPA,BMPR1B,ZIC4,STAC,IDO2,ZIC1,PCDH11X,NPTX2,GALNT13,PCDH17,EYA4,PLEKHM3</TD></TR>
<TR><TD>1.360e-03</TD><TD>-6.60</TD><TD>GO_AROMATIC_AMINO_ACID_FAMILY_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_AROMATIC_AMINO_ACID_FAMILY_CATABOLIC_PROCESS</TD><TD>19</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.378e-03</TD><TD>-6.59</TD><TD>skin-face-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-carcinoma-squamous_cell_carcinoma</TD><TD>2067</TD><TD>14</TD><TD>17255</TD><TD>49</TD>
<TD>DCDC2,KYNU,GPC5,EPHA3,PCDH20,STAC,SPAG6,CDKN2A,CRB1,GALNT13,PAPPA,PLCH1,USP2,GRIA2</TD></TR>
<TR><TD>1.393e-03</TD><TD>-6.58</TD><TD>FOXJ2 (forkhead box J2)</TD><TD>protein interactions</TD><TD>55810</TD><TD>77</TD><TD>3</TD><TD>17456</TD><TD>50</TD>
<TD>SATB2,EYA4,ZFHX4</TD></TR>
<TR><TD>1.434e-03</TD><TD>-6.55</TD><TD>DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN</TD><TD>MSigDB lists</TD><TD>DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN</TD><TD>169</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,PLAG1,ZFHX4,ZIC1</TD></TR>
<TR><TD>1.436e-03</TD><TD>-6.55</TD><TD>GHANDHI_BYSTANDER_IRRADIATION_UP</TD><TD>MSigDB lists</TD><TD>GHANDHI_BYSTANDER_IRRADIATION_UP</TD><TD>77</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,SLC6A15,RNF128</TD></TR>
<TR><TD>1.439e-03</TD><TD>-6.54</TD><TD>cartilage condensation</TD><TD>biological process</TD><TD>GO:0001502</TD><TD>20</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,BMPR1B</TD></TR>
<TR><TD>1.459e-03</TD><TD>-6.53</TD><TD>nervous system development</TD><TD>biological process</TD><TD>GO:0007399</TD><TD>2329</TD><TD>15</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,ZIC4,GABRB2,CRB1,PLAG1,HEY1,PCDH17,SATB2,ZIC1,NPTX2,DCDC2,EPHA3,CLDN1,FOXA2,BMPR1B</TD></TR>
<TR><TD>1.471e-03</TD><TD>-6.52</TD><TD>ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_DN</TD><TD>MSigDB lists</TD><TD>ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_DN</TD><TD>290</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>NPTX2,FST,EYA4,EPHA3,CLDN1</TD></TR>
<TR><TD>1.487e-03</TD><TD>-6.51</TD><TD>pancreas-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma</TD><TD>15111</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,HS3ST3B1,EYA4,ZIC4,PAPPA,FST,ENPP5,MEIS2,AZGP1,PAX9,SATB2,FOXA2,NPTX2,GABRB2,IDO2,EPHA3,BMPR1B,PEX5L,CLVS2,PCDH20,CLDN1,CRB1,GALNT13,RBM11,GPC5,SCGB3A2,STAC,SPAG6,MTSS1,ZIC1,LSR,CXCL14,CPEB2,PCDH17,DCDC2,SLC6A15,IL7,ALX1,HEY1,ZFHX4,PLAG1,PLCH1,RNF128,PCDH11X,USP2,GRIA2,KYNU,PLEKHM3,EDA2R</TD></TR>
<TR><TD>1.497e-03</TD><TD>-6.50</TD><TD>GSE30971_CTRL_VS_LPS_STIM_MACROPHAGE_WBP7_KO_2H_UP</TD><TD>MSigDB lists</TD><TD>GSE30971_CTRL_VS_LPS_STIM_MACROPHAGE_WBP7_KO_2H_UP</TD><TD>171</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,HS3ST3B1,HEY1,EYA4</TD></TR>
<TR><TD>1.499e-03</TD><TD>-6.50</TD><TD>cerebellum</TD><TD>COSMIC cancer mutations</TD><TD>cerebellum</TD><TD>783</TD><TD>8</TD><TD>17255</TD><TD>49</TD>
<TD>STAC,SPAG6,GPC5,EPHA3,PCDH11X,MEIS2,EYA4,CDKN2A</TD></TR>
<TR><TD>1.501e-03</TD><TD>-6.50</TD><TD>Endoderm Differentiation</TD><TD>WikiPathways</TD><TD>WP2853</TD><TD>145</TD><TD>4</TD><TD>5311</TD><TD>19</TD>
<TD>PAX9,PLCH1,FOXA2,ZFHX4</TD></TR>
<TR><TD>1.509e-03</TD><TD>-6.50</TD><TD>GO_CELL_AGGREGATION</TD><TD>MSigDB lists</TD><TD>GO_CELL_AGGREGATION</TD><TD>20</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ALX1,BMPR1B</TD></TR>
<TR><TD>1.509e-03</TD><TD>-6.50</TD><TD>SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A</TD><TD>MSigDB lists</TD><TD>SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A</TD><TD>20</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,KYNU</TD></TR>
<TR><TD>1.509e-03</TD><TD>-6.50</TD><TD>GO_AMINE_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_AMINE_CATABOLIC_PROCESS</TD><TD>20</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.526e-03</TD><TD>-6.49</TD><TD>intrinsic component of plasma membrane</TD><TD>cellular component</TD><TD>GO:0031226</TD><TD>1704</TD><TD>12</TD><TD>18985</TD><TD>51</TD>
<TD>GABRB2,BMPR1B,EDA2R,EPHA3,SLC6A15,PCDH20,PCDH11X,CLDN1,GPC5,GRIA2,PCDH17,HS3ST3B1</TD></TR>
<TR><TD>1.546e-03</TD><TD>-6.47</TD><TD>RYAAAKNNNNNNTTGW_UNKNOWN</TD><TD>MSigDB lists</TD><TD>RYAAAKNNNNNNTTGW_UNKNOWN</TD><TD>79</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,PLAG1,ZIC1</TD></TR>
<TR><TD>1.563e-03</TD><TD>-6.46</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN</TD><TD>294</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,ZIC1,NPTX2,CLDN1,CDKN2A</TD></TR>
<TR><TD>1.572e-03</TD><TD>-6.46</TD><TD>CTTTGT_LEF1_Q2</TD><TD>MSigDB lists</TD><TD>CTTTGT_LEF1_Q2</TD><TD>1817</TD><TD>13</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,MEIS2,GABRB2,BMPR1B,FOXA2,PCDH11X,ZIC1,FST,EYA4,SCGB3A2,ZIC4,LSR,HEY1</TD></TR>
<TR><TD>1.587e-03</TD><TD>-6.45</TD><TD>animal organ development</TD><TD>biological process</TD><TD>GO:0048513</TD><TD>3131</TD><TD>18</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,USP2,HEY1,PLAG1,ZIC1,FST,MEIS2,CXCL14,GABRB2,CRB1,SATB2,CLDN1,IL7,LSR,MTSS1,FOXA2,BMPR1B,PAX9</TD></TR>
<TR><TD>1.588e-03</TD><TD>-6.45</TD><TD>amine catabolic process</TD><TD>biological process</TD><TD>GO:0009310</TD><TD>21</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.588e-03</TD><TD>-6.45</TD><TD>cell aggregation</TD><TD>biological process</TD><TD>GO:0098743</TD><TD>21</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B,ALX1</TD></TR>
<TR><TD>1.588e-03</TD><TD>-6.45</TD><TD>cellular biogenic amine catabolic process</TD><TD>biological process</TD><TD>GO:0042402</TD><TD>21</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.609e-03</TD><TD>-6.43</TD><TD>GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT</TD><TD>1594</TD><TD>12</TD><TD>17275</TD><TD>50</TD>
<TD>FST,IL7,PAX9,HEY1,PLAG1,USP2,BMPR1B,MEIS2,ALX1,EPHA3,FOXA2,CDKN2A</TD></TR>
<TR><TD>1.630e-03</TD><TD>-6.42</TD><TD>GSE37301_LYMPHOID_PRIMED_MPP_VS_PRO_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE37301_LYMPHOID_PRIMED_MPP_VS_PRO_BCELL_DN</TD><TD>175</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,EYA4,FOXA2,CRB1</TD></TR>
<TR><TD>1.650e-03</TD><TD>-6.41</TD><TD>hepatocellular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>hepatocellular_carcinoma</TD><TD>15143</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>DCDC2,SLC6A15,ALX1,IL7,LSR,ZIC1,PCDH17,CXCL14,CPEB2,KYNU,PLEKHM3,EDA2R,ZFHX4,HEY1,RNF128,PLCH1,PLAG1,USP2,GRIA2,PCDH11X,FOXA2,NPTX2,GABRB2,IDO2,EPHA3,BMPR1B,CLVS2,PEX5L,PCDH20,CLDN1,HS3ST3B1,ZIC4,CDKN2A,EYA4,MEIS2,AZGP1,ENPP5,FST,PAPPA,SATB2,PAX9,SCGB3A2,GPC5,SPAG6,MTSS1,STAC,CRB1,GALNT13,RBM11</TD></TR>
<TR><TD>1.650e-03</TD><TD>-6.41</TD><TD>liver-carcinoma-hepatocellular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>liver-carcinoma-hepatocellular_carcinoma</TD><TD>15143</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>SATB2,PAX9,MEIS2,AZGP1,FST,ENPP5,PAPPA,ZIC4,EYA4,HS3ST3B1,CDKN2A,CLDN1,PCDH20,PEX5L,CLVS2,IDO2,BMPR1B,EPHA3,GABRB2,NPTX2,FOXA2,RBM11,GALNT13,CRB1,SPAG6,MTSS1,STAC,SCGB3A2,GPC5,PCDH17,CPEB2,CXCL14,LSR,ZIC1,ALX1,IL7,SLC6A15,DCDC2,USP2,GRIA2,PCDH11X,RNF128,PLCH1,PLAG1,ZFHX4,HEY1,EDA2R,PLEKHM3,KYNU</TD></TR>
<TR><TD>1.687e-03</TD><TD>-6.38</TD><TD>anatomical structure morphogenesis</TD><TD>biological process</TD><TD>GO:0009653</TD><TD>2114</TD><TD>14</TD><TD>18054</TD><TD>51</TD>
<TD>CRB1,EYA4,ALX1,HEY1,PLAG1,SATB2,ZIC1,DCDC2,FOXA2,IL7,MTSS1,BMPR1B,PAX9,EPHA3</TD></TR>
<TR><TD>1.699e-03</TD><TD>-6.38</TD><TD>PRC2_EED_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>PRC2_EED_UP.V1_UP</TD><TD>177</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,SLC6A15,MTSS1,PLAG1</TD></TR>
<TR><TD>1.734e-03</TD><TD>-6.36</TD><TD>GSE3982_DC_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_DC_VS_EFF_MEMORY_CD4_TCELL_DN</TD><TD>178</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,AZGP1,EDA2R,ALX1</TD></TR>
<TR><TD>1.734e-03</TD><TD>-6.36</TD><TD>GSE29618_PRE_VS_DAY7_POST_TIV_FLU_VACCINE_MONOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE29618_PRE_VS_DAY7_POST_TIV_FLU_VACCINE_MONOCYTE_UP</TD><TD>178</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,RNF128,ZIC1,PCDH17</TD></TR>
<TR><TD>1.734e-03</TD><TD>-6.36</TD><TD>GSE41176_UNSTIM_VS_ANTI_IGM_STIM_TAK1_KO_BCELL_3H_DN</TD><TD>MSigDB lists</TD><TD>GSE41176_UNSTIM_VS_ANTI_IGM_STIM_TAK1_KO_BCELL_3H_DN</TD><TD>178</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>SPAG6,FOXA2,LSR,ZIC1</TD></TR>
<TR><TD>1.740e-03</TD><TD>-6.35</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP</TD><TD>446</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>DCDC2,EPHA3,HS3ST3B1,RNF128,ENPP5,USP2</TD></TR>
<TR><TD>1.758e-03</TD><TD>-6.34</TD><TD>TTGCCAA_MIR182</TD><TD>MSigDB lists</TD><TD>TTGCCAA_MIR182</TD><TD>302</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,PLCH1,SATB2,MEIS2,PCDH17</TD></TR>
<TR><TD>1.770e-03</TD><TD>-6.34</TD><TD>ESC_J1_UP_LATE.V1_UP</TD><TD>MSigDB lists</TD><TD>ESC_J1_UP_LATE.V1_UP</TD><TD>179</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>FST,FOXA2,ENPP5,RNF128</TD></TR>
<TR><TD>1.791e-03</TD><TD>-6.33</TD><TD>SIX2 (SIX homeobox 2)</TD><TD>protein interactions</TD><TD>10736</TD><TD>22</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>EYA4,CDKN2A</TD></TR>
<TR><TD>1.799e-03</TD><TD>-6.32</TD><TD>GO_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY_SEQUENCE_SPECIFIC_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY_SEQUENCE_SPECIFIC_DNA_BINDING</TD><TD>612</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>ALX1,PAX9,HEY1,PLAG1,FOXA2,ZIC1,MEIS2</TD></TR>
<TR><TD>1.828e-03</TD><TD>-6.30</TD><TD>NEWMAN_ERCC6_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>NEWMAN_ERCC6_TARGETS_UP</TD><TD>22</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ALX1,KYNU</TD></TR>
<TR><TD>1.828e-03</TD><TD>-6.30</TD><TD>GO_BENZENE_CONTAINING_COMPOUND_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_BENZENE_CONTAINING_COMPOUND_METABOLIC_PROCESS</TD><TD>22</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.844e-03</TD><TD>-6.30</TD><TD>GSE41176_WT_VS_TAK1_KO_ANTI_IGM_STIM_BCELL_1H_DN</TD><TD>MSigDB lists</TD><TD>GSE41176_WT_VS_TAK1_KO_ANTI_IGM_STIM_BCELL_1H_DN</TD><TD>181</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ALX1,PLCH1,SCGB3A2,STAC</TD></TR>
<TR><TD>1.881e-03</TD><TD>-6.28</TD><TD>P53_DN.V1_UP</TD><TD>MSigDB lists</TD><TD>P53_DN.V1_UP</TD><TD>182</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,AZGP1,CDKN2A,LSR</TD></TR>
<TR><TD>1.910e-03</TD><TD>-6.26</TD><TD>GO_SEQUENCE_SPECIFIC_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_SEQUENCE_SPECIFIC_DNA_BINDING</TD><TD>989</TD><TD>9</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,FOXA2,ALX1,ZFHX4,ZIC1,HEY1,PAX9,SATB2,PLAG1</TD></TR>
<TR><TD>1.919e-03</TD><TD>-6.26</TD><TD>multicellular organismal process</TD><TD>biological process</TD><TD>GO:0032501</TD><TD>6841</TD><TD>30</TD><TD>18054</TD><TD>51</TD>
<TD>AZGP1,CXCL14,FST,MEIS2,EPHA3,DCDC2,ZIC1,EDA2R,PLAG1,PCDH17,HEY1,USP2,ZIC4,ALX1,EYA4,PAX9,SPAG6,PAPPA,BMPR1B,MTSS1,FOXA2,RBM11,IL7,LSR,CLDN1,NPTX2,SATB2,CRB1,GABRB2,STAC</TD></TR>
<TR><TD>1.949e-03</TD><TD>-6.24</TD><TD>human chr3p22.3-p22.2</TD><TD>chromosome location</TD><TD>human chr3p22.3-p22.2</TD><TD>1</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>STAC</TD></TR>
<TR><TD>1.949e-03</TD><TD>-6.24</TD><TD>human chr2q23.3-q24.1</TD><TD>chromosome location</TD><TD>human chr2q23.3-q24.1</TD><TD>1</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>GALNT13</TD></TR>
<TR><TD>1.949e-03</TD><TD>-6.24</TD><TD>human chr2q22.2</TD><TD>chromosome location</TD><TD>human chr2q22.2</TD><TD>1</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.958e-03</TD><TD>-6.24</TD><TD>ALOXE3 (arachidonate lipoxygenase 3)</TD><TD>protein interactions</TD><TD>59344</TD><TD>23</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>ZFHX4,ZIC1</TD></TR>
<TR><TD>1.997e-03</TD><TD>-6.22</TD><TD>GSE7568_CTRL_VS_24H_TGFB_TREATED_MACROPHAGES_WITH_IL4_AND_DEXAMETHASONE_DN</TD><TD>MSigDB lists</TD><TD>GSE7568_CTRL_VS_24H_TGFB_TREATED_MACROPHAGES_WITH_IL4_AND_DEXAMETHASONE_DN</TD><TD>185</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,CLDN1,PLAG1,ALX1</TD></TR>
<TR><TD>1.998e-03</TD><TD>-6.22</TD><TD>LI_CISPLATIN_RESISTANCE_UP</TD><TD>MSigDB lists</TD><TD>LI_CISPLATIN_RESISTANCE_UP</TD><TD>23</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,EPHA3</TD></TR>
<TR><TD>2.027e-03</TD><TD>-6.20</TD><TD>GO_TRANSCRIPTIONAL_ACTIVATOR_ACTIVITY_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATORY_REGION_SEQUENCE_SPECIFIC_BINDING</TD><TD>MSigDB lists</TD><TD>GO_TRANSCRIPTIONAL_ACTIVATOR_ACTIVITY_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATORY_REGION_SEQUENCE_SPECIFIC_BINDING</TD><TD>312</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,ALX1,PAX9,ZIC1,MEIS2</TD></TR>
<TR><TD>2.036e-03</TD><TD>-6.20</TD><TD>FOXD3_01</TD><TD>MSigDB lists</TD><TD>FOXD3_01</TD><TD>186</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,PLAG1,FST,PCDH17</TD></TR>
<TR><TD>2.038e-03</TD><TD>-6.20</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5</TD><TD>MSigDB lists</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5</TD><TD>87</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,PAPPA,IL7</TD></TR>
<TR><TD>2.075e-03</TD><TD>-6.18</TD><TD>indole-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0042430</TD><TD>24</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>2.099e-03</TD><TD>-6.17</TD><TD>regulation of epithelial to mesenchymal transition</TD><TD>biological process</TD><TD>GO:0010717</TD><TD>90</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,EPHA3,FOXA2</TD></TR>
<TR><TD>2.170e-03</TD><TD>-6.13</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP</TD><TD>MSigDB lists</TD><TD>ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP</TD><TD>466</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,GALNT13,CLDN1,HS3ST3B1,EDA2R,SLC6A15</TD></TR>
<TR><TD>2.175e-03</TD><TD>-6.13</TD><TD>BONCI_TARGETS_OF_MIR15A_AND_MIR16_1</TD><TD>MSigDB lists</TD><TD>BONCI_TARGETS_OF_MIR15A_AND_MIR16_1</TD><TD>89</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,CPEB2,PLAG1</TD></TR>
<TR><TD>2.176e-03</TD><TD>-6.13</TD><TD>ABBUD_LIF_SIGNALING_1_DN</TD><TD>MSigDB lists</TD><TD>ABBUD_LIF_SIGNALING_1_DN</TD><TD>24</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2,FOXA2</TD></TR>
<TR><TD>2.191e-03</TD><TD>-6.12</TD><TD>GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_GENE_EXPRESSION</TD><TD>1429</TD><TD>11</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,PAX9,HEY1,SATB2,CPEB2,FST,ALX1,CDKN2A,FOXA2,USP2,MEIS2</TD></TR>
<TR><TD>2.200e-03</TD><TD>-6.12</TD><TD>GSE17721_POLYIC_VS_CPG_0.5H_BMDC_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_POLYIC_VS_CPG_0.5H_BMDC_DN</TD><TD>190</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,ZFHX4,RNF128,CXCL14</TD></TR>
<TR><TD>2.202e-03</TD><TD>-6.12</TD><TD>face</TD><TD>COSMIC cancer mutations</TD><TD>face</TD><TD>2170</TD><TD>14</TD><TD>17255</TD><TD>49</TD>
<TD>SPAG6,STAC,PCDH20,EPHA3,GPC5,DCDC2,KYNU,GRIA2,USP2,PLCH1,PAPPA,GALNT13,CDKN2A,CRB1</TD></TR>
<TR><TD>2.219e-03</TD><TD>-6.11</TD><TD>GGGAGGRR_MAZ_Q6</TD><TD>MSigDB lists</TD><TD>GGGAGGRR_MAZ_Q6</TD><TD>2127</TD><TD>14</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,PEX5L,PCDH20,ZIC4,DCDC2,PLAG1,LSR,PAPPA,MEIS2,PCDH17,CXCL14,USP2,FOXA2,PCDH11X</TD></TR>
<TR><TD>2.242e-03</TD><TD>-6.10</TD><TD>CEBP_C</TD><TD>MSigDB lists</TD><TD>CEBP_C</TD><TD>191</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,ZIC1,PLAG1,ZIC4</TD></TR>
<TR><TD>2.242e-03</TD><TD>-6.10</TD><TD>GSE43955_TH0_VS_TGFB_IL6_TH17_ACT_CD4_TCELL_60H_DN</TD><TD>MSigDB lists</TD><TD>GSE43955_TH0_VS_TGFB_IL6_TH17_ACT_CD4_TCELL_60H_DN</TD><TD>191</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,FOXA2,ZIC4,BMPR1B</TD></TR>
<TR><TD>2.252e-03</TD><TD>-6.10</TD><TD>benzene-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0042537</TD><TD>25</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.285e-03</TD><TD>-6.08</TD><TD>GSE339_CD4POS_VS_CD4CD8DN_DC_IN_CULTURE_DN</TD><TD>MSigDB lists</TD><TD>GSE339_CD4POS_VS_CD4CD8DN_DC_IN_CULTURE_DN</TD><TD>192</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,LSR,MEIS2,GABRB2</TD></TR>
<TR><TD>2.285e-03</TD><TD>-6.08</TD><TD>GO_CELL_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES</TD><TD>MSigDB lists</TD><TD>GO_CELL_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES</TD><TD>192</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,PCDH11X,PCDH20,PCDH17</TD></TR>
<TR><TD>2.313e-03</TD><TD>-6.07</TD><TD>FCGR1A (Fc fragment of IgG receptor Ia)</TD><TD>protein interactions</TD><TD>2209</TD><TD>25</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20,PCDH17</TD></TR>
<TR><TD>2.317e-03</TD><TD>-6.07</TD><TD>CAATGCA_MIR33</TD><TD>MSigDB lists</TD><TD>CAATGCA_MIR33</TD><TD>91</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,PAPPA,MEIS2</TD></TR>
<TR><TD>2.360e-03</TD><TD>-6.05</TD><TD>GO_INDOLE_CONTAINING_COMPOUND_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_INDOLE_CONTAINING_COMPOUND_METABOLIC_PROCESS</TD><TD>25</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>2.453e-03</TD><TD>-6.01</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K27ME3</TD><TD>326</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,PAPPA,GALNT13,LSR,ALX1</TD></TR>
<TR><TD>2.462e-03</TD><TD>-6.01</TD><TD>ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN</TD><TD>MSigDB lists</TD><TD>ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN</TD><TD>196</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,PCDH11X,ZFHX4,SATB2</TD></TR>
<TR><TD>2.501e-03</TD><TD>-5.99</TD><TD>AZGP1 (alpha-2-glycoprotein 1, zinc-binding)</TD><TD>protein interactions</TD><TD>563</TD><TD>26</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>AZGP1,ZIC1</TD></TR>
<TR><TD>2.508e-03</TD><TD>-5.99</TD><TD>TTTGCAG_MIR518A2</TD><TD>MSigDB lists</TD><TD>TTTGCAG_MIR518A2</TD><TD>197</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZIC1,CPEB2,SATB2</TD></TR>
<TR><TD>2.552e-03</TD><TD>-5.97</TD><TD>DING_LUNG_CANCER_MUTATED_SIGNIFICANTLY</TD><TD>MSigDB lists</TD><TD>DING_LUNG_CANCER_MUTATED_SIGNIFICANTLY</TD><TD>26</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,CDKN2A</TD></TR>
<TR><TD>2.595e-03</TD><TD>-5.95</TD><TD>GO_SENSORY_ORGAN_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_SENSORY_ORGAN_DEVELOPMENT</TD><TD>483</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>CRB1,BMPR1B,GABRB2,MEIS2,ZIC1,CXCL14</TD></TR>
<TR><TD>2.650e-03</TD><TD>-5.93</TD><TD>dedifferentiated</TD><TD>COSMIC cancer mutations</TD><TD>dedifferentiated</TD><TD>27</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,HEY1</TD></TR>
<TR><TD>2.658e-03</TD><TD>-5.93</TD><TD>calcium-dependent phospholipase C activity</TD><TD>molecular function</TD><TD>GO:0050429</TD><TD>1</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>PLCH1</TD></TR>
<TR><TD>2.658e-03</TD><TD>-5.93</TD><TD>3-hydroxykynureninase activity</TD><TD>molecular function</TD><TD>GO:0061981</TD><TD>1</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.658e-03</TD><TD>-5.93</TD><TD>kynureninase activity</TD><TD>molecular function</TD><TD>GO:0030429</TD><TD>1</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.697e-03</TD><TD>-5.92</TD><TD>ATGCTGC_MIR103_MIR107</TD><TD>MSigDB lists</TD><TD>ATGCTGC_MIR103_MIR107</TD><TD>201</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,MTSS1,PLAG1,SATB2</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>Tumor_suppres_ARF</TD><TD>interpro domains</TD><TD>IPR010868</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>IL-7</TD><TD>interpro domains</TD><TD>IPR001181</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>IL7</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>PAPPA</TD><TD>interpro domains</TD><TD>IPR030433</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PAPPA</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>Protocadherin-17</TD><TD>interpro domains</TD><TD>IPR030709</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PCDH17</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>CXCL14</TD><TD>interpro domains</TD><TD>IPR039088</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CXCL14</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>STAC1</TD><TD>interpro domains</TD><TD>IPR035508</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>STAC</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>Glypican-5</TD><TD>interpro domains</TD><TD>IPR031188</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>GPC5</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>Claudin1</TD><TD>interpro domains</TD><TD>IPR003548</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>EYA4</TD><TD>interpro domains</TD><TD>IPR028478</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EYA4</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>PLC-eta1</TD><TD>interpro domains</TD><TD>IPR028392</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PLCH1</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>Clavesin-2</TD><TD>interpro domains</TD><TD>IPR028636</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CLVS2</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>PEX5-rel</TD><TD>interpro domains</TD><TD>IPR024112</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PEX5L</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>MTSS1</TD><TD>interpro domains</TD><TD>IPR027682</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>MTSS1</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>TNFR_27</TD><TD>interpro domains</TD><TD>IPR022319</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>TNFRSF27_N</TD><TD>interpro domains</TD><TD>IPR034060</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>RBM11_RRM</TD><TD>interpro domains</TD><TD>IPR034501</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>RBM11</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>DCDC2</TD><TD>interpro domains</TD><TD>IPR033036</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>EphA3_rcpt_lig-bd</TD><TD>interpro domains</TD><TD>IPR034266</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EPHA3</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>PLEKHM3_PH_1</TD><TD>interpro domains</TD><TD>IPR037812</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PLEKHM3</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>PAX9</TD><TD>interpro domains</TD><TD>IPR033204</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>ALX1</TD><TD>interpro domains</TD><TD>IPR033209</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>ALX1</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>IL7_sf</TD><TD>interpro domains</TD><TD>IPR038325</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>IL7</TD></TR>
<TR><TD>2.740e-03</TD><TD>-5.90</TD><TD>Kynureninase</TD><TD>interpro domains</TD><TD>IPR010111</TD><TD>1</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.752e-03</TD><TD>-5.90</TD><TD>chr8q12</TD><TD>MSigDB lists</TD><TD>chr8q12</TD><TD>27</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,PLAG1</TD></TR>
<TR><TD>2.752e-03</TD><TD>-5.90</TD><TD>GO_AROMATIC_AMINO_ACID_FAMILY_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_AROMATIC_AMINO_ACID_FAMILY_METABOLIC_PROCESS</TD><TD>27</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.752e-03</TD><TD>-5.90</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G2</TD><TD>MSigDB lists</TD><TD>BOYAULT_LIVER_CANCER_SUBCLASS_G2</TD><TD>27</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,SATB2</TD></TR>
<TR><TD>2.819e-03</TD><TD>-5.87</TD><TD>P19Arf_N</TD><TD>pfam domains</TD><TD>PF07392</TD><TD>1</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.822e-03</TD><TD>-5.87</TD><TD>aromatic amino acid family catabolic process</TD><TD>biological process</TD><TD>GO:0009074</TD><TD>28</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.822e-03</TD><TD>-5.87</TD><TD>NAD biosynthetic process</TD><TD>biological process</TD><TD>GO:0009435</TD><TD>28</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>presynaptic active zone assembly</TD><TD>biological process</TD><TD>GO:1904071</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PCDH17</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>cellular response to butyrate</TD><TD>biological process</TD><TD>GO:1903545</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>tricellular tight junction assembly</TD><TD>biological process</TD><TD>GO:1904274</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>LSR</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>regulation of detection of glucose</TD><TD>biological process</TD><TD>GO:2000970</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>negative regulation of transcription by glucose</TD><TD>biological process</TD><TD>GO:0061986</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>negative regulation of detection of glucose</TD><TD>biological process</TD><TD>GO:2000971</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>response to butyrate</TD><TD>biological process</TD><TD>GO:1903544</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>response to vitamin B6</TD><TD>biological process</TD><TD>GO:0034516</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>xenobiotic transport across blood-nerve barrier</TD><TD>biological process</TD><TD>GO:0061772</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.825e-03</TD><TD>-5.87</TD><TD>negative regulation of transcription from RNA polymerase II promoter by glucose</TD><TD>biological process</TD><TD>GO:0061987</TD><TD>1</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.831e-03</TD><TD>-5.87</TD><TD>AAAYRNCTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>AAAYRNCTG_UNKNOWN</TD><TD>337</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,BMPR1B,PCDH17,ZIC1,FST</TD></TR>
<TR><TD>2.844e-03</TD><TD>-5.86</TD><TD>CART1_01</TD><TD>MSigDB lists</TD><TD>CART1_01</TD><TD>204</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>NPTX2,PAPPA,KYNU,MEIS2</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Arhgdia (Rho GDP dissociation inhibitor (GDI) alpha)</TD><TD>protein interactions</TD><TD>192662</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>RNF128</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>CCDC78 (coiled-coil domain containing 78)</TD><TD>protein interactions</TD><TD>124093</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Nptxr (neuronal pentraxin receptor)</TD><TD>protein interactions</TD><TD>81005</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Lztr1 (leucine-zipper-like transcriptional regulator, 1)</TD><TD>protein interactions</TD><TD>66863</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>1700006A11Rik (RIKEN cDNA 1700006A11 gene)</TD><TD>protein interactions</TD><TD>71824</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Srgap1 (SLIT-ROBO Rho GTPase activating protein 1)</TD><TD>protein interactions</TD><TD>117600</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Arhgdib (Rho, GDP dissociation inhibitor (GDI) beta)</TD><TD>protein interactions</TD><TD>11857</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>RNF128</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Bcl6 (B cell leukemia/lymphoma 6)</TD><TD>protein interactions</TD><TD>12053</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Dcaf7 (DDB1 and CUL4 associated factor 7)</TD><TD>protein interactions</TD><TD>71833</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Sae1 (SUMO1 activating enzyme subunit 1)</TD><TD>protein interactions</TD><TD>56459</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Uba2 (ubiquitin-like modifier activating enzyme 2)</TD><TD>protein interactions</TD><TD>50995</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>PIGL (phosphatidylinositol glycan anchor biosynthesis class L)</TD><TD>protein interactions</TD><TD>9487</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Nptx1 (neuronal pentraxin 1)</TD><TD>protein interactions</TD><TD>266777</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.864e-03</TD><TD>-5.86</TD><TD>Eda2r (ectodysplasin A2 receptor)</TD><TD>protein interactions</TD><TD>245527</TD><TD>1</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.867e-03</TD><TD>-5.85</TD><TD>CTAWWWATA_RSRFC4_Q2</TD><TD>MSigDB lists</TD><TD>CTAWWWATA_RSRFC4_Q2</TD><TD>338</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,GABRB2,STAC,PCDH11X,ZIC4</TD></TR>
<TR><TD>2.913e-03</TD><TD>-5.84</TD><TD>RNA polymerase II proximal promoter sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000978</TD><TD>540</TD><TD>6</TD><TD>17306</TD><TD>46</TD>
<TD>FOXA2,MEIS2,ZFHX4,ZIC1,PLAG1,SATB2</TD></TR>
<TR><TD>2.925e-03</TD><TD>-5.83</TD><TD>lymphoid_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>lymphoid_neoplasm</TD><TD>12511</TD><TD>44</TD><TD>17255</TD><TD>49</TD>
<TD>CLVS2,PEX5L,PCDH20,CLDN1,GABRB2,NPTX2,EPHA3,BMPR1B,IDO2,FST,PAPPA,AZGP1,MEIS2,PAX9,SATB2,CDKN2A,ZIC4,HS3ST3B1,EYA4,STAC,SPAG6,MTSS1,GPC5,SCGB3A2,RBM11,CRB1,GALNT13,IL7,ALX1,DCDC2,SLC6A15,CPEB2,PCDH17,LSR,ZIC1,KYNU,PLEKHM3,PLAG1,RNF128,PLCH1,PCDH11X,USP2,GRIA2,ZFHX4</TD></TR>
<TR><TD>2.930e-03</TD><TD>-5.83</TD><TD>GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>1711</TD><TD>12</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,HEY1,SATB2,PLAG1,ZIC1,FST,CDKN2A,FOXA2,ALX1,MEIS2,BMPR1B,USP2</TD></TR>
<TR><TD>2.944e-03</TD><TD>-5.83</TD><TD>HS-GAG biosynthesis</TD><TD>REACTOME pathways</TD><TD>R-HSA-2022928</TD><TD>31</TD><TD>2</TD><TD>10287</TD><TD>27</TD>
<TD>HS3ST3B1,GPC5</TD></TR>
<TR><TD>2.958e-03</TD><TD>-5.82</TD><TD>GO_PROTEOGLYCAN_BINDING</TD><TD>MSigDB lists</TD><TD>GO_PROTEOGLYCAN_BINDING</TD><TD>28</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>FST,GPC5</TD></TR>
<TR><TD>2.958e-03</TD><TD>-5.82</TD><TD>STAEGE_EWING_FAMILY_TUMOR</TD><TD>MSigDB lists</TD><TD>STAEGE_EWING_FAMILY_TUMOR</TD><TD>28</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,PCDH11X</TD></TR>
<TR><TD>3.020e-03</TD><TD>-5.80</TD><TD>GO_BEHAVIOR</TD><TD>MSigDB lists</TD><TD>GO_BEHAVIOR</TD><TD>498</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,USP2,NPTX2,MEIS2,ZIC1,PCDH17</TD></TR>
<TR><TD>3.029e-03</TD><TD>-5.80</TD><TD>GSE37605_C57BL6_VS_NOD_FOXP3_FUSION_GFP_TREG_UP</TD><TD>MSigDB lists</TD><TD>GSE37605_C57BL6_VS_NOD_FOXP3_FUSION_GFP_TREG_UP</TD><TD>100</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,CDKN2A,ZIC4</TD></TR>
<TR><TD>3.051e-03</TD><TD>-5.79</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.20.1250.50</TD><TD>1</TD><TD>1</TD><TD>8522</TD><TD>26</TD>
<TD>IL7</TD></TR>
<TR><TD>3.146e-03</TD><TD>-5.76</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>GOZGIT_ESR1_TARGETS_DN</TD><TD>676</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,KYNU,DCDC2,PLCH1,MTSS1,CPEB2,EPHA3</TD></TR>
<TR><TD>3.150e-03</TD><TD>-5.76</TD><TD>central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-atypical_teratoid-rhabdoid_tumour</TD><TD>214</TD><TD>4</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,GABRB2,PLEKHM3,PCDH17</TD></TR>
<TR><TD>3.150e-03</TD><TD>-5.76</TD><TD>atypical_teratoid-rhabdoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>atypical_teratoid-rhabdoid_tumour</TD><TD>214</TD><TD>4</TD><TD>17255</TD><TD>49</TD>
<TD>PLEKHM3,CDKN2A,GABRB2,PCDH17</TD></TR>
<TR><TD>3.171e-03</TD><TD>-5.75</TD><TD>MODULE_497</TD><TD>MSigDB lists</TD><TD>MODULE_497</TD><TD>29</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,ALX1</TD></TR>
<TR><TD>3.225e-03</TD><TD>-5.74</TD><TD>TGTTTGY_HNF3_Q6</TD><TD>MSigDB lists</TD><TD>TGTTTGY_HNF3_Q6</TD><TD>679</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH11X,ZIC4,FOXA2,RBM11,PEX5L,MEIS2,ZIC1</TD></TR>
<TR><TD>3.236e-03</TD><TD>-5.73</TD><TD>BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B</TD><TD>MSigDB lists</TD><TD>BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B</TD><TD>505</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,ENPP5,RNF128,PAPPA,EYA4,GABRB2</TD></TR>
<TR><TD>3.266e-03</TD><TD>-5.72</TD><TD>NKX3A_01</TD><TD>MSigDB lists</TD><TD>NKX3A_01</TD><TD>212</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,PAX9,ZIC4,ZIC1</TD></TR>
<TR><TD>3.266e-03</TD><TD>-5.72</TD><TD>bone-pelvis-chondrosarcoma-central</TD><TD>COSMIC cancer mutations</TD><TD>bone-pelvis-chondrosarcoma-central</TD><TD>30</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>EPHA3,CDKN2A</TD></TR>
<TR><TD>3.299e-03</TD><TD>-5.71</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>2787</TD><TD>16</TD><TD>17255</TD><TD>49</TD>
<TD>GPC5,STAC,GALNT13,ZFHX4,CRB1,PCDH11X,PLCH1,PLAG1,EPHA3,PCDH20,PEX5L,CDKN2A,PCDH17,PAX9,MEIS2,PAPPA</TD></TR>
<TR><TD>3.315e-03</TD><TD>-5.71</TD><TD>Cadherin_CS</TD><TD>interpro domains</TD><TD>IPR020894</TD><TD>109</TD><TD>3</TD><TD>18616</TD><TD>51</TD>
<TD>PCDH17,PCDH20,PCDH11X</TD></TR>
<TR><TD>3.335e-03</TD><TD>-5.70</TD><TD>proximal promoter sequence-specific DNA binding</TD><TD>molecular function</TD><TD>GO:0000987</TD><TD>555</TD><TD>6</TD><TD>17306</TD><TD>46</TD>
<TD>SATB2,PLAG1,ZFHX4,MEIS2,ZIC1,FOXA2</TD></TR>
<TR><TD>3.368e-03</TD><TD>-5.69</TD><TD>TGGAAA_NFAT_Q4_01</TD><TD>MSigDB lists</TD><TD>TGGAAA_NFAT_Q4_01</TD><TD>1740</TD><TD>12</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,PLAG1,HS3ST3B1,ZIC4,PCDH20,FST,ZIC1,RNF128,SPAG6,MTSS1,USP2,KYNU</TD></TR>
<TR><TD>3.377e-03</TD><TD>-5.69</TD><TD>FOXJ2_02</TD><TD>MSigDB lists</TD><TD>FOXJ2_02</TD><TD>214</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,ZFHX4,NPTX2,USP2</TD></TR>
<TR><TD>3.382e-03</TD><TD>-5.69</TD><TD>integral component of plasma membrane</TD><TD>cellular component</TD><TD>GO:0005887</TD><TD>1625</TD><TD>11</TD><TD>18985</TD><TD>51</TD>
<TD>PCDH11X,CLDN1,HS3ST3B1,GRIA2,PCDH17,EDA2R,BMPR1B,GABRB2,SLC6A15,EPHA3,PCDH20</TD></TR>
<TR><TD>3.391e-03</TD><TD>-5.69</TD><TD>REACTOME_HS_GAG_BIOSYNTHESIS</TD><TD>MSigDB lists</TD><TD>REACTOME_HS_GAG_BIOSYNTHESIS</TD><TD>30</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,HS3ST3B1</TD></TR>
<TR><TD>3.452e-03</TD><TD>-5.67</TD><TD>pyridine nucleotide biosynthetic process</TD><TD>biological process</TD><TD>GO:0019363</TD><TD>31</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.452e-03</TD><TD>-5.67</TD><TD>nicotinamide nucleotide biosynthetic process</TD><TD>biological process</TD><TD>GO:0019359</TD><TD>31</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.453e-03</TD><TD>-5.67</TD><TD>YATTNATC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YATTNATC_UNKNOWN</TD><TD>353</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,NPTX2,SCGB3A2,BMPR1B,SPAG6</TD></TR>
<TR><TD>3.485e-03</TD><TD>-5.66</TD><TD>GO_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS</TD><TD>1081</TD><TD>9</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,BMPR1B,ALX1,EPHA3,CDKN2A,FOXA2,FST,IL7,PLAG1</TD></TR>
<TR><TD>3.485e-03</TD><TD>-5.66</TD><TD>bone-pelvis-chondrosarcoma-peripheral</TD><TD>COSMIC cancer mutations</TD><TD>bone-pelvis-chondrosarcoma-peripheral</TD><TD>31</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,ZFHX4</TD></TR>
<TR><TD>3.532e-03</TD><TD>-5.65</TD><TD>negative regulation of cellular process</TD><TD>biological process</TD><TD>GO:0048523</TD><TD>4821</TD><TD>23</TD><TD>18054</TD><TD>51</TD>
<TD>CPEB2,HEY1,PCDH17,ALX1,EYA4,USP2,ZFHX4,FST,EPHA3,PLCH1,MEIS2,RNF128,AZGP1,CXCL14,CDKN2A,PCDH11X,SATB2,GABRB2,BMPR1B,PAX9,FOXA2,IL7,MTSS1</TD></TR>
<TR><TD>3.608e-03</TD><TD>-5.62</TD><TD>MZF1_01</TD><TD>MSigDB lists</TD><TD>MZF1_01</TD><TD>218</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,CXCL14,FOXA2,PCDH11X</TD></TR>
<TR><TD>3.618e-03</TD><TD>-5.62</TD><TD>FRIDMAN_IMMORTALIZATION_DN</TD><TD>MSigDB lists</TD><TD>FRIDMAN_IMMORTALIZATION_DN</TD><TD>31</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,CDKN2A</TD></TR>
<TR><TD>3.657e-03</TD><TD>-5.61</TD><TD>CLAUDIN1</TD><TD>prints domains</TD><TD>PR01377</TD><TD>1</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.657e-03</TD><TD>-5.61</TD><TD>TNFACTORR27</TD><TD>prints domains</TD><TD>PR01973</TD><TD>1</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>EDA2R</TD></TR>
<TR><TD>3.657e-03</TD><TD>-5.61</TD><TD>INTERLEUKIN7</TD><TD>prints domains</TD><TD>PR00435</TD><TD>1</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>IL7</TD></TR>
<TR><TD>3.668e-03</TD><TD>-5.61</TD><TD>NKX61_01</TD><TD>MSigDB lists</TD><TD>NKX61_01</TD><TD>219</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,SLC6A15,SATB2,GABRB2</TD></TR>
<TR><TD>3.672e-03</TD><TD>-5.61</TD><TD>negative regulation of macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:0010558</TD><TD>1562</TD><TD>11</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,CPEB2,HEY1,USP2,ALX1,PAX9,ZFHX4,FST,MEIS2,RNF128,CDKN2A</TD></TR>
<TR><TD>3.676e-03</TD><TD>-5.61</TD><TD>nicotinamide nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0046496</TD><TD>32</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.676e-03</TD><TD>-5.61</TD><TD>pyridine nucleotide metabolic process</TD><TD>biological process</TD><TD>GO:0019362</TD><TD>32</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.713e-03</TD><TD>-5.60</TD><TD>Homeobox_dom</TD><TD>interpro domains</TD><TD>IPR001356</TD><TD>232</TD><TD>4</TD><TD>18616</TD><TD>51</TD>
<TD>ZFHX4,ALX1,MEIS2,SATB2</TD></TR>
<TR><TD>3.728e-03</TD><TD>-5.59</TD><TD>EVI1_04</TD><TD>MSigDB lists</TD><TD>EVI1_04</TD><TD>220</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,MEIS2,ZIC4,PLAG1</TD></TR>
<TR><TD>3.728e-03</TD><TD>-5.59</TD><TD>CCTGCTG_MIR214</TD><TD>MSigDB lists</TD><TD>CCTGCTG_MIR214</TD><TD>220</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,ZIC1,PCDH17,PCDH20</TD></TR>
<TR><TD>3.742e-03</TD><TD>-5.59</TD><TD>Regulation of TP53 Degradation</TD><TD>REACTOME pathways</TD><TD>R-HSA-6804757</TD><TD>35</TD><TD>2</TD><TD>10287</TD><TD>27</TD>
<TD>USP2,CDKN2A</TD></TR>
<TR><TD>3.761e-03</TD><TD>-5.58</TD><TD>Cadherin-like_dom</TD><TD>interpro domains</TD><TD>IPR002126</TD><TD>114</TD><TD>3</TD><TD>18616</TD><TD>51</TD>
<TD>PCDH17,PCDH20,PCDH11X</TD></TR>
<TR><TD>3.763e-03</TD><TD>-5.58</TD><TD>COMP1_01</TD><TD>MSigDB lists</TD><TD>COMP1_01</TD><TD>108</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZIC1,ZIC4</TD></TR>
<TR><TD>3.771e-03</TD><TD>-5.58</TD><TD>YCATTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YCATTAA_UNKNOWN</TD><TD>521</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,SATB2,PAX9,PLAG1,NPTX2,CXCL14</TD></TR>
<TR><TD>3.799e-03</TD><TD>-5.57</TD><TD>IL7</TD><TD>smart domains</TD><TD>SM00127</TD><TD>1</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>IL7</TD></TR>
<TR><TD>3.861e-03</TD><TD>-5.56</TD><TD>GO_REGULATION_OF_STEM_CELL_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_STEM_CELL_DIFFERENTIATION</TD><TD>109</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ALX1,EPHA3,FOXA2</TD></TR>
<TR><TD>3.912e-03</TD><TD>-5.54</TD><TD>RSRFC4_01</TD><TD>MSigDB lists</TD><TD>RSRFC4_01</TD><TD>223</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH11X,STAC,FST,USP2</TD></TR>
<TR><TD>3.921e-03</TD><TD>-5.54</TD><TD>cell adhesion</TD><TD>biological process</TD><TD>GO:0007155</TD><TD>917</TD><TD>8</TD><TD>18054</TD><TD>51</TD>
<TD>AZGP1,MTSS1,CLDN1,EPHA3,PCDH20,PCDH11X,PCDH17,CRB1</TD></TR>
<TR><TD>3.933e-03</TD><TD>-5.54</TD><TD>sensory organ development</TD><TD>biological process</TD><TD>GO:0007423</TD><TD>538</TD><TD>6</TD><TD>18054</TD><TD>51</TD>
<TD>GABRB2,CRB1,ZIC1,MEIS2,BMPR1B,CXCL14</TD></TR>
<TR><TD>3.949e-03</TD><TD>-5.53</TD><TD>Cadherin-like_sf</TD><TD>interpro domains</TD><TD>IPR015919</TD><TD>116</TD><TD>3</TD><TD>18616</TD><TD>51</TD>
<TD>PCDH20,PCDH17,PCDH11X</TD></TR>
<TR><TD>3.956e-03</TD><TD>-5.53</TD><TD>Regulation of TP53 Expression and Degradation</TD><TD>REACTOME pathways</TD><TD>R-HSA-6806003</TD><TD>36</TD><TD>2</TD><TD>10287</TD><TD>27</TD>
<TD>USP2,CDKN2A</TD></TR>
<TR><TD>3.964e-03</TD><TD>-5.53</TD><TD>Cadherin</TD><TD>pfam domains</TD><TD>PF00028</TD><TD>113</TD><TD>3</TD><TD>17385</TD><TD>49</TD>
<TD>PCDH20,PCDH11X,PCDH17</TD></TR>
<TR><TD>4.071e-03</TD><TD>-5.50</TD><TD>receptor complex</TD><TD>cellular component</TD><TD>GO:0043235</TD><TD>395</TD><TD>5</TD><TD>18985</TD><TD>51</TD>
<TD>GRIA2,GABRB2,BMPR1B,EPHA3,PEX5L</TD></TR>
<TR><TD>4.105e-03</TD><TD>-5.50</TD><TD>biological adhesion</TD><TD>biological process</TD><TD>GO:0022610</TD><TD>924</TD><TD>8</TD><TD>18054</TD><TD>51</TD>
<TD>PCDH17,CRB1,CLDN1,PCDH20,EPHA3,AZGP1,MTSS1,PCDH11X</TD></TR>
<TR><TD>4.167e-03</TD><TD>-5.48</TD><TD>FOXO1_01</TD><TD>MSigDB lists</TD><TD>FOXO1_01</TD><TD>227</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>CRB1,PLAG1,PAPPA,FST</TD></TR>
<TR><TD>4.217e-03</TD><TD>-5.47</TD><TD>ODONNELL_TFRC_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ODONNELL_TFRC_TARGETS_UP</TD><TD>370</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,IL7,PCDH11X,CLDN1,GALNT13</TD></TR>
<TR><TD>4.298e-03</TD><TD>-5.45</TD><TD>NFAT_Q6</TD><TD>MSigDB lists</TD><TD>NFAT_Q6</TD><TD>229</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,ZIC1,RNF128,ZIC4</TD></TR>
<TR><TD>4.298e-03</TD><TD>-5.45</TD><TD>PLASARI_TGFB1_TARGETS_10HR_DN</TD><TD>MSigDB lists</TD><TD>PLASARI_TGFB1_TARGETS_10HR_DN</TD><TD>229</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,MEIS2,EYA4,ZFHX4</TD></TR>
<TR><TD>4.298e-03</TD><TD>-5.45</TD><TD>E47_02</TD><TD>MSigDB lists</TD><TD>E47_02</TD><TD>229</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>LSR,NPTX2,MEIS2,PCDH17</TD></TR>
<TR><TD>4.341e-03</TD><TD>-5.44</TD><TD>CERVERA_SDHB_TARGETS_1_DN</TD><TD>MSigDB lists</TD><TD>CERVERA_SDHB_TARGETS_1_DN</TD><TD>34</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,NPTX2</TD></TR>
<TR><TD>4.359e-03</TD><TD>-5.44</TD><TD>TEAD2 (TEA domain transcription factor 2)</TD><TD>protein interactions</TD><TD>8463</TD><TD>115</TD><TD>3</TD><TD>17456</TD><TD>50</TD>
<TD>SATB2,CDKN2A,ZFHX4</TD></TR>
<TR><TD>4.365e-03</TD><TD>-5.43</TD><TD>HNF1_01</TD><TD>MSigDB lists</TD><TD>HNF1_01</TD><TD>230</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,EPHA3,ZFHX4,SATB2</TD></TR>
<TR><TD>4.365e-03</TD><TD>-5.43</TD><TD>GATA1_04</TD><TD>MSigDB lists</TD><TD>GATA1_04</TD><TD>230</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,PAPPA,ZIC1,EYA4</TD></TR>
<TR><TD>4.383e-03</TD><TD>-5.43</TD><TD>GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>718</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,MEIS2,FST,HEY1,ALX1,SATB2,FOXA2</TD></TR>
<TR><TD>4.386e-03</TD><TD>-5.43</TD><TD>pyridine-containing compound biosynthetic process</TD><TD>biological process</TD><TD>GO:0072525</TD><TD>35</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>4.486e-03</TD><TD>-5.41</TD><TD>AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_UP</TD><TD>MSigDB lists</TD><TD>AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_UP</TD><TD>115</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,CLDN1,FST</TD></TR>
<TR><TD>4.513e-03</TD><TD>-5.40</TD><TD>AAGCACA_MIR218</TD><TD>MSigDB lists</TD><TD>AAGCACA_MIR218</TD><TD>376</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PEX5L,GRIA2,SATB2,GALNT13,HS3ST3B1</TD></TR>
<TR><TD>4.570e-03</TD><TD>-5.39</TD><TD>HMGIY_Q6</TD><TD>MSigDB lists</TD><TD>HMGIY_Q6</TD><TD>233</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,PEX5L,ZIC1,ZIC4</TD></TR>
<TR><TD>4.570e-03</TD><TD>-5.39</TD><TD>S8_01</TD><TD>MSigDB lists</TD><TD>S8_01</TD><TD>233</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZFHX4,SLC6A15,CXCL14,FST</TD></TR>
<TR><TD>4.574e-03</TD><TD>-5.39</TD><TD>TLE1 (TLE family member 1, transcriptional corepressor)</TD><TD>protein interactions</TD><TD>7088</TD><TD>117</TD><TD>3</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2,PAX9,HEY1</TD></TR>
<TR><TD>4.635e-03</TD><TD>-5.37</TD><TD>negative regulation of extrinsic apoptotic signaling pathway in absence of ligand</TD><TD>biological process</TD><TD>GO:2001240</TD><TD>36</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>EYA4,IL7</TD></TR>
<TR><TD>4.635e-03</TD><TD>-5.37</TD><TD>negative regulation of signal transduction in absence of ligand</TD><TD>biological process</TD><TD>GO:1901099</TD><TD>36</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IL7,EYA4</TD></TR>
<TR><TD>4.708e-03</TD><TD>-5.36</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP</TD><TD>MSigDB lists</TD><TD>IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP</TD><TD>117</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,SATB2,MTSS1</TD></TR>
<TR><TD>4.781e-03</TD><TD>-5.34</TD><TD>HSIAO_LIVER_SPECIFIC_GENES</TD><TD>MSigDB lists</TD><TD>HSIAO_LIVER_SPECIFIC_GENES</TD><TD>236</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>LSR,KYNU,FST,AZGP1</TD></TR>
<TR><TD>4.797e-03</TD><TD>-5.34</TD><TD>GO_DOUBLE_STRANDED_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_DOUBLE_STRANDED_DNA_BINDING</TD><TD>730</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,PLAG1,PAX9,ALX1,HEY1,MEIS2,ZIC1</TD></TR>
<TR><TD>4.853e-03</TD><TD>-5.33</TD><TD>PBX1_01</TD><TD>MSigDB lists</TD><TD>PBX1_01</TD><TD>237</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,PAPPA,ZIC1,ZIC4</TD></TR>
<TR><TD>4.872e-03</TD><TD>-5.32</TD><TD>negative regulation of cellular biosynthetic process</TD><TD>biological process</TD><TD>GO:0031327</TD><TD>1621</TD><TD>11</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,USP2,HEY1,SATB2,CPEB2,CDKN2A,FST,MEIS2,RNF128,ZFHX4,PAX9</TD></TR>
<TR><TD>4.892e-03</TD><TD>-5.32</TD><TD>tight junction assembly</TD><TD>biological process</TD><TD>GO:0120192</TD><TD>37</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1,LSR</TD></TR>
<TR><TD>4.903e-03</TD><TD>-5.32</TD><TD>behavior</TD><TD>biological process</TD><TD>GO:0007610</TD><TD>563</TD><TD>6</TD><TD>18054</TD><TD>51</TD>
<TD>NPTX2,USP2,ZIC1,FOXA2,PCDH17,MEIS2</TD></TR>
<TR><TD>4.905e-03</TD><TD>-5.32</TD><TD>lung-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-adenocarcinoma</TD><TD>15483</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>DCDC2,SLC6A15,ALX1,IL7,ZIC1,LSR,PCDH17,CPEB2,CXCL14,KYNU,EDA2R,PLEKHM3,ZFHX4,HEY1,RNF128,PLCH1,PLAG1,USP2,GRIA2,PCDH11X,NPTX2,GABRB2,FOXA2,IDO2,BMPR1B,EPHA3,CLVS2,PCDH20,PEX5L,CLDN1,ZIC4,EYA4,HS3ST3B1,CDKN2A,MEIS2,AZGP1,ENPP5,PAPPA,FST,SATB2,PAX9,SCGB3A2,GPC5,MTSS1,SPAG6,STAC,CRB1,GALNT13,RBM11</TD></TR>
<TR><TD>4.926e-03</TD><TD>-5.31</TD><TD>HLF_01</TD><TD>MSigDB lists</TD><TD>HLF_01</TD><TD>238</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,USP2,FOXA2,PLAG1</TD></TR>
<TR><TD>4.926e-03</TD><TD>-5.31</TD><TD>FOXO4_02</TD><TD>MSigDB lists</TD><TD>FOXO4_02</TD><TD>238</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,SATB2,PAPPA,MEIS2</TD></TR>
<TR><TD>4.935e-03</TD><TD>-5.31</TD><TD>EVI1_02</TD><TD>MSigDB lists</TD><TD>EVI1_02</TD><TD>119</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,KYNU,PLAG1</TD></TR>
<TR><TD>4.935e-03</TD><TD>-5.31</TD><TD>NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON</TD><TD>MSigDB lists</TD><TD>NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON</TD><TD>119</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZFHX4,HEY1,IL7</TD></TR>
<TR><TD>4.943e-03</TD><TD>-5.31</TD><TD>mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>mantle_cell_lymphoma</TD><TD>2900</TD><TD>16</TD><TD>17255</TD><TD>49</TD>
<TD>GPC5,STAC,ZFHX4,CRB1,GALNT13,PLCH1,PLAG1,PCDH11X,EPHA3,PCDH20,PEX5L,CDKN2A,MEIS2,PAPPA,PCDH17,PAX9</TD></TR>
<TR><TD>5.023e-03</TD><TD>-5.29</TD><TD>EPHA3 (EPH receptor A3)</TD><TD>protein interactions</TD><TD>2042</TD><TD>37</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3,CDKN2A</TD></TR>
<TR><TD>5.034e-03</TD><TD>-5.29</TD><TD>cell development</TD><TD>biological process</TD><TD>GO:0048468</TD><TD>1628</TD><TD>11</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,GABRB2,CRB1,SATB2,DCDC2,NPTX2,EPHA3,CLDN1,LSR,BMPR1B,SPAG6</TD></TR>
<TR><TD>5.073e-03</TD><TD>-5.28</TD><TD>TEF_Q6</TD><TD>MSigDB lists</TD><TD>TEF_Q6</TD><TD>240</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,CRB1,PCDH11X,NPTX2</TD></TR>
<TR><TD>5.125e-03</TD><TD>-5.27</TD><TD>CTCTATG_MIR368</TD><TD>MSigDB lists</TD><TD>CTCTATG_MIR368</TD><TD>37</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,SATB2</TD></TR>
<TR><TD>5.223e-03</TD><TD>-5.25</TD><TD>STAT6_02</TD><TD>MSigDB lists</TD><TD>STAT6_02</TD><TD>242</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,PAX9,USP2,MEIS2</TD></TR>
<TR><TD>5.226e-03</TD><TD>-5.25</TD><TD>stomach-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-adenocarcinoma</TD><TD>15503</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>KYNU,EDA2R,PLEKHM3,RNF128,PLCH1,PLAG1,USP2,GRIA2,PCDH11X,ZFHX4,HEY1,ALX1,IL7,DCDC2,SLC6A15,PCDH17,CXCL14,CPEB2,LSR,ZIC1,MTSS1,SPAG6,STAC,SCGB3A2,GPC5,RBM11,CRB1,GALNT13,CLVS2,PEX5L,PCDH20,CLDN1,NPTX2,FOXA2,GABRB2,EPHA3,BMPR1B,IDO2,MEIS2,AZGP1,PAPPA,FST,ENPP5,SATB2,PAX9,CDKN2A,HS3ST3B1,ZIC4,EYA4</TD></TR>
<TR><TD>5.292e-03</TD><TD>-5.24</TD><TD>TMEM231 (transmembrane protein 231)</TD><TD>protein interactions</TD><TD>79583</TD><TD>38</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3,LSR</TD></TR>
<TR><TD>5.299e-03</TD><TD>-5.24</TD><TD>GR_Q6</TD><TD>MSigDB lists</TD><TD>GR_Q6</TD><TD>243</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,CXCL14,MEIS2,PLAG1</TD></TR>
<TR><TD>5.299e-03</TD><TD>-5.24</TD><TD>NKX25_02</TD><TD>MSigDB lists</TD><TD>NKX25_02</TD><TD>243</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,CXCL14,SLC6A15,PLAG1</TD></TR>
<TR><TD>5.309e-03</TD><TD>-5.24</TD><TD>proline:sodium symporter activity</TD><TD>molecular function</TD><TD>GO:0005298</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>5.309e-03</TD><TD>-5.24</TD><TD>[heparan sulfate]-glucosamine 3-sulfotransferase 3 activity</TD><TD>molecular function</TD><TD>GO:0033872</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>HS3ST3B1</TD></TR>
<TR><TD>5.309e-03</TD><TD>-5.24</TD><TD>interleukin-7 receptor binding</TD><TD>molecular function</TD><TD>GO:0005139</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>IL7</TD></TR>
<TR><TD>5.309e-03</TD><TD>-5.24</TD><TD>peroxisome matrix targeting signal-1 binding</TD><TD>molecular function</TD><TD>GO:0005052</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>PEX5L</TD></TR>
<TR><TD>5.309e-03</TD><TD>-5.24</TD><TD>indoleamine 2,3-dioxygenase activity</TD><TD>molecular function</TD><TD>GO:0033754</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>IDO2</TD></TR>
<TR><TD>5.309e-03</TD><TD>-5.24</TD><TD>activin receptor antagonist activity</TD><TD>molecular function</TD><TD>GO:0038102</TD><TD>2</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>5.316e-03</TD><TD>-5.24</TD><TD>TAATTA_CHX10_01</TD><TD>MSigDB lists</TD><TD>TAATTA_CHX10_01</TD><TD>744</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>FST,ZIC1,STAC,BMPR1B,ZIC4,MTSS1,ZFHX4</TD></TR>
<TR><TD>5.376e-03</TD><TD>-5.23</TD><TD>AATGTGA_MIR23A_MIR23B</TD><TD>MSigDB lists</TD><TD>AATGTGA_MIR23A_MIR23B</TD><TD>392</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,MEIS2,SATB2,CPEB2,MTSS1</TD></TR>
<TR><TD>5.376e-03</TD><TD>-5.23</TD><TD>TCF1P_Q6</TD><TD>MSigDB lists</TD><TD>TCF1P_Q6</TD><TD>244</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,MEIS2,FOXA2,MTSS1</TD></TR>
<TR><TD>5.376e-03</TD><TD>-5.23</TD><TD>YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN</TD><TD>MSigDB lists</TD><TD>YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN</TD><TD>244</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,PAX9,ZIC1,PAPPA</TD></TR>
<TR><TD>5.423e-03</TD><TD>-5.22</TD><TD>tight junction organization</TD><TD>biological process</TD><TD>GO:0120193</TD><TD>39</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>5.423e-03</TD><TD>-5.22</TD><TD>aromatic amino acid family metabolic process</TD><TD>biological process</TD><TD>GO:0009072</TD><TD>39</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>5.425e-03</TD><TD>-5.22</TD><TD>Nicotine addiction</TD><TD>KEGG pathways</TD><TD>hsa05033</TD><TD>40</TD><TD>2</TD><TD>7161</TD><TD>20</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>5.425e-03</TD><TD>-5.22</TD><TD>Nicotine addiction</TD><TD>KEGG pathways</TD><TD>ko05033</TD><TD>40</TD><TD>2</TD><TD>7161</TD><TD>20</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>5.425e-03</TD><TD>-5.22</TD><TD>Tryptophan metabolism</TD><TD>KEGG pathways</TD><TD>ko00380</TD><TD>40</TD><TD>2</TD><TD>7161</TD><TD>20</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>5.425e-03</TD><TD>-5.22</TD><TD>Tryptophan metabolism</TD><TD>KEGG pathways</TD><TD>hsa00380</TD><TD>40</TD><TD>2</TD><TD>7161</TD><TD>20</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>5.443e-03</TD><TD>-5.21</TD><TD>negative regulation of biosynthetic process</TD><TD>biological process</TD><TD>GO:0009890</TD><TD>1645</TD><TD>11</TD><TD>18054</TD><TD>51</TD>
<TD>PAX9,FST,MEIS2,RNF128,ZFHX4,CDKN2A,HEY1,SATB2,CPEB2,USP2,ALX1</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>Forkhead_box_C</TD><TD>interpro domains</TD><TD>IPR018533</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>SATB_CUTL_sf</TD><TD>interpro domains</TD><TD>IPR038216</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>TMEM255</TD><TD>interpro domains</TD><TD>IPR028014</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>TMEM255A</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>PTS1R_family</TD><TD>interpro domains</TD><TD>IPR024111</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PEX5L</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>Indolamine_dOase</TD><TD>interpro domains</TD><TD>IPR000898</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>IDO2</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>Secretoglobin_3A</TD><TD>interpro domains</TD><TD>IPR040301</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>SATB_ULD_sf</TD><TD>interpro domains</TD><TD>IPR038224</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>CUTL</TD><TD>interpro domains</TD><TD>IPR032355</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>IL-7/IL-9_CS</TD><TD>interpro domains</TD><TD>IPR018049</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>IL7</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>Peptidase_M43</TD><TD>interpro domains</TD><TD>IPR008754</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PAPPA</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>SATB1/SATB2</TD><TD>interpro domains</TD><TD>IPR039673</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>MTSS1/MTSS2</TD><TD>interpro domains</TD><TD>IPR030127</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>MTSS1</TD></TR>
<TR><TD>5.472e-03</TD><TD>-5.21</TD><TD>ULD</TD><TD>interpro domains</TD><TD>IPR032392</TD><TD>2</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.484e-03</TD><TD>-5.21</TD><TD>bone-humerus-chondrosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-chondrosarcoma</TD><TD>126</TD><TD>3</TD><TD>17255</TD><TD>49</TD>
<TD>ZFHX4,CDKN2A,EYA4</TD></TR>
<TR><TD>5.533e-03</TD><TD>-5.20</TD><TD>OSF2_Q6</TD><TD>MSigDB lists</TD><TD>OSF2_Q6</TD><TD>246</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,HEY1,FST,ZIC1</TD></TR>
<TR><TD>5.612e-03</TD><TD>-5.18</TD><TD>GO_ENDOCYTIC_VESICLE</TD><TD>MSigDB lists</TD><TD>GO_ENDOCYTIC_VESICLE</TD><TD>247</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>SCGB3A2,GRIA2,MTSS1,CLVS2</TD></TR>
<TR><TD>5.623e-03</TD><TD>-5.18</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm</TD><TD>252</TD><TD>4</TD><TD>17255</TD><TD>49</TD>
<TD>CRB1,ZFHX4,GPC5,GALNT13</TD></TR>
<TR><TD>5.623e-03</TD><TD>-5.18</TD><TD>mast_cell_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>mast_cell_neoplasm</TD><TD>252</TD><TD>4</TD><TD>17255</TD><TD>49</TD>
<TD>ZFHX4,CRB1,GALNT13,GPC5</TD></TR>
<TR><TD>5.629e-03</TD><TD>-5.18</TD><TD>CUTL</TD><TD>pfam domains</TD><TD>PF16557</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.629e-03</TD><TD>-5.18</TD><TD>HNF_C</TD><TD>pfam domains</TD><TD>PF09354</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>FOXA2</TD></TR>
<TR><TD>5.629e-03</TD><TD>-5.18</TD><TD>ULD</TD><TD>pfam domains</TD><TD>PF16534</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>SATB2</TD></TR>
<TR><TD>5.629e-03</TD><TD>-5.18</TD><TD>IDO</TD><TD>pfam domains</TD><TD>PF01231</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>IDO2</TD></TR>
<TR><TD>5.629e-03</TD><TD>-5.18</TD><TD>Peptidase_M43</TD><TD>pfam domains</TD><TD>PF05572</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>PAPPA</TD></TR>
<TR><TD>5.629e-03</TD><TD>-5.18</TD><TD>FAM70</TD><TD>pfam domains</TD><TD>PF14967</TD><TD>2</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>TMEM255A</TD></TR>
<TR><TD>5.642e-03</TD><TD>-5.18</TD><TD>negative regulation of cytoplasmic translational elongation</TD><TD>biological process</TD><TD>GO:1900248</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>5.642e-03</TD><TD>-5.18</TD><TD>umbilical cord morphogenesis</TD><TD>biological process</TD><TD>GO:0036304</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>5.642e-03</TD><TD>-5.18</TD><TD>umbilical cord development</TD><TD>biological process</TD><TD>GO:0061027</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>5.642e-03</TD><TD>-5.18</TD><TD>tryptophan catabolic process to acetyl-CoA</TD><TD>biological process</TD><TD>GO:0019442</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>5.642e-03</TD><TD>-5.18</TD><TD>fasciculation of motor neuron axon</TD><TD>biological process</TD><TD>GO:0097156</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>EPHA3</TD></TR>
<TR><TD>5.642e-03</TD><TD>-5.18</TD><TD>nephron tubule epithelial cell differentiation</TD><TD>biological process</TD><TD>GO:0072160</TD><TD>2</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>MTSS1</TD></TR>
<TR><TD>5.682e-03</TD><TD>-5.17</TD><TD>KEGG_TRYPTOPHAN_METABOLISM</TD><TD>MSigDB lists</TD><TD>KEGG_TRYPTOPHAN_METABOLISM</TD><TD>39</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>5.682e-03</TD><TD>-5.17</TD><TD>MUELLER_METHYLATED_IN_GLIOBLASTOMA</TD><TD>MSigDB lists</TD><TD>MUELLER_METHYLATED_IN_GLIOBLASTOMA</TD><TD>39</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>LSR,NPTX2</TD></TR>
<TR><TD>5.698e-03</TD><TD>-5.17</TD><TD>pyridine-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0072524</TD><TD>40</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Mknk2 (MAP kinase-interacting serine/threonine kinase 2)</TD><TD>protein interactions</TD><TD>17347</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Grip1 (glutamate receptor interacting protein 1)</TD><TD>protein interactions</TD><TD>84016</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GRIA2</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Klhl1 (kelch-like 1)</TD><TD>protein interactions</TD><TD>93688</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform)</TD><TD>protein interactions</TD><TD>19057</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Fbxo34 (F-box protein 34)</TD><TD>protein interactions</TD><TD>78938</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Bcr (breakpoint cluster region)</TD><TD>protein interactions</TD><TD>110279</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Fkbp1b (FK506 binding protein 1b)</TD><TD>protein interactions</TD><TD>14226</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Atg16l1 (autophagy related 16-like 1 (S. cerevisiae))</TD><TD>protein interactions</TD><TD>77040</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Irf7 (interferon regulatory factor 7)</TD><TD>protein interactions</TD><TD>54123</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Bmpr2 (bone morphogenetic protein receptor, type II (serine/threonine kinase))</TD><TD>protein interactions</TD><TD>12168</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Usp2 (ubiquitin specific peptidase 2)</TD><TD>protein interactions</TD><TD>53376</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>MGC34796 (sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase) pseudogene)</TD><TD>protein interactions</TD><TD>414927</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Fkbp1a (FK506 binding protein 1a)</TD><TD>protein interactions</TD><TD>14225</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.721e-03</TD><TD>-5.16</TD><TD>Sh3kbp1 (SH3-domain kinase binding protein 1)</TD><TD>protein interactions</TD><TD>58194</TD><TD>2</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>5.752e-03</TD><TD>-5.16</TD><TD>lower_back</TD><TD>COSMIC cancer mutations</TD><TD>lower_back</TD><TD>40</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>5.772e-03</TD><TD>-5.15</TD><TD>POU3F2_02</TD><TD>MSigDB lists</TD><TD>POU3F2_02</TD><TD>249</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,ZIC4,SLC6A15,NPTX2</TD></TR>
<TR><TD>5.788e-03</TD><TD>-5.15</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>RIGGI_EWING_SARCOMA_PROGENITOR_UP</TD><TD>399</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>NPTX2,PCDH17,CLDN1,EPHA3,GRIA2</TD></TR>
<TR><TD>5.864e-03</TD><TD>-5.14</TD><TD>Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-6788656</TD><TD>44</TD><TD>2</TD><TD>10287</TD><TD>27</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>5.904e-03</TD><TD>-5.13</TD><TD>positive regulation of transcription by RNA polymerase II</TD><TD>biological process</TD><TD>GO:0045944</TD><TD>1199</TD><TD>9</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,PLAG1,HEY1,ALX1,MEIS2,PAX9,BMPR1B,FOXA2,ZIC1</TD></TR>
<TR><TD>5.936e-03</TD><TD>-5.13</TD><TD>negative regulation of transcription, DNA-templated</TD><TD>biological process</TD><TD>GO:0045892</TD><TD>1200</TD><TD>9</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A,PAX9,ZFHX4,FST,MEIS2,USP2,ALX1,SATB2,HEY1</TD></TR>
<TR><TD>5.936e-03</TD><TD>-5.13</TD><TD>NFAT_Q4_01</TD><TD>MSigDB lists</TD><TD>NFAT_Q4_01</TD><TD>251</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,PCDH17,RNF128,ZIC4</TD></TR>
<TR><TD>5.939e-03</TD><TD>-5.13</TD><TD>Cytokine-cytokine receptor interaction</TD><TD>KEGG pathways</TD><TD>hsa04060</TD><TD>270</TD><TD>4</TD><TD>7161</TD><TD>20</TD>
<TD>IL7,BMPR1B,EDA2R,CXCL14</TD></TR>
<TR><TD>5.939e-03</TD><TD>-5.13</TD><TD>Cytokine-cytokine receptor interaction</TD><TD>KEGG pathways</TD><TD>ko04060</TD><TD>270</TD><TD>4</TD><TD>7161</TD><TD>20</TD>
<TD>EDA2R,IL7,BMPR1B,CXCL14</TD></TR>
<TR><TD>5.940e-03</TD><TD>-5.13</TD><TD>CADHERIN_1</TD><TD>prosite domains</TD><TD>PS00232</TD><TD>109</TD><TD>3</TD><TD>12079</TD><TD>41</TD>
<TD>PCDH17,PCDH11X,PCDH20</TD></TR>
<TR><TD>6.015e-03</TD><TD>-5.11</TD><TD>neuron differentiation</TD><TD>biological process</TD><TD>GO:0030182</TD><TD>985</TD><TD>8</TD><TD>18054</TD><TD>51</TD>
<TD>NPTX2,DCDC2,FOXA2,BMPR1B,EPHA3,CRB1,GABRB2,SATB2</TD></TR>
<TR><TD>6.093e-03</TD><TD>-5.10</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.10.20.710</TD><TD>2</TD><TD>1</TD><TD>8522</TD><TD>26</TD>
<TD>SATB2</TD></TR>
<TR><TD>6.093e-03</TD><TD>-5.10</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.10.260.70</TD><TD>2</TD><TD>1</TD><TD>8522</TD><TD>26</TD>
<TD>SATB2</TD></TR>
<TR><TD>6.264e-03</TD><TD>-5.07</TD><TD>PID_BMP_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_BMP_PATHWAY</TD><TD>41</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,FST</TD></TR>
<TR><TD>6.273e-03</TD><TD>-5.07</TD><TD>ATTCTTT_MIR186</TD><TD>MSigDB lists</TD><TD>ATTCTTT_MIR186</TD><TD>255</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2,CLDN1,ZFHX4,PAPPA</TD></TR>
<TR><TD>6.273e-03</TD><TD>-5.07</TD><TD>KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION</TD><TD>MSigDB lists</TD><TD>KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION</TD><TD>255</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,CXCL14,BMPR1B,EDA2R</TD></TR>
<TR><TD>6.359e-03</TD><TD>-5.06</TD><TD>IK1_01</TD><TD>MSigDB lists</TD><TD>IK1_01</TD><TD>256</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,ZIC4,PCDH17,CXCL14</TD></TR>
<TR><TD>6.436e-03</TD><TD>-5.05</TD><TD>TGACAGNY_MEIS1_01</TD><TD>MSigDB lists</TD><TD>TGACAGNY_MEIS1_01</TD><TD>771</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,EYA4,MEIS2,PCDH17,ZFHX4,EPHA3,MTSS1</TD></TR>
<TR><TD>6.524e-03</TD><TD>-5.03</TD><TD>GO_REGULATION_OF_CELL_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_CELL_DIFFERENTIATION</TD><TD>1414</TD><TD>10</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,FOXA2,EPHA3,ALX1,CXCL14,MEIS2,BMPR1B,PLAG1,HEY1,IL7</TD></TR>
<TR><TD>6.546e-03</TD><TD>-5.03</TD><TD>GO_PATTERN_SPECIFICATION_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_PATTERN_SPECIFICATION_PROCESS</TD><TD>411</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,ALX1,FOXA2,BMPR1B,ZIC1</TD></TR>
<TR><TD>6.578e-03</TD><TD>-5.02</TD><TD>GO_ADULT_BEHAVIOR</TD><TD>MSigDB lists</TD><TD>GO_ADULT_BEHAVIOR</TD><TD>132</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,PCDH17,ZIC1</TD></TR>
<TR><TD>6.604e-03</TD><TD>-5.02</TD><TD>HOMEOBOX_2</TD><TD>prosite domains</TD><TD>PS50071</TD><TD>222</TD><TD>4</TD><TD>12079</TD><TD>41</TD>
<TD>SATB2,MEIS2,ZFHX4,ALX1</TD></TR>
<TR><TD>6.712e-03</TD><TD>-5.00</TD><TD>MORF_MDM2</TD><TD>MSigDB lists</TD><TD>MORF_MDM2</TD><TD>260</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,STAC,IL7,GABRB2</TD></TR>
<TR><TD>6.725e-03</TD><TD>-5.00</TD><TD>CADHERIN_2</TD><TD>prosite domains</TD><TD>PS50268</TD><TD>114</TD><TD>3</TD><TD>12079</TD><TD>41</TD>
<TD>PCDH17,PCDH20,PCDH11X</TD></TR>
<TR><TD>6.777e-03</TD><TD>-4.99</TD><TD>GO_BIOLOGICAL_ADHESION</TD><TD>MSigDB lists</TD><TD>GO_BIOLOGICAL_ADHESION</TD><TD>982</TD><TD>8</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,PCDH11X,CLDN1,EPHA3,MTSS1,AZGP1,IL7,PCDH20</TD></TR>
<TR><TD>6.777e-03</TD><TD>-4.99</TD><TD>INTERLEUKIN_7_9</TD><TD>prosite domains</TD><TD>PS00255</TD><TD>2</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>IL7</TD></TR>
<TR><TD>6.893e-03</TD><TD>-4.98</TD><TD>STK33_UP</TD><TD>MSigDB lists</TD><TD>STK33_UP</TD><TD>262</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,MTSS1,CPEB2,KYNU</TD></TR>
<TR><TD>6.998e-03</TD><TD>-4.96</TD><TD>KRAS.KIDNEY_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.KIDNEY_UP.V1_UP</TD><TD>135</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,GRIA2,HEY1</TD></TR>
<TR><TD>6.998e-03</TD><TD>-4.96</TD><TD>RORA2_01</TD><TD>MSigDB lists</TD><TD>RORA2_01</TD><TD>135</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,GABRB2,EPHA3</TD></TR>
<TR><TD>7.045e-03</TD><TD>-4.96</TD><TD>ion binding</TD><TD>molecular function</TD><TD>GO:0043167</TD><TD>6160</TD><TD>25</TD><TD>17306</TD><TD>46</TD>
<TD>PCDH11X,NPTX2,GALNT13,PCDH17,EYA4,FST,PLEKHM3,ENPP5,PAPPA,BMPR1B,ZIC4,STAC,ZIC1,IDO2,PCDH20,EPHA3,CRB1,PLAG1,CLVS2,KYNU,PLCH1,RNF128,USP2,ARHGAP45,ZFHX4</TD></TR>
<TR><TD>7.077e-03</TD><TD>-4.95</TD><TD>GATA1_05</TD><TD>MSigDB lists</TD><TD>GATA1_05</TD><TD>264</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,ZIC1,IL7,HEY1</TD></TR>
<TR><TD>7.112e-03</TD><TD>-4.95</TD><TD>endometrium-carcinoma-serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-serous_carcinoma</TD><TD>1461</TD><TD>10</TD><TD>17255</TD><TD>49</TD>
<TD>EPHA3,GPC5,ZIC1,ZFHX4,CDKN2A,CRB1,PCDH17,PLCH1,PLAG1,PAPPA</TD></TR>
<TR><TD>7.163e-03</TD><TD>-4.94</TD><TD>GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION</TD><TD>1668</TD><TD>11</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,EDA2R,PLAG1,PAX9,HEY1,SATB2,MEIS2,BMPR1B,FOXA2,CDKN2A,ALX1</TD></TR>
<TR><TD>7.187e-03</TD><TD>-4.94</TD><TD>ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>MSigDB lists</TD><TD>ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF</TD><TD>44</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,PAX9</TD></TR>
<TR><TD>7.206e-03</TD><TD>-4.93</TD><TD>skin-neck-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-malignant_melanoma</TD><TD>1233</TD><TD>9</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,CRB1,PAPPA,PLCH1,DCDC2,KYNU,GPC5,SLC6A15,EPHA3</TD></TR>
<TR><TD>7.287e-03</TD><TD>-4.92</TD><TD>MEL18_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>MEL18_DN.V1_DN</TD><TD>137</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,EYA4,CXCL14</TD></TR>
<TR><TD>7.407e-03</TD><TD>-4.91</TD><TD>negative regulation of cellular macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:2000113</TD><TD>1474</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>PAX9,ZFHX4,FST,MEIS2,CDKN2A,CPEB2,SATB2,HEY1,USP2,ALX1</TD></TR>
<TR><TD>7.420e-03</TD><TD>-4.90</TD><TD>CADHERIN</TD><TD>prints domains</TD><TD>PR00205</TD><TD>113</TD><TD>3</TD><TD>4648</TD><TD>17</TD>
<TD>PCDH17,PCDH11X,PCDH20</TD></TR>
<TR><TD>7.455e-03</TD><TD>-4.90</TD><TD>MORF_CAMK4</TD><TD>MSigDB lists</TD><TD>MORF_CAMK4</TD><TD>268</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,IL7,GABRB2,PAX9</TD></TR>
<TR><TD>7.461e-03</TD><TD>-4.90</TD><TD>pharynx</TD><TD>COSMIC cancer mutations</TD><TD>pharynx</TD><TD>2748</TD><TD>15</TD><TD>17255</TD><TD>49</TD>
<TD>ALX1,PCDH20,PEX5L,MTSS1,EPHA3,GPC5,PLEKHM3,PLCH1,PCDH17,PAX9,ZFHX4,EYA4,CRB1,CDKN2A,ZIC1</TD></TR>
<TR><TD>7.508e-03</TD><TD>-4.89</TD><TD>TCTAGAG_MIR517</TD><TD>MSigDB lists</TD><TD>TCTAGAG_MIR517</TD><TD>45</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,FST</TD></TR>
<TR><TD>7.508e-03</TD><TD>-4.89</TD><TD>SILIGAN_BOUND_BY_EWS_FLT1_FUSION</TD><TD>MSigDB lists</TD><TD>SILIGAN_BOUND_BY_EWS_FLT1_FUSION</TD><TD>45</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,HEY1</TD></TR>
<TR><TD>7.508e-03</TD><TD>-4.89</TD><TD>OSADA_ASCL1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>OSADA_ASCL1_TARGETS_UP</TD><TD>45</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,RNF128</TD></TR>
<TR><TD>7.509e-03</TD><TD>-4.89</TD><TD>neck</TD><TD>COSMIC cancer mutations</TD><TD>neck</TD><TD>1241</TD><TD>9</TD><TD>17255</TD><TD>49</TD>
<TD>KYNU,DCDC2,EPHA3,SLC6A15,GPC5,PLCH1,PAPPA,CDKN2A,CRB1</TD></TR>
<TR><TD>7.551e-03</TD><TD>-4.89</TD><TD>vulva</TD><TD>COSMIC cancer mutations</TD><TD>vulva</TD><TD>46</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>7.552e-03</TD><TD>-4.89</TD><TD>MORF_NOS2A</TD><TD>MSigDB lists</TD><TD>MORF_NOS2A</TD><TD>269</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,STAC,IL7,PAX9</TD></TR>
<TR><TD>7.647e-03</TD><TD>-4.87</TD><TD>GO_NEGATIVE_REGULATION_OF_NITROGEN_COMPOUND_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_NITROGEN_COMPOUND_METABOLIC_PROCESS</TD><TD>1447</TD><TD>10</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,USP2,CDKN2A,FOXA2,ALX1,FST,CPEB2,PAX9,SATB2,HEY1</TD></TR>
<TR><TD>7.649e-03</TD><TD>-4.87</TD><TD>ACTTTAT_MIR1425P</TD><TD>MSigDB lists</TD><TD>ACTTTAT_MIR1425P</TD><TD>270</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,EYA4,CPEB2,RNF128</TD></TR>
<TR><TD>7.679e-03</TD><TD>-4.87</TD><TD>TRADD (TNFRSF1A associated via death domain)</TD><TD>protein interactions</TD><TD>8717</TD><TD>46</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A,USP2</TD></TR>
<TR><TD>7.679e-03</TD><TD>-4.87</TD><TD>CEACAM21 (carcinoembryonic antigen related cell adhesion molecule 21)</TD><TD>protein interactions</TD><TD>90273</TD><TD>46</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20,EPHA3</TD></TR>
<TR><TD>7.773e-03</TD><TD>-4.86</TD><TD>human chr3p11.1</TD><TD>chromosome location</TD><TD>human chr3p11.1</TD><TD>4</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>EPHA3</TD></TR>
<TR><TD>7.798e-03</TD><TD>-4.85</TD><TD>regulation of extrinsic apoptotic signaling pathway in absence of ligand</TD><TD>biological process</TD><TD>GO:2001239</TD><TD>47</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IL7,EYA4</TD></TR>
<TR><TD>7.823e-03</TD><TD>-4.85</TD><TD>negative regulation of nucleic acid-templated transcription</TD><TD>biological process</TD><TD>GO:1903507</TD><TD>1253</TD><TD>9</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A,ZFHX4,MEIS2,FST,PAX9,ALX1,USP2,SATB2,HEY1</TD></TR>
<TR><TD>7.825e-03</TD><TD>-4.85</TD><TD>adult behavior</TD><TD>biological process</TD><TD>GO:0030534</TD><TD>144</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2,PCDH17,ZIC1</TD></TR>
<TR><TD>7.885e-03</TD><TD>-4.84</TD><TD>GSE1112_OT1_CD8AB_VS_HY_CD8AA_THYMOCYTE_RTOC_CULTURE_UP</TD><TD>MSigDB lists</TD><TD>GSE1112_OT1_CD8AB_VS_HY_CD8AA_THYMOCYTE_RTOC_CULTURE_UP</TD><TD>141</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,PLEKHM3,RBM11</TD></TR>
<TR><TD>7.902e-03</TD><TD>-4.84</TD><TD>negative regulation of RNA biosynthetic process</TD><TD>biological process</TD><TD>GO:1902679</TD><TD>1255</TD><TD>9</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,USP2,SATB2,HEY1,CDKN2A,ZFHX4,FST,MEIS2,PAX9</TD></TR>
<TR><TD>7.905e-03</TD><TD>-4.84</TD><TD>DNA-binding transcription factor activity, RNA polymerase II-specific</TD><TD>molecular function</TD><TD>GO:0000981</TD><TD>1591</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>ALX1,ZIC1,MEIS2,ZFHX4,FOXA2,PAX9,ZIC4,PLAG1,SATB2,HEY1</TD></TR>
<TR><TD>7.910e-03</TD><TD>-4.84</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_UP</TD><TD>608</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>PLCH1,CDKN2A,SLC6A15,CLDN1,NPTX2,ZIC1</TD></TR>
<TR><TD>7.953e-03</TD><TD>-4.83</TD><TD>tryptophan 2,3-dioxygenase activity</TD><TD>molecular function</TD><TD>GO:0004833</TD><TD>3</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>IDO2</TD></TR>
<TR><TD>7.953e-03</TD><TD>-4.83</TD><TD>hydrolase activity, acting on acid carbon-carbon bonds</TD><TD>molecular function</TD><TD>GO:0016822</TD><TD>3</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>7.953e-03</TD><TD>-4.83</TD><TD>hydrolase activity, acting on acid carbon-carbon bonds, in ketonic substances</TD><TD>molecular function</TD><TD>GO:0016823</TD><TD>3</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>KYNU</TD></TR>
<TR><TD>7.974e-03</TD><TD>-4.83</TD><TD>sensory perception of sound</TD><TD>biological process</TD><TD>GO:0007605</TD><TD>145</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>EYA4,DCDC2,GABRB2</TD></TR>
<TR><TD>8.038e-03</TD><TD>-4.82</TD><TD>senescence-associated heterochromatin focus</TD><TD>cellular component</TD><TD>GO:0035985</TD><TD>3</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.039e-03</TD><TD>-4.82</TD><TD>GO_CARTILAGE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_CARTILAGE_DEVELOPMENT</TD><TD>142</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ALX1,SATB2,BMPR1B</TD></TR>
<TR><TD>8.168e-03</TD><TD>-4.81</TD><TD>YAMASHITA_LIVER_CANCER_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>YAMASHITA_LIVER_CANCER_STEM_CELL_UP</TD><TD>47</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,CLDN1</TD></TR>
<TR><TD>8.197e-03</TD><TD>-4.80</TD><TD>GABAAb_rcpt</TD><TD>interpro domains</TD><TD>IPR002289</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>GABRB2</TD></TR>
<TR><TD>8.197e-03</TD><TD>-4.80</TD><TD>Trp/Indoleamine_2_3_dOase-like</TD><TD>interpro domains</TD><TD>IPR037217</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>IDO2</TD></TR>
<TR><TD>8.197e-03</TD><TD>-4.80</TD><TD>LISCH7</TD><TD>interpro domains</TD><TD>IPR008664</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>LSR</TD></TR>
<TR><TD>8.197e-03</TD><TD>-4.80</TD><TD>Fork-head_N</TD><TD>interpro domains</TD><TD>IPR013638</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>8.197e-03</TD><TD>-4.80</TD><TD>STAC1/2/3</TD><TD>interpro domains</TD><TD>IPR039688</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>STAC</TD></TR>
<TR><TD>8.197e-03</TD><TD>-4.80</TD><TD>Myxo_disulph_rpt</TD><TD>interpro domains</TD><TD>IPR011936</TD><TD>3</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PAPPA</TD></TR>
<TR><TD>8.267e-03</TD><TD>-4.80</TD><TD>DELYS_THYROID_CANCER_UP</TD><TD>MSigDB lists</TD><TD>DELYS_THYROID_CANCER_UP</TD><TD>435</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,LSR,CLDN1,NPTX2,STAC</TD></TR>
<TR><TD>8.352e-03</TD><TD>-4.79</TD><TD>GO_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS</TD><TD>MSigDB lists</TD><TD>GO_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS</TD><TD>144</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,GABRB2,DCDC2</TD></TR>
<TR><TD>8.432e-03</TD><TD>-4.78</TD><TD>Forkhead_N</TD><TD>pfam domains</TD><TD>PF08430</TD><TD>3</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>FOXA2</TD></TR>
<TR><TD>8.432e-03</TD><TD>-4.78</TD><TD>LSR</TD><TD>pfam domains</TD><TD>PF05624</TD><TD>3</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>LSR</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>regulation of transcription from RNA polymerase II promoter by glucose</TD><TD>biological process</TD><TD>GO:0000430</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>leucine transport</TD><TD>biological process</TD><TD>GO:0015820</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>establishment of blood-nerve barrier</TD><TD>biological process</TD><TD>GO:0008065</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>ovarian cumulus expansion</TD><TD>biological process</TD><TD>GO:0001550</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>L-kynurenine catabolic process</TD><TD>biological process</TD><TD>GO:0097053</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>fused antrum stage</TD><TD>biological process</TD><TD>GO:0048165</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>senescence-associated heterochromatin focus assembly</TD><TD>biological process</TD><TD>GO:0035986</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>quinolinate biosynthetic process</TD><TD>biological process</TD><TD>GO:0019805</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>negative regulation of transcription from RNA polymerase II promoter involved in smooth muscle cell differentiation</TD><TD>biological process</TD><TD>GO:2000820</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>anthranilate metabolic process</TD><TD>biological process</TD><TD>GO:0043420</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>positive regulation of transcription from RNA polymerase II promoter by glucose</TD><TD>biological process</TD><TD>GO:0000432</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>positive regulation of macrophage apoptotic process</TD><TD>biological process</TD><TD>GO:2000111</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.451e-03</TD><TD>-4.77</TD><TD>fasciculation of sensory neuron axon</TD><TD>biological process</TD><TD>GO:0097155</TD><TD>3</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>EPHA3</TD></TR>
<TR><TD>8.453e-03</TD><TD>-4.77</TD><TD>oxidoreduction coenzyme metabolic process</TD><TD>biological process</TD><TD>GO:0006733</TD><TD>49</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-buttock-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-buttock-benign_melanocytic_nevus-dysplastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>central_nervous_system-supratentorial-glioma-ependymoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-supratentorial-glioma-ependymoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>vulvar_intraepithelial_neoplasia_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>vulvar_intraepithelial_neoplasia_Grade_III</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>bone-osteosarcoma-mixed</TD><TD>COSMIC cancer mutations</TD><TD>bone-osteosarcoma-mixed</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>epithelial_predominant</TD><TD>COSMIC cancer mutations</TD><TD>epithelial_predominant</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>bone-clavicle-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-clavicle-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-leg-benign_melanocytic_nevus-junctional</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-benign_melanocytic_nevus-junctional</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>bone-femur-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-sun_exposed_site-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-sun_exposed_site-carcinoma-squamous_cell_carcinoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-abdomen-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-abdomen-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-back-benign_melanocytic_nevus-junctional</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus-junctional</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>with_rhabdomyosarcomatous_differentiation</TD><TD>COSMIC cancer mutations</TD><TD>with_rhabdomyosarcomatous_differentiation</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>salivary_gland-mandible-carcinoma-mucoepidermoid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-mandible-carcinoma-mucoepidermoid_carcinoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>central_nervous_system-frontotemporal-glioma-gliosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontotemporal-glioma-gliosarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>bone-pelvis-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-pelvis-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-sun_exposed_site-in_situ_epithelial_neoplasm-actinic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>skin-sun_exposed_site-in_situ_epithelial_neoplasm-actinic_keratosis</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>parosteal</TD><TD>COSMIC cancer mutations</TD><TD>parosteal</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>soft_tissue-nerve_sheath-malignant_peripheral_nerve_sheath_tumour-with_rhabdomyosarcomatous_differentiation</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-nerve_sheath-malignant_peripheral_nerve_sheath_tumour-with_rhabdomyosarcomatous_differentiation</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-upper_leg-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_leg-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-upper_leg-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_leg-benign_melanocytic_nevus-dysplastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-flank-benign_melanocytic_nevus-junctional</TD><TD>COSMIC cancer mutations</TD><TD>skin-flank-benign_melanocytic_nevus-junctional</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_I</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-acral-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-acral-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>vulva-in_situ_neoplasm-vulvar_intraepithelial_neoplasia_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>vulva-in_situ_neoplasm-vulvar_intraepithelial_neoplasia_Grade_III</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-back-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-breast-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-breast-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-upper_extremity-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_extremity-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-shoulder-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-shoulder-benign_melanocytic_nevus-compound</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-genital-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-genital-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>central_nervous_system-tectum-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-tectum-glioma-astrocytoma_Grade_I</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-lower_extremity-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_extremity-malignant_melanoma-superficial_spreading</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-breast-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-breast-benign_melanocytic_nevus-intradermal</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>liver-other-normal</TD><TD>COSMIC cancer mutations</TD><TD>liver-other-normal</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>central_nervous_system-frontotemporal-glioma-oligodendroglioma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontotemporal-glioma-oligodendroglioma_Grade_III</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>salivary_gland-parotid-carcinoma-salivary_duct_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-parotid-carcinoma-salivary_duct_carcinoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>genital_tract-extragonadal-germ_cell_tumour-choriocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>genital_tract-extragonadal-germ_cell_tumour-choriocarcinoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-forearm-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-forearm-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-back-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus-dysplastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>telangiectatic</TD><TD>COSMIC cancer mutations</TD><TD>telangiectatic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>bone-tibia-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-elbow-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-elbow-malignant_melanoma-nodular</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-T_cell_large_granular_lymphocytic_leukaemia</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>bone-ischium-osteosarcoma-chondroblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-ischium-osteosarcoma-chondroblastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>bone-tibia-osteosarcoma-fibroblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-osteosarcoma-fibroblastic</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>upper_aerodigestive_tract-larynx-other-papilloma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-other-papilloma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-buttock-benign_melanocytic_nevus-junctional</TD><TD>COSMIC cancer mutations</TD><TD>skin-buttock-benign_melanocytic_nevus-junctional</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>thymus-thymoma-epithelial_predominant</TD><TD>COSMIC cancer mutations</TD><TD>thymus-thymoma-epithelial_predominant</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>skin-buttock-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-buttock-benign_melanocytic_nevus-intradermal</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.496e-03</TD><TD>-4.77</TD><TD>bone-humerus-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-malignant_fibrous_histiocytoma-pleomorphic_sarcoma</TD><TD>3</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>8.507e-03</TD><TD>-4.77</TD><TD>MCDOWELL_ACUTE_LUNG_INJURY_DN</TD><TD>MSigDB lists</TD><TD>MCDOWELL_ACUTE_LUNG_INJURY_DN</TD><TD>48</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,SCGB3A2</TD></TR>
<TR><TD>8.507e-03</TD><TD>-4.77</TD><TD>PID_HEDGEHOG_GLI_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_HEDGEHOG_GLI_PATHWAY</TD><TD>48</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,FOXA2</TD></TR>
<TR><TD>8.511e-03</TD><TD>-4.77</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP</TD><TD>MSigDB lists</TD><TD>TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP</TD><TD>145</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>RBM11,MTSS1,HS3ST3B1</TD></TR>
<TR><TD>8.559e-03</TD><TD>-4.76</TD><TD>lymph_node</TD><TD>COSMIC cancer mutations</TD><TD>lymph_node</TD><TD>1744</TD><TD>11</TD><TD>17255</TD><TD>49</TD>
<TD>SPAG6,EPHA3,GPC5,GRIA2,SATB2,PCDH11X,MEIS2,PLAG1,ZFHX4,CDKN2A,ZIC4</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>MARCO (macrophage receptor with collagenous structure)</TD><TD>protein interactions</TD><TD>8685</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>MEIS3 (Meis homeobox 3)</TD><TD>protein interactions</TD><TD>56917</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1)</TD><TD>protein interactions</TD><TD>27276</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>Rap2a (RAS related protein 2a)</TD><TD>protein interactions</TD><TD>76108</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>Usp45 (ubiquitin specific petidase 45)</TD><TD>protein interactions</TD><TD>77593</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>Stk35 (serine/threonine kinase 35)</TD><TD>protein interactions</TD><TD>67333</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>EN2 (engrailed homeobox 2)</TD><TD>protein interactions</TD><TD>2020</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>Fbxw5 (F-box and WD-40 domain protein 5)</TD><TD>protein interactions</TD><TD>30839</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>PLA2G4E (phospholipase A2 group IVE)</TD><TD>protein interactions</TD><TD>123745</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>Chn1 (chimerin 1)</TD><TD>protein interactions</TD><TD>108699</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.569e-03</TD><TD>-4.76</TD><TD>Smad6 (SMAD family member 6)</TD><TD>protein interactions</TD><TD>17130</TD><TD>3</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>8.670e-03</TD><TD>-4.75</TD><TD>MORF_MLLT10</TD><TD>MSigDB lists</TD><TD>MORF_MLLT10</TD><TD>280</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,IL7,STAC,GABRB2</TD></TR>
<TR><TD>8.672e-03</TD><TD>-4.75</TD><TD>GO_HOMOPHILIC_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES</TD><TD>MSigDB lists</TD><TD>GO_HOMOPHILIC_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES</TD><TD>146</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,PCDH11X,PCDH20</TD></TR>
<TR><TD>8.728e-03</TD><TD>-4.74</TD><TD>Heparan sulfate/heparin (HS-GAG) metabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-1638091</TD><TD>54</TD><TD>2</TD><TD>10287</TD><TD>27</TD>
<TD>GPC5,HS3ST3B1</TD></TR>
<TR><TD>8.836e-03</TD><TD>-4.73</TD><TD>DODD_NASOPHARYNGEAL_CARCINOMA_UP</TD><TD>MSigDB lists</TD><TD>DODD_NASOPHARYNGEAL_CARCINOMA_UP</TD><TD>1478</TD><TD>10</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,PCDH20,DCDC2,EYA4,ENPP5,SPAG6,MTSS1,BMPR1B,USP2,MEIS2</TD></TR>
<TR><TD>8.853e-03</TD><TD>-4.73</TD><TD>MCCLUNG_DELTA_FOSB_TARGETS_8WK</TD><TD>MSigDB lists</TD><TD>MCCLUNG_DELTA_FOSB_TARGETS_8WK</TD><TD>49</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2,USP2</TD></TR>
<TR><TD>8.853e-03</TD><TD>-4.73</TD><TD>GO_PROTEIN_TRANSMEMBRANE_TRANSPORT</TD><TD>MSigDB lists</TD><TD>GO_PROTEIN_TRANSMEMBRANE_TRANSPORT</TD><TD>49</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PEX5L,AZGP1</TD></TR>
<TR><TD>8.856e-03</TD><TD>-4.73</TD><TD>CA</TD><TD>smart domains</TD><TD>SM00112</TD><TD>113</TD><TD>3</TD><TD>9476</TD><TD>36</TD>
<TD>PCDH17,PCDH11X,PCDH20</TD></TR>
<TR><TD>8.872e-03</TD><TD>-4.72</TD><TD>upper_aerodigestive_tract-tonsil-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-tonsil-carcinoma-squamous_cell_carcinoma</TD><TD>50</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>KYNU,CDKN2A</TD></TR>
<TR><TD>8.997e-03</TD><TD>-4.71</TD><TD>negative regulation of transcription by RNA polymerase II</TD><TD>biological process</TD><TD>GO:0000122</TD><TD>841</TD><TD>7</TD><TD>18054</TD><TD>51</TD>
<TD>FST,MEIS2,ZFHX4,HEY1,SATB2,ALX1,USP2</TD></TR>
<TR><TD>9.023e-03</TD><TD>-4.71</TD><TD>CEBPE (CCAAT enhancer binding protein epsilon)</TD><TD>protein interactions</TD><TD>1053</TD><TD>50</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>IL7,EDA2R</TD></TR>
<TR><TD>9.166e-03</TD><TD>-4.69</TD><TD>GSE9988_LPS_VS_LOW_LPS_MONOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE9988_LPS_VS_LOW_LPS_MONOCYTE_DN</TD><TD>149</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CRB1,PAX9,EPHA3</TD></TR>
<TR><TD>9.205e-03</TD><TD>-4.69</TD><TD>chr8q21</TD><TD>MSigDB lists</TD><TD>chr8q21</TD><TD>50</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,ZFHX4</TD></TR>
<TR><TD>9.294e-03</TD><TD>-4.68</TD><TD>urinary_tract-bladder-carcinoma-transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-bladder-carcinoma-transitional_cell_carcinoma</TD><TD>6151</TD><TD>26</TD><TD>17255</TD><TD>49</TD>
<TD>ENPP5,PAPPA,PAX9,PCDH17,SATB2,ZIC4,HS3ST3B1,CDKN2A,EYA4,ZIC1,PEX5L,CLDN1,DCDC2,GABRB2,NPTX2,EPHA3,RNF128,PLCH1,PCDH11X,GRIA2,GALNT13,SPAG6,MTSS1,KYNU,GPC5,PLEKHM3</TD></TR>
<TR><TD>9.294e-03</TD><TD>-4.68</TD><TD>generation of neurons</TD><TD>biological process</TD><TD>GO:0048699</TD><TD>1524</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>CRB1,GABRB2,HEY1,PLAG1,SATB2,NPTX2,DCDC2,FOXA2,BMPR1B,EPHA3</TD></TR>
<TR><TD>9.320e-03</TD><TD>-4.68</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_STEM_CELL_UP</TD><TD>448</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,FST,NPTX2,STAC,CXCL14</TD></TR>
<TR><TD>9.335e-03</TD><TD>-4.67</TD><TD>GSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN</TD><TD>MSigDB lists</TD><TD>GSE45365_WT_VS_IFNAR_KO_CD11B_DC_MCMV_INFECTION_DN</TD><TD>150</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,RBM11,CLDN1</TD></TR>
<TR><TD>9.338e-03</TD><TD>-4.67</TD><TD>transitional_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>transitional_cell_carcinoma</TD><TD>6153</TD><TD>26</TD><TD>17255</TD><TD>49</TD>
<TD>NPTX2,GABRB2,DCDC2,EPHA3,PEX5L,CLDN1,EYA4,ZIC4,CDKN2A,HS3ST3B1,ZIC1,ENPP5,PAPPA,SATB2,PCDH17,PAX9,KYNU,GPC5,PLEKHM3,SPAG6,MTSS1,GALNT13,RNF128,PLCH1,GRIA2,PCDH11X</TD></TR>
<TR><TD>9.400e-03</TD><TD>-4.67</TD><TD>plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>plasma_cell_myeloma</TD><TD>1286</TD><TD>9</TD><TD>17255</TD><TD>49</TD>
<TD>ALX1,PCDH20,SCGB3A2,EPHA3,IDO2,PCDH17,GRIA2,CDKN2A,LSR</TD></TR>
<TR><TD>9.400e-03</TD><TD>-4.67</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma</TD><TD>1286</TD><TD>9</TD><TD>17255</TD><TD>49</TD>
<TD>ALX1,PCDH20,EPHA3,IDO2,SCGB3A2,GRIA2,PCDH17,LSR,CDKN2A</TD></TR>
<TR><TD>9.470e-03</TD><TD>-4.66</TD><TD>GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS</TD><TD>1733</TD><TD>11</TD><TD>17275</TD><TD>50</TD>
<TD>EDA2R,PLAG1,HEY1,SATB2,PAX9,ZIC1,FOXA2,CDKN2A,ALX1,MEIS2,BMPR1B</TD></TR>
<TR><TD>9.502e-03</TD><TD>-4.66</TD><TD>positive regulation of transcription, DNA-templated</TD><TD>biological process</TD><TD>GO:0045893</TD><TD>1529</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>ZFHX4,MEIS2,BMPR1B,PAX9,FOXA2,ZIC1,SATB2,HEY1,PLAG1,ALX1</TD></TR>
<TR><TD>9.505e-03</TD><TD>-4.66</TD><TD>SNF5_DN.V1_DN</TD><TD>MSigDB lists</TD><TD>SNF5_DN.V1_DN</TD><TD>151</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,CDKN2A,PAPPA</TD></TR>
<TR><TD>9.563e-03</TD><TD>-4.65</TD><TD>ROVERSI_GLIOMA_COPY_NUMBER_DN</TD><TD>MSigDB lists</TD><TD>ROVERSI_GLIOMA_COPY_NUMBER_DN</TD><TD>51</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,CDKN2A</TD></TR>
<TR><TD>9.563e-03</TD><TD>-4.65</TD><TD>REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM</TD><TD>51</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,HS3ST3B1</TD></TR>
<TR><TD>9.563e-03</TD><TD>-4.65</TD><TD>MORF_ITGA2</TD><TD>MSigDB lists</TD><TD>MORF_ITGA2</TD><TD>51</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,IL7</TD></TR>
<TR><TD>9.564e-03</TD><TD>-4.65</TD><TD>regulation of extrinsic apoptotic signaling pathway</TD><TD>biological process</TD><TD>GO:2001236</TD><TD>155</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>EYA4,IL7,BMPR1B</TD></TR>
<TR><TD>9.591e-03</TD><TD>-4.65</TD><TD>primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>15696</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>LSR,ZIC1,PCDH17,CXCL14,CPEB2,SLC6A15,DCDC2,ALX1,IL7,HEY1,ZFHX4,GRIA2,USP2,PCDH11X,RNF128,PLCH1,PLAG1,EDA2R,PLEKHM3,KYNU,HS3ST3B1,ZIC4,EYA4,CDKN2A,SATB2,PAX9,MEIS2,AZGP1,ENPP5,FST,PAPPA,BMPR1B,IDO2,EPHA3,NPTX2,FOXA2,GABRB2,CLDN1,PCDH20,PEX5L,CLVS2,GALNT13,CRB1,RBM11,SCGB3A2,GPC5,SPAG6,MTSS1,STAC</TD></TR>
<TR><TD>9.899e-03</TD><TD>-4.62</TD><TD>HOX</TD><TD>smart domains</TD><TD>SM00389</TD><TD>224</TD><TD>4</TD><TD>9476</TD><TD>36</TD>
<TD>ZFHX4,SATB2,MEIS2,ALX1</TD></TR>
<TR><TD>9.915e-03</TD><TD>-4.61</TD><TD>Hedgehog signaling events mediated by Gli proteins</TD><TD>Pathway Interaction DB</TD><TD>hedgehog_glipathway</TD><TD>44</TD><TD>2</TD><TD>2226</TD><TD>8</TD>
<TD>MTSS1,FOXA2</TD></TR>
<TR><TD>9.927e-03</TD><TD>-4.61</TD><TD>CDPCR3_01</TD><TD>MSigDB lists</TD><TD>CDPCR3_01</TD><TD>52</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,ZIC4</TD></TR>
<TR><TD>1.003e-02</TD><TD>-4.60</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_6H_ACT_CD4_TCELL_UP</TD><TD>154</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,ZFHX4,RNF128</TD></TR>
<TR><TD>1.003e-02</TD><TD>-4.60</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_4H_ACT_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_4H_ACT_CD4_TCELL_DN</TD><TD>154</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,GRIA2,CRB1</TD></TR>
<TR><TD>1.014e-02</TD><TD>-4.59</TD><TD>pulmonary_blastoma</TD><TD>COSMIC cancer mutations</TD><TD>pulmonary_blastoma</TD><TD>654</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>ZFHX4,BMPR1B,SLC6A15,PCDH20,STAC,SATB2</TD></TR>
<TR><TD>1.014e-02</TD><TD>-4.59</TD><TD>pleura-pulmonary_blastoma</TD><TD>COSMIC cancer mutations</TD><TD>pleura-pulmonary_blastoma</TD><TD>654</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH20,STAC,SATB2,ZFHX4,SLC6A15,BMPR1B</TD></TR>
<TR><TD>1.017e-02</TD><TD>-4.59</TD><TD>skin-upper_leg-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_leg-malignant_melanoma</TD><TD>858</TD><TD>7</TD><TD>17255</TD><TD>49</TD>
<TD>EPHA3,GABRB2,CDKN2A,STAC,PLCH1,PEX5L,PCDH20</TD></TR>
<TR><TD>1.039e-02</TD><TD>-4.57</TD><TD>central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV</TD><TD>2575</TD><TD>14</TD><TD>17255</TD><TD>49</TD>
<TD>GABRB2,DCDC2,EPHA3,SLC6A15,GPC5,PLEKHM3,PEX5L,ZFHX4,CDKN2A,GALNT13,MEIS2,RNF128,PAPPA,PCDH11X</TD></TR>
<TR><TD>1.041e-02</TD><TD>-4.57</TD><TD>skin-head_neck-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-head_neck-carcinoma-squamous_cell_carcinoma</TD><TD>14500</TD><TD>47</TD><TD>17255</TD><TD>49</TD>
<TD>RBM11,CRB1,GALNT13,SPAG6,MTSS1,STAC,SCGB3A2,GPC5,MEIS2,AZGP1,ENPP5,PAPPA,FST,SATB2,PAX9,EYA4,CDKN2A,ZIC4,HS3ST3B1,CLVS2,PCDH20,PEX5L,NPTX2,GABRB2,FOXA2,BMPR1B,IDO2,EPHA3,PLCH1,PLAG1,USP2,GRIA2,PCDH11X,ZFHX4,HEY1,KYNU,EDA2R,PLEKHM3,PCDH17,CXCL14,CPEB2,LSR,ZIC1,ALX1,IL7,DCDC2,SLC6A15</TD></TR>
<TR><TD>1.046e-02</TD><TD>-4.56</TD><TD>Antagonism of Activin by Follistatin</TD><TD>REACTOME pathways</TD><TD>R-HSA-2473224</TD><TD>4</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>FST</TD></TR>
<TR><TD>1.046e-02</TD><TD>-4.56</TD><TD>Activation of AMPA receptors</TD><TD>REACTOME pathways</TD><TD>R-HSA-399710</TD><TD>4</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GRIA2</TD></TR>
<TR><TD>1.059e-02</TD><TD>-4.55</TD><TD>AMPA glutamate receptor activity</TD><TD>molecular function</TD><TD>GO:0004971</TD><TD>4</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>GRIA2</TD></TR>
<TR><TD>1.067e-02</TD><TD>-4.54</TD><TD>AMIT_SERUM_RESPONSE_240_MCF10A</TD><TD>MSigDB lists</TD><TD>AMIT_SERUM_RESPONSE_240_MCF10A</TD><TD>54</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,FST</TD></TR>
<TR><TD>1.070e-02</TD><TD>-4.54</TD><TD>tricellular tight junction</TD><TD>cellular component</TD><TD>GO:0061689</TD><TD>4</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>LSR</TD></TR>
<TR><TD>1.075e-02</TD><TD>-4.53</TD><TD>FOXA transcription factor networks</TD><TD>Pathway Interaction DB</TD><TD>hnf3pathway</TD><TD>3</TD><TD>1</TD><TD>2226</TD><TD>8</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.080e-02</TD><TD>-4.53</TD><TD>central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype</TD><TD>663</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>EYA4,EPHA3,MEIS2,PCDH11X,STAC,SPAG6</TD></TR>
<TR><TD>1.083e-02</TD><TD>-4.53</TD><TD>MEISSNER_NPC_HCP_WITH_H3K4ME2</TD><TD>MSigDB lists</TD><TD>MEISSNER_NPC_HCP_WITH_H3K4ME2</TD><TD>465</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,LSR,IL7,NPTX2,USP2</TD></TR>
<TR><TD>1.087e-02</TD><TD>-4.52</TD><TD>SHH_subtype</TD><TD>COSMIC cancer mutations</TD><TD>SHH_subtype</TD><TD>664</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>MEIS2,PCDH11X,STAC,SPAG6,EYA4,EPHA3</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>EYA_dom_sf</TD><TD>interpro domains</TD><TD>IPR038102</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>CEBP_ZZ_sf</TD><TD>interpro domains</TD><TD>IPR038446</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>EYA_dom_metazoan</TD><TD>interpro domains</TD><TD>IPR042577</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>EYA_fam</TD><TD>interpro domains</TD><TD>IPR028472</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>LamG-like</TD><TD>interpro domains</TD><TD>IPR006558</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PAPPA</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>EYA_dom</TD><TD>interpro domains</TD><TD>IPR006545</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.091e-02</TD><TD>-4.52</TD><TD>CEBP_ZZ</TD><TD>interpro domains</TD><TD>IPR032296</TD><TD>4</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>UEDA_PERIFERAL_CLOCK</TD><TD>MSigDB lists</TD><TD>UEDA_PERIFERAL_CLOCK</TD><TD>159</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,LSR,USP2</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>positive regulation of protein localization to plasma membrane</TD><TD>biological process</TD><TD>GO:1903078</TD><TD>56</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>STAC,EPHA3</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>cellular biogenic amine metabolic process</TD><TD>biological process</TD><TD>GO:0006576</TD><TD>56</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.093e-02</TD><TD>-4.52</TD><TD>GABAARBETA</TD><TD>prints domains</TD><TD>PR01160</TD><TD>3</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>GABRB2</TD></TR>
<TR><TD>1.094e-02</TD><TD>-4.52</TD><TD>RTAAACA_FREAC2_01</TD><TD>MSigDB lists</TD><TD>RTAAACA_FREAC2_01</TD><TD>853</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,FST,CRB1,SATB2,RNF128,PLAG1,ZFHX4</TD></TR>
<TR><TD>1.103e-02</TD><TD>-4.51</TD><TD>peripheral</TD><TD>COSMIC cancer mutations</TD><TD>peripheral</TD><TD>56</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,ZFHX4</TD></TR>
<TR><TD>1.106e-02</TD><TD>-4.50</TD><TD>WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2</TD><TD>MSigDB lists</TD><TD>WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2</TD><TD>55</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,CLDN1</TD></TR>
<TR><TD>1.106e-02</TD><TD>-4.50</TD><TD>GO_REGULATION_OF_B_CELL_PROLIFERATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_B_CELL_PROLIFERATION</TD><TD>55</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,IL7</TD></TR>
<TR><TD>1.106e-02</TD><TD>-4.50</TD><TD>EVI1_03</TD><TD>MSigDB lists</TD><TD>EVI1_03</TD><TD>55</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,PLAG1</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>CEBP_ZZ</TD><TD>pfam domains</TD><TD>PF16366</TD><TD>4</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>RRM_7</TD><TD>pfam domains</TD><TD>PF16367</TD><TD>4</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.123e-02</TD><TD>-4.49</TD><TD>bone-humerus-other-chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-other-chondroblastoma</TD><TD>308</TD><TD>4</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH11X,MTSS1,GPC5,KYNU</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>positive regulation of transcription by glucose</TD><TD>biological process</TD><TD>GO:0046016</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>positive regulation of cardiac muscle myoblast proliferation</TD><TD>biological process</TD><TD>GO:0110024</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>protein import into peroxisome matrix, docking</TD><TD>biological process</TD><TD>GO:0016560</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PEX5L</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>epithelial cell proliferation involved in renal tubule morphogenesis</TD><TD>biological process</TD><TD>GO:2001013</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>negative regulation of chondrocyte proliferation</TD><TD>biological process</TD><TD>GO:1902731</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>quinolinate metabolic process</TD><TD>biological process</TD><TD>GO:0046874</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>microspike assembly</TD><TD>biological process</TD><TD>GO:0030035</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>carbon catabolite regulation of transcription from RNA polymerase II promoter</TD><TD>biological process</TD><TD>GO:0000429</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>carbon catabolite activation of transcription from RNA polymerase II promoter</TD><TD>biological process</TD><TD>GO:0000436</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>positive regulation of bicellular tight junction assembly</TD><TD>biological process</TD><TD>GO:1903348</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>1.125e-02</TD><TD>-4.49</TD><TD>negative regulation of translational elongation</TD><TD>biological process</TD><TD>GO:0045900</TD><TD>4</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>GSE26488_WT_VS_HDAC7_KO_DOUBLE_POSITIVE_THYMOCYTE_DN</TD><TD>MSigDB lists</TD><TD>GSE26488_WT_VS_HDAC7_KO_DOUBLE_POSITIVE_THYMOCYTE_DN</TD><TD>161</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,USP2,EDA2R</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>GSE21063_WT_VS_NFATC1_KO_16H_ANTI_IGM_STIM_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE21063_WT_VS_NFATC1_KO_16H_ANTI_IGM_STIM_BCELL_DN</TD><TD>161</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,SATB2,PAX9</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>cellular amine metabolic process</TD><TD>biological process</TD><TD>GO:0044106</TD><TD>57</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>pancreas-carcinoma-small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-small_cell_carcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>small_cell_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>small_cell_adenocarcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>bone-humerus-osteosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-osteosarcoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-flank-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-flank-benign_melanocytic_nevus-intradermal</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-arm-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-arm-benign_melanocytic_nevus-compound</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>pituitary-adenoma-FSH</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-FSH</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>amelanotic</TD><TD>COSMIC cancer mutations</TD><TD>amelanotic</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-forearm-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-forearm-other-atypical_Spitzoid_tumour</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>oesophagus-other-dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-other-dysplasia</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>salivary_gland-tongue-carcinoma-mucoepidermoid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-tongue-carcinoma-mucoepidermoid_carcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_leukaemia_not_otherwise_specified</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-T_cell_leukaemia_not_otherwise_specified</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>stomach-carcinoma-small_cell_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-small_cell_adenocarcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>vocal_cord</TD><TD>COSMIC cancer mutations</TD><TD>vocal_cord</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>FSH</TD><TD>COSMIC cancer mutations</TD><TD>FSH</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>central_nervous_system-frontotemporal-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontotemporal-glioma-astrocytoma_Grade_IV</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>upper_aerodigestive_tract-vocal_cord-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-vocal_cord-carcinoma-squamous_cell_carcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-malignant_melanoma-amelanotic</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma-amelanotic</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>pancreas-carcinoma-large_cell_neuroendocrine_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-large_cell_neuroendocrine_carcinoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>central_nervous_system-other-neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-other-neoplasm</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-ankle-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-ankle-other-atypical_Spitzoid_tumour</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>bone-humerus-chondrosarcoma-dedifferentiated</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-chondrosarcoma-dedifferentiated</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>T_cell_leukaemia_not_otherwise_specified</TD><TD>COSMIC cancer mutations</TD><TD>T_cell_leukaemia_not_otherwise_specified</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-shoulder-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-shoulder-benign_melanocytic_nevus-intradermal</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-upper_arm-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_arm-benign_melanocytic_nevus-intradermal</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-face-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-malignant_melanoma-superficial_spreading</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-neck-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-benign_melanocytic_nevus-compound</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-malignant_melanoma-vertical_growth_phase</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma-vertical_growth_phase</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-ear-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-ear-other-atypical_Spitzoid_tumour</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-leg-benign_melanocytic_nevus-compound</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-benign_melanocytic_nevus-compound</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>vertical_growth_phase</TD><TD>COSMIC cancer mutations</TD><TD>vertical_growth_phase</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>oesophagus-other-intraepithelial_neoplasia</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-other-intraepithelial_neoplasia</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-lower_extremity-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_extremity-malignant_melanoma-nodular</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-back-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus-intradermal</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-face-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-benign_melanocytic_nevus-dysplastic</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>skin-knee-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-knee-other-atypical_Spitzoid_tumour</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>metacarpus</TD><TD>COSMIC cancer mutations</TD><TD>metacarpus</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.131e-02</TD><TD>-4.48</TD><TD>upper_aerodigestive_tract-head_neck-other-dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-head_neck-other-dysplasia</TD><TD>4</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.133e-02</TD><TD>-4.48</TD><TD>sensory perception of mechanical stimulus</TD><TD>biological process</TD><TD>GO:0050954</TD><TD>165</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>GABRB2,DCDC2,EYA4</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>SSX4 (SSX family member 4)</TD><TD>protein interactions</TD><TD>6759</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PAX9</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>Pick1 (protein interacting with PRKCA 1)</TD><TD>protein interactions</TD><TD>84591</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GRIA2</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>CCDC196 (coiled-coil domain containing 196)</TD><TD>protein interactions</TD><TD>440184</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>ZGRF1 (zinc finger GRF-type containing 1)</TD><TD>protein interactions</TD><TD>55345</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>ATP6 (ATP synthase F0 subunit 6)</TD><TD>protein interactions</TD><TD>4508</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>Nkiras1 (NFKB inhibitor interacting Ras-like protein 1)</TD><TD>protein interactions</TD><TD>69721</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>HLA-DOB (major histocompatibility complex, class II, DO beta)</TD><TD>protein interactions</TD><TD>3112</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6)</TD><TD>protein interactions</TD><TD>73341</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>Cdk14 (cyclin-dependent kinase 14)</TD><TD>protein interactions</TD><TD>18647</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>VEPH1 (ventricular zone expressed PH domain containing 1)</TD><TD>protein interactions</TD><TD>79674</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit)</TD><TD>protein interactions</TD><TD>67877</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>CARF (calcium responsive transcription factor)</TD><TD>protein interactions</TD><TD>79800</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C)</TD><TD>protein interactions</TD><TD>67444</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>Rhebl1 (Ras homolog enriched in brain like 1)</TD><TD>protein interactions</TD><TD>69159</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>Cdk4 (cyclin-dependent kinase 4)</TD><TD>protein interactions</TD><TD>12567</TD><TD>4</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.141e-02</TD><TD>-4.47</TD><TD>superpathway of tryptophan utilization</TD><TD>BIOCYC pathways</TD><TD>HUMAN_PWY66-401</TD><TD>32</TD><TD>2</TD><TD>902</TD><TD>5</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.143e-02</TD><TD>-4.47</TD><TD>Heart Development</TD><TD>WikiPathways</TD><TD>WP1591</TD><TD>46</TD><TD>2</TD><TD>5311</TD><TD>19</TD>
<TD>HEY1,FOXA2</TD></TR>
<TR><TD>1.144e-02</TD><TD>-4.47</TD><TD>brainstem</TD><TD>COSMIC cancer mutations</TD><TD>brainstem</TD><TD>3161</TD><TD>16</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,SATB2,MEIS2,PAPPA,SLC6A15,EPHA3,GABRB2,DCDC2,ALX1,PEX5L,GALNT13,ZFHX4,PCDH11X,RNF128,PLEKHM3,GPC5</TD></TR>
<TR><TD>1.144e-02</TD><TD>-4.47</TD><TD>TATCTGG_MIR488</TD><TD>MSigDB lists</TD><TD>TATCTGG_MIR488</TD><TD>56</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,SATB2</TD></TR>
<TR><TD>1.144e-02</TD><TD>-4.47</TD><TD>HUTTMANN_B_CLL_POOR_SURVIVAL_DN</TD><TD>MSigDB lists</TD><TD>HUTTMANN_B_CLL_POOR_SURVIVAL_DN</TD><TD>56</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,PLAG1</TD></TR>
<TR><TD>1.144e-02</TD><TD>-4.47</TD><TD>DAWSON_METHYLATED_IN_LYMPHOMA_TCL1</TD><TD>MSigDB lists</TD><TD>DAWSON_METHYLATED_IN_LYMPHOMA_TCL1</TD><TD>56</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CLVS2,CDKN2A</TD></TR>
<TR><TD>1.145e-02</TD><TD>-4.47</TD><TD>transmitter-gated channel activity</TD><TD>molecular function</TD><TD>GO:0022835</TD><TD>61</TD><TD>2</TD><TD>17306</TD><TD>46</TD>
<TD>GRIA2,GABRB2</TD></TR>
<TR><TD>1.145e-02</TD><TD>-4.47</TD><TD>transmitter-gated ion channel activity</TD><TD>molecular function</TD><TD>GO:0022824</TD><TD>61</TD><TD>2</TD><TD>17306</TD><TD>46</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>1.147e-02</TD><TD>-4.47</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma</TD><TD>481</TD><TD>5</TD><TD>17255</TD><TD>49</TD>
<TD>MEIS2,PCDH11X,CDKN2A,GPC5,EPHA3</TD></TR>
<TR><TD>1.147e-02</TD><TD>-4.47</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL</TD><TD>MSigDB lists</TD><TD>FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL</TD><TD>304</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,KYNU,CLDN1,PLCH1</TD></TR>
<TR><TD>1.164e-02</TD><TD>-4.45</TD><TD>human chrXq21.31</TD><TD>chromosome location</TD><TD>human chrXq21.31</TD><TD>6</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>PCDH11X</TD></TR>
<TR><TD>1.165e-02</TD><TD>-4.45</TD><TD>DNA-binding transcription factor activity</TD><TD>molecular function</TD><TD>GO:0003700</TD><TD>1685</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>ALX1,PAX9,ZIC4,FOXA2,ZFHX4,ZIC1,MEIS2,SATB2,PLAG1,HEY1</TD></TR>
<TR><TD>1.170e-02</TD><TD>-4.45</TD><TD>homophilic cell adhesion via plasma membrane adhesion molecules</TD><TD>biological process</TD><TD>GO:0007156</TD><TD>167</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>PCDH20,PCDH17,PCDH11X</TD></TR>
<TR><TD>1.184e-02</TD><TD>-4.44</TD><TD>GO_PROTEOGLYCAN_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_PROTEOGLYCAN_BIOSYNTHETIC_PROCESS</TD><TD>57</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>HS3ST3B1,BMPR1B</TD></TR>
<TR><TD>1.188e-02</TD><TD>-4.43</TD><TD>GSE45365_HEALTHY_VS_MCMV_INFECTION_CD11B_DC_IFNAR_KO_DN</TD><TD>MSigDB lists</TD><TD>GSE45365_HEALTHY_VS_MCMV_INFECTION_CD11B_DC_IFNAR_KO_DN</TD><TD>164</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,RBM11,CLDN1</TD></TR>
<TR><TD>1.188e-02</TD><TD>-4.43</TD><TD>MORF_PRKCA</TD><TD>MSigDB lists</TD><TD>MORF_PRKCA</TD><TD>164</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,IL7,GABRB2</TD></TR>
<TR><TD>1.188e-02</TD><TD>-4.43</TD><TD>GSE22601_DOUBLE_NEGATIVE_VS_DOUBLE_POSITIVE_THYMOCYTE_UP</TD><TD>MSigDB lists</TD><TD>GSE22601_DOUBLE_NEGATIVE_VS_DOUBLE_POSITIVE_THYMOCYTE_UP</TD><TD>164</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2,GALNT13,ENPP5</TD></TR>
<TR><TD>1.205e-02</TD><TD>-4.42</TD><TD>soft_tissue</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue</TD><TD>5935</TD><TD>25</TD><TD>17255</TD><TD>49</TD>
<TD>MTSS1,EDA2R,GPC5,KYNU,USP2,PCDH11X,PLCH1,GALNT13,ZFHX4,CRB1,CLDN1,PCDH20,PEX5L,EPHA3,GABRB2,DCDC2,SATB2,PCDH17,MEIS2,PAPPA,ZIC1,LSR,CDKN2A,HS3ST3B1,EYA4</TD></TR>
<TR><TD>1.205e-02</TD><TD>-4.42</TD><TD>negative regulation of RNA metabolic process</TD><TD>biological process</TD><TD>GO:0051253</TD><TD>1343</TD><TD>9</TD><TD>18054</TD><TD>51</TD>
<TD>PAX9,ZFHX4,FST,MEIS2,CDKN2A,SATB2,HEY1,USP2,ALX1</TD></TR>
<TR><TD>1.208e-02</TD><TD>-4.42</TD><TD>GSE41867_DAY6_VS_DAY15_LCMV_ARMSTRONG_EFFECTOR_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE41867_DAY6_VS_DAY15_LCMV_ARMSTRONG_EFFECTOR_CD8_TCELL_UP</TD><TD>165</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>IDO2,HS3ST3B1,SLC6A15</TD></TR>
<TR><TD>1.208e-02</TD><TD>-4.42</TD><TD>protein transmembrane transport</TD><TD>biological process</TD><TD>GO:0071806</TD><TD>59</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>AZGP1,PEX5L</TD></TR>
<TR><TD>1.210e-02</TD><TD>-4.41</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>MSigDB lists</TD><TD>DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN</TD><TD>478</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,CDKN2A,CPEB2,USP2,KYNU</TD></TR>
<TR><TD>1.214e-02</TD><TD>-4.41</TD><TD>upper_leg</TD><TD>COSMIC cancer mutations</TD><TD>upper_leg</TD><TD>888</TD><TD>7</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1,PEX5L,PCDH20,STAC,GABRB2,CDKN2A,EPHA3</TD></TR>
<TR><TD>1.215e-02</TD><TD>-4.41</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.40.50.12350</TD><TD>4</TD><TD>1</TD><TD>8522</TD><TD>26</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.215e-02</TD><TD>-4.41</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.30.40.130</TD><TD>4</TD><TD>1</TD><TD>8522</TD><TD>26</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.224e-02</TD><TD>-4.40</TD><TD>ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_UP</TD><TD>MSigDB lists</TD><TD>ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_UP</TD><TD>58</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>HS3ST3B1,PCDH20</TD></TR>
<TR><TD>1.227e-02</TD><TD>-4.40</TD><TD>cartilage development</TD><TD>biological process</TD><TD>GO:0051216</TD><TD>170</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,SATB2,BMPR1B</TD></TR>
<TR><TD>1.227e-02</TD><TD>-4.40</TD><TD>MORF_BCL2L11</TD><TD>MSigDB lists</TD><TD>MORF_BCL2L11</TD><TD>166</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,STAC,PAX9</TD></TR>
<TR><TD>1.227e-02</TD><TD>-4.40</TD><TD>GSE2706_R848_VS_LPS_8H_STIM_DC_DN</TD><TD>MSigDB lists</TD><TD>GSE2706_R848_VS_LPS_8H_STIM_DC_DN</TD><TD>166</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2,IDO2,NPTX2</TD></TR>
<TR><TD>1.230e-02</TD><TD>-4.40</TD><TD>WTTGKCTG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>WTTGKCTG_UNKNOWN</TD><TD>480</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,MTSS1,PCDH20,PCDH17,FST</TD></TR>
<TR><TD>1.232e-02</TD><TD>-4.40</TD><TD>TGCCAAR_NF1_Q6</TD><TD>MSigDB lists</TD><TD>TGCCAAR_NF1_Q6</TD><TD>669</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,FOXA2,PEX5L,STAC,MEIS2,CXCL14</TD></TR>
<TR><TD>1.268e-02</TD><TD>-4.37</TD><TD>MORF_MAP2K7</TD><TD>MSigDB lists</TD><TD>MORF_MAP2K7</TD><TD>168</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,STAC,GABRB2</TD></TR>
<TR><TD>1.276e-02</TD><TD>-4.36</TD><TD>cell-cell adhesion</TD><TD>biological process</TD><TD>GO:0098609</TD><TD>496</TD><TD>5</TD><TD>18054</TD><TD>51</TD>
<TD>PCDH17,PCDH20,CLDN1,PCDH11X,CRB1</TD></TR>
<TR><TD>1.293e-02</TD><TD>-4.35</TD><TD>PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_UP</TD><TD>MSigDB lists</TD><TD>PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_UP</TD><TD>315</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,BMPR1B,PAPPA,NPTX2</TD></TR>
<TR><TD>1.299e-02</TD><TD>-4.34</TD><TD>temporoparietal</TD><TD>COSMIC cancer mutations</TD><TD>temporoparietal</TD><TD>61</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>AZGP1,CDKN2A</TD></TR>
<TR><TD>1.300e-02</TD><TD>-4.34</TD><TD>GO_INTRINSIC_COMPONENT_OF_PLASMA_MEMBRANE</TD><TD>MSigDB lists</TD><TD>GO_INTRINSIC_COMPONENT_OF_PLASMA_MEMBRANE</TD><TD>1566</TD><TD>10</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,GABRB2,PCDH11X,CLDN1,GPC5,EPHA3,HS3ST3B1,SLC6A15,EDA2R,GRIA2</TD></TR>
<TR><TD>1.306e-02</TD><TD>-4.34</TD><TD>YRCCAKNNGNCGC_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YRCCAKNNGNCGC_UNKNOWN</TD><TD>60</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PEX5L,CLDN1</TD></TR>
<TR><TD>1.308e-02</TD><TD>-4.34</TD><TD>GSE37416_CTRL_VS_48H_F_TULARENSIS_LVS_NEUTROPHIL_UP</TD><TD>MSigDB lists</TD><TD>GSE37416_CTRL_VS_48H_F_TULARENSIS_LVS_NEUTROPHIL_UP</TD><TD>170</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,GRIA2,SATB2</TD></TR>
<TR><TD>1.308e-02</TD><TD>-4.34</TD><TD>GSE36476_YOUNG_VS_OLD_DONOR_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE36476_YOUNG_VS_OLD_DONOR_MEMORY_CD4_TCELL_DN</TD><TD>170</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,SATB2,SPAG6</TD></TR>
<TR><TD>1.308e-02</TD><TD>-4.34</TD><TD>PRC2_SUZ12_UP.V1_DN</TD><TD>MSigDB lists</TD><TD>PRC2_SUZ12_UP.V1_DN</TD><TD>170</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,MEIS2,ZIC4</TD></TR>
<TR><TD>1.315e-02</TD><TD>-4.33</TD><TD>positive regulation of nucleobase-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0045935</TD><TD>1857</TD><TD>11</TD><TD>18054</TD><TD>51</TD>
<TD>ZIC1,FOXA2,PAX9,BMPR1B,MEIS2,ZFHX4,EYA4,ALX1,PLAG1,HEY1,SATB2</TD></TR>
<TR><TD>1.322e-02</TD><TD>-4.33</TD><TD>peroxisome targeting sequence binding</TD><TD>molecular function</TD><TD>GO:0000268</TD><TD>5</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>PEX5L</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>Cadherin_N</TD><TD>interpro domains</TD><TD>IPR013164</TD><TD>64</TD><TD>2</TD><TD>18616</TD><TD>51</TD>
<TD>PCDH11X,PCDH17</TD></TR>
<TR><TD>1.331e-02</TD><TD>-4.32</TD><TD>PE/DAG-bd</TD><TD>interpro domains</TD><TD>IPR002219</TD><TD>64</TD><TD>2</TD><TD>18616</TD><TD>51</TD>
<TD>STAC,ARHGAP45</TD></TR>
<TR><TD>1.350e-02</TD><TD>-4.31</TD><TD>MORF_CTSB</TD><TD>MSigDB lists</TD><TD>MORF_CTSB</TD><TD>172</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,IL7,GABRB2</TD></TR>
<TR><TD>1.350e-02</TD><TD>-4.31</TD><TD>Ectoderm Differentiation</TD><TD>WikiPathways</TD><TD>WP2858</TD><TD>143</TD><TD>3</TD><TD>5311</TD><TD>19</TD>
<TD>FOXA2,EDA2R,ZFHX4</TD></TR>
<TR><TD>1.361e-02</TD><TD>-4.30</TD><TD>positive regulation of nucleic acid-templated transcription</TD><TD>biological process</TD><TD>GO:1903508</TD><TD>1614</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,PLAG1,HEY1,ALX1,ZFHX4,MEIS2,PAX9,BMPR1B,FOXA2,ZIC1</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>CPEB</TD><TD>interpro domains</TD><TD>IPR034819</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>Protocadherin</TD><TD>interpro domains</TD><TD>IPR013585</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PCDH11X</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>Pentaxin_CS</TD><TD>interpro domains</TD><TD>IPR030476</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>NPTX2</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>Follistatin/Osteonectin_EGF</TD><TD>interpro domains</TD><TD>IPR015369</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>FST</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>I-BAR_dom</TD><TD>interpro domains</TD><TD>IPR013606</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>Zf-RING_9</TD><TD>interpro domains</TD><TD>IPR025258</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PLEKHM3</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>PKNOX/Meis_N</TD><TD>interpro domains</TD><TD>IPR032453</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.362e-02</TD><TD>-4.30</TD><TD>Neutral_aa_SLC6</TD><TD>interpro domains</TD><TD>IPR002438</TD><TD>5</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.363e-02</TD><TD>-4.30</TD><TD>Tryptophan Metabolism</TD><TD>SMPDB pathways</TD><TD>SMP0000063</TD><TD>19</TD><TD>1</TD><TD>1394</TD><TD>1</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.366e-02</TD><TD>-4.29</TD><TD>positive regulation of RNA biosynthetic process</TD><TD>biological process</TD><TD>GO:1902680</TD><TD>1615</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,HEY1,PLAG1,SATB2,ZIC1,FOXA2,BMPR1B,PAX9,MEIS2,ZFHX4</TD></TR>
<TR><TD>1.369e-02</TD><TD>-4.29</TD><TD>positive regulation of protein localization to cell periphery</TD><TD>biological process</TD><TD>GO:1904377</TD><TD>63</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>STAC,EPHA3</TD></TR>
<TR><TD>1.378e-02</TD><TD>-4.28</TD><TD>GO_RECEPTOR_COMPLEX</TD><TD>MSigDB lists</TD><TD>GO_RECEPTOR_COMPLEX</TD><TD>321</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,GABRB2,PEX5L,GRIA2</TD></TR>
<TR><TD>1.378e-02</TD><TD>-4.28</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_DN</TD><TD>MSigDB lists</TD><TD>IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_DN</TD><TD>321</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,HS3ST3B1,GALNT13,ZFHX4</TD></TR>
<TR><TD>1.390e-02</TD><TD>-4.28</TD><TD>GO_REGULATION_OF_SMOOTHENED_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_SMOOTHENED_SIGNALING_PATHWAY</TD><TD>62</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>DCDC2,ZIC1</TD></TR>
<TR><TD>1.392e-02</TD><TD>-4.27</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_RESPONSE_NOT_VIA_P38</TD><TD>322</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,CLDN1,ZFHX4,HEY1</TD></TR>
<TR><TD>1.396e-02</TD><TD>-4.27</TD><TD>regionalization</TD><TD>biological process</TD><TD>GO:0003002</TD><TD>330</TD><TD>4</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,BMPR1B,FOXA2,HEY1</TD></TR>
<TR><TD>1.401e-02</TD><TD>-4.27</TD><TD>zf-RING_9</TD><TD>pfam domains</TD><TD>PF13901</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>PLEKHM3</TD></TR>
<TR><TD>1.401e-02</TD><TD>-4.27</TD><TD>Meis_PKNOX_N</TD><TD>pfam domains</TD><TD>PF16493</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.401e-02</TD><TD>-4.27</TD><TD>Protocadherin</TD><TD>pfam domains</TD><TD>PF08374</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>PCDH11X</TD></TR>
<TR><TD>1.401e-02</TD><TD>-4.27</TD><TD>IMD</TD><TD>pfam domains</TD><TD>PF08397</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.401e-02</TD><TD>-4.27</TD><TD>FOLN</TD><TD>pfam domains</TD><TD>PF09289</TD><TD>5</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>FST</TD></TR>
<TR><TD>1.404e-02</TD><TD>-4.27</TD><TD>Cadherin_2</TD><TD>pfam domains</TD><TD>PF08266</TD><TD>64</TD><TD>2</TD><TD>17385</TD><TD>49</TD>
<TD>PCDH17,PCDH11X</TD></TR>
<TR><TD>1.405e-02</TD><TD>-4.27</TD><TD>regulation of transcription by glucose</TD><TD>biological process</TD><TD>GO:0046015</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.405e-02</TD><TD>-4.27</TD><TD>negative regulation of glucokinase activity</TD><TD>biological process</TD><TD>GO:0033132</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.405e-02</TD><TD>-4.27</TD><TD>carbon catabolite regulation of transcription</TD><TD>biological process</TD><TD>GO:0045990</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.405e-02</TD><TD>-4.27</TD><TD>positive regulation of protein catabolic process in the vacuole</TD><TD>biological process</TD><TD>GO:1904352</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>RNF128</TD></TR>
<TR><TD>1.405e-02</TD><TD>-4.27</TD><TD>negative regulation of hexokinase activity</TD><TD>biological process</TD><TD>GO:1903300</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.405e-02</TD><TD>-4.27</TD><TD>cellular response to lead ion</TD><TD>biological process</TD><TD>GO:0071284</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>1.405e-02</TD><TD>-4.27</TD><TD>carbon catabolite activation of transcription</TD><TD>biological process</TD><TD>GO:0045991</TD><TD>5</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.411e-02</TD><TD>-4.26</TD><TD>neurogenesis</TD><TD>biological process</TD><TD>GO:0022008</TD><TD>1623</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>PLAG1,HEY1,SATB2,GABRB2,CRB1,EPHA3,FOXA2,BMPR1B,NPTX2,DCDC2</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>large_intestine-colon-other-dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-colon-other-dysplasia</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_II</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>complex-atypical</TD><TD>COSMIC cancer mutations</TD><TD>complex-atypical</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>bone-tibia-osteosarcoma-chondroblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-osteosarcoma-chondroblastic</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>skin-ear-malignant_melanoma-spitzoid</TD><TD>COSMIC cancer mutations</TD><TD>skin-ear-malignant_melanoma-spitzoid</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>skin-head_neck-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-head_neck-other-keratoacanthoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>thyroid-carcinoma-mucoepidermoid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thyroid-carcinoma-mucoepidermoid_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>upper_aerodigestive_tract-mouth-other-leukoplakia-hyperplakia-erythroplakia</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-mouth-other-leukoplakia-hyperplakia-erythroplakia</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>leukoplakia-hyperplakia-erythroplakia</TD><TD>COSMIC cancer mutations</TD><TD>leukoplakia-hyperplakia-erythroplakia</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_III</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>upper_aerodigestive_tract-trachea-other-papilloma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-trachea-other-papilloma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>endometrium-hyperplasia-complex-atypical</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-hyperplasia-complex-atypical</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>skin-back-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-other-atypical_Spitzoid_tumour</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>central_nervous_system-supratentorial-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-supratentorial-glioma-astrocytoma_Grade_III</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>central_nervous_system-pineal_gland-primitive_neuroectodermal_tumour-medulloblastoma-pineoblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-pineal_gland-primitive_neuroectodermal_tumour-medulloblastoma-pineoblastoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>bone-humerus-osteosarcoma-osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-humerus-osteosarcoma-osteoblastic</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>haematopoietic_and_lymphoid_tissue-mouth-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-mouth-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>lung-right-other-papilloma</TD><TD>COSMIC cancer mutations</TD><TD>lung-right-other-papilloma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>haematopoietic_and_lymphoid_tissue-extranodal-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-extranodal-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>cervical_intraepithelial_neoplasia_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>cervical_intraepithelial_neoplasia_Grade_II</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-primary_effusion_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-primary_effusion_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>central_nervous_system-frontoparietal-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontoparietal-glioma-astrocytoma_Grade_IV</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>acetabulum</TD><TD>COSMIC cancer mutations</TD><TD>acetabulum</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>central_nervous_system-frontotemporal-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontotemporal-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>bone-chondrosarcoma-peripheral</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-peripheral</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>bone-extraskeletal-chondrosarcoma-mesenchymal</TD><TD>COSMIC cancer mutations</TD><TD>bone-extraskeletal-chondrosarcoma-mesenchymal</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>tectum</TD><TD>COSMIC cancer mutations</TD><TD>tectum</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>large_cell_neuroendocrine_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_cell_neuroendocrine_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>cerebral_hemisphere</TD><TD>COSMIC cancer mutations</TD><TD>cerebral_hemisphere</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>pineoblastoma</TD><TD>COSMIC cancer mutations</TD><TD>pineoblastoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>autonomic_ganglia-abdomen-paraganglioma-malignant</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-abdomen-paraganglioma-malignant</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>endometrium-carcinoma-mixed_serous_and_clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-mixed_serous_and_clear_cell_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>skin-trunk-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-trunk-other-keratoacanthoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>bone-osteosarcoma-chondroblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-osteosarcoma-chondroblastic</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>skin-trunk-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-trunk-carcinoma-squamous_cell_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>central_nervous_system-supratentorial-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-supratentorial-glioma-astrocytoma_Grade_IV</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>large_intestine-anus-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-anus-carcinoma-adenocarcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>central_nervous_system-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-glioma-astrocytoma_Grade_IV</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>skin-leg-other-keratoacanthoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-other-keratoacanthoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>ependymoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>ependymoma_Grade_I</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>urinary_tract-renal_pelvis-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-renal_pelvis-carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>intraepithelial_neoplasia</TD><TD>COSMIC cancer mutations</TD><TD>intraepithelial_neoplasia</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>astroblastoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>astroblastoma_Grade_III</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>skin-foot-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-foot-other-atypical_Spitzoid_tumour</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>mixed_serous_and_clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>mixed_serous_and_clear_cell_carcinoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.412e-02</TD><TD>-4.26</TD><TD>primary_effusion_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>primary_effusion_lymphoma</TD><TD>5</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.414e-02</TD><TD>-4.26</TD><TD>FREAC7_01</TD><TD>MSigDB lists</TD><TD>FREAC7_01</TD><TD>175</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH11X,PLAG1,FST</TD></TR>
<TR><TD>1.414e-02</TD><TD>-4.26</TD><TD>GSE2585_AIRE_KO_VS_WT_CD80_LOW_MTEC_UP</TD><TD>MSigDB lists</TD><TD>GSE2585_AIRE_KO_VS_WT_CD80_LOW_MTEC_UP</TD><TD>175</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,EDA2R,SLC6A15</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>Rhobtb1 (Rho-related BTB domain containing 1)</TD><TD>protein interactions</TD><TD>69288</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>Rhoj (ras homolog family member J)</TD><TD>protein interactions</TD><TD>80837</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>NPTXR (neuronal pentraxin receptor)</TD><TD>protein interactions</TD><TD>23467</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>NPTX2</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>Rab38 (RAB38, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>72433</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>PBX4 (PBX homeobox 4)</TD><TD>protein interactions</TD><TD>80714</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>SASH3 (SAM and SH3 domain containing 3)</TD><TD>protein interactions</TD><TD>54440</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>KLHL1 (kelch like family member 1)</TD><TD>protein interactions</TD><TD>57626</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>GDF6 (growth differentiation factor 6)</TD><TD>protein interactions</TD><TD>392255</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>ZNF774 (zinc finger protein 774)</TD><TD>protein interactions</TD><TD>342132</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>RBM11</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>Vhl (von Hippel-Lindau tumor suppressor)</TD><TD>protein interactions</TD><TD>24874</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>TLCD1 (TLC domain containing 1)</TD><TD>protein interactions</TD><TD>116238</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>Rab6b (RAB6B, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>270192</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.424e-02</TD><TD>-4.25</TD><TD>Rras2 (related RAS viral (r-ras) oncogene 2)</TD><TD>protein interactions</TD><TD>66922</TD><TD>5</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.435e-02</TD><TD>-4.24</TD><TD>HNF3_Q6</TD><TD>MSigDB lists</TD><TD>HNF3_Q6</TD><TD>176</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,PLAG1,PCDH17</TD></TR>
<TR><TD>1.435e-02</TD><TD>-4.24</TD><TD>GO_LOCOMOTORY_BEHAVIOR</TD><TD>MSigDB lists</TD><TD>GO_LOCOMOTORY_BEHAVIOR</TD><TD>176</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,ZIC1,FOXA2</TD></TR>
<TR><TD>1.435e-02</TD><TD>-4.24</TD><TD>GSE2585_THYMIC_MACROPHAGE_VS_MTEC_UP</TD><TD>MSigDB lists</TD><TD>GSE2585_THYMIC_MACROPHAGE_VS_MTEC_UP</TD><TD>176</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,IL7,CDKN2A</TD></TR>
<TR><TD>1.435e-02</TD><TD>-4.24</TD><TD>GSE22443_NAIVE_VS_ACT_AND_IL12_TREATED_CD8_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE22443_NAIVE_VS_ACT_AND_IL12_TREATED_CD8_TCELL_DN</TD><TD>176</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,ALX1,CLVS2</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>TCGATGG_MIR213</TD><TD>MSigDB lists</TD><TD>TCGATGG_MIR213</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>RAFFEL_VEGFA_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>RAFFEL_VEGFA_TARGETS_DN</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>JU_AGING_TERC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>JU_AGING_TERC_TARGETS_DN</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>IL7</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>FUJIWARA_PARK2_IN_LIVER_CANCER_DN</TD><TD>MSigDB lists</TD><TD>FUJIWARA_PARK2_IN_LIVER_CANCER_DN</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>TESAR_ALK_TARGETS_HUMAN_ES_5D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_HUMAN_ES_5D_UP</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>chr3p11</TD><TD>MSigDB lists</TD><TD>chr3p11</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_UP</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>ALONSO_METASTASIS_EMT_DN</TD><TD>MSigDB lists</TD><TD>ALONSO_METASTASIS_EMT_DN</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA</TD></TR>
<TR><TD>1.439e-02</TD><TD>-4.24</TD><TD>TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP</TD><TD>5</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>1.457e-02</TD><TD>-4.23</TD><TD>GSE3982_MAST_CELL_VS_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_MAST_CELL_VS_DC_UP</TD><TD>177</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,MEIS2,HEY1</TD></TR>
<TR><TD>1.457e-02</TD><TD>-4.23</TD><TD>MORF_IL4</TD><TD>MSigDB lists</TD><TD>MORF_IL4</TD><TD>177</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,IL7,GABRB2</TD></TR>
<TR><TD>1.457e-02</TD><TD>-4.23</TD><TD>GSE2585_CTEC_VS_THYMIC_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE2585_CTEC_VS_THYMIC_DC_UP</TD><TD>177</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>IDO2,PAX9,EYA4</TD></TR>
<TR><TD>1.457e-02</TD><TD>-4.23</TD><TD>GSE27786_NKCELL_VS_NEUTROPHIL_DN</TD><TD>MSigDB lists</TD><TD>GSE27786_NKCELL_VS_NEUTROPHIL_DN</TD><TD>177</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2,CDKN2A,CLVS2</TD></TR>
<TR><TD>1.466e-02</TD><TD>-4.22</TD><TD>skin-foot-malignant_melanoma-acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>skin-foot-malignant_melanoma-acral_lentiginous</TD><TD>65</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>1.470e-02</TD><TD>-4.22</TD><TD>lung-middle_lobe-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-middle_lobe-carcinoma-adenocarcinoma</TD><TD>1383</TD><TD>9</TD><TD>17255</TD><TD>49</TD>
<TD>PEX5L,PAPPA,PCDH11X,PCDH17,ZIC4,EYA4,CRB1,ZFHX4,ZIC1</TD></TR>
<TR><TD>1.471e-02</TD><TD>-4.22</TD><TD>skin-trunk-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-trunk-malignant_melanoma</TD><TD>2683</TD><TD>14</TD><TD>17255</TD><TD>49</TD>
<TD>SLC6A15,DCDC2,SPAG6,MTSS1,ZFHX4,CDKN2A,EYA4,CRB1,GRIA2,CPEB2,CXCL14,MEIS2,PLCH1,PAPPA</TD></TR>
<TR><TD>1.476e-02</TD><TD>-4.22</TD><TD>GO_CELLULAR_KETONE_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_KETONE_METABOLIC_PROCESS</TD><TD>64</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.476e-02</TD><TD>-4.22</TD><TD>GENTILE_UV_LOW_DOSE_DN</TD><TD>MSigDB lists</TD><TD>GENTILE_UV_LOW_DOSE_DN</TD><TD>64</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,SATB2</TD></TR>
<TR><TD>1.479e-02</TD><TD>-4.21</TD><TD>PROVENZANI_METASTASIS_UP</TD><TD>MSigDB lists</TD><TD>PROVENZANI_METASTASIS_UP</TD><TD>178</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,CDKN2A,FOXA2</TD></TR>
<TR><TD>1.479e-02</TD><TD>-4.21</TD><TD>GSE26030_UNSTIM_VS_RESTIM_TH17_DAY5_POST_POLARIZATION_DN</TD><TD>MSigDB lists</TD><TD>GSE26030_UNSTIM_VS_RESTIM_TH17_DAY5_POST_POLARIZATION_DN</TD><TD>178</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>RBM11,FST,CLDN1</TD></TR>
<TR><TD>1.479e-02</TD><TD>-4.21</TD><TD>GSE22282_HYPOXIA_VS_NORMOXIA_MYELOID_DC_DN</TD><TD>MSigDB lists</TD><TD>GSE22282_HYPOXIA_VS_NORMOXIA_MYELOID_DC_DN</TD><TD>178</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,GABRB2,RBM11</TD></TR>
<TR><TD>1.493e-02</TD><TD>-4.20</TD><TD>MODULE_95</TD><TD>MSigDB lists</TD><TD>MODULE_95</TD><TD>504</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>SCGB3A2,BMPR1B,GALNT13,CRB1,GPC5</TD></TR>
<TR><TD>1.496e-02</TD><TD>-4.20</TD><TD>amine metabolic process</TD><TD>biological process</TD><TD>GO:0009308</TD><TD>66</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>1.501e-02</TD><TD>-4.20</TD><TD>GSE8515_CTRL_VS_IL6_4H_STIM_MAC_DN</TD><TD>MSigDB lists</TD><TD>GSE8515_CTRL_VS_IL6_4H_STIM_MAC_DN</TD><TD>179</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,MEIS2,SLC6A15</TD></TR>
<TR><TD>1.501e-02</TD><TD>-4.20</TD><TD>GSE33513_TCF7_KO_VS_HET_EARLY_THYMIC_PROGENITOR_UP</TD><TD>MSigDB lists</TD><TD>GSE33513_TCF7_KO_VS_HET_EARLY_THYMIC_PROGENITOR_UP</TD><TD>179</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2,HEY1,HS3ST3B1</TD></TR>
<TR><TD>1.506e-02</TD><TD>-4.20</TD><TD>GO_CELL_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_CELL_DEVELOPMENT</TD><TD>1361</TD><TD>9</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,SATB2,CRB1,LSR,ALX1,SPAG6,EPHA3,BMPR1B,GABRB2</TD></TR>
<TR><TD>1.511e-02</TD><TD>-4.19</TD><TD>LamGL</TD><TD>smart domains</TD><TD>SM00560</TD><TD>4</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>PAPPA</TD></TR>
<TR><TD>1.524e-02</TD><TD>-4.18</TD><TD>GSE32986_GMCSF_AND_CURDLAN_LOWDOSE_VS_GMCSF_AND_CURDLAN_HIGHDOSE_STIM_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE32986_GMCSF_AND_CURDLAN_LOWDOSE_VS_GMCSF_AND_CURDLAN_HIGHDOSE_STIM_DC_UP</TD><TD>180</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,MTSS1,PLEKHM3</TD></TR>
<TR><TD>1.524e-02</TD><TD>-4.18</TD><TD>GSE9960_HEALTHY_VS_GRAM_NEG_SEPSIS_PBMC_DN</TD><TD>MSigDB lists</TD><TD>GSE9960_HEALTHY_VS_GRAM_NEG_SEPSIS_PBMC_DN</TD><TD>180</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLEKHM3,GABRB2,IL7</TD></TR>
<TR><TD>1.524e-02</TD><TD>-4.18</TD><TD>AAAGACA_MIR511</TD><TD>MSigDB lists</TD><TD>AAAGACA_MIR511</TD><TD>180</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,PCDH17,EYA4</TD></TR>
<TR><TD>1.524e-02</TD><TD>-4.18</TD><TD>ESC_V6.5_UP_LATE.V1_UP</TD><TD>MSigDB lists</TD><TD>ESC_V6.5_UP_LATE.V1_UP</TD><TD>180</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,RNF128,HEY1</TD></TR>
<TR><TD>1.539e-02</TD><TD>-4.17</TD><TD>proteoglycan biosynthetic process</TD><TD>biological process</TD><TD>GO:0030166</TD><TD>67</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B,HS3ST3B1</TD></TR>
<TR><TD>1.540e-02</TD><TD>-4.17</TD><TD>MODULE_163</TD><TD>MSigDB lists</TD><TD>MODULE_163</TD><TD>508</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>SCGB3A2,BMPR1B,GPC5,GALNT13,CRB1</TD></TR>
<TR><TD>1.542e-02</TD><TD>-4.17</TD><TD>ZF_DAG_PE_1</TD><TD>prosite domains</TD><TD>PS00479</TD><TD>56</TD><TD>2</TD><TD>12079</TD><TD>41</TD>
<TD>STAC,ARHGAP45</TD></TR>
<TR><TD>1.546e-02</TD><TD>-4.17</TD><TD>GSE7460_WT_VS_FOXP3_HET_ACT_WITH_TGFB_TCONV_UP</TD><TD>MSigDB lists</TD><TD>GSE7460_WT_VS_FOXP3_HET_ACT_WITH_TGFB_TCONV_UP</TD><TD>181</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,CPEB2,HS3ST3B1</TD></TR>
<TR><TD>1.546e-02</TD><TD>-4.17</TD><TD>GSE24634_IL4_VS_CTRL_TREATED_NAIVE_CD4_TCELL_DAY7_DN</TD><TD>MSigDB lists</TD><TD>GSE24634_IL4_VS_CTRL_TREATED_NAIVE_CD4_TCELL_DAY7_DN</TD><TD>181</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,KYNU,RNF128</TD></TR>
<TR><TD>1.546e-02</TD><TD>-4.17</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_EFF_MEMORY_CD4_TCELL_VS_TH2_UP</TD><TD>181</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PEX5L,ZIC1,ALX1</TD></TR>
<TR><TD>1.546e-02</TD><TD>-4.17</TD><TD>GSE3982_MAST_CELL_VS_EFF_MEMORY_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE3982_MAST_CELL_VS_EFF_MEMORY_CD4_TCELL_UP</TD><TD>181</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,MEIS2,HEY1</TD></TR>
<TR><TD>1.546e-02</TD><TD>-4.17</TD><TD>GSE19825_NAIVE_VS_IL2RAHIGH_DAY3_EFF_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE19825_NAIVE_VS_IL2RAHIGH_DAY3_EFF_CD8_TCELL_UP</TD><TD>181</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,GPC5,FOXA2</TD></TR>
<TR><TD>1.549e-02</TD><TD>-4.17</TD><TD>human chr13q21.2</TD><TD>chromosome location</TD><TD>human chr13q21.2</TD><TD>8</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>PCDH20</TD></TR>
<TR><TD>1.549e-02</TD><TD>-4.17</TD><TD>human chr13q21.1</TD><TD>chromosome location</TD><TD>human chr13q21.1</TD><TD>8</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>PCDH17</TD></TR>
<TR><TD>1.553e-02</TD><TD>-4.16</TD><TD>vertebrae</TD><TD>COSMIC cancer mutations</TD><TD>vertebrae</TD><TD>67</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>1.554e-02</TD><TD>-4.16</TD><TD>breast-carcinoma-ductolobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-ductolobular_carcinoma</TD><TD>1642</TD><TD>10</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH11X,CDKN2A,CRB1,EYA4,ZFHX4,SPAG6,PEX5L,PCDH20,SCGB3A2,EPHA3</TD></TR>
<TR><TD>1.554e-02</TD><TD>-4.16</TD><TD>ductolobular_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ductolobular_carcinoma</TD><TD>1642</TD><TD>10</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH20,PEX5L,SPAG6,EPHA3,SCGB3A2,PCDH11X,EYA4,CRB1,CDKN2A,ZFHX4</TD></TR>
<TR><TD>1.562e-02</TD><TD>-4.16</TD><TD>middle_lobe</TD><TD>COSMIC cancer mutations</TD><TD>middle_lobe</TD><TD>1397</TD><TD>9</TD><TD>17255</TD><TD>49</TD>
<TD>PEX5L,PAPPA,PCDH17,PCDH11X,ZFHX4,CRB1,ZIC4,EYA4,ZIC1</TD></TR>
<TR><TD>1.562e-02</TD><TD>-4.16</TD><TD>GABA-ergic synapse</TD><TD>cellular component</TD><TD>GO:0098982</TD><TD>71</TD><TD>2</TD><TD>18985</TD><TD>51</TD>
<TD>GABRB2,PCDH17</TD></TR>
<TR><TD>1.565e-02</TD><TD>-4.16</TD><TD>NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON</TD><TD>MSigDB lists</TD><TD>NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON</TD><TD>66</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,NPTX2</TD></TR>
<TR><TD>1.565e-02</TD><TD>-4.16</TD><TD>LINDSTEDT_DENDRITIC_CELL_MATURATION_A</TD><TD>MSigDB lists</TD><TD>LINDSTEDT_DENDRITIC_CELL_MATURATION_A</TD><TD>66</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IL7</TD></TR>
<TR><TD>1.569e-02</TD><TD>-4.15</TD><TD>KONDO_PROSTATE_CANCER_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>KONDO_PROSTATE_CANCER_WITH_H3K27ME3</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,ZIC4,ENPP5</TD></TR>
<TR><TD>1.569e-02</TD><TD>-4.15</TD><TD>GSE3982_DC_VS_NEUTROPHIL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_DC_VS_NEUTROPHIL_DN</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,MEIS2,AZGP1</TD></TR>
<TR><TD>1.569e-02</TD><TD>-4.15</TD><TD>GSE29618_PRE_VS_DAY7_POST_LAIV_FLU_VACCINE_PDC_UP</TD><TD>MSigDB lists</TD><TD>GSE29618_PRE_VS_DAY7_POST_LAIV_FLU_VACCINE_PDC_UP</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,ZIC4,EDA2R</TD></TR>
<TR><TD>1.569e-02</TD><TD>-4.15</TD><TD>GSE2585_CD80_HIGH_VS_LOW_MTEC_UP</TD><TD>MSigDB lists</TD><TD>GSE2585_CD80_HIGH_VS_LOW_MTEC_UP</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GALNT13,FOXA2,DCDC2</TD></TR>
<TR><TD>1.569e-02</TD><TD>-4.15</TD><TD>GSE16385_ROSIGLITAZONE_IL4_VS_ROSIGLITAZONE_ALONE_STIM_MACROPHAGE_UP</TD><TD>MSigDB lists</TD><TD>GSE16385_ROSIGLITAZONE_IL4_VS_ROSIGLITAZONE_ALONE_STIM_MACROPHAGE_UP</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,CLDN1,MTSS1</TD></TR>
<TR><TD>1.569e-02</TD><TD>-4.15</TD><TD>GSE8835_CD4_VS_CD8_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE8835_CD4_VS_CD8_TCELL_DN</TD><TD>182</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,FOXA2,HS3ST3B1</TD></TR>
<TR><TD>1.582e-02</TD><TD>-4.15</TD><TD>regulation of protein localization to membrane</TD><TD>biological process</TD><TD>GO:1905475</TD><TD>187</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>GPC5,STAC,EPHA3</TD></TR>
<TR><TD>1.592e-02</TD><TD>-4.14</TD><TD>GSE3982_NEUTROPHIL_VS_CENT_MEMORY_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_NEUTROPHIL_VS_CENT_MEMORY_CD4_TCELL_DN</TD><TD>183</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,PLAG1,CLDN1</TD></TR>
<TR><TD>1.615e-02</TD><TD>-4.13</TD><TD>GSE11961_FOLLICULAR_BCELL_VS_MARGINAL_ZONE_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE11961_FOLLICULAR_BCELL_VS_MARGINAL_ZONE_BCELL_UP</TD><TD>184</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,AZGP1,CXCL14</TD></TR>
<TR><TD>1.619e-02</TD><TD>-4.12</TD><TD>stomach-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-adenocarcinoma</TD><TD>4170</TD><TD>19</TD><TD>17255</TD><TD>49</TD>
<TD>PAPPA,MEIS2,EYA4,HS3ST3B1,ZIC1,LSR,PCDH20,CLVS2,ALX1,EPHA3,PLCH1,PCDH11X,GRIA2,HEY1,GALNT13,MTSS1,SPAG6,GPC5,PLEKHM3</TD></TR>
<TR><TD>1.633e-02</TD><TD>-4.11</TD><TD>Glypican_CS</TD><TD>interpro domains</TD><TD>IPR019803</TD><TD>6</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>GPC5</TD></TR>
<TR><TD>1.633e-02</TD><TD>-4.11</TD><TD>Aminotrans_V_dom</TD><TD>interpro domains</TD><TD>IPR000192</TD><TD>6</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.633e-02</TD><TD>-4.11</TD><TD>Glypican</TD><TD>interpro domains</TD><TD>IPR001863</TD><TD>6</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>GPC5</TD></TR>
<TR><TD>1.650e-02</TD><TD>-4.10</TD><TD>inner ear development</TD><TD>biological process</TD><TD>GO:0048839</TD><TD>190</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>CXCL14,GABRB2,ZIC1</TD></TR>
<TR><TD>1.654e-02</TD><TD>-4.10</TD><TD>negative regulation of biological process</TD><TD>biological process</TD><TD>GO:0048519</TD><TD>5753</TD><TD>24</TD><TD>18054</TD><TD>51</TD>
<TD>USP2,ALX1,EYA4,CPEB2,PLAG1,PCDH17,HEY1,CDKN2A,PCDH11X,AZGP1,CXCL14,ZFHX4,PLCH1,FST,MEIS2,EPHA3,RNF128,GABRB2,SATB2,BMPR1B,PAX9,MTSS1,IL7,FOXA2</TD></TR>
<TR><TD>1.662e-02</TD><TD>-4.10</TD><TD>GSE43863_DAY6_EFF_VS_DAY150_MEM_TFH_CD4_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE43863_DAY6_EFF_VS_DAY150_MEM_TFH_CD4_TCELL_DN</TD><TD>186</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,PLAG1,GABRB2</TD></TR>
<TR><TD>1.662e-02</TD><TD>-4.10</TD><TD>GSE11961_FOLLICULAR_BCELL_VS_MEMORY_BCELL_DAY40_DN</TD><TD>MSigDB lists</TD><TD>GSE11961_FOLLICULAR_BCELL_VS_MEMORY_BCELL_DAY40_DN</TD><TD>186</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>RBM11,ALX1,ZFHX4</TD></TR>
<TR><TD>1.662e-02</TD><TD>-4.10</TD><TD>GSE3982_MAST_CELL_VS_NEUTROPHIL_DN</TD><TD>MSigDB lists</TD><TD>GSE3982_MAST_CELL_VS_NEUTROPHIL_DN</TD><TD>186</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,AZGP1,GRIA2</TD></TR>
<TR><TD>1.662e-02</TD><TD>-4.10</TD><TD>GSE22611_MUTANT_NOD2_TRANSDUCED_VS_CTRL_HEK293T_STIMULATED_WITH_MDP_6H_DN</TD><TD>MSigDB lists</TD><TD>GSE22611_MUTANT_NOD2_TRANSDUCED_VS_CTRL_HEK293T_STIMULATED_WITH_MDP_6H_DN</TD><TD>186</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,PAPPA,CXCL14</TD></TR>
<TR><TD>1.673e-02</TD><TD>-4.09</TD><TD>central_nervous_system-brainstem-glioma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brainstem-glioma</TD><TD>347</TD><TD>4</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,GPC5,PCDH11X,SATB2</TD></TR>
<TR><TD>1.679e-02</TD><TD>-4.09</TD><TD>Glypican</TD><TD>pfam domains</TD><TD>PF01153</TD><TD>6</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>GPC5</TD></TR>
<TR><TD>1.679e-02</TD><TD>-4.09</TD><TD>Aminotran_5</TD><TD>pfam domains</TD><TD>PF00266</TD><TD>6</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.683e-02</TD><TD>-4.08</TD><TD>histone dephosphorylation</TD><TD>biological process</TD><TD>GO:0016576</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>EYA4</TD></TR>
<TR><TD>1.683e-02</TD><TD>-4.08</TD><TD>arterial endothelial cell differentiation</TD><TD>biological process</TD><TD>GO:0060842</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.683e-02</TD><TD>-4.08</TD><TD>branched-chain amino acid transport</TD><TD>biological process</TD><TD>GO:0015803</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.683e-02</TD><TD>-4.08</TD><TD>heparan sulfate proteoglycan biosynthetic process, enzymatic modification</TD><TD>biological process</TD><TD>GO:0015015</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HS3ST3B1</TD></TR>
<TR><TD>1.683e-02</TD><TD>-4.08</TD><TD>positive regulation of natural killer cell chemotaxis</TD><TD>biological process</TD><TD>GO:2000503</TD><TD>6</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CXCL14</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>GSE1925_CTRL_VS_3H_IFNG_STIM_MACROPHAGE_DN</TD><TD>MSigDB lists</TD><TD>GSE1925_CTRL_VS_3H_IFNG_STIM_MACROPHAGE_DN</TD><TD>187</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EDA2R,HS3ST3B1,GABRB2</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>GO_CONNECTIVE_TISSUE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_CONNECTIVE_TISSUE_DEVELOPMENT</TD><TD>187</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,ALX1,BMPR1B</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>CTTGTAT_MIR381</TD><TD>MSigDB lists</TD><TD>CTTGTAT_MIR381</TD><TD>187</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,EPHA3,MEIS2</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>GSE17186_NAIVE_VS_CD21HIGH_TRANSITIONAL_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE17186_NAIVE_VS_CD21HIGH_TRANSITIONAL_BCELL_DN</TD><TD>187</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ENPP5,CLVS2,LSR</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>HEN1_02</TD><TD>MSigDB lists</TD><TD>HEN1_02</TD><TD>187</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SPAG6,LSR,CRB1</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>IMD</TD><TD>prosite domains</TD><TD>PS51338</TD><TD>5</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>MTSS1</TD></TR>
<TR><TD>1.686e-02</TD><TD>-4.08</TD><TD>PTX_1</TD><TD>prosite domains</TD><TD>PS00289</TD><TD>5</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>NPTX2</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-benign_melanocytic_nevus-dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>skin-benign_melanocytic_nevus-dysplastic</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-arm-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-arm-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>lung-left_lower_lobe-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-left_lower_lobe-carcinoma-squamous_cell_carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>bone-fibula-osteosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-fibula-osteosarcoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>chondroblastic</TD><TD>COSMIC cancer mutations</TD><TD>chondroblastic</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>pituitary-adenoma-TSH</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-TSH</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>central_nervous_system-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-glioma-astrocytoma_Grade_II</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>central_nervous_system-intraventricular-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-intraventricular-glioma-astrocytoma_Grade_II</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-skin-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>ischium</TD><TD>COSMIC cancer mutations</TD><TD>ischium</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-head_neck-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-head_neck-malignant_melanoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-penis-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-penis-carcinoma-squamous_cell_carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>central_nervous_system-temporal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>bone-extraskeletal-chondrosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-extraskeletal-chondrosarcoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-upper_arm-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_arm-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>angiomatous</TD><TD>COSMIC cancer mutations</TD><TD>angiomatous</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>meninges-meningioma-psammomatous</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-psammomatous</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>clavicle</TD><TD>COSMIC cancer mutations</TD><TD>clavicle</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>upper_aerodigestive_tract-mouth-other-epithelial_hyperplasia</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-mouth-other-epithelial_hyperplasia</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>meninges-meningioma-angiomatous</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-angiomatous</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>bone-cranium-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-cranium-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>urinary_tract-ureter-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-ureter-carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>TSH</TD><TD>COSMIC cancer mutations</TD><TD>TSH</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>soft_tissue-nerve_sheath-neurofibroma-plexiform</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-nerve_sheath-neurofibroma-plexiform</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>central_nervous_system-frontal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>bone-chondrosarcoma-clear_cell</TD><TD>COSMIC cancer mutations</TD><TD>bone-chondrosarcoma-clear_cell</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-leg-other-atypical_Spitzoid_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-other-atypical_Spitzoid_tumour</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-adenoid_cystic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma-adenoid_cystic_carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>psammomatous</TD><TD>COSMIC cancer mutations</TD><TD>psammomatous</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>salivary_gland-head_neck-carcinoma-adenoid_cystic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-head_neck-carcinoma-adenoid_cystic_carcinoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>plexiform</TD><TD>COSMIC cancer mutations</TD><TD>plexiform</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>autonomic_ganglia-ganglioneuroma</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-ganglioneuroma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-lymphoplasmacytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-lymphoplasmacytic_lymphoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-trunk-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-trunk-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>ganglioneuroma</TD><TD>COSMIC cancer mutations</TD><TD>ganglioneuroma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-hand-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-hand-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>epithelial_hyperplasia</TD><TD>COSMIC cancer mutations</TD><TD>epithelial_hyperplasia</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>bone-femur-chondrosarcoma-dedifferentiated</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-chondrosarcoma-dedifferentiated</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-malignant_melanoma-in_situ_melanotic_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma-in_situ_melanotic_neoplasm</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-in_situ_epithelial_neoplasm-actinic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>skin-in_situ_epithelial_neoplasm-actinic_keratosis</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>in_situ_melanotic_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>in_situ_melanotic_neoplasm</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>skin-foot-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-foot-malignant_melanoma-superficial_spreading</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>spitzoid</TD><TD>COSMIC cancer mutations</TD><TD>spitzoid</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>pituitary-adenoma-ACTH_non_functioning</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-ACTH_non_functioning</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>central_nervous_system-parietal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-parietal_lobe-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-central_nervous_system-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.692e-02</TD><TD>-4.08</TD><TD>central_nervous_system-intraventricular-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-intraventricular-glioma-astrocytoma_Grade_III</TD><TD>6</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.696e-02</TD><TD>-4.08</TD><TD>extracellular ligand-gated ion channel activity</TD><TD>molecular function</TD><TD>GO:0005230</TD><TD>75</TD><TD>2</TD><TD>17306</TD><TD>46</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>1.697e-02</TD><TD>-4.08</TD><TD>locomotory behavior</TD><TD>biological process</TD><TD>GO:0007626</TD><TD>192</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2,USP2,ZIC1</TD></TR>
<TR><TD>1.705e-02</TD><TD>-4.07</TD><TD>Mesodermal Commitment Pathway</TD><TD>WikiPathways</TD><TD>WP2857</TD><TD>156</TD><TD>3</TD><TD>5311</TD><TD>19</TD>
<TD>PLCH1,FOXA2,ZFHX4</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>Map2k3 (mitogen-activated protein kinase kinase 3)</TD><TD>protein interactions</TD><TD>26397</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>Rhod (ras homolog family member D)</TD><TD>protein interactions</TD><TD>11854</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>Rps27a (ribosomal protein S27A)</TD><TD>protein interactions</TD><TD>78294</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>GSC (goosecoid homeobox)</TD><TD>protein interactions</TD><TD>145258</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>GDPD3 (glycerophosphodiester phosphodiesterase domain containing 3)</TD><TD>protein interactions</TD><TD>79153</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>Fancl (Fanconi anemia, complementation group L)</TD><TD>protein interactions</TD><TD>67030</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>SEMA4B (semaphorin 4B)</TD><TD>protein interactions</TD><TD>10509</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>TMA7 (translation machinery associated 7 homolog)</TD><TD>protein interactions</TD><TD>51372</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>TRMO (tRNA methyltransferase O)</TD><TD>protein interactions</TD><TD>51531</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>STAC</TD></TR>
<TR><TD>1.707e-02</TD><TD>-4.07</TD><TD>SPAG16 (sperm associated antigen 16)</TD><TD>protein interactions</TD><TD>79582</TD><TD>6</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>SPAG6</TD></TR>
<TR><TD>1.710e-02</TD><TD>-4.07</TD><TD>GSE17721_CPG_VS_GARDIQUIMOD_24H_BMDC_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_CPG_VS_GARDIQUIMOD_24H_BMDC_UP</TD><TD>188</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,CDKN2A,SATB2</TD></TR>
<TR><TD>1.717e-02</TD><TD>-4.06</TD><TD>cellular ketone metabolic process</TD><TD>biological process</TD><TD>GO:0042180</TD><TD>71</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>1.724e-02</TD><TD>-4.06</TD><TD>PLASARI_TGFB1_TARGETS_1HR_DN</TD><TD>MSigDB lists</TD><TD>PLASARI_TGFB1_TARGETS_1HR_DN</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.724e-02</TD><TD>-4.06</TD><TD>chr6p11</TD><TD>MSigDB lists</TD><TD>chr6p11</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>ENPP5</TD></TR>
<TR><TD>1.724e-02</TD><TD>-4.06</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.724e-02</TD><TD>-4.06</TD><TD>TESAR_JAK_TARGETS_MOUSE_ES_D3_UP</TD><TD>MSigDB lists</TD><TD>TESAR_JAK_TARGETS_MOUSE_ES_D3_UP</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.724e-02</TD><TD>-4.06</TD><TD>GGCGGCA_MIR371</TD><TD>MSigDB lists</TD><TD>GGCGGCA_MIR371</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4</TD></TR>
<TR><TD>1.724e-02</TD><TD>-4.06</TD><TD>SEF1_C</TD><TD>MSigDB lists</TD><TD>SEF1_C</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.724e-02</TD><TD>-4.06</TD><TD>WEBER_METHYLATED_HCP_IN_FIBROBLAST_UP</TD><TD>MSigDB lists</TD><TD>WEBER_METHYLATED_HCP_IN_FIBROBLAST_UP</TD><TD>6</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>SPAG6</TD></TR>
<TR><TD>1.733e-02</TD><TD>-4.06</TD><TD>upper_aerodigestive_tract-sinonasal_and_nasal_cavity-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-sinonasal_and_nasal_cavity-carcinoma-squamous_cell_carcinoma</TD><TD>71</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,PCDH17</TD></TR>
<TR><TD>1.734e-02</TD><TD>-4.05</TD><TD>GSE17721_0.5H_VS_4H_POLYIC_BMDC_UP</TD><TD>MSigDB lists</TD><TD>GSE17721_0.5H_VS_4H_POLYIC_BMDC_UP</TD><TD>189</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,ENPP5,ZIC1</TD></TR>
<TR><TD>1.734e-02</TD><TD>-4.05</TD><TD>GSE16385_ROSIGLITAZONE_IFNG_TNF_VS_IL4_STIM_MACROPHAGE_UP</TD><TD>MSigDB lists</TD><TD>GSE16385_ROSIGLITAZONE_IFNG_TNF_VS_IL4_STIM_MACROPHAGE_UP</TD><TD>189</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GALNT13,SCGB3A2,KYNU</TD></TR>
<TR><TD>1.734e-02</TD><TD>-4.05</TD><TD>MORF_IFNA1</TD><TD>MSigDB lists</TD><TD>MORF_IFNA1</TD><TD>189</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,STAC,GABRB2</TD></TR>
<TR><TD>1.734e-02</TD><TD>-4.05</TD><TD>GSE39556_UNTREATED_VS_3H_POLYIC_INJ_MOUSE_CD8A_DC_UP</TD><TD>MSigDB lists</TD><TD>GSE39556_UNTREATED_VS_3H_POLYIC_INJ_MOUSE_CD8A_DC_UP</TD><TD>189</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,FST,MTSS1</TD></TR>
<TR><TD>1.741e-02</TD><TD>-4.05</TD><TD>human chr4q22.3</TD><TD>chromosome location</TD><TD>human chr4q22.3</TD><TD>9</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.741e-02</TD><TD>-4.05</TD><TD>human chrXq12</TD><TD>chromosome location</TD><TD>human chrXq12</TD><TD>9</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>EDA2R</TD></TR>
<TR><TD>1.753e-02</TD><TD>-4.04</TD><TD>thyroid-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thyroid-carcinoma</TD><TD>4202</TD><TD>19</TD><TD>17255</TD><TD>49</TD>
<TD>KYNU,GPC5,SPAG6,CRB1,ZFHX4,RBM11,PLAG1,PLCH1,RNF128,PCDH11X,GRIA2,USP2,DCDC2,NPTX2,EYA4,CDKN2A,ZIC1,LSR,AZGP1</TD></TR>
<TR><TD>1.758e-02</TD><TD>-4.04</TD><TD>GSE46606_DAY1_VS_DAY3_CD40L_IL2_IL5_STIMULATED_IRF4HIGH_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE46606_DAY1_VS_DAY3_CD40L_IL2_IL5_STIMULATED_IRF4HIGH_BCELL_UP</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EDA2R,MTSS1,GABRB2</TD></TR>
<TR><TD>1.758e-02</TD><TD>-4.04</TD><TD>GSE27670_CTRL_VS_LMP1_TRANSDUCED_GC_BCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE27670_CTRL_VS_LMP1_TRANSDUCED_GC_BCELL_UP</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,LSR,CLDN1</TD></TR>
<TR><TD>1.758e-02</TD><TD>-4.04</TD><TD>GSE29164_DAY3_VS_DAY7_CD8_TCELL_AND_IL12_TREATED_MELANOMA_DN</TD><TD>MSigDB lists</TD><TD>GSE29164_DAY3_VS_DAY7_CD8_TCELL_AND_IL12_TREATED_MELANOMA_DN</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SPAG6,DCDC2,CRB1</TD></TR>
<TR><TD>1.758e-02</TD><TD>-4.04</TD><TD>GSE7764_IL15_TREATED_VS_CTRL_NK_CELL_24H_DN</TD><TD>MSigDB lists</TD><TD>GSE7764_IL15_TREATED_VS_CTRL_NK_CELL_24H_DN</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>RBM11,CPEB2,ZIC4</TD></TR>
<TR><TD>1.758e-02</TD><TD>-4.04</TD><TD>GSE22443_NAIVE_VS_ACT_AND_IL2_TREATED_CD8_TCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE22443_NAIVE_VS_ACT_AND_IL2_TREATED_CD8_TCELL_DN</TD><TD>190</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,PAX9,USP2</TD></TR>
<TR><TD>1.763e-02</TD><TD>-4.04</TD><TD>pancreas development</TD><TD>biological process</TD><TD>GO:0031016</TD><TD>72</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2,MEIS2</TD></TR>
<TR><TD>1.779e-02</TD><TD>-4.03</TD><TD>cortisol_producing</TD><TD>COSMIC cancer mutations</TD><TD>cortisol_producing</TD><TD>72</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH17,GRIA2</TD></TR>
<TR><TD>1.779e-02</TD><TD>-4.03</TD><TD>adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-cortisol_producing</TD><TD>COSMIC cancer mutations</TD><TD>adrenal_gland-adrenal_gland-adrenal_cortical_adenoma-cortisol_producing</TD><TD>72</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>GRIA2,PCDH17</TD></TR>
<TR><TD>1.780e-02</TD><TD>-4.03</TD><TD>kidney-carcinoma-clear_cell_renal_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>kidney-carcinoma-clear_cell_renal_cell_carcinoma</TD><TD>14203</TD><TD>46</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH17,CXCL14,CPEB2,LSR,ZIC1,ALX1,IL7,DCDC2,SLC6A15,RNF128,PLCH1,PLAG1,USP2,GRIA2,PCDH11X,HEY1,ZFHX4,KYNU,EDA2R,PLEKHM3,MEIS2,AZGP1,ENPP5,PAPPA,SATB2,PAX9,CDKN2A,ZIC4,HS3ST3B1,EYA4,CLVS2,PCDH20,PEX5L,FOXA2,NPTX2,EPHA3,IDO2,BMPR1B,RBM11,CRB1,GALNT13,SPAG6,MTSS1,STAC,SCGB3A2,GPC5</TD></TR>
<TR><TD>1.780e-02</TD><TD>-4.03</TD><TD>clear_cell_renal_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>clear_cell_renal_cell_carcinoma</TD><TD>14203</TD><TD>46</TD><TD>17255</TD><TD>49</TD>
<TD>SCGB3A2,GPC5,SPAG6,MTSS1,STAC,CRB1,GALNT13,RBM11,FOXA2,NPTX2,BMPR1B,EPHA3,IDO2,PCDH20,CLVS2,PEX5L,EYA4,HS3ST3B1,ZIC4,CDKN2A,MEIS2,AZGP1,ENPP5,PAPPA,SATB2,PAX9,KYNU,EDA2R,PLEKHM3,ZFHX4,HEY1,PLCH1,RNF128,PLAG1,GRIA2,USP2,PCDH11X,DCDC2,SLC6A15,ALX1,IL7,ZIC1,LSR,PCDH17,CXCL14,CPEB2</TD></TR>
<TR><TD>1.782e-02</TD><TD>-4.03</TD><TD>GSE43955_1H_VS_10H_ACT_CD4_TCELL_WITH_TGFB_IL6_DN</TD><TD>MSigDB lists</TD><TD>GSE43955_1H_VS_10H_ACT_CD4_TCELL_WITH_TGFB_IL6_DN</TD><TD>191</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,AZGP1,BMPR1B</TD></TR>
<TR><TD>1.782e-02</TD><TD>-4.03</TD><TD>GSE41978_ID2_KO_VS_ID2_KO_AND_BIM_KO_KLRG1_LOW_EFFECTOR_CD8_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE41978_ID2_KO_VS_ID2_KO_AND_BIM_KO_KLRG1_LOW_EFFECTOR_CD8_TCELL_UP</TD><TD>191</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH20,SPAG6,STAC</TD></TR>
<TR><TD>1.797e-02</TD><TD>-4.02</TD><TD>GO_ASSOCIATIVE_LEARNING</TD><TD>MSigDB lists</TD><TD>GO_ASSOCIATIVE_LEARNING</TD><TD>71</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,NPTX2</TD></TR>
<TR><TD>1.797e-02</TD><TD>-4.02</TD><TD>GCAAGGA_MIR502</TD><TD>MSigDB lists</TD><TD>GCAAGGA_MIR502</TD><TD>71</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,IDO2</TD></TR>
<TR><TD>1.807e-02</TD><TD>-4.01</TD><TD>GSE17721_POLYIC_VS_CPG_1H_BMDC_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_POLYIC_VS_CPG_1H_BMDC_DN</TD><TD>192</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2,CPEB2</TD></TR>
<TR><TD>1.807e-02</TD><TD>-4.01</TD><TD>GO_EAR_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_EAR_DEVELOPMENT</TD><TD>192</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,ZIC1,GABRB2</TD></TR>
<TR><TD>1.807e-02</TD><TD>-4.01</TD><TD>GSE43957_UNTREATED_VS_NACL_TREATED_ANTI_CD3_CD28_STIM_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE43957_UNTREATED_VS_NACL_TREATED_ANTI_CD3_CD28_STIM_CD4_TCELL_UP</TD><TD>192</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,FOXA2,ZIC4</TD></TR>
<TR><TD>1.809e-02</TD><TD>-4.01</TD><TD>PTPRD (protein tyrosine phosphatase receptor type D)</TD><TD>protein interactions</TD><TD>5789</TD><TD>72</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20,MTSS1</TD></TR>
<TR><TD>1.810e-02</TD><TD>-4.01</TD><TD>regulation of neurotransmitter receptor activity</TD><TD>biological process</TD><TD>GO:0099601</TD><TD>73</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>GRIA2,NPTX2</TD></TR>
<TR><TD>1.811e-02</TD><TD>-4.01</TD><TD>cell periphery</TD><TD>cellular component</TD><TD>GO:0071944</TD><TD>5419</TD><TD>22</TD><TD>18985</TD><TD>51</TD>
<TD>AZGP1,GRIA2,CRB1,PLCH1,ARHGAP45,PLEKHM3,PCDH11X,GABRB2,SLC6A15,GPC5,HS3ST3B1,PCDH17,NPTX2,STAC,LSR,CLDN1,PCDH20,DCDC2,BMPR1B,EDA2R,EPHA3,ENPP5</TD></TR>
<TR><TD>1.813e-02</TD><TD>-4.01</TD><TD>ZF_DAG_PE_2</TD><TD>prosite domains</TD><TD>PS50081</TD><TD>61</TD><TD>2</TD><TD>12079</TD><TD>41</TD>
<TD>STAC,ARHGAP45</TD></TR>
<TR><TD>1.816e-02</TD><TD>-4.01</TD><TD>ORPHTRNSPORT</TD><TD>prints domains</TD><TD>PR01206</TD><TD>5</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.843e-02</TD><TD>-3.99</TD><TD>AH/BAR_dom_sf</TD><TD>interpro domains</TD><TD>IPR027267</TD><TD>76</TD><TD>2</TD><TD>18616</TD><TD>51</TD>
<TD>MTSS1,ARHGAP45</TD></TR>
<TR><TD>1.845e-02</TD><TD>-3.99</TD><TD>QUINTENS_EMBRYONIC_BRAIN_RESPONSE_TO_IR</TD><TD>MSigDB lists</TD><TD>QUINTENS_EMBRYONIC_BRAIN_RESPONSE_TO_IR</TD><TD>72</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,EDA2R</TD></TR>
<TR><TD>1.845e-02</TD><TD>-3.99</TD><TD>GO_CILIARY_PLASM</TD><TD>MSigDB lists</TD><TD>GO_CILIARY_PLASM</TD><TD>72</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>DCDC2,SPAG6</TD></TR>
<TR><TD>1.845e-02</TD><TD>-3.99</TD><TD>GO_CELL_CELL_JUNCTION_ASSEMBLY</TD><TD>MSigDB lists</TD><TD>GO_CELL_CELL_JUNCTION_ASSEMBLY</TD><TD>72</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>1.845e-02</TD><TD>-3.99</TD><TD>GO_PANCREAS_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_PANCREAS_DEVELOPMENT</TD><TD>72</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,FOXA2</TD></TR>
<TR><TD>1.846e-02</TD><TD>-3.99</TD><TD>transforming growth factor beta receptor activity, type I</TD><TD>molecular function</TD><TD>GO:0005025</TD><TD>7</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.846e-02</TD><TD>-3.99</TD><TD>[heparan sulfate]-glucosamine 3-sulfotransferase 1 activity</TD><TD>molecular function</TD><TD>GO:0008467</TD><TD>7</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>HS3ST3B1</TD></TR>
<TR><TD>1.846e-02</TD><TD>-3.99</TD><TD>GPI-linked ephrin receptor activity</TD><TD>molecular function</TD><TD>GO:0005004</TD><TD>7</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>1.857e-02</TD><TD>-3.99</TD><TD>BMPR2 (bone morphogenetic protein receptor type 2)</TD><TD>protein interactions</TD><TD>659</TD><TD>73</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>FST,BMPR1B</TD></TR>
<TR><TD>1.857e-02</TD><TD>-3.99</TD><TD>negative regulation of nucleobase-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0045934</TD><TD>1443</TD><TD>9</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A,PAX9,ZFHX4,FST,MEIS2,USP2,ALX1,SATB2,HEY1</TD></TR>
<TR><TD>1.857e-02</TD><TD>-3.99</TD><TD>GO_SKELETAL_SYSTEM_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_SKELETAL_SYSTEM_MORPHOGENESIS</TD><TD>194</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,ALX1,SATB2</TD></TR>
<TR><TD>1.857e-02</TD><TD>-3.99</TD><TD>GSE17721_PAM3CSK4_VS_GADIQUIMOD_12H_BMDC_DN</TD><TD>MSigDB lists</TD><TD>GSE17721_PAM3CSK4_VS_GADIQUIMOD_12H_BMDC_DN</TD><TD>194</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH20,EPHA3,GABRB2</TD></TR>
<TR><TD>1.857e-02</TD><TD>-3.99</TD><TD>HNF3ALPHA_Q6</TD><TD>MSigDB lists</TD><TD>HNF3ALPHA_Q6</TD><TD>194</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,FOXA2,PLAG1</TD></TR>
<TR><TD>1.857e-02</TD><TD>-3.99</TD><TD>GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN</TD><TD>MSigDB lists</TD><TD>GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN</TD><TD>194</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,FOXA2,CDKN2A</TD></TR>
<TR><TD>1.857e-02</TD><TD>-3.99</TD><TD>MODULE_67</TD><TD>MSigDB lists</TD><TD>MODULE_67</TD><TD>194</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,PEX5L,EYA4</TD></TR>
<TR><TD>1.886e-02</TD><TD>-3.97</TD><TD>DUF4206</TD><TD>smart domains</TD><TD>SM01175</TD><TD>5</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>PLEKHM3</TD></TR>
<TR><TD>1.887e-02</TD><TD>-3.97</TD><TD>stomach</TD><TD>COSMIC cancer mutations</TD><TD>stomach</TD><TD>15914</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>ENPP5,FST,PAPPA,AZGP1,MEIS2,PAX9,SATB2,HS3ST3B1,ZIC4,CDKN2A,EYA4,PEX5L,CLVS2,PCDH20,CLDN1,GABRB2,FOXA2,NPTX2,IDO2,BMPR1B,EPHA3,RBM11,CRB1,GALNT13,STAC,MTSS1,SPAG6,GPC5,SCGB3A2,CXCL14,CPEB2,PCDH17,LSR,ZIC1,IL7,ALX1,DCDC2,SLC6A15,PLAG1,PLCH1,RNF128,PCDH11X,USP2,GRIA2,HEY1,ZFHX4,KYNU,EDA2R,PLEKHM3</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>KUNINGER_IGF1_VS_PDGFB_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>KUNINGER_IGF1_VS_PDGFB_TARGETS_UP</TD><TD>73</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,FST</TD></TR>
<TR><TD>1.893e-02</TD><TD>-3.97</TD><TD>GO_EXTRACELLULAR_LIGAND_GATED_ION_CHANNEL_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_EXTRACELLULAR_LIGAND_GATED_ION_CHANNEL_ACTIVITY</TD><TD>73</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>1.895e-02</TD><TD>-3.97</TD><TD>positive regulation of RNA metabolic process</TD><TD>biological process</TD><TD>GO:0051254</TD><TD>1699</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>ZIC1,MEIS2,ZFHX4,FOXA2,BMPR1B,PAX9,ALX1,HEY1,PLAG1,SATB2</TD></TR>
<TR><TD>1.902e-02</TD><TD>-3.96</TD><TD>Notch_dom</TD><TD>interpro domains</TD><TD>IPR000800</TD><TD>7</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PAPPA</TD></TR>
<TR><TD>1.902e-02</TD><TD>-3.96</TD><TD>CUT_dom</TD><TD>interpro domains</TD><TD>IPR003350</TD><TD>7</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SATB2</TD></TR>
<TR><TD>1.902e-02</TD><TD>-3.96</TD><TD>GS_dom</TD><TD>interpro domains</TD><TD>IPR003605</TD><TD>7</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.903e-02</TD><TD>-3.96</TD><TD>GO_CELL_CELL_SIGNALING</TD><TD>MSigDB lists</TD><TD>GO_CELL_CELL_SIGNALING</TD><TD>737</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,CXCL14,NPTX2,GABRB2,GRIA2,CRB1</TD></TR>
<TR><TD>1.905e-02</TD><TD>-3.96</TD><TD>C6orf141 (chromosome 6 open reading frame 141)</TD><TD>protein interactions</TD><TD>135398</TD><TD>74</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>SATB2,PLCH1</TD></TR>
<TR><TD>1.908e-02</TD><TD>-3.96</TD><TD>RSRFC4_Q2</TD><TD>MSigDB lists</TD><TD>RSRFC4_Q2</TD><TD>196</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,GABRB2,USP2</TD></TR>
<TR><TD>1.908e-02</TD><TD>-3.96</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>MSigDB lists</TD><TD>MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN</TD><TD>196</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,MEIS2,EYA4</TD></TR>
<TR><TD>1.913e-02</TD><TD>-3.96</TD><TD>CACGTG_MYC_Q2</TD><TD>MSigDB lists</TD><TD>CACGTG_MYC_Q2</TD><TD>953</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,USP2,EYA4,SLC6A15,SATB2,RNF128,PLAG1</TD></TR>
<TR><TD>1.932e-02</TD><TD>-3.95</TD><TD>human chr14q13.3</TD><TD>chromosome location</TD><TD>human chr14q13.3</TD><TD>10</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>PAX9</TD></TR>
<TR><TD>1.933e-02</TD><TD>-3.95</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>MSigDB lists</TD><TD>RODWELL_AGING_KIDNEY_NO_BLOOD_UP</TD><TD>197</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,CLDN1,DCDC2</TD></TR>
<TR><TD>1.944e-02</TD><TD>-3.94</TD><TD>chondroblastoma</TD><TD>COSMIC cancer mutations</TD><TD>chondroblastoma</TD><TD>550</TD><TD>5</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH11X,MTSS1,GPC5,GALNT13,KYNU</TD></TR>
<TR><TD>1.950e-02</TD><TD>-3.94</TD><TD>Homeodomain</TD><TD>pfam domains</TD><TD>PF00046</TD><TD>203</TD><TD>3</TD><TD>17385</TD><TD>49</TD>
<TD>ALX1,SATB2,ZFHX4</TD></TR>
<TR><TD>1.957e-02</TD><TD>-3.93</TD><TD>TGF_beta_GS</TD><TD>pfam domains</TD><TD>PF08515</TD><TD>7</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.957e-02</TD><TD>-3.93</TD><TD>DCX</TD><TD>pfam domains</TD><TD>PF03607</TD><TD>7</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>DCDC2</TD></TR>
<TR><TD>1.957e-02</TD><TD>-3.93</TD><TD>CUT</TD><TD>pfam domains</TD><TD>PF02376</TD><TD>7</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>SATB2</TD></TR>
<TR><TD>1.957e-02</TD><TD>-3.93</TD><TD>CRAL_TRIO_N</TD><TD>pfam domains</TD><TD>PF03765</TD><TD>7</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>CLVS2</TD></TR>
<TR><TD>1.958e-02</TD><TD>-3.93</TD><TD>GO_CORE_PROMOTER_PROXIMAL_REGION_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_CORE_PROMOTER_PROXIMAL_REGION_DNA_BINDING</TD><TD>357</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,PLAG1,MEIS2,ZIC1</TD></TR>
<TR><TD>1.960e-02</TD><TD>-3.93</TD><TD>transmembrane receptor protein kinase activity</TD><TD>molecular function</TD><TD>GO:0019199</TD><TD>81</TD><TD>2</TD><TD>17306</TD><TD>46</TD>
<TD>EPHA3,BMPR1B</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>establishment of blood-brain barrier</TD><TD>biological process</TD><TD>GO:0060856</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>LSR</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>commitment of neuronal cell to specific neuron type in forebrain</TD><TD>biological process</TD><TD>GO:0021902</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>protein sulfation</TD><TD>biological process</TD><TD>GO:0006477</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HS3ST3B1</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>ectodermal cell differentiation</TD><TD>biological process</TD><TD>GO:0010668</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>EDA2R</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>L-kynurenine metabolic process</TD><TD>biological process</TD><TD>GO:0097052</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>antral ovarian follicle growth</TD><TD>biological process</TD><TD>GO:0001547</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>presynaptic active zone organization</TD><TD>biological process</TD><TD>GO:1990709</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PCDH17</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>mammalian oogenesis stage</TD><TD>biological process</TD><TD>GO:0022605</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.961e-02</TD><TD>-3.93</TD><TD>regulation of cardiac muscle myoblast proliferation</TD><TD>biological process</TD><TD>GO:0110022</TD><TD>7</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>central_nervous_system-spinal_cord-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-spinal_cord-glioma-astrocytoma_Grade_III</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>skin-lower_extremity-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_extremity-malignant_melanoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>pituitary-adenoma-multihormonal</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-multihormonal</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>skin-face-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-malignant_melanoma-nodular</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>bone-scapula-chordoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-scapula-chordoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>bone-extraskeletal-Askins_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-extraskeletal-Askins_tumour</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>mixed_serous_and_endometrioid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>mixed_serous_and_endometrioid_carcinoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>skin-upper_extremity-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-upper_extremity-malignant_melanoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>dysplastic</TD><TD>COSMIC cancer mutations</TD><TD>dysplastic</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>Barrett_oesophagus</TD><TD>COSMIC cancer mutations</TD><TD>Barrett_oesophagus</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>bone-femur-osteosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-osteosarcoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>oesophagus-other-Barrett_oesophagus</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-other-Barrett_oesophagus</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>skin-face-malignant_melanoma-acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>skin-face-malignant_melanoma-acral_lentiginous</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_II</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>haemangioblastoma</TD><TD>COSMIC cancer mutations</TD><TD>haemangioblastoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>bone-femur-osteosarcoma-osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-femur-osteosarcoma-osteoblastic</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>central_nervous_system-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>central_nervous_system-occipital_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-occipital_lobe-glioma-astrocytoma_Grade_II</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>endometrium-carcinoma-mixed_serous_and_endometrioid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-mixed_serous_and_endometrioid_carcinoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>skin-lower_back-benign_melanocytic_nevus-congenital</TD><TD>COSMIC cancer mutations</TD><TD>skin-lower_back-benign_melanocytic_nevus-congenital</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>Askins_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Askins_tumour</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>skin-benign_melanocytic_nevus-intradermal</TD><TD>COSMIC cancer mutations</TD><TD>skin-benign_melanocytic_nevus-intradermal</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>bone-osteosarcoma-osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-osteosarcoma-osteoblastic</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>bone-extraskeletal-chordoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-extraskeletal-chordoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>stomach-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>soft_tissue-blood_vessel-haemangioblastoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-blood_vessel-haemangioblastoma</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.971e-02</TD><TD>-3.93</TD><TD>bone-tibia-osteosarcoma-osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-osteosarcoma-osteoblastic</TD><TD>7</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.985e-02</TD><TD>-3.92</TD><TD>MODULE_342</TD><TD>MSigDB lists</TD><TD>MODULE_342</TD><TD>199</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,AZGP1,CXCL14</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>B4GALNT1 (beta-1,4-N-acetyl-galactosaminyltransferase 1)</TD><TD>protein interactions</TD><TD>2583</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>EFNA2 (ephrin A2)</TD><TD>protein interactions</TD><TD>1943</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>FAM222A (family with sequence similarity 222 member A)</TD><TD>protein interactions</TD><TD>84915</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>BMP5 (bone morphogenetic protein 5)</TD><TD>protein interactions</TD><TD>653</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>TBRG1 (transforming growth factor beta regulator 1)</TD><TD>protein interactions</TD><TD>84897</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>HOXA13 (homeobox A13)</TD><TD>protein interactions</TD><TD>3209</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>RGMB (repulsive guidance molecule BMP co-receptor b)</TD><TD>protein interactions</TD><TD>285704</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>TEX2 (testis expressed 2)</TD><TD>protein interactions</TD><TD>55852</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>LHX1 (LIM homeobox 1)</TD><TD>protein interactions</TD><TD>3975</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>Smad7 (SMAD family member 7)</TD><TD>protein interactions</TD><TD>17131</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>Ikbip (IKBKB interacting protein)</TD><TD>protein interactions</TD><TD>67454</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>AZGP1</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>Uhmk1 (U2AF homology motif (UHM) kinase 1)</TD><TD>protein interactions</TD><TD>16589</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>BMP15 (bone morphogenetic protein 15)</TD><TD>protein interactions</TD><TD>9210</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.988e-02</TD><TD>-3.92</TD><TD>Fbxo3 (F-box protein 3)</TD><TD>protein interactions</TD><TD>57443</TD><TD>7</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>1.992e-02</TD><TD>-3.92</TD><TD>FRIDMAN_SENESCENCE_UP</TD><TD>MSigDB lists</TD><TD>FRIDMAN_SENESCENCE_UP</TD><TD>75</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,CDKN2A</TD></TR>
<TR><TD>1.992e-02</TD><TD>-3.92</TD><TD>CTCCAAG_MIR432</TD><TD>MSigDB lists</TD><TD>CTCCAAG_MIR432</TD><TD>75</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2,CPEB2</TD></TR>
<TR><TD>2.000e-02</TD><TD>-3.91</TD><TD>regulation of smoothened signaling pathway</TD><TD>biological process</TD><TD>GO:0008589</TD><TD>77</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>ZIC1,DCDC2</TD></TR>
<TR><TD>2.000e-02</TD><TD>-3.91</TD><TD>adult locomotory behavior</TD><TD>biological process</TD><TD>GO:0008344</TD><TD>77</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>ZIC1,FOXA2</TD></TR>
<TR><TD>2.007e-02</TD><TD>-3.91</TD><TD>-</TD><TD>gene3d domains</TD><TD>1.20.1270.60</TD><TD>72</TD><TD>2</TD><TD>8522</TD><TD>26</TD>
<TD>ARHGAP45,MTSS1</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_9</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_9</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>TESAR_ALK_TARGETS_EPISC_4D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_EPISC_4D_UP</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>BUSA_SAM68_TARGETS_UP</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>IKEDA_MIR1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>IKEDA_MIR1_TARGETS_DN</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>LUCAS_HNF4A_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>LUCAS_HNF4A_TARGETS_DN</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>TESAR_ALK_TARGETS_EPISC_3D_UP</TD><TD>MSigDB lists</TD><TD>TESAR_ALK_TARGETS_EPISC_3D_UP</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>2.009e-02</TD><TD>-3.91</TD><TD>chrxq11</TD><TD>MSigDB lists</TD><TD>chrxq11</TD><TD>7</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.011e-02</TD><TD>-3.91</TD><TD>ATATGCA_MIR448</TD><TD>MSigDB lists</TD><TD>ATATGCA_MIR448</TD><TD>200</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2,ZFHX4,PAPPA</TD></TR>
<TR><TD>2.013e-02</TD><TD>-3.91</TD><TD>MORF_RAD51L3</TD><TD>MSigDB lists</TD><TD>MORF_RAD51L3</TD><TD>360</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,STAC,IL7,GABRB2</TD></TR>
<TR><TD>2.020e-02</TD><TD>-3.90</TD><TD>GLYPICAN</TD><TD>prosite domains</TD><TD>PS01207</TD><TD>6</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>GPC5</TD></TR>
<TR><TD>2.029e-02</TD><TD>-3.90</TD><TD>serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>serous_carcinoma</TD><TD>11226</TD><TD>39</TD><TD>17255</TD><TD>49</TD>
<TD>CLVS2,PCDH20,PEX5L,FOXA2,EPHA3,BMPR1B,IDO2,PAPPA,ENPP5,FST,MEIS2,AZGP1,PAX9,SATB2,CDKN2A,EYA4,STAC,SPAG6,MTSS1,GPC5,SCGB3A2,CRB1,GALNT13,IL7,ALX1,DCDC2,SLC6A15,PCDH17,ZIC1,LSR,KYNU,PLEKHM3,PLAG1,RNF128,PLCH1,PCDH11X,GRIA2,USP2,ZFHX4</TD></TR>
<TR><TD>2.042e-02</TD><TD>-3.89</TD><TD>STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP</TD><TD>MSigDB lists</TD><TD>STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP</TD><TD>76</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,CLDN1</TD></TR>
<TR><TD>2.049e-02</TD><TD>-3.89</TD><TD>associative learning</TD><TD>biological process</TD><TD>GO:0008306</TD><TD>78</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>MEIS2,NPTX2</TD></TR>
<TR><TD>2.052e-02</TD><TD>-3.89</TD><TD>Nedd4 (neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase)</TD><TD>protein interactions</TD><TD>25489</TD><TD>77</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>STAC,BMPR1B</TD></TR>
<TR><TD>2.064e-02</TD><TD>-3.88</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3</TD><TD>202</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,SLC6A15,GPC5</TD></TR>
<TR><TD>2.081e-02</TD><TD>-3.87</TD><TD>Release of Hh-Np from the secreting cell</TD><TD>REACTOME pathways</TD><TD>R-HSA-5362798</TD><TD>8</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GPC5</TD></TR>
<TR><TD>2.095e-02</TD><TD>-3.87</TD><TD>TATAAA_TATA_01</TD><TD>MSigDB lists</TD><TD>TATAAA_TATA_01</TD><TD>1200</TD><TD>8</TD><TD>17275</TD><TD>50</TD>
<TD>FST,STAC,PLAG1,SATB2,PAPPA,MEIS2,GABRB2,BMPR1B</TD></TR>
<TR><TD>2.109e-02</TD><TD>-3.86</TD><TD>NRAS (NRAS proto-oncogene, GTPase)</TD><TD>protein interactions</TD><TD>4893</TD><TD>369</TD><TD>4</TD><TD>17456</TD><TD>50</TD>
<TD>SLC6A15,PCDH11X,LSR,EPHA3</TD></TR>
<TR><TD>2.109e-02</TD><TD>-3.86</TD><TD>oesophagus</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus</TD><TD>15321</TD><TD>48</TD><TD>17255</TD><TD>49</TD>
<TD>CRB1,GALNT13,RBM11,GPC5,STAC,SPAG6,MTSS1,ZIC4,HS3ST3B1,CDKN2A,EYA4,ENPP5,FST,PAPPA,MEIS2,AZGP1,PAX9,SATB2,FOXA2,GABRB2,NPTX2,IDO2,EPHA3,BMPR1B,PEX5L,PCDH20,CLVS2,CLDN1,ZFHX4,HEY1,PLAG1,RNF128,PLCH1,PCDH11X,USP2,GRIA2,KYNU,PLEKHM3,EDA2R,LSR,ZIC1,CXCL14,CPEB2,PCDH17,DCDC2,SLC6A15,IL7,ALX1</TD></TR>
<TR><TD>2.117e-02</TD><TD>-3.86</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.10.20.230</TD><TD>7</TD><TD>1</TD><TD>8522</TD><TD>26</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.129e-02</TD><TD>-3.85</TD><TD>HFE-transferrin receptor complex</TD><TD>cellular component</TD><TD>GO:1990712</TD><TD>8</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.129e-02</TD><TD>-3.85</TD><TD>9+2 non-motile cilium</TD><TD>cellular component</TD><TD>GO:0097732</TD><TD>8</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.129e-02</TD><TD>-3.85</TD><TD>postsynaptic endocytic zone</TD><TD>cellular component</TD><TD>GO:0098843</TD><TD>8</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>GRIA2</TD></TR>
<TR><TD>2.129e-02</TD><TD>-3.85</TD><TD>kinocilium</TD><TD>cellular component</TD><TD>GO:0060091</TD><TD>8</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.144e-02</TD><TD>-3.84</TD><TD>MCAATNNNNNGCG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>MCAATNNNNNGCG_UNKNOWN</TD><TD>78</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,ZIC1</TD></TR>
<TR><TD>2.144e-02</TD><TD>-3.84</TD><TD>LEIN_MIDBRAIN_MARKERS</TD><TD>MSigDB lists</TD><TD>LEIN_MIDBRAIN_MARKERS</TD><TD>78</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,ZFHX4</TD></TR>
<TR><TD>2.152e-02</TD><TD>-3.84</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm</TD><TD>773</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>PEX5L,ZFHX4,CRB1,EPHA3,GPC5,GALNT13</TD></TR>
<TR><TD>2.161e-02</TD><TD>-3.83</TD><TD>plasma membrane bounded cell projection</TD><TD>cellular component</TD><TD>GO:0120025</TD><TD>2099</TD><TD>11</TD><TD>18985</TD><TD>51</TD>
<TD>NPTX2,GRIA2,ARHGAP45,SPAG6,CRB1,DCDC2,MTSS1,BMPR1B,GABRB2,CPEB2,EPHA3</TD></TR>
<TR><TD>2.171e-02</TD><TD>-3.83</TD><TD>Paired_dom</TD><TD>interpro domains</TD><TD>IPR001523</TD><TD>8</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.171e-02</TD><TD>-3.83</TD><TD>Doublecortin_dom</TD><TD>interpro domains</TD><TD>IPR003533</TD><TD>8</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.173e-02</TD><TD>-3.83</TD><TD>AAGCAAT_MIR137</TD><TD>MSigDB lists</TD><TD>AAGCAAT_MIR137</TD><TD>206</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,RNF128,DCDC2</TD></TR>
<TR><TD>2.176e-02</TD><TD>-3.83</TD><TD>ACTIVIN2R</TD><TD>prints domains</TD><TD>PR00653</TD><TD>6</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.189e-02</TD><TD>-3.82</TD><TD>positive regulation of gene expression</TD><TD>biological process</TD><TD>GO:0010628</TD><TD>2000</TD><TD>11</TD><TD>18054</TD><TD>51</TD>
<TD>ZIC1,MEIS2,ZFHX4,IL7,FOXA2,PAX9,BMPR1B,ALX1,HEY1,PLAG1,SATB2</TD></TR>
<TR><TD>2.195e-02</TD><TD>-3.82</TD><TD>GO_ADULT_LOCOMOTORY_BEHAVIOR</TD><TD>MSigDB lists</TD><TD>GO_ADULT_LOCOMOTORY_BEHAVIOR</TD><TD>79</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,ZIC1</TD></TR>
<TR><TD>2.200e-02</TD><TD>-3.82</TD><TD>MEF2_02</TD><TD>MSigDB lists</TD><TD>MEF2_02</TD><TD>207</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,USP2,GABRB2</TD></TR>
<TR><TD>2.204e-02</TD><TD>-3.81</TD><TD>CDC6 (cell division cycle 6)</TD><TD>protein interactions</TD><TD>990</TD><TD>80</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>HEY1,CDKN2A</TD></TR>
<TR><TD>2.219e-02</TD><TD>-3.81</TD><TD>SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP</TD><TD>MSigDB lists</TD><TD>SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP</TD><TD>371</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,KYNU,PAPPA,FST</TD></TR>
<TR><TD>2.233e-02</TD><TD>-3.80</TD><TD>PAX</TD><TD>pfam domains</TD><TD>PF00292</TD><TD>8</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.237e-02</TD><TD>-3.80</TD><TD>ConA-like_dom_sf</TD><TD>interpro domains</TD><TD>IPR013320</TD><TD>220</TD><TD>3</TD><TD>18616</TD><TD>51</TD>
<TD>PAPPA,NPTX2,CRB1</TD></TR>
<TR><TD>2.237e-02</TD><TD>-3.80</TD><TD>GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN</TD><TD>MSigDB lists</TD><TD>GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN</TD><TD>984</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,RNF128,HEY1,ENPP5,PLEKHM3,CPEB2,GRIA2</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>negative regulation of cytoplasmic translation</TD><TD>biological process</TD><TD>GO:2000766</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>cellular response to histamine</TD><TD>biological process</TD><TD>GO:0071420</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>atrioventricular valve formation</TD><TD>biological process</TD><TD>GO:0003190</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>blood vessel endothelial cell differentiation</TD><TD>biological process</TD><TD>GO:0060837</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>dorsal aorta morphogenesis</TD><TD>biological process</TD><TD>GO:0035912</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>glomerulus morphogenesis</TD><TD>biological process</TD><TD>GO:0072102</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>MTSS1</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>protein O-linked glycosylation via threonine</TD><TD>biological process</TD><TD>GO:0018243</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>GALNT13</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>hyperosmotic salinity response</TD><TD>biological process</TD><TD>GO:0042538</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.238e-02</TD><TD>-3.80</TD><TD>positive regulation of myeloid cell apoptotic process</TD><TD>biological process</TD><TD>GO:0033034</TD><TD>8</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.247e-02</TD><TD>-3.80</TD><TD>GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY</TD><TD>80</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,EPHA3</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>cranium</TD><TD>COSMIC cancer mutations</TD><TD>cranium</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>bone-skull-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-skull-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>meninges-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>meninges-malignant_melanoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>endometrium-carcinoma-mucinous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-mucinous_carcinoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>salivary_gland-parotid-carcinoma-mucoepidermoid_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-parotid-carcinoma-mucoepidermoid_carcinoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>central_nervous_system-posterior_fossa-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-posterior_fossa-glioma-astrocytoma_Grade_III</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>central_nervous_system-brain-other-central_neurocytoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-other-central_neurocytoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_II</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>testis-germ_cell_tumour-yolk_sac_tumour</TD><TD>COSMIC cancer mutations</TD><TD>testis-germ_cell_tumour-yolk_sac_tumour</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>central_neurocytoma</TD><TD>COSMIC cancer mutations</TD><TD>central_neurocytoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>actinic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>actinic_keratosis</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>multihormonal</TD><TD>COSMIC cancer mutations</TD><TD>multihormonal</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>cervical_intraepithelial_neoplasia_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>cervical_intraepithelial_neoplasia_Grade_I</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>bone-coccyx-chordoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-coccyx-chordoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>junctional</TD><TD>COSMIC cancer mutations</TD><TD>junctional</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>vulva-other-lichen_sclerosus</TD><TD>COSMIC cancer mutations</TD><TD>vulva-other-lichen_sclerosus</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>lichen_sclerosus</TD><TD>COSMIC cancer mutations</TD><TD>lichen_sclerosus</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>autonomic_ganglia-abdomen-paraganglioma-benign</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-abdomen-paraganglioma-benign</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>salivary_gland-parotid-adenoma-pleomorphic</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-parotid-adenoma-pleomorphic</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>eye-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>eye-malignant_melanoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-lymphoplasmacytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-lymphoplasmacytic_lymphoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>bone-tibia-osteosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-tibia-osteosarcoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>salivary_gland-retromolar-carcinoma-adenoid_cystic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-retromolar-carcinoma-adenoid_cystic_carcinoma</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>ovary-germ_cell_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>skin-neck-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-malignant_melanoma-nodular</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>skin-neck-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-neck-malignant_melanoma-superficial_spreading</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>central_nervous_system-basal_ganglia-glioma-astrocytoma_Grade_IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-basal_ganglia-glioma-astrocytoma_Grade_IV</TD><TD>8</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.250e-02</TD><TD>-3.79</TD><TD>endothelial cell differentiation</TD><TD>biological process</TD><TD>GO:0045446</TD><TD>82</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1,HEY1</TD></TR>
<TR><TD>2.253e-02</TD><TD>-3.79</TD><TD>TGF-beta signaling pathway</TD><TD>KEGG pathways</TD><TD>hsa04350</TD><TD>84</TD><TD>2</TD><TD>7161</TD><TD>20</TD>
<TD>FST,BMPR1B</TD></TR>
<TR><TD>2.253e-02</TD><TD>-3.79</TD><TD>TGF-beta signaling pathway</TD><TD>KEGG pathways</TD><TD>ko04350</TD><TD>84</TD><TD>2</TD><TD>7161</TD><TD>20</TD>
<TD>FST,BMPR1B</TD></TR>
<TR><TD>2.254e-02</TD><TD>-3.79</TD><TD>anterior/posterior pattern specification</TD><TD>biological process</TD><TD>GO:0009952</TD><TD>214</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,FOXA2,HEY1</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>ARHGEF25 (Rho guanine nucleotide exchange factor 25)</TD><TD>protein interactions</TD><TD>115557</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>KLF12 (Kruppel like factor 12)</TD><TD>protein interactions</TD><TD>11278</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>IDO2</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>Rasd2 (RASD family, member 2)</TD><TD>protein interactions</TD><TD>75141</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>ONECUT1 (one cut homeobox 1)</TD><TD>protein interactions</TD><TD>3175</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>LRRC3 (leucine rich repeat containing 3)</TD><TD>protein interactions</TD><TD>81543</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GALNT13</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>GRIP2 (glutamate receptor interacting protein 2)</TD><TD>protein interactions</TD><TD>80852</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GRIA2</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>ZNF580 (zinc finger protein 580)</TD><TD>protein interactions</TD><TD>51157</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>Faap100 (Fanconi anemia core complex associated protein 100)</TD><TD>protein interactions</TD><TD>71885</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>TRIM34 (tripartite motif containing 34)</TD><TD>protein interactions</TD><TD>53840</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>2.269e-02</TD><TD>-3.79</TD><TD>USP26 (ubiquitin specific peptidase 26)</TD><TD>protein interactions</TD><TD>83844</TD><TD>8</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.284e-02</TD><TD>-3.78</TD><TD>GO_REGULATION_OF_PROTEIN_STABILITY</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_PROTEIN_STABILITY</TD><TD>210</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,CDKN2A,RNF128</TD></TR>
<TR><TD>2.289e-02</TD><TD>-3.78</TD><TD>lung-carcinoma-bronchioloalveolar_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-bronchioloalveolar_adenocarcinoma</TD><TD>784</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH11X,SATB2,CDKN2A,GALNT13,EPHA3,BMPR1B</TD></TR>
<TR><TD>2.289e-02</TD><TD>-3.78</TD><TD>bronchioloalveolar_adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>bronchioloalveolar_adenocarcinoma</TD><TD>784</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,GALNT13,EPHA3,BMPR1B,PCDH11X,SATB2</TD></TR>
<TR><TD>2.293e-02</TD><TD>-3.78</TD><TD>FUJIWARA_PARK2_IN_LIVER_CANCER_UP</TD><TD>MSigDB lists</TD><TD>FUJIWARA_PARK2_IN_LIVER_CANCER_UP</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>2.293e-02</TD><TD>-3.78</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX6_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX6_UP</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA</TD></TR>
<TR><TD>2.293e-02</TD><TD>-3.78</TD><TD>CGCAAAA_MIR450</TD><TD>MSigDB lists</TD><TD>CGCAAAA_MIR450</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>2.293e-02</TD><TD>-3.78</TD><TD>OHM_EMBRYONIC_CARCINOMA_DN</TD><TD>MSigDB lists</TD><TD>OHM_EMBRYONIC_CARCINOMA_DN</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.293e-02</TD><TD>-3.78</TD><TD>PHONG_TNF_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>PHONG_TNF_TARGETS_DN</TD><TD>8</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.300e-02</TD><TD>-3.77</TD><TD>CAGGGTC_MIR504</TD><TD>MSigDB lists</TD><TD>CAGGGTC_MIR504</TD><TD>81</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,USP2</TD></TR>
<TR><TD>2.300e-02</TD><TD>-3.77</TD><TD>GO_PROTEOGLYCAN_METABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_PROTEOGLYCAN_METABOLIC_PROCESS</TD><TD>81</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,HS3ST3B1</TD></TR>
<TR><TD>2.300e-02</TD><TD>-3.77</TD><TD>CTGYNNCTYTAA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>CTGYNNCTYTAA_UNKNOWN</TD><TD>81</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,PEX5L</TD></TR>
<TR><TD>2.314e-02</TD><TD>-3.77</TD><TD>human chr10p12.2</TD><TD>chromosome location</TD><TD>human chr10p12.2</TD><TD>12</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>SPAG6</TD></TR>
<TR><TD>2.323e-02</TD><TD>-3.76</TD><TD>central</TD><TD>COSMIC cancer mutations</TD><TD>central</TD><TD>83</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>EPHA3,CDKN2A</TD></TR>
<TR><TD>2.337e-02</TD><TD>-3.76</TD><TD>ear development</TD><TD>biological process</TD><TD>GO:0043583</TD><TD>217</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>ZIC1,GABRB2,CXCL14</TD></TR>
<TR><TD>2.338e-02</TD><TD>-3.76</TD><TD>SMTTTTGT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>SMTTTTGT_UNKNOWN</TD><TD>377</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,MTSS1,USP2,MEIS2</TD></TR>
<TR><TD>2.341e-02</TD><TD>-3.75</TD><TD>OCT1_03</TD><TD>MSigDB lists</TD><TD>OCT1_03</TD><TD>212</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,NPTX2,PLAG1</TD></TR>
<TR><TD>2.341e-02</TD><TD>-3.75</TD><TD>CHX10_01</TD><TD>MSigDB lists</TD><TD>CHX10_01</TD><TD>212</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,ZFHX4,ZIC4</TD></TR>
<TR><TD>2.342e-02</TD><TD>-3.75</TD><TD>acinar_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>acinar_carcinoma</TD><TD>2014</TD><TD>11</TD><TD>17255</TD><TD>49</TD>
<TD>AZGP1,PAPPA,PLAG1,PCDH11X,ZFHX4,CDKN2A,HS3ST3B1,ZIC4,MTSS1,DCDC2,BMPR1B</TD></TR>
<TR><TD>2.342e-02</TD><TD>-3.75</TD><TD>pancreas-carcinoma-acinar_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoma-acinar_carcinoma</TD><TD>2014</TD><TD>11</TD><TD>17255</TD><TD>49</TD>
<TD>PLAG1,PAPPA,AZGP1,PCDH11X,HS3ST3B1,CDKN2A,ZIC4,ZFHX4,MTSS1,DCDC2,BMPR1B</TD></TR>
<TR><TD>2.353e-02</TD><TD>-3.75</TD><TD>GS</TD><TD>prosite domains</TD><TD>PS51256</TD><TD>7</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.353e-02</TD><TD>-3.75</TD><TD>CUT</TD><TD>prosite domains</TD><TD>PS51042</TD><TD>7</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>SATB2</TD></TR>
<TR><TD>2.353e-02</TD><TD>-3.75</TD><TD>AGGCACT_MIR5153P</TD><TD>MSigDB lists</TD><TD>AGGCACT_MIR5153P</TD><TD>82</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,SLC6A15</TD></TR>
<TR><TD>2.353e-02</TD><TD>-3.75</TD><TD>CAMPS_COLON_CANCER_COPY_NUMBER_UP</TD><TD>MSigDB lists</TD><TD>CAMPS_COLON_CANCER_COPY_NUMBER_UP</TD><TD>82</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PEX5L,PAX9</TD></TR>
<TR><TD>2.367e-02</TD><TD>-3.74</TD><TD>tumor necrosis factor-activated receptor activity</TD><TD>molecular function</TD><TD>GO:0005031</TD><TD>9</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.371e-02</TD><TD>-3.74</TD><TD>C1</TD><TD>smart domains</TD><TD>SM00109</TD><TD>63</TD><TD>2</TD><TD>9476</TD><TD>36</TD>
<TD>ARHGAP45,STAC</TD></TR>
<TR><TD>2.375e-02</TD><TD>-3.74</TD><TD>sinonasal_and_nasal_cavity</TD><TD>COSMIC cancer mutations</TD><TD>sinonasal_and_nasal_cavity</TD><TD>84</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,PCDH17</TD></TR>
<TR><TD>2.407e-02</TD><TD>-3.73</TD><TD>chr2q33</TD><TD>MSigDB lists</TD><TD>chr2q33</TD><TD>83</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,PLEKHM3</TD></TR>
<TR><TD>2.414e-02</TD><TD>-3.72</TD><TD>PIAS2 (protein inhibitor of activated STAT 2)</TD><TD>protein interactions</TD><TD>9063</TD><TD>84</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>PLAG1,CDKN2A</TD></TR>
<TR><TD>2.439e-02</TD><TD>-3.71</TD><TD>TB_dom</TD><TD>interpro domains</TD><TD>IPR017878</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>FST</TD></TR>
<TR><TD>2.439e-02</TD><TD>-3.71</TD><TD>Fol_N</TD><TD>interpro domains</TD><TD>IPR003645</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>FST</TD></TR>
<TR><TD>2.439e-02</TD><TD>-3.71</TD><TD>Secretoglobin</TD><TD>interpro domains</TD><TD>IPR016126</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>2.439e-02</TD><TD>-3.71</TD><TD>Doublecortin_dom_sf</TD><TD>interpro domains</TD><TD>IPR036572</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.439e-02</TD><TD>-3.71</TD><TD>Activin_recp</TD><TD>interpro domains</TD><TD>IPR000472</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.439e-02</TD><TD>-3.71</TD><TD>MHC_I_a_a1/a2</TD><TD>interpro domains</TD><TD>IPR001039</TD><TD>9</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>AZGP1</TD></TR>
<TR><TD>2.442e-02</TD><TD>-3.71</TD><TD>neuron development</TD><TD>biological process</TD><TD>GO:0048666</TD><TD>799</TD><TD>6</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B,EPHA3,GABRB2,NPTX2,DCDC2,CRB1</TD></TR>
<TR><TD>2.449e-02</TD><TD>-3.71</TD><TD>OTUB1 (OTU deubiquitinase, ubiquitin aldehyde binding 1)</TD><TD>protein interactions</TD><TD>55611</TD><TD>218</TD><TD>3</TD><TD>17456</TD><TD>50</TD>
<TD>RNF128,BMPR1B,CPEB2</TD></TR>
<TR><TD>2.461e-02</TD><TD>-3.70</TD><TD>KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION</TD><TD>MSigDB lists</TD><TD>KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION</TD><TD>84</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ENPP5,PAPPA</TD></TR>
<TR><TD>2.461e-02</TD><TD>-3.70</TD><TD>GO_PALATE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_PALATE_DEVELOPMENT</TD><TD>84</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,ALX1</TD></TR>
<TR><TD>2.461e-02</TD><TD>-3.70</TD><TD>CCAGGGG_MIR331</TD><TD>MSigDB lists</TD><TD>CCAGGGG_MIR331</TD><TD>84</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,MEIS2</TD></TR>
<TR><TD>2.479e-02</TD><TD>-3.70</TD><TD>connective tissue development</TD><TD>biological process</TD><TD>GO:0061448</TD><TD>222</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,BMPR1B,SATB2</TD></TR>
<TR><TD>2.480e-02</TD><TD>-3.70</TD><TD>MORF_FOSL1</TD><TD>MSigDB lists</TD><TD>MORF_FOSL1</TD><TD>384</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,STAC,IL7,GABRB2</TD></TR>
<TR><TD>2.509e-02</TD><TD>-3.69</TD><TD>Activin_recp</TD><TD>pfam domains</TD><TD>PF01064</TD><TD>9</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.509e-02</TD><TD>-3.69</TD><TD>Uteroglobin</TD><TD>pfam domains</TD><TD>PF01099</TD><TD>9</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>2.510e-02</TD><TD>-3.68</TD><TD>upper_arm</TD><TD>COSMIC cancer mutations</TD><TD>upper_arm</TD><TD>588</TD><TD>5</TD><TD>17255</TD><TD>49</TD>
<TD>CRB1,CDKN2A,PLCH1,CPEB2,PCDH17</TD></TR>
<TR><TD>2.511e-02</TD><TD>-3.68</TD><TD>ovary-carcinoma-serous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-carcinoma-serous_carcinoma</TD><TD>10941</TD><TD>38</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,EYA4,FST,PAPPA,ENPP5,MEIS2,AZGP1,PAX9,SATB2,FOXA2,BMPR1B,EPHA3,IDO2,PCDH20,PEX5L,CLVS2,CRB1,GALNT13,GPC5,SCGB3A2,STAC,MTSS1,SPAG6,ZIC1,LSR,PCDH17,DCDC2,SLC6A15,IL7,ALX1,ZFHX4,PLCH1,RNF128,PCDH11X,USP2,GRIA2,KYNU,PLEKHM3</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>dorsal aorta development</TD><TD>biological process</TD><TD>GO:0035907</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>ketone catabolic process</TD><TD>biological process</TD><TD>GO:0042182</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>inhibitory synapse assembly</TD><TD>biological process</TD><TD>GO:1904862</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>positive regulation of myoblast proliferation</TD><TD>biological process</TD><TD>GO:2000288</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>MEIS2</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>proline transport</TD><TD>biological process</TD><TD>GO:0015824</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>regulation of natural killer cell chemotaxis</TD><TD>biological process</TD><TD>GO:2000501</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CXCL14</TD></TR>
<TR><TD>2.514e-02</TD><TD>-3.68</TD><TD>regulation of synaptic vesicle clustering</TD><TD>biological process</TD><TD>GO:2000807</TD><TD>9</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PCDH17</TD></TR>
<TR><TD>2.516e-02</TD><TD>-3.68</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1</TD><TD>MSigDB lists</TD><TD>SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1</TD><TD>218</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,CLDN1,SATB2</TD></TR>
<TR><TD>2.516e-02</TD><TD>-3.68</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN</TD><TD>MSigDB lists</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN</TD><TD>85</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GALNT13,CPEB2</TD></TR>
<TR><TD>2.516e-02</TD><TD>-3.68</TD><TD>KEGG_TGF_BETA_SIGNALING_PATHWAY</TD><TD>MSigDB lists</TD><TD>KEGG_TGF_BETA_SIGNALING_PATHWAY</TD><TD>85</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>FST,BMPR1B</TD></TR>
<TR><TD>2.516e-02</TD><TD>-3.68</TD><TD>SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER</TD><TD>MSigDB lists</TD><TD>SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER</TD><TD>85</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH11X,FOXA2</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>frontotemporal</TD><TD>COSMIC cancer mutations</TD><TD>frontotemporal</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>ACTH_non_functioning</TD><TD>COSMIC cancer mutations</TD><TD>ACTH_non_functioning</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>upper_aerodigestive_tract-larynx-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-larynx-carcinoma</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>in_situ_epithelial_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>in_situ_epithelial_neoplasm</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>central_nervous_system-frontal_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontal_lobe-glioma-astrocytoma_Grade_II</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>skin-mucosal-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-mucosal-malignant_melanoma-nodular</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>skin-chest-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-chest-malignant_melanoma-superficial_spreading</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>peritoneum-mesothelioma-epithelial</TD><TD>COSMIC cancer mutations</TD><TD>peritoneum-mesothelioma-epithelial</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>central_nervous_system-frontal_lobe-glioma-oligodendroglioma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontal_lobe-glioma-oligodendroglioma_Grade_III</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma-pleomorphic</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-striated_muscle-rhabdomyosarcoma-pleomorphic</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>chronic_pancreatitis</TD><TD>COSMIC cancer mutations</TD><TD>chronic_pancreatitis</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>basal_ganglia</TD><TD>COSMIC cancer mutations</TD><TD>basal_ganglia</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>compound</TD><TD>COSMIC cancer mutations</TD><TD>compound</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>skin-other-seborrhoeic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>skin-other-seborrhoeic_keratosis</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>pancreas-other-chronic_pancreatitis</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-other-chronic_pancreatitis</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>Bowen_disease</TD><TD>COSMIC cancer mutations</TD><TD>Bowen_disease</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>coccyx</TD><TD>COSMIC cancer mutations</TD><TD>coccyx</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>bone-scapula-chondrosarcoma-central</TD><TD>COSMIC cancer mutations</TD><TD>bone-scapula-chondrosarcoma-central</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>sun_exposed_site</TD><TD>COSMIC cancer mutations</TD><TD>sun_exposed_site</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.528e-02</TD><TD>-3.68</TD><TD>central_nervous_system-medulla-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-glioma-astrocytoma_Grade_I</TD><TD>9</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.534e-02</TD><TD>-3.68</TD><TD>GO_REGULATORY_REGION_NUCLEIC_ACID_BINDING</TD><TD>MSigDB lists</TD><TD>GO_REGULATORY_REGION_NUCLEIC_ACID_BINDING</TD><TD>787</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,ALX1,PAX9,FOXA2,MEIS2,ZIC1</TD></TR>
<TR><TD>2.546e-02</TD><TD>-3.67</TD><TD>MEF2_03</TD><TD>MSigDB lists</TD><TD>MEF2_03</TD><TD>219</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,GABRB2,STAC</TD></TR>
<TR><TD>2.546e-02</TD><TD>-3.67</TD><TD>OCT1_04</TD><TD>MSigDB lists</TD><TD>OCT1_04</TD><TD>219</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>NPTX2,ZIC1,ZIC4</TD></TR>
<TR><TD>2.549e-02</TD><TD>-3.67</TD><TD>RAB38 (RAB38, member RAS oncogene family)</TD><TD>protein interactions</TD><TD>23682</TD><TD>9</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.549e-02</TD><TD>-3.67</TD><TD>EFNA3 (ephrin A3)</TD><TD>protein interactions</TD><TD>1944</TD><TD>9</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>2.549e-02</TD><TD>-3.67</TD><TD>PCDH17 (protocadherin 17)</TD><TD>protein interactions</TD><TD>27253</TD><TD>9</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>2.566e-02</TD><TD>-3.66</TD><TD>regulation of cell junction assembly</TD><TD>biological process</TD><TD>GO:1901888</TD><TD>88</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1,EPHA3</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>FUJIWARA_PARK2_HEPATOCYTE_PROLIFERATION_UP</TD><TD>MSigDB lists</TD><TD>FUJIWARA_PARK2_HEPATOCYTE_PROLIFERATION_UP</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>BENPORATH_ES_CORE_NINE</TD><TD>MSigDB lists</TD><TD>BENPORATH_ES_CORE_NINE</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>GO_REGULATION_OF_HEXOKINASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_HEXOKINASE_ACTIVITY</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>FREDERICK_PRKCI_TARGETS</TD><TD>MSigDB lists</TD><TD>FREDERICK_PRKCI_TARGETS</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_16</TD><TD>MSigDB lists</TD><TD>MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_16</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>GO_REGULATION_OF_CELL_CELL_ADHESION_MEDIATED_BY_CADHERIN</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_CELL_CELL_ADHESION_MEDIATED_BY_CADHERIN</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>MATZUK_CUMULUS_EXPANSION</TD><TD>MSigDB lists</TD><TD>MATZUK_CUMULUS_EXPANSION</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.576e-02</TD><TD>-3.66</TD><TD>MARSON_FOXP3_TARGETS_STIMULATED_DN</TD><TD>MSigDB lists</TD><TD>MARSON_FOXP3_TARGETS_STIMULATED_DN</TD><TD>9</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.579e-02</TD><TD>-3.66</TD><TD>ovary-other-neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>ovary-other-neoplasm</TD><TD>12999</TD><TD>43</TD><TD>17255</TD><TD>49</TD>
<TD>HEY1,ZFHX4,PCDH11X,GRIA2,USP2,PLAG1,RNF128,PLCH1,PLEKHM3,KYNU,ZIC1,LSR,CXCL14,PCDH17,SLC6A15,DCDC2,IL7,ALX1,GALNT13,CRB1,RBM11,GPC5,SCGB3A2,STAC,SPAG6,MTSS1,HS3ST3B1,CDKN2A,PAX9,SATB2,FST,PAPPA,AZGP1,MEIS2,BMPR1B,EPHA3,NPTX2,GABRB2,FOXA2,CLDN1,PCDH20,PEX5L,CLVS2</TD></TR>
<TR><TD>2.580e-02</TD><TD>-3.66</TD><TD>breast-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma</TD><TD>15396</TD><TD>48</TD><TD>17255</TD><TD>49</TD>
<TD>PLAG1,PLCH1,RNF128,PCDH11X,USP2,GRIA2,ZFHX4,HEY1,KYNU,EDA2R,PLEKHM3,CPEB2,PCDH17,LSR,ZIC1,IL7,ALX1,DCDC2,SLC6A15,RBM11,CRB1,GALNT13,STAC,SPAG6,MTSS1,GPC5,SCGB3A2,PAPPA,ENPP5,FST,AZGP1,MEIS2,PAX9,SATB2,HS3ST3B1,ZIC4,CDKN2A,EYA4,PEX5L,CLVS2,PCDH20,CLDN1,NPTX2,FOXA2,GABRB2,BMPR1B,IDO2,EPHA3</TD></TR>
<TR><TD>2.592e-02</TD><TD>-3.65</TD><TD>breast-carcinoma-HER-positive_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>breast-carcinoma-HER-positive_carcinoma</TD><TD>2045</TD><TD>11</TD><TD>17255</TD><TD>49</TD>
<TD>EPHA3,BMPR1B,PLEKHM3,GPC5,DCDC2,USP2,PLCH1,PLAG1,FST,HEY1,CDKN2A</TD></TR>
<TR><TD>2.592e-02</TD><TD>-3.65</TD><TD>HER-positive_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>HER-positive_carcinoma</TD><TD>2045</TD><TD>11</TD><TD>17255</TD><TD>49</TD>
<TD>HEY1,CDKN2A,PLCH1,FST,PLAG1,USP2,DCDC2,BMPR1B,EPHA3,PLEKHM3,GPC5</TD></TR>
<TR><TD>2.600e-02</TD><TD>-3.65</TD><TD>GO_CELL_CELL_ADHESION</TD><TD>MSigDB lists</TD><TD>GO_CELL_CELL_ADHESION</TD><TD>582</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH20,CLDN1,PCDH11X,IL7,PCDH17</TD></TR>
<TR><TD>2.606e-02</TD><TD>-3.65</TD><TD>E2F1_Q6_01</TD><TD>MSigDB lists</TD><TD>E2F1_Q6_01</TD><TD>221</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,MEIS2,USP2</TD></TR>
<TR><TD>2.606e-02</TD><TD>-3.65</TD><TD>DELYS_THYROID_CANCER_DN</TD><TD>MSigDB lists</TD><TD>DELYS_THYROID_CANCER_DN</TD><TD>221</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLCH1,EPHA3,MEIS2</TD></TR>
<TR><TD>2.620e-02</TD><TD>-3.64</TD><TD>roof of mouth development</TD><TD>biological process</TD><TD>GO:0060021</TD><TD>89</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,SATB2</TD></TR>
<TR><TD>2.630e-02</TD><TD>-3.64</TD><TD>NL</TD><TD>smart domains</TD><TD>SM00004</TD><TD>7</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>PAPPA</TD></TR>
<TR><TD>2.630e-02</TD><TD>-3.64</TD><TD>GS</TD><TD>smart domains</TD><TD>SM00467</TD><TD>7</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.630e-02</TD><TD>-3.64</TD><TD>CUT</TD><TD>smart domains</TD><TD>SM01109</TD><TD>7</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>SATB2</TD></TR>
<TR><TD>2.632e-02</TD><TD>-3.64</TD><TD>HNRNPLL (heterogeneous nuclear ribonucleoprotein L like)</TD><TD>protein interactions</TD><TD>92906</TD><TD>88</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>ZFHX4,HEY1</TD></TR>
<TR><TD>2.636e-02</TD><TD>-3.64</TD><TD>MZF1_02</TD><TD>MSigDB lists</TD><TD>MZF1_02</TD><TD>222</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,CXCL14,MEIS2</TD></TR>
<TR><TD>2.655e-02</TD><TD>-3.63</TD><TD>messenger ribonucleoprotein complex</TD><TD>cellular component</TD><TD>GO:1990124</TD><TD>10</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>SOX9_B1</TD><TD>MSigDB lists</TD><TD>SOX9_B1</TD><TD>223</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,ZIC1,ZIC4</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>GO_CELL_FATE_COMMITMENT</TD><TD>MSigDB lists</TD><TD>GO_CELL_FATE_COMMITMENT</TD><TD>223</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,SATB2,IL7</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>NFKB_Q6_01</TD><TD>MSigDB lists</TD><TD>NFKB_Q6_01</TD><TD>223</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,PAPPA,IL7</TD></TR>
<TR><TD>2.667e-02</TD><TD>-3.62</TD><TD>CHOP_01</TD><TD>MSigDB lists</TD><TD>CHOP_01</TD><TD>223</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>STAC,FST,PCDH17</TD></TR>
<TR><TD>2.683e-02</TD><TD>-3.62</TD><TD>GO_REGULATION_OF_CELL_MATRIX_ADHESION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_CELL_MATRIX_ADHESION</TD><TD>88</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,EPHA3</TD></TR>
<TR><TD>2.684e-02</TD><TD>-3.62</TD><TD>PAIRED_1</TD><TD>prosite domains</TD><TD>PS00034</TD><TD>8</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.684e-02</TD><TD>-3.62</TD><TD>PAIRED_2</TD><TD>prosite domains</TD><TD>PS51057</TD><TD>8</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.684e-02</TD><TD>-3.62</TD><TD>DC</TD><TD>prosite domains</TD><TD>PS50309</TD><TD>8</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>DCDC2</TD></TR>
<TR><TD>2.688e-02</TD><TD>-3.62</TD><TD>CCDC88A (coiled-coil domain containing 88A)</TD><TD>protein interactions</TD><TD>55704</TD><TD>89</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>EYA4,HEY1</TD></TR>
<TR><TD>2.688e-02</TD><TD>-3.62</TD><TD>MDM4 (MDM4 regulator of p53)</TD><TD>protein interactions</TD><TD>4194</TD><TD>89</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>USP2,CDKN2A</TD></TR>
<TR><TD>2.693e-02</TD><TD>-3.61</TD><TD>MORF_MAGEA9</TD><TD>MSigDB lists</TD><TD>MORF_MAGEA9</TD><TD>394</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,GABRB2,IL7,STAC</TD></TR>
<TR><TD>2.695e-02</TD><TD>-3.61</TD><TD>human chr9q33.1</TD><TD>chromosome location</TD><TD>human chr9q33.1</TD><TD>14</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>PAPPA</TD></TR>
<TR><TD>2.698e-02</TD><TD>-3.61</TD><TD>POU1F1_Q6</TD><TD>MSigDB lists</TD><TD>POU1F1_Q6</TD><TD>224</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,ZIC1,MEIS2</TD></TR>
<TR><TD>2.707e-02</TD><TD>-3.61</TD><TD>TB_dom_sf</TD><TD>interpro domains</TD><TD>IPR036773</TD><TD>10</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>FST</TD></TR>
<TR><TD>2.707e-02</TD><TD>-3.61</TD><TD>Phosphodiest/P_Trfase</TD><TD>interpro domains</TD><TD>IPR002591</TD><TD>10</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>ENPP5</TD></TR>
<TR><TD>2.728e-02</TD><TD>-3.60</TD><TD>cell projection</TD><TD>cellular component</TD><TD>GO:0042995</TD><TD>2174</TD><TD>11</TD><TD>18985</TD><TD>51</TD>
<TD>DCDC2,MTSS1,GABRB2,CPEB2,BMPR1B,EPHA3,NPTX2,GRIA2,CRB1,ARHGAP45,SPAG6</TD></TR>
<TR><TD>2.729e-02</TD><TD>-3.60</TD><TD>CTTTGCA_MIR527</TD><TD>MSigDB lists</TD><TD>CTTTGCA_MIR527</TD><TD>225</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,SATB2,ENPP5</TD></TR>
<TR><TD>2.729e-02</TD><TD>-3.60</TD><TD>GO_TRANSCRIPTIONAL_ACTIVATOR_ACTIVITY_RNA_POLYMERASE_II_CORE_PROMOTER_PROXIMAL_REGION_SEQUENCE_SPECIFIC_BINDING</TD><TD>MSigDB lists</TD><TD>GO_TRANSCRIPTIONAL_ACTIVATOR_ACTIVITY_RNA_POLYMERASE_II_CORE_PROMOTER_PROXIMAL_REGION_SEQUENCE_SPECIFIC_BINDING</TD><TD>225</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZIC1,PLAG1</TD></TR>
<TR><TD>2.740e-02</TD><TD>-3.60</TD><TD>HOLLERN_EMT_BREAST_TUMOR_DN</TD><TD>MSigDB lists</TD><TD>HOLLERN_EMT_BREAST_TUMOR_DN</TD><TD>89</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,LSR</TD></TR>
<TR><TD>2.747e-02</TD><TD>-3.59</TD><TD>L-tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde</TD><TD>BIOCYC pathways</TD><TD>META_PWY-5651</TD><TD>5</TD><TD>1</TD><TD>902</TD><TD>5</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.760e-02</TD><TD>-3.59</TD><TD>GATA1_01</TD><TD>MSigDB lists</TD><TD>GATA1_01</TD><TD>226</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>HS3ST3B1,ZIC4,ZIC1</TD></TR>
<TR><TD>2.784e-02</TD><TD>-3.58</TD><TD>Phosphodiest</TD><TD>pfam domains</TD><TD>PF01663</TD><TD>10</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>ENPP5</TD></TR>
<TR><TD>2.784e-02</TD><TD>-3.58</TD><TD>Pentaxin</TD><TD>pfam domains</TD><TD>PF00354</TD><TD>10</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.786e-02</TD><TD>-3.58</TD><TD>proteoglycan metabolic process</TD><TD>biological process</TD><TD>GO:0006029</TD><TD>92</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B,HS3ST3B1</TD></TR>
<TR><TD>2.786e-02</TD><TD>-3.58</TD><TD>negative regulation of cellular metabolic process</TD><TD>biological process</TD><TD>GO:0031324</TD><TD>2627</TD><TD>13</TD><TD>18054</TD><TD>51</TD>
<TD>FST,RNF128,MEIS2,ZFHX4,FOXA2,PAX9,CDKN2A,PCDH11X,HEY1,SATB2,CPEB2,ALX1,USP2</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>primitive streak formation</TD><TD>biological process</TD><TD>GO:0090009</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>forebrain neuron fate commitment</TD><TD>biological process</TD><TD>GO:0021877</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>positive regulation of cell-cell adhesion mediated by cadherin</TD><TD>biological process</TD><TD>GO:2000049</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>regulation of macrophage apoptotic process</TD><TD>biological process</TD><TD>GO:2000109</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>regulation of protein catabolic process in the vacuole</TD><TD>biological process</TD><TD>GO:1904350</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>RNF128</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>heterochromatin assembly</TD><TD>biological process</TD><TD>GO:0031507</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>regulation of glucokinase activity</TD><TD>biological process</TD><TD>GO:0033131</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>negative regulation of activin receptor signaling pathway</TD><TD>biological process</TD><TD>GO:0032926</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FST</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>protein O-linked glycosylation via serine</TD><TD>biological process</TD><TD>GO:0018242</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>GALNT13</TD></TR>
<TR><TD>2.790e-02</TD><TD>-3.58</TD><TD>response to interleukin-18</TD><TD>biological process</TD><TD>GO:0070673</TD><TD>10</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.791e-02</TD><TD>-3.58</TD><TD>NKX62_Q2</TD><TD>MSigDB lists</TD><TD>NKX62_Q2</TD><TD>227</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,ZIC4,PLAG1</TD></TR>
<TR><TD>2.791e-02</TD><TD>-3.58</TD><TD>FOXO1_02</TD><TD>MSigDB lists</TD><TD>FOXO1_02</TD><TD>227</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,PLAG1,SATB2</TD></TR>
<TR><TD>2.797e-02</TD><TD>-3.58</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP</TD><TD>MSigDB lists</TD><TD>GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP</TD><TD>90</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,IL7</TD></TR>
<TR><TD>2.797e-02</TD><TD>-3.58</TD><TD>GO_ALPHA_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_ALPHA_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>90</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>2.797e-02</TD><TD>-3.58</TD><TD>ACAWYAAAG_UNKNOWN</TD><TD>MSigDB lists</TD><TD>ACAWYAAAG_UNKNOWN</TD><TD>90</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,GABRB2</TD></TR>
<TR><TD>2.797e-02</TD><TD>-3.58</TD><TD>GAGACTG_MIR452</TD><TD>MSigDB lists</TD><TD>GAGACTG_MIR452</TD><TD>90</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,PCDH17</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>skin-abdomen-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-abdomen-malignant_melanoma-superficial_spreading</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>skin-shoulder-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-shoulder-malignant_melanoma-superficial_spreading</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>kidney-carcinoma-renal_cell_carcinoma_unclassified</TD><TD>COSMIC cancer mutations</TD><TD>kidney-carcinoma-renal_cell_carcinoma_unclassified</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>pancreas-carcinoid-endocrine_tumour-gastrinoma</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoid-endocrine_tumour-gastrinoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>testis-germ_cell_tumour-teratoma</TD><TD>COSMIC cancer mutations</TD><TD>testis-germ_cell_tumour-teratoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>central_nervous_system-frontal_lobe-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-frontal_lobe-glioma-astrocytoma_Grade_III</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>upper_aerodigestive_tract-sinonasal_and_nasal_cavity-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-sinonasal_and_nasal_cavity-carcinoma-adenocarcinoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>ovary-adenoma-Brenner_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-adenoma-Brenner_tumour</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>large_intestine-left-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-left-carcinoma-adenocarcinoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>large_intestine-right-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_intestine-right-carcinoma-adenocarcinoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>elbow</TD><TD>COSMIC cancer mutations</TD><TD>elbow</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>stomach-carcinoid-endocrine_tumour</TD><TD>COSMIC cancer mutations</TD><TD>stomach-carcinoid-endocrine_tumour</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>ovary-germ_cell_tumour-mixed</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-mixed</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>skin-back-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-malignant_melanoma-nodular</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>metaplasia</TD><TD>COSMIC cancer mutations</TD><TD>metaplasia</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>osteoblastic</TD><TD>COSMIC cancer mutations</TD><TD>osteoblastic</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>central_nervous_system-cerebral_cortex-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebral_cortex-glioma-astrocytoma_Grade_II</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>intradermal</TD><TD>COSMIC cancer mutations</TD><TD>intradermal</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>cervical_intraepithelial_neoplasia_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>cervical_intraepithelial_neoplasia_Grade_III</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-MALT_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-MALT_lymphoma</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.804e-02</TD><TD>-3.57</TD><TD>renal_cell_carcinoma_unclassified</TD><TD>COSMIC cancer mutations</TD><TD>renal_cell_carcinoma_unclassified</TD><TD>10</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.813e-02</TD><TD>-3.57</TD><TD>plasma membrane</TD><TD>cellular component</TD><TD>GO:0005886</TD><TD>5298</TD><TD>21</TD><TD>18985</TD><TD>51</TD>
<TD>GPC5,STAC,NPTX2,HS3ST3B1,PCDH17,CLDN1,LSR,PCDH20,EDA2R,BMPR1B,EPHA3,ENPP5,GRIA2,AZGP1,PCDH11X,PLEKHM3,PLCH1,ARHGAP45,CRB1,GABRB2,SLC6A15</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>NAD Biosynthesis II (from tryptophan)</TD><TD>WikiPathways</TD><TD>WP2485</TD><TD>8</TD><TD>1</TD><TD>5311</TD><TD>19</TD>
<TD>KYNU</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>BAMBI (BMP and activin membrane bound inhibitor)</TD><TD>protein interactions</TD><TD>25805</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>ZNF227 (zinc finger protein 227)</TD><TD>protein interactions</TD><TD>7770</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>TJP3 (tight junction protein 3)</TD><TD>protein interactions</TD><TD>27134</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>URGCP (upregulator of cell proliferation)</TD><TD>protein interactions</TD><TD>55665</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EYA4</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>ERI3 (ERI1 exoribonuclease family member 3)</TD><TD>protein interactions</TD><TD>79033</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>HHV8GK18_gp82 (ORF72)</TD><TD>protein interactions</TD><TD>4961471</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>TDRD7 (tudor domain containing 7)</TD><TD>protein interactions</TD><TD>23424</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>CLDN3 (claudin 3)</TD><TD>protein interactions</TD><TD>1365</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CLDN1</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>INHA (inhibin subunit alpha)</TD><TD>protein interactions</TD><TD>3623</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>2.828e-02</TD><TD>-3.57</TD><TD>EFNA4 (ephrin A4)</TD><TD>protein interactions</TD><TD>1945</TD><TD>10</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>2.836e-02</TD><TD>-3.56</TD><TD>GEORGES_TARGETS_OF_MIR192_AND_MIR215</TD><TD>MSigDB lists</TD><TD>GEORGES_TARGETS_OF_MIR192_AND_MIR215</TD><TD>808</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>HS3ST3B1,SATB2,CDKN2A,MTSS1,IL7,MEIS2</TD></TR>
<TR><TD>2.842e-02</TD><TD>-3.56</TD><TD>embryonic skeletal system morphogenesis</TD><TD>biological process</TD><TD>GO:0048704</TD><TD>93</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,ALX1</TD></TR>
<TR><TD>2.842e-02</TD><TD>-3.56</TD><TD>synapse assembly</TD><TD>biological process</TD><TD>GO:0007416</TD><TD>93</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>PCDH17,GABRB2</TD></TR>
<TR><TD>2.844e-02</TD><TD>-3.56</TD><TD>EphrinA-EPHA pathway</TD><TD>Pathway Interaction DB</TD><TD>ephrina_ephapathway</TD><TD>8</TD><TD>1</TD><TD>2226</TD><TD>8</TD>
<TD>EPHA3</TD></TR>
<TR><TD>2.849e-02</TD><TD>-3.56</TD><TD>GO_EMBRYONIC_ORGAN_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_EMBRYONIC_ORGAN_DEVELOPMENT</TD><TD>401</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,HEY1,ALX1,SATB2</TD></TR>
<TR><TD>2.855e-02</TD><TD>-3.56</TD><TD>CEBPA_01</TD><TD>MSigDB lists</TD><TD>CEBPA_01</TD><TD>229</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,MEIS2,SLC6A15</TD></TR>
<TR><TD>2.855e-02</TD><TD>-3.56</TD><TD>MACAEVA_PBMC_RESPONSE_TO_IR</TD><TD>MSigDB lists</TD><TD>MACAEVA_PBMC_RESPONSE_TO_IR</TD><TD>91</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>EDA2R,PAPPA</TD></TR>
<TR><TD>2.858e-02</TD><TD>-3.56</TD><TD>GO_PRIMITIVE_STREAK_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_PRIMITIVE_STREAK_FORMATION</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>2.858e-02</TD><TD>-3.56</TD><TD>GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_DN</TD><TD>MSigDB lists</TD><TD>GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_DN</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1</TD></TR>
<TR><TD>2.858e-02</TD><TD>-3.56</TD><TD>GO_RESPONSE_TO_HISTAMINE</TD><TD>MSigDB lists</TD><TD>GO_RESPONSE_TO_HISTAMINE</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2</TD></TR>
<TR><TD>2.858e-02</TD><TD>-3.56</TD><TD>MIKKELSEN_PARTIALLY_REPROGRAMMED_TO_PLURIPOTENCY</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_PARTIALLY_REPROGRAMMED_TO_PLURIPOTENCY</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>2.858e-02</TD><TD>-3.56</TD><TD>GO_MHC_CLASS_I_PROTEIN_COMPLEX</TD><TD>MSigDB lists</TD><TD>GO_MHC_CLASS_I_PROTEIN_COMPLEX</TD><TD>10</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1</TD></TR>
<TR><TD>2.871e-02</TD><TD>-3.55</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN</TD><TD>402</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH20,GABRB2,PEX5L,PAPPA</TD></TR>
<TR><TD>2.885e-02</TD><TD>-3.55</TD><TD>human chr21q11.2</TD><TD>chromosome location</TD><TD>human chr21q11.2</TD><TD>15</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>RBM11</TD></TR>
<TR><TD>2.886e-02</TD><TD>-3.55</TD><TD>death receptor activity</TD><TD>molecular function</TD><TD>GO:0005035</TD><TD>11</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>EDA2R</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.55</TD><TD>MTF1_Q4</TD><TD>MSigDB lists</TD><TD>MTF1_Q4</TD><TD>230</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,MTSS1,FST</TD></TR>
<TR><TD>2.887e-02</TD><TD>-3.55</TD><TD>E2F1_Q3_01</TD><TD>MSigDB lists</TD><TD>E2F1_Q3_01</TD><TD>230</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,USP2,SATB2</TD></TR>
<TR><TD>2.888e-02</TD><TD>-3.54</TD><TD>bladder</TD><TD>COSMIC cancer mutations</TD><TD>bladder</TD><TD>14410</TD><TD>46</TD><TD>17255</TD><TD>49</TD>
<TD>RBM11,GALNT13,CRB1,STAC,MTSS1,SPAG6,GPC5,PAX9,SATB2,FST,ENPP5,PAPPA,MEIS2,ZIC4,HS3ST3B1,CDKN2A,EYA4,CLDN1,PCDH20,PEX5L,CLVS2,EPHA3,IDO2,BMPR1B,FOXA2,GABRB2,NPTX2,PCDH11X,USP2,GRIA2,PLAG1,RNF128,PLCH1,ZFHX4,HEY1,EDA2R,PLEKHM3,KYNU,CXCL14,PCDH17,ZIC1,LSR,IL7,ALX1,SLC6A15,DCDC2</TD></TR>
<TR><TD>2.888e-02</TD><TD>-3.54</TD><TD>urinary_tract</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract</TD><TD>14410</TD><TD>46</TD><TD>17255</TD><TD>49</TD>
<TD>CXCL14,PCDH17,ZIC1,LSR,IL7,ALX1,DCDC2,SLC6A15,PLAG1,PLCH1,RNF128,PCDH11X,GRIA2,USP2,ZFHX4,HEY1,KYNU,PLEKHM3,EDA2R,ENPP5,PAPPA,FST,MEIS2,PAX9,SATB2,CDKN2A,HS3ST3B1,ZIC4,EYA4,CLVS2,PEX5L,PCDH20,CLDN1,GABRB2,FOXA2,NPTX2,IDO2,EPHA3,BMPR1B,RBM11,CRB1,GALNT13,STAC,SPAG6,MTSS1,GPC5</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>PENTAXIN</TD><TD>prints domains</TD><TD>PR00895</TD><TD>8</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.891e-02</TD><TD>-3.54</TD><TD>PAIREDBOX</TD><TD>prints domains</TD><TD>PR00027</TD><TD>8</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>PAX9</TD></TR>
<TR><TD>2.899e-02</TD><TD>-3.54</TD><TD>regulation of biomineral tissue development</TD><TD>biological process</TD><TD>GO:0070167</TD><TD>94</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B,HEY1</TD></TR>
<TR><TD>2.900e-02</TD><TD>-3.54</TD><TD>skeletal system morphogenesis</TD><TD>biological process</TD><TD>GO:0048705</TD><TD>236</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,BMPR1B,SATB2</TD></TR>
<TR><TD>2.913e-02</TD><TD>-3.54</TD><TD>MORF_PTPRR</TD><TD>MSigDB lists</TD><TD>MORF_PTPRR</TD><TD>92</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,STAC</TD></TR>
<TR><TD>2.913e-02</TD><TD>-3.54</TD><TD>GO_EMBRYONIC_SKELETAL_SYSTEM_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_EMBRYONIC_SKELETAL_SYSTEM_MORPHOGENESIS</TD><TD>92</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,ALX1</TD></TR>
<TR><TD>2.919e-02</TD><TD>-3.53</TD><TD>HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP</TD><TD>MSigDB lists</TD><TD>HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP</TD><TD>231</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,PAPPA,IL7</TD></TR>
<TR><TD>2.919e-02</TD><TD>-3.53</TD><TD>CMYB_01</TD><TD>MSigDB lists</TD><TD>CMYB_01</TD><TD>231</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,USP2,ZIC4</TD></TR>
<TR><TD>2.919e-02</TD><TD>-3.53</TD><TD>DBP_Q6</TD><TD>MSigDB lists</TD><TD>DBP_Q6</TD><TD>231</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH11X,PLAG1,PCDH17</TD></TR>
<TR><TD>2.951e-02</TD><TD>-3.52</TD><TD>GATA1_03</TD><TD>MSigDB lists</TD><TD>GATA1_03</TD><TD>232</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,MEIS2,ZIC1</TD></TR>
<TR><TD>2.956e-02</TD><TD>-3.52</TD><TD>plasma membrane organization</TD><TD>biological process</TD><TD>GO:0007009</TD><TD>95</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>MTSS1,CRB1</TD></TR>
<TR><TD>2.956e-02</TD><TD>-3.52</TD><TD>regulation of protein localization to plasma membrane</TD><TD>biological process</TD><TD>GO:1903076</TD><TD>95</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>EPHA3,STAC</TD></TR>
<TR><TD>2.971e-02</TD><TD>-3.52</TD><TD>TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP</TD><TD>MSigDB lists</TD><TD>TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP</TD><TD>93</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,GRIA2</TD></TR>
<TR><TD>2.973e-02</TD><TD>-3.52</TD><TD>SEC24B (SEC24 homolog B, COPII coat complex component)</TD><TD>protein interactions</TD><TD>10427</TD><TD>94</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>EYA4,TMEM255A</TD></TR>
<TR><TD>2.973e-02</TD><TD>-3.52</TD><TD>Pentraxin-related</TD><TD>interpro domains</TD><TD>IPR001759</TD><TD>11</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>NPTX2</TD></TR>
<TR><TD>2.973e-02</TD><TD>-3.52</TD><TD>NST/OST</TD><TD>interpro domains</TD><TD>IPR037359</TD><TD>11</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>HS3ST3B1</TD></TR>
<TR><TD>2.984e-02</TD><TD>-3.51</TD><TD>ICSBP_Q6</TD><TD>MSigDB lists</TD><TD>ICSBP_Q6</TD><TD>233</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,KYNU,SATB2</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>PAX</TD><TD>smart domains</TD><TD>SM00351</TD><TD>8</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>PAX9</TD></TR>
<TR><TD>3.000e-02</TD><TD>-3.51</TD><TD>DCX</TD><TD>smart domains</TD><TD>SM00537</TD><TD>8</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>DCDC2</TD></TR>
<TR><TD>3.009e-02</TD><TD>-3.50</TD><TD>MIKKELSEN_MCV6_HCP_WITH_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_MCV6_HCP_WITH_H3K27ME3</TD><TD>408</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,ZIC1,NPTX2,GRIA2</TD></TR>
<TR><TD>3.011e-02</TD><TD>-3.50</TD><TD>-</TD><TD>gene3d domains</TD><TD>3.90.290.10</TD><TD>10</TD><TD>1</TD><TD>8522</TD><TD>26</TD>
<TD>FST</TD></TR>
<TR><TD>3.014e-02</TD><TD>-3.50</TD><TD>endothelium development</TD><TD>biological process</TD><TD>GO:0003158</TD><TD>96</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1,HEY1</TD></TR>
<TR><TD>3.015e-02</TD><TD>-3.50</TD><TD>TB</TD><TD>prosite domains</TD><TD>PS51364</TD><TD>9</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>FST</TD></TR>
<TR><TD>3.016e-02</TD><TD>-3.50</TD><TD>IPF1_Q4</TD><TD>MSigDB lists</TD><TD>IPF1_Q4</TD><TD>234</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZIC1,ZIC4</TD></TR>
<TR><TD>3.021e-02</TD><TD>-3.50</TD><TD>prostate-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>prostate-carcinoma-adenocarcinoma</TD><TD>12652</TD><TD>42</TD><TD>17255</TD><TD>49</TD>
<TD>SLC6A15,DCDC2,ALX1,IL7,ZIC1,LSR,PCDH17,CXCL14,PLEKHM3,KYNU,ZFHX4,HEY1,USP2,GRIA2,PCDH11X,RNF128,PLCH1,BMPR1B,EPHA3,GABRB2,NPTX2,FOXA2,PEX5L,PCDH20,CLVS2,ZIC4,EYA4,HS3ST3B1,CDKN2A,SATB2,PAX9,AZGP1,MEIS2,PAPPA,FST,ENPP5,GPC5,MTSS1,SPAG6,STAC,GALNT13,CRB1</TD></TR>
<TR><TD>3.033e-02</TD><TD>-3.50</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP</TD><TD>MSigDB lists</TD><TD>CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP</TD><TD>409</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>ENPP5,LSR,PLCH1,AZGP1</TD></TR>
<TR><TD>3.041e-02</TD><TD>-3.49</TD><TD>meninges-meningioma-haemangiopericytic</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-haemangiopericytic</TD><TD>96</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,PLCH1</TD></TR>
<TR><TD>3.041e-02</TD><TD>-3.49</TD><TD>haemangiopericytic</TD><TD>COSMIC cancer mutations</TD><TD>haemangiopericytic</TD><TD>96</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,PLCH1</TD></TR>
<TR><TD>3.043e-02</TD><TD>-3.49</TD><TD>prostate-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>prostate-carcinoma</TD><TD>9161</TD><TD>33</TD><TD>17255</TD><TD>49</TD>
<TD>SLC6A15,DCDC2,PCDH17,CXCL14,CPEB2,ZIC1,PLEKHM3,KYNU,USP2,GRIA2,PCDH11X,PLCH1,PLAG1,ZFHX4,HEY1,PEX5L,CLVS2,BMPR1B,EPHA3,GABRB2,NPTX2,SATB2,MEIS2,AZGP1,PAPPA,ZIC4,CDKN2A,MTSS1,SPAG6,STAC,GPC5,GALNT13,CRB1</TD></TR>
<TR><TD>3.049e-02</TD><TD>-3.49</TD><TD>ZHENG_GLIOBLASTOMA_PLASTICITY_UP</TD><TD>MSigDB lists</TD><TD>ZHENG_GLIOBLASTOMA_PLASTICITY_UP</TD><TD>235</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,RNF128,BMPR1B</TD></TR>
<TR><TD>3.049e-02</TD><TD>-3.49</TD><TD>ISRE_01</TD><TD>MSigDB lists</TD><TD>ISRE_01</TD><TD>235</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,EYA4,PLAG1</TD></TR>
<TR><TD>3.049e-02</TD><TD>-3.49</TD><TD>FREAC2_01</TD><TD>MSigDB lists</TD><TD>FREAC2_01</TD><TD>235</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZFHX4,PLAG1,PAPPA</TD></TR>
<TR><TD>3.056e-02</TD><TD>-3.49</TD><TD>PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_DN</TD><TD>MSigDB lists</TD><TD>PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_DN</TD><TD>410</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,HS3ST3B1,PAX9,PCDH20</TD></TR>
<TR><TD>3.058e-02</TD><TD>-3.49</TD><TD>Hairy_orange</TD><TD>pfam domains</TD><TD>PF07527</TD><TD>11</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.065e-02</TD><TD>-3.49</TD><TD>regulation of hexokinase activity</TD><TD>biological process</TD><TD>GO:1903299</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>3.065e-02</TD><TD>-3.49</TD><TD>Notch signaling involved in heart development</TD><TD>biological process</TD><TD>GO:0061314</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.065e-02</TD><TD>-3.49</TD><TD>prostate gland growth</TD><TD>biological process</TD><TD>GO:0060736</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PLAG1</TD></TR>
<TR><TD>3.065e-02</TD><TD>-3.49</TD><TD>response to histamine</TD><TD>biological process</TD><TD>GO:0034776</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.065e-02</TD><TD>-3.49</TD><TD>regulation of cytoplasmic translational elongation</TD><TD>biological process</TD><TD>GO:1900247</TD><TD>11</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.074e-02</TD><TD>-3.48</TD><TD>human chr3q25.31</TD><TD>chromosome location</TD><TD>human chr3q25.31</TD><TD>16</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>retromolar</TD><TD>COSMIC cancer mutations</TD><TD>retromolar</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>frontoparietal</TD><TD>COSMIC cancer mutations</TD><TD>frontoparietal</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>congenital</TD><TD>COSMIC cancer mutations</TD><TD>congenital</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-sarcoma-spindle</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-sarcoma-spindle</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>skin-back-malignant_melanoma-superficial_spreading</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-malignant_melanoma-superficial_spreading</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>skin-back-benign_melanocytic_nevus</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-benign_melanocytic_nevus</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>gastrinoma</TD><TD>COSMIC cancer mutations</TD><TD>gastrinoma</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>seborrhoeic_keratosis</TD><TD>COSMIC cancer mutations</TD><TD>seborrhoeic_keratosis</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>central_nervous_system-spinal_cord-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-spinal_cord-glioma-astrocytoma_Grade_I</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_II</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>pancreas-carcinoid-endocrine_tumour-non_functioning</TD><TD>COSMIC cancer mutations</TD><TD>pancreas-carcinoid-endocrine_tumour-non_functioning</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>skin-scalp-malignant_melanoma-lentigo_maligna</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-malignant_melanoma-lentigo_maligna</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>skin-hand-malignant_melanoma-acral_lentiginous</TD><TD>COSMIC cancer mutations</TD><TD>skin-hand-malignant_melanoma-acral_lentiginous</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>pleura-mesothelioma-sarcomatous-fibrous</TD><TD>COSMIC cancer mutations</TD><TD>pleura-mesothelioma-sarcomatous-fibrous</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_III</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>endometrium-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>chiasm</TD><TD>COSMIC cancer mutations</TD><TD>chiasm</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_III</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>upper_aerodigestive_tract-mouth-other-dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>upper_aerodigestive_tract-mouth-other-dysplasia</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>central_nervous_system-posterior_fossa-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-posterior_fossa-glioma-astrocytoma_Grade_I</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-B_cell_lymphoma_unspecified</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-B_cell_lymphoma_unspecified</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.081e-02</TD><TD>-3.48</TD><TD>skin-foot-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-foot-malignant_melanoma-nodular</TD><TD>11</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.082e-02</TD><TD>-3.48</TD><TD>MORF_PTPRB</TD><TD>MSigDB lists</TD><TD>MORF_PTPRB</TD><TD>236</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,IL7,STAC</TD></TR>
<TR><TD>3.082e-02</TD><TD>-3.48</TD><TD>STAT6_01</TD><TD>MSigDB lists</TD><TD>STAT6_01</TD><TD>236</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,FST,PCDH17</TD></TR>
<TR><TD>3.090e-02</TD><TD>-3.48</TD><TD>REN_ALVEOLAR_RHABDOMYOSARCOMA_UP</TD><TD>MSigDB lists</TD><TD>REN_ALVEOLAR_RHABDOMYOSARCOMA_UP</TD><TD>95</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,PCDH17</TD></TR>
<TR><TD>3.090e-02</TD><TD>-3.48</TD><TD>GAGCCTG_MIR484</TD><TD>MSigDB lists</TD><TD>GAGCCTG_MIR484</TD><TD>95</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,IDO2</TD></TR>
<TR><TD>3.090e-02</TD><TD>-3.48</TD><TD>GSE5589_WT_VS_IL6_KO_LPS_AND_IL10_STIM_MACROPHAGE_180MIN_UP</TD><TD>MSigDB lists</TD><TD>GSE5589_WT_VS_IL6_KO_LPS_AND_IL10_STIM_MACROPHAGE_180MIN_UP</TD><TD>95</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,RNF128</TD></TR>
<TR><TD>3.090e-02</TD><TD>-3.48</TD><TD>WINZEN_DEGRADED_VIA_KHSRP</TD><TD>MSigDB lists</TD><TD>WINZEN_DEGRADED_VIA_KHSRP</TD><TD>95</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,FST</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>Defective EXT1 causes exostoses 1, TRPS2 and CHDS</TD><TD>REACTOME pathways</TD><TD>R-HSA-3656253</TD><TD>12</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GPC5</TD></TR>
<TR><TD>3.106e-02</TD><TD>-3.47</TD><TD>Defective EXT2 causes exostoses 2</TD><TD>REACTOME pathways</TD><TD>R-HSA-3656237</TD><TD>12</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GPC5</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>C2orf48 (chromosome 2 open reading frame 48)</TD><TD>protein interactions</TD><TD>348738</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>NKIRAS1 (NFKB inhibitor interacting Ras like 1)</TD><TD>protein interactions</TD><TD>28512</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>MIP (major intrinsic protein of lens fiber)</TD><TD>protein interactions</TD><TD>4284</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>PCDHGA11 (protocadherin gamma subfamily A, 11)</TD><TD>protein interactions</TD><TD>56105</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>GRID2 (glutamate ionotropic receptor delta type subunit 2)</TD><TD>protein interactions</TD><TD>2895</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GRIA2</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>GPAT3 (glycerol-3-phosphate acyltransferase 3)</TD><TD>protein interactions</TD><TD>84803</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>ATP1B2 (ATPase Na+/K+ transporting subunit beta 2)</TD><TD>protein interactions</TD><TD>482</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>PLEKHB1 (pleckstrin homology domain containing B1)</TD><TD>protein interactions</TD><TD>58473</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>GALNT1 (polypeptide N-acetylgalactosaminyltransferase 1)</TD><TD>protein interactions</TD><TD>2589</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GALNT13</TD></TR>
<TR><TD>3.107e-02</TD><TD>-3.47</TD><TD>PRSS37 (serine protease 37)</TD><TD>protein interactions</TD><TD>136242</TD><TD>11</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>3.116e-02</TD><TD>-3.47</TD><TD>MORF_MAGEA8</TD><TD>MSigDB lists</TD><TD>MORF_MAGEA8</TD><TD>237</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,STAC,IL7</TD></TR>
<TR><TD>3.121e-02</TD><TD>-3.47</TD><TD>regulation of transcription by RNA polymerase II</TD><TD>biological process</TD><TD>GO:0006357</TD><TD>2668</TD><TD>13</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2,BMPR1B,PAX9,FST,MEIS2,ZFHX4,ZIC1,HEY1,PLAG1,SATB2,USP2,ALX1,ZIC4</TD></TR>
<TR><TD>3.139e-02</TD><TD>-3.46</TD><TD>GO_PROSTATE_GLAND_GROWTH</TD><TD>MSigDB lists</TD><TD>GO_PROSTATE_GLAND_GROWTH</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1</TD></TR>
<TR><TD>3.139e-02</TD><TD>-3.46</TD><TD>GO_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_INVOLVED_IN_ENDOCARDIAL_CUSHION_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_INVOLVED_IN_ENDOCARDIAL_CUSHION_FORMATION</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.139e-02</TD><TD>-3.46</TD><TD>ZHOU_PANCREATIC_EXOCRINE_PROGENITOR</TD><TD>MSigDB lists</TD><TD>ZHOU_PANCREATIC_EXOCRINE_PROGENITOR</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>3.139e-02</TD><TD>-3.46</TD><TD>REACTOME_IL_7_SIGNALING</TD><TD>MSigDB lists</TD><TD>REACTOME_IL_7_SIGNALING</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>IL7</TD></TR>
<TR><TD>3.139e-02</TD><TD>-3.46</TD><TD>GO_HETEROCHROMATIN_ORGANIZATION</TD><TD>MSigDB lists</TD><TD>GO_HETEROCHROMATIN_ORGANIZATION</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.139e-02</TD><TD>-3.46</TD><TD>GO_POSITIVE_REGULATION_OF_HAIR_CYCLE</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_HAIR_CYCLE</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>3.139e-02</TD><TD>-3.46</TD><TD>GO_POSITIVE_REGULATION_OF_MUSCLE_CELL_APOPTOTIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_MUSCLE_CELL_APOPTOTIC_PROCESS</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.139e-02</TD><TD>-3.46</TD><TD>GO_POSITIVE_REGULATION_OF_PROTEIN_SUMOYLATION</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_PROTEIN_SUMOYLATION</TD><TD>11</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.144e-02</TD><TD>-3.46</TD><TD>cyclin-dependent protein serine/threonine kinase inhibitor activity</TD><TD>molecular function</TD><TD>GO:0004861</TD><TD>12</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.149e-02</TD><TD>-3.46</TD><TD>STAT5A_03</TD><TD>MSigDB lists</TD><TD>STAT5A_03</TD><TD>238</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,FST,MTSS1</TD></TR>
<TR><TD>3.149e-02</TD><TD>-3.46</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP</TD><TD>MSigDB lists</TD><TD>DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP</TD><TD>238</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,PCDH17,FST</TD></TR>
<TR><TD>3.149e-02</TD><TD>-3.46</TD><TD>TFIIA_Q6</TD><TD>MSigDB lists</TD><TD>TFIIA_Q6</TD><TD>238</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,MEIS2,PLAG1</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>KCCGNSWTTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>KCCGNSWTTT_UNKNOWN</TD><TD>96</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,FOXA2</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>TAVAZOIE_METASTASIS</TD><TD>MSigDB lists</TD><TD>TAVAZOIE_METASTASIS</TD><TD>96</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,KYNU</TD></TR>
<TR><TD>3.150e-02</TD><TD>-3.46</TD><TD>LIM_MAMMARY_LUMINAL_MATURE_DN</TD><TD>MSigDB lists</TD><TD>LIM_MAMMARY_LUMINAL_MATURE_DN</TD><TD>96</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,MEIS2</TD></TR>
<TR><TD>3.151e-02</TD><TD>-3.46</TD><TD>TGANTCA_AP1_C</TD><TD>MSigDB lists</TD><TD>TGANTCA_AP1_C</TD><TD>1057</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>FST,PAPPA,CXCL14,PCDH17,USP2,HS3ST3B1,GALNT13</TD></TR>
<TR><TD>3.156e-02</TD><TD>-3.46</TD><TD>cell fate commitment</TD><TD>biological process</TD><TD>GO:0045165</TD><TD>244</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,IL7,FOXA2</TD></TR>
<TR><TD>3.173e-02</TD><TD>-3.45</TD><TD>Retrograde endocannabinoid signaling</TD><TD>KEGG pathways</TD><TD>hsa04723</TD><TD>101</TD><TD>2</TD><TD>7161</TD><TD>20</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>3.173e-02</TD><TD>-3.45</TD><TD>Retrograde endocannabinoid signaling</TD><TD>KEGG pathways</TD><TD>ko04723</TD><TD>101</TD><TD>2</TD><TD>7161</TD><TD>20</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>3.175e-02</TD><TD>-3.45</TD><TD>embryonic organ development</TD><TD>biological process</TD><TD>GO:0048568</TD><TD>425</TD><TD>4</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,ZIC1,HEY1,SATB2</TD></TR>
<TR><TD>3.175e-02</TD><TD>-3.45</TD><TD>human chr7q22.1</TD><TD>chromosome location</TD><TD>human chr7q22.1</TD><TD>143</TD><TD>2</TD><TD>26169</TD><TD>51</TD>
<TD>NPTX2,AZGP1</TD></TR>
<TR><TD>3.176e-02</TD><TD>-3.45</TD><TD>miR-148a/miR-31/FIH1/HIF1&alpha;-Notch signaling in glioblastoma</TD><TD>WikiPathways</TD><TD>WP3593</TD><TD>9</TD><TD>1</TD><TD>5311</TD><TD>19</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.183e-02</TD><TD>-3.45</TD><TD>PAX2_02</TD><TD>MSigDB lists</TD><TD>PAX2_02</TD><TD>239</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZIC4,CRB1</TD></TR>
<TR><TD>3.183e-02</TD><TD>-3.45</TD><TD>TTAYRTAA_E4BP4_01</TD><TD>MSigDB lists</TD><TD>TTAYRTAA_E4BP4_01</TD><TD>239</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,NPTX2,FST</TD></TR>
<TR><TD>3.183e-02</TD><TD>-3.45</TD><TD>DR4_Q2</TD><TD>MSigDB lists</TD><TD>DR4_Q2</TD><TD>239</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,NPTX2,MEIS2</TD></TR>
<TR><TD>3.183e-02</TD><TD>-3.45</TD><TD>AREB6_03</TD><TD>MSigDB lists</TD><TD>AREB6_03</TD><TD>239</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>LSR,FST,MEIS2</TD></TR>
<TR><TD>3.210e-02</TD><TD>-3.44</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_C</TD><TD>MSigDB lists</TD><TD>RICKMAN_HEAD_AND_NECK_CANCER_C</TD><TD>97</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,SLC6A15</TD></TR>
<TR><TD>3.210e-02</TD><TD>-3.44</TD><TD>CTGTTAC_MIR194</TD><TD>MSigDB lists</TD><TD>CTGTTAC_MIR194</TD><TD>97</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZFHX4</TD></TR>
<TR><TD>3.217e-02</TD><TD>-3.44</TD><TD>AP2_Q3</TD><TD>MSigDB lists</TD><TD>AP2_Q3</TD><TD>240</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,HEY1,EPHA3</TD></TR>
<TR><TD>3.239e-02</TD><TD>-3.43</TD><TD>TGFB_receptor</TD><TD>interpro domains</TD><TD>IPR000333</TD><TD>12</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.239e-02</TD><TD>-3.43</TD><TD>CRAL/TRIO_N_dom</TD><TD>interpro domains</TD><TD>IPR011074</TD><TD>12</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CLVS2</TD></TR>
<TR><TD>3.239e-02</TD><TD>-3.43</TD><TD>Orange_dom</TD><TD>interpro domains</TD><TD>IPR003650</TD><TD>12</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.239e-02</TD><TD>-3.43</TD><TD>PLC_EF-hand-like</TD><TD>interpro domains</TD><TD>IPR015359</TD><TD>12</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.247e-02</TD><TD>-3.43</TD><TD>MHCCLASSI</TD><TD>prints domains</TD><TD>PR01638</TD><TD>9</TD><TD>1</TD><TD>4648</TD><TD>17</TD>
<TD>AZGP1</TD></TR>
<TR><TD>3.251e-02</TD><TD>-3.43</TD><TD>CAGCTTT_MIR320</TD><TD>MSigDB lists</TD><TD>CAGCTTT_MIR320</TD><TD>241</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,PLAG1,SATB2</TD></TR>
<TR><TD>3.251e-02</TD><TD>-3.43</TD><TD>NRF2_Q4</TD><TD>MSigDB lists</TD><TD>NRF2_Q4</TD><TD>241</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZFHX4,ZIC4,ZIC1</TD></TR>
<TR><TD>3.251e-02</TD><TD>-3.43</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>MSigDB lists</TD><TD>ONDER_CDH1_TARGETS_2_UP</TD><TD>241</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>NPTX2,SATB2,ZFHX4</TD></TR>
<TR><TD>3.252e-02</TD><TD>-3.43</TD><TD>TGACATY_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TGACATY_UNKNOWN</TD><TD>618</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,SPAG6,ZIC4,MEIS2,ZIC1</TD></TR>
<TR><TD>3.263e-02</TD><TD>-3.42</TD><TD>human chr1q31.3</TD><TD>chromosome location</TD><TD>human chr1q31.3</TD><TD>17</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>CRB1</TD></TR>
<TR><TD>3.271e-02</TD><TD>-3.42</TD><TD>HALLMARK_ANDROGEN_RESPONSE</TD><TD>MSigDB lists</TD><TD>HALLMARK_ANDROGEN_RESPONSE</TD><TD>98</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,BMPR1B</TD></TR>
<TR><TD>3.285e-02</TD><TD>-3.42</TD><TD>PPAR_DR1_Q2</TD><TD>MSigDB lists</TD><TD>PPAR_DR1_Q2</TD><TD>242</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,ZIC4,RNF128</TD></TR>
<TR><TD>3.285e-02</TD><TD>-3.42</TD><TD>LEF1_Q6</TD><TD>MSigDB lists</TD><TD>LEF1_Q6</TD><TD>242</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,FST,ZIC4</TD></TR>
<TR><TD>3.298e-02</TD><TD>-3.41</TD><TD>skin-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma</TD><TD>16096</TD><TD>49</TD><TD>17255</TD><TD>49</TD>
<TD>EDA2R,PLEKHM3,KYNU,PCDH11X,USP2,GRIA2,PLAG1,RNF128,PLCH1,HEY1,ZFHX4,IL7,ALX1,SLC6A15,DCDC2,CXCL14,CPEB2,PCDH17,ZIC1,LSR,STAC,MTSS1,SPAG6,GPC5,SCGB3A2,RBM11,GALNT13,CRB1,CLDN1,PCDH20,PEX5L,CLVS2,IDO2,BMPR1B,EPHA3,GABRB2,FOXA2,NPTX2,PAX9,SATB2,ENPP5,PAPPA,FST,AZGP1,MEIS2,CDKN2A,EYA4,HS3ST3B1,ZIC4</TD></TR>
<TR><TD>3.319e-02</TD><TD>-3.41</TD><TD>RACCACAR_AML_Q6</TD><TD>MSigDB lists</TD><TD>RACCACAR_AML_Q6</TD><TD>243</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,ZIC4,BMPR1B</TD></TR>
<TR><TD>3.322e-02</TD><TD>-3.40</TD><TD>TGCACTT_MIR519C_MIR519B_MIR519A</TD><TD>MSigDB lists</TD><TD>TGCACTT_MIR519C_MIR519B_MIR519A</TD><TD>421</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH20,CPEB2,ENPP5,ZFHX4</TD></TR>
<TR><TD>3.331e-02</TD><TD>-3.40</TD><TD>EF-hand_like</TD><TD>pfam domains</TD><TD>PF09279</TD><TD>12</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.331e-02</TD><TD>-3.40</TD><TD>Ephrin_rec_like</TD><TD>pfam domains</TD><TD>PF07699</TD><TD>12</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.333e-02</TD><TD>-3.40</TD><TD>TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA</TD><TD>MSigDB lists</TD><TD>TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA</TD><TD>99</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,PAX9</TD></TR>
<TR><TD>3.333e-02</TD><TD>-3.40</TD><TD>RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP</TD><TD>MSigDB lists</TD><TD>RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP</TD><TD>99</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,HS3ST3B1</TD></TR>
<TR><TD>3.339e-02</TD><TD>-3.40</TD><TD>positive regulation of hair follicle development</TD><TD>biological process</TD><TD>GO:0051798</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FST</TD></TR>
<TR><TD>3.339e-02</TD><TD>-3.40</TD><TD>positive regulation of B cell differentiation</TD><TD>biological process</TD><TD>GO:0045579</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>IL7</TD></TR>
<TR><TD>3.339e-02</TD><TD>-3.40</TD><TD>replicative senescence</TD><TD>biological process</TD><TD>GO:0090399</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.339e-02</TD><TD>-3.40</TD><TD>positive regulation of voltage-gated calcium channel activity</TD><TD>biological process</TD><TD>GO:1901387</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>STAC</TD></TR>
<TR><TD>3.339e-02</TD><TD>-3.40</TD><TD>positive regulation of gastrulation</TD><TD>biological process</TD><TD>GO:2000543</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>3.339e-02</TD><TD>-3.40</TD><TD>locomotor rhythm</TD><TD>biological process</TD><TD>GO:0045475</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>USP2</TD></TR>
<TR><TD>3.339e-02</TD><TD>-3.40</TD><TD>regulation of postsynaptic neurotransmitter receptor activity</TD><TD>biological process</TD><TD>GO:0098962</TD><TD>12</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>NPTX2</TD></TR>
<TR><TD>3.354e-02</TD><TD>-3.40</TD><TD>E12_Q6</TD><TD>MSigDB lists</TD><TD>E12_Q6</TD><TD>244</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,USP2,CXCL14</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>trachea</TD><TD>COSMIC cancer mutations</TD><TD>trachea</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>skin-abdomen-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-abdomen-malignant_melanoma-nodular</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>pituitary-adenoma-GH-PRL</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-GH-PRL</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>GH-PRL</TD><TD>COSMIC cancer mutations</TD><TD>GH-PRL</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>lymphoplasmacytic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>lymphoplasmacytic_lymphoma</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>clear_cell</TD><TD>COSMIC cancer mutations</TD><TD>clear_cell</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>left</TD><TD>COSMIC cancer mutations</TD><TD>left</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>desmoid_tumour-fibromatosis</TD><TD>COSMIC cancer mutations</TD><TD>desmoid_tumour-fibromatosis</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>ovary-low_malignant_potential_(borderline)_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-low_malignant_potential_(borderline)_tumour</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>bone-sacrum-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>bone-sacrum-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>haematopoietic_and_lymphoid_tissue-mediastinum-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-mediastinum-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-desmoid_tumour-fibromatosis</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-desmoid_tumour-fibromatosis</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.356e-02</TD><TD>-3.39</TD><TD>cervix-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>cervix-carcinoma-mixed_adenosquamous_carcinoma</TD><TD>12</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.361e-02</TD><TD>-3.39</TD><TD>GABA A receptor activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-977441</TD><TD>13</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.361e-02</TD><TD>-3.39</TD><TD>TNFR1-induced proapoptotic signaling</TD><TD>REACTOME pathways</TD><TD>R-HSA-5357786</TD><TD>13</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>USP2</TD></TR>
<TR><TD>3.361e-02</TD><TD>-3.39</TD><TD>Signaling by Activin</TD><TD>REACTOME pathways</TD><TD>R-HSA-1502540</TD><TD>13</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>FST</TD></TR>
<TR><TD>3.365e-02</TD><TD>-3.39</TD><TD>oesophagus-upper_third-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>oesophagus-upper_third-carcinoma-squamous_cell_carcinoma</TD><TD>636</TD><TD>5</TD><TD>17255</TD><TD>49</TD>
<TD>PEX5L,CDKN2A,ZFHX4,EPHA3,SLC6A15</TD></TR>
<TR><TD>3.365e-02</TD><TD>-3.39</TD><TD>upper_third</TD><TD>COSMIC cancer mutations</TD><TD>upper_third</TD><TD>636</TD><TD>5</TD><TD>17255</TD><TD>49</TD>
<TD>ZFHX4,CDKN2A,EPHA3,SLC6A15,PEX5L</TD></TR>
<TR><TD>3.369e-02</TD><TD>-3.39</TD><TD>ORANGE</TD><TD>smart domains</TD><TD>SM00511</TD><TD>9</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.369e-02</TD><TD>-3.39</TD><TD>FOLN</TD><TD>smart domains</TD><TD>SM00274</TD><TD>9</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>FST</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>CAPN15 (calpain 15)</TD><TD>protein interactions</TD><TD>6650</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>SRGAP1 (SLIT-ROBO Rho GTPase activating protein 1)</TD><TD>protein interactions</TD><TD>57522</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>MAB21L1 (mab-21 like 1)</TD><TD>protein interactions</TD><TD>4081</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>RASL12 (RAS like family 12)</TD><TD>protein interactions</TD><TD>51285</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>TUBA3D (tubulin alpha 3d)</TD><TD>protein interactions</TD><TD>113457</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>DCDC2B (doublecortin domain containing 2B)</TD><TD>protein interactions</TD><TD>149069</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>SIX4 (SIX homeobox 4)</TD><TD>protein interactions</TD><TD>51804</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EYA4</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>SDR9C7 (short chain dehydrogenase/reductase family 9C member 7)</TD><TD>protein interactions</TD><TD>121214</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>IL1RL2 (interleukin 1 receptor like 2)</TD><TD>protein interactions</TD><TD>8808</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>ZP3 (zona pellucida glycoprotein 3)</TD><TD>protein interactions</TD><TD>7784</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH17</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>VAMP1 (vesicle associated membrane protein 1)</TD><TD>protein interactions</TD><TD>6843</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>CD40LG (CD40 ligand)</TD><TD>protein interactions</TD><TD>959</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>RNF128</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>RBM18 (RNA binding motif protein 18)</TD><TD>protein interactions</TD><TD>92400</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.385e-02</TD><TD>-3.39</TD><TD>GABRB3 (gamma-aminobutyric acid type A receptor beta3 subunit)</TD><TD>protein interactions</TD><TD>2562</TD><TD>12</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.389e-02</TD><TD>-3.38</TD><TD>AML_Q6</TD><TD>MSigDB lists</TD><TD>AML_Q6</TD><TD>245</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,HEY1,PAPPA</TD></TR>
<TR><TD>3.389e-02</TD><TD>-3.38</TD><TD>JAEGER_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>JAEGER_METASTASIS_DN</TD><TD>245</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>LSR,FST,CXCL14</TD></TR>
<TR><TD>3.395e-02</TD><TD>-3.38</TD><TD>GSE11367_CTRL_VS_IL17_TREATED_SMOOTH_MUSCLE_CELL_DN</TD><TD>MSigDB lists</TD><TD>GSE11367_CTRL_VS_IL17_TREATED_SMOOTH_MUSCLE_CELL_DN</TD><TD>100</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,GABRB2</TD></TR>
<TR><TD>3.395e-02</TD><TD>-3.38</TD><TD>MIKKELSEN_IPS_WITH_HCP_H3K27ME3</TD><TD>MSigDB lists</TD><TD>MIKKELSEN_IPS_WITH_HCP_H3K27ME3</TD><TD>100</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,PCDH11X</TD></TR>
<TR><TD>3.402e-02</TD><TD>-3.38</TD><TD>amino acid:sodium symporter activity</TD><TD>molecular function</TD><TD>GO:0005283</TD><TD>13</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.402e-02</TD><TD>-3.38</TD><TD>GABA-gated chloride ion channel activity</TD><TD>molecular function</TD><TD>GO:0022851</TD><TD>13</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.402e-02</TD><TD>-3.38</TD><TD>ribosomal large subunit binding</TD><TD>molecular function</TD><TD>GO:0043023</TD><TD>13</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_NEGATIVE_REGULATION_OF_SKELETAL_MUSCLE_TISSUE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_SKELETAL_MUSCLE_TISSUE_DEVELOPMENT</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>REACTOME_GABA_A_RECEPTOR_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_GABA_A_RECEPTOR_ACTIVATION</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_ACTIVIN_BINDING</TD><TD>MSigDB lists</TD><TD>GO_ACTIVIN_BINDING</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>SA_REG_CASCADE_OF_CYCLIN_EXPR</TD><TD>MSigDB lists</TD><TD>SA_REG_CASCADE_OF_CYCLIN_EXPR</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_NAD_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_NAD_BIOSYNTHETIC_PROCESS</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_CYCLIN_DEPENDENT_PROTEIN_SERINE_THREONINE_KINASE_INHIBITOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_CYCLIN_DEPENDENT_PROTEIN_SERINE_THREONINE_KINASE_INHIBITOR_ACTIVITY</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_FOREBRAIN_NEURON_FATE_COMMITMENT</TD><TD>MSigDB lists</TD><TD>GO_FOREBRAIN_NEURON_FATE_COMMITMENT</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_REPLICATIVE_SENESCENCE</TD><TD>MSigDB lists</TD><TD>GO_REPLICATIVE_SENESCENCE</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>ITO_PTTG1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ITO_PTTG1_TARGETS_UP</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_UP</TD><TD>MSigDB lists</TD><TD>SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_UP</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_HEART_VALVE_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_HEART_VALVE_FORMATION</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_REGULATION_OF_CYTOPLASMIC_TRANSLATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_CYTOPLASMIC_TRANSLATION</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_SODIUM_AMINO_ACID_SYMPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_SODIUM_AMINO_ACID_SYMPORTER_ACTIVITY</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.420e-02</TD><TD>-3.38</TD><TD>GO_RIBOSOMAL_SMALL_SUBUNIT_BINDING</TD><TD>MSigDB lists</TD><TD>GO_RIBOSOMAL_SMALL_SUBUNIT_BINDING</TD><TD>12</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.424e-02</TD><TD>-3.37</TD><TD>OCT1_Q6</TD><TD>MSigDB lists</TD><TD>OCT1_Q6</TD><TD>246</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,PCDH20,SATB2</TD></TR>
<TR><TD>3.424e-02</TD><TD>-3.37</TD><TD>AP1_Q4_01</TD><TD>MSigDB lists</TD><TD>AP1_Q4_01</TD><TD>246</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,PCDH17,PAPPA</TD></TR>
<TR><TD>3.429e-02</TD><TD>-3.37</TD><TD>glycosaminoglycan biosynthetic process</TD><TD>biological process</TD><TD>GO:0006024</TD><TD>103</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>HS3ST3B1,GPC5</TD></TR>
<TR><TD>3.431e-02</TD><TD>-3.37</TD><TD>large_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>large_cell_carcinoma</TD><TD>862</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>SLC6A15,EPHA3,BMPR1B,GALNT13,CDKN2A,CRB1</TD></TR>
<TR><TD>3.431e-02</TD><TD>-3.37</TD><TD>lung-carcinoma-large_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-large_cell_carcinoma</TD><TD>862</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>CRB1,CDKN2A,EPHA3,SLC6A15,BMPR1B,GALNT13</TD></TR>
<TR><TD>3.438e-02</TD><TD>-3.37</TD><TD>chylomicron</TD><TD>cellular component</TD><TD>GO:0042627</TD><TD>13</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>LSR</TD></TR>
<TR><TD>3.444e-02</TD><TD>-3.37</TD><TD>GO_NEURON_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_NEURON_DIFFERENTIATION</TD><TD>846</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,EPHA3,SATB2,CRB1,GABRB2,BMPR1B</TD></TR>
<TR><TD>3.446e-02</TD><TD>-3.37</TD><TD>positive regulation of macromolecule biosynthetic process</TD><TD>biological process</TD><TD>GO:0010557</TD><TD>1872</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>ZIC1,MEIS2,ZFHX4,FOXA2,BMPR1B,PAX9,ALX1,PLAG1,HEY1,SATB2</TD></TR>
<TR><TD>3.457e-02</TD><TD>-3.36</TD><TD>GO_REGULATION_OF_B_CELL_ACTIVATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_B_CELL_ACTIVATION</TD><TD>101</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,CDKN2A</TD></TR>
<TR><TD>3.457e-02</TD><TD>-3.36</TD><TD>GHANDHI_DIRECT_IRRADIATION_UP</TD><TD>MSigDB lists</TD><TD>GHANDHI_DIRECT_IRRADIATION_UP</TD><TD>101</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,KYNU</TD></TR>
<TR><TD>3.459e-02</TD><TD>-3.36</TD><TD>CEBPB_01</TD><TD>MSigDB lists</TD><TD>CEBPB_01</TD><TD>247</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,MTSS1,ZIC1</TD></TR>
<TR><TD>3.459e-02</TD><TD>-3.36</TD><TD>AP2_Q6</TD><TD>MSigDB lists</TD><TD>AP2_Q6</TD><TD>247</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,MEIS2,HS3ST3B1</TD></TR>
<TR><TD>3.459e-02</TD><TD>-3.36</TD><TD>MORF_PAX7</TD><TD>MSigDB lists</TD><TD>MORF_PAX7</TD><TD>247</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,STAC,PAX9</TD></TR>
<TR><TD>3.459e-02</TD><TD>-3.36</TD><TD>TTF1_Q6</TD><TD>MSigDB lists</TD><TD>TTF1_Q6</TD><TD>247</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,ZIC1,PCDH17</TD></TR>
<TR><TD>3.460e-02</TD><TD>-3.36</TD><TD>eye-uveal_tract-malignant_melanoma-mixed</TD><TD>COSMIC cancer mutations</TD><TD>eye-uveal_tract-malignant_melanoma-mixed</TD><TD>103</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,RBM11</TD></TR>
<TR><TD>3.490e-02</TD><TD>-3.36</TD><TD>negative regulation of extrinsic apoptotic signaling pathway</TD><TD>biological process</TD><TD>GO:2001237</TD><TD>104</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IL7,EYA4</TD></TR>
<TR><TD>3.490e-02</TD><TD>-3.36</TD><TD>cell-cell junction assembly</TD><TD>biological process</TD><TD>GO:0007043</TD><TD>104</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>3.490e-02</TD><TD>-3.36</TD><TD>alpha-amino acid catabolic process</TD><TD>biological process</TD><TD>GO:1901606</TD><TD>104</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU,IDO2</TD></TR>
<TR><TD>3.494e-02</TD><TD>-3.35</TD><TD>OCT1_B</TD><TD>MSigDB lists</TD><TD>OCT1_B</TD><TD>248</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,PCDH20,SATB2</TD></TR>
<TR><TD>3.498e-02</TD><TD>-3.35</TD><TD>HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP</TD><TD>MSigDB lists</TD><TD>HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP</TD><TD>428</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>NPTX2,RNF128,EPHA3,SPAG6</TD></TR>
<TR><TD>3.505e-02</TD><TD>-3.35</TD><TD>CRAL/TRIO_N_dom_sf</TD><TD>interpro domains</TD><TD>IPR036273</TD><TD>13</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>CLVS2</TD></TR>
<TR><TD>3.520e-02</TD><TD>-3.35</TD><TD>GO_REGULATION_OF_T_CELL_DIFFERENTIATION</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_T_CELL_DIFFERENTIATION</TD><TD>102</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IL7,CDKN2A</TD></TR>
<TR><TD>3.520e-02</TD><TD>-3.35</TD><TD>LABBE_TGFB1_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>LABBE_TGFB1_TARGETS_DN</TD><TD>102</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,NPTX2</TD></TR>
<TR><TD>3.530e-02</TD><TD>-3.34</TD><TD>SOX5_01</TD><TD>MSigDB lists</TD><TD>SOX5_01</TD><TD>249</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>FST,NPTX2,SATB2</TD></TR>
<TR><TD>3.566e-02</TD><TD>-3.33</TD><TD>MORF_BRCA1</TD><TD>MSigDB lists</TD><TD>MORF_BRCA1</TD><TD>250</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PAX9,STAC,GABRB2</TD></TR>
<TR><TD>3.566e-02</TD><TD>-3.33</TD><TD>MYCMAX_02</TD><TD>MSigDB lists</TD><TD>MYCMAX_02</TD><TD>250</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,RNF128,SATB2</TD></TR>
<TR><TD>3.602e-02</TD><TD>-3.32</TD><TD>HNF4_01</TD><TD>MSigDB lists</TD><TD>HNF4_01</TD><TD>251</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,ZIC4,KYNU</TD></TR>
<TR><TD>3.602e-02</TD><TD>-3.32</TD><TD>BOQUEST_STEM_CELL_UP</TD><TD>MSigDB lists</TD><TD>BOQUEST_STEM_CELL_UP</TD><TD>251</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,FST,CXCL14</TD></TR>
<TR><TD>3.612e-02</TD><TD>-3.32</TD><TD>heart valve formation</TD><TD>biological process</TD><TD>GO:0003188</TD><TD>13</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.612e-02</TD><TD>-3.32</TD><TD>positive regulation of hair cycle</TD><TD>biological process</TD><TD>GO:0042635</TD><TD>13</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FST</TD></TR>
<TR><TD>3.612e-02</TD><TD>-3.32</TD><TD>protein import into peroxisome matrix</TD><TD>biological process</TD><TD>GO:0016558</TD><TD>13</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PEX5L</TD></TR>
<TR><TD>3.612e-02</TD><TD>-3.32</TD><TD>heart trabecula formation</TD><TD>biological process</TD><TD>GO:0060347</TD><TD>13</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>ovary-adenoma-mucinous</TD><TD>COSMIC cancer mutations</TD><TD>ovary-adenoma-mucinous</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>soft_tissue-fat-lipoma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fat-lipoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>anus</TD><TD>COSMIC cancer mutations</TD><TD>anus</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>intraventricular</TD><TD>COSMIC cancer mutations</TD><TD>intraventricular</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-Burkitt_lymphoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>pituitary-adenoma-PRL</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-PRL</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>chest_wall</TD><TD>COSMIC cancer mutations</TD><TD>chest_wall</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>sarcomatous-fibrous</TD><TD>COSMIC cancer mutations</TD><TD>sarcomatous-fibrous</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>cervix-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>cervix-carcinoma-adenocarcinoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>skin-malignant_melanoma-lentigo_maligna</TD><TD>COSMIC cancer mutations</TD><TD>skin-malignant_melanoma-lentigo_maligna</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>stomach-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>stomach-adenoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Hodgkin_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Hodgkin_lymphoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>radius</TD><TD>COSMIC cancer mutations</TD><TD>radius</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>skin-vulva-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-vulva-malignant_melanoma</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>PRL</TD><TD>COSMIC cancer mutations</TD><TD>PRL</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>skin-scalp-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-malignant_melanoma-nodular</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.631e-02</TD><TD>-3.32</TD><TD>Brenner_tumour</TD><TD>COSMIC cancer mutations</TD><TD>Brenner_tumour</TD><TD>13</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.638e-02</TD><TD>-3.31</TD><TD>MYCMAX_B</TD><TD>MSigDB lists</TD><TD>MYCMAX_B</TD><TD>252</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,HS3ST3B1,FOXA2</TD></TR>
<TR><TD>3.638e-02</TD><TD>-3.31</TD><TD>CEBP_01</TD><TD>MSigDB lists</TD><TD>CEBP_01</TD><TD>252</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>MTSS1,HS3ST3B1,HEY1</TD></TR>
<TR><TD>3.638e-02</TD><TD>-3.31</TD><TD>MCBRYAN_PUBERTAL_BREAST_4_5WK_UP</TD><TD>MSigDB lists</TD><TD>MCBRYAN_PUBERTAL_BREAST_4_5WK_UP</TD><TD>252</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,HEY1,CXCL14</TD></TR>
<TR><TD>3.638e-02</TD><TD>-3.31</TD><TD>COREBINDINGFACTOR_Q6</TD><TD>MSigDB lists</TD><TD>COREBINDINGFACTOR_Q6</TD><TD>252</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1,BMPR1B,MEIS2</TD></TR>
<TR><TD>3.640e-02</TD><TD>-3.31</TD><TD>human chr4p15.32</TD><TD>chromosome location</TD><TD>human chr4p15.32</TD><TD>19</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.646e-02</TD><TD>-3.31</TD><TD>GO_AMINOGLYCAN_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_AMINOGLYCAN_BIOSYNTHETIC_PROCESS</TD><TD>104</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,HS3ST3B1</TD></TR>
<TR><TD>3.646e-02</TD><TD>-3.31</TD><TD>GSE5589_WT_VS_IL10_KO_LPS_AND_IL10_STIM_MACROPHAGE_180MIN_DN</TD><TD>MSigDB lists</TD><TD>GSE5589_WT_VS_IL10_KO_LPS_AND_IL10_STIM_MACROPHAGE_180MIN_DN</TD><TD>104</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,GABRB2</TD></TR>
<TR><TD>3.656e-02</TD><TD>-3.31</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>MSigDB lists</TD><TD>SMID_BREAST_CANCER_BASAL_DN</TD><TD>638</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2,EPHA3,CXCL14,BMPR1B,AZGP1</TD></TR>
<TR><TD>3.659e-02</TD><TD>-3.31</TD><TD>activin binding</TD><TD>molecular function</TD><TD>GO:0048185</TD><TD>14</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>3.659e-02</TD><TD>-3.31</TD><TD>translation repressor activity, mRNA regulatory element binding</TD><TD>molecular function</TD><TD>GO:0000900</TD><TD>14</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.659e-02</TD><TD>-3.31</TD><TD>GTPase inhibitor activity</TD><TD>molecular function</TD><TD>GO:0005095</TD><TD>14</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>PLBD1 (phospholipase B domain containing 1)</TD><TD>protein interactions</TD><TD>79887</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>RIN2 (Ras and Rab interactor 2)</TD><TD>protein interactions</TD><TD>54453</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2)</TD><TD>protein interactions</TD><TD>10555</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>KIAA1958 (KIAA1958)</TD><TD>protein interactions</TD><TD>158405</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>STAC</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>IGSF1 (immunoglobulin superfamily member 1)</TD><TD>protein interactions</TD><TD>3547</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>Sept7 (septin 7)</TD><TD>protein interactions</TD><TD>235072</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>ATP8B2 (ATPase phospholipid transporting 8B2)</TD><TD>protein interactions</TD><TD>57198</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>BMP6 (bone morphogenetic protein 6)</TD><TD>protein interactions</TD><TD>654</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>IGFBP4 (insulin like growth factor binding protein 4)</TD><TD>protein interactions</TD><TD>3487</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PAPPA</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>GLIS1 (GLIS family zinc finger 1)</TD><TD>protein interactions</TD><TD>148979</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>RUFY2 (RUN and FYVE domain containing 2)</TD><TD>protein interactions</TD><TD>55680</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.662e-02</TD><TD>-3.31</TD><TD>FOXN2 (forkhead box N2)</TD><TD>protein interactions</TD><TD>3344</TD><TD>13</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>3.670e-02</TD><TD>-3.30</TD><TD>trunk</TD><TD>COSMIC cancer mutations</TD><TD>trunk</TD><TD>3603</TD><TD>16</TD><TD>17255</TD><TD>49</TD>
<TD>SPAG6,MTSS1,STAC,ZFHX4,CRB1,GRIA2,PLCH1,EPHA3,SLC6A15,DCDC2,EYA4,CDKN2A,CPEB2,CXCL14,MEIS2,PAPPA</TD></TR>
<TR><TD>3.673e-02</TD><TD>-3.30</TD><TD>PTX_2</TD><TD>prosite domains</TD><TD>PS51828</TD><TD>11</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>NPTX2</TD></TR>
<TR><TD>3.674e-02</TD><TD>-3.30</TD><TD>HOXA4_Q2</TD><TD>MSigDB lists</TD><TD>HOXA4_Q2</TD><TD>253</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,BMPR1B,ZIC1</TD></TR>
<TR><TD>3.674e-02</TD><TD>-3.30</TD><TD>MODULE_112</TD><TD>MSigDB lists</TD><TD>MODULE_112</TD><TD>253</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,KYNU,CDKN2A</TD></TR>
<TR><TD>3.696e-02</TD><TD>-3.30</TD><TD>skin-scalp-carcinoma-squamous_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-scalp-carcinoma-squamous_cell_carcinoma</TD><TD>1622</TD><TD>9</TD><TD>17255</TD><TD>49</TD>
<TD>PEX5L,STAC,GPC5,PCDH11X,SATB2,GRIA2,HS3ST3B1,CRB1,CDKN2A</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>GO_LOW_DENSITY_LIPOPROTEIN_PARTICLE</TD><TD>MSigDB lists</TD><TD>GO_LOW_DENSITY_LIPOPROTEIN_PARTICLE</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>LSR</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>GO_CHYLOMICRON</TD><TD>MSigDB lists</TD><TD>GO_CHYLOMICRON</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>LSR</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>GO_DICARBOXYLIC_ACID_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_DICARBOXYLIC_ACID_BIOSYNTHETIC_PROCESS</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>GO_PROTEIN_IMPORT_INTO_PEROXISOME_MATRIX</TD><TD>MSigDB lists</TD><TD>GO_PROTEIN_IMPORT_INTO_PEROXISOME_MATRIX</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>PEX5L</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>GO_POSITIVE_REGULATION_OF_DNA_DAMAGE_RESPONSE_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_DNA_DAMAGE_RESPONSE_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>GO_REGULATION_OF_VASCULOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_VASCULOGENESIS</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>chr21q11</TD><TD>MSigDB lists</TD><TD>chr21q11</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>RBM11</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>LEE_SP4_THYMOCYTE</TD><TD>MSigDB lists</TD><TD>LEE_SP4_THYMOCYTE</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.699e-02</TD><TD>-3.30</TD><TD>GO_REGULATION_OF_SMOOTH_MUSCLE_CELL_APOPTOTIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_SMOOTH_MUSCLE_CELL_APOPTOTIC_PROCESS</TD><TD>13</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.702e-02</TD><TD>-3.30</TD><TD>GO_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS</TD><TD>1338</TD><TD>8</TD><TD>17275</TD><TD>50</TD>
<TD>FST,IL7,PLAG1,USP2,BMPR1B,ALX1,EPHA3,FOXA2</TD></TR>
<TR><TD>3.709e-02</TD><TD>-3.29</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I</TD><TD>107</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>GPC5,CDKN2A</TD></TR>
<TR><TD>3.710e-02</TD><TD>-3.29</TD><TD>GCTTGAA_MIR498</TD><TD>MSigDB lists</TD><TD>GCTTGAA_MIR498</TD><TD>105</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2,ZIC4</TD></TR>
<TR><TD>3.710e-02</TD><TD>-3.29</TD><TD>LE_EGR2_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>LE_EGR2_TARGETS_DN</TD><TD>105</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,CPEB2</TD></TR>
<TR><TD>3.710e-02</TD><TD>-3.29</TD><TD>SENESE_HDAC2_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SENESE_HDAC2_TARGETS_UP</TD><TD>105</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,SLC6A15</TD></TR>
<TR><TD>3.711e-02</TD><TD>-3.29</TD><TD>GO_MULTICELLULAR_ORGANISMAL_HOMEOSTASIS</TD><TD>MSigDB lists</TD><TD>GO_MULTICELLULAR_ORGANISMAL_HOMEOSTASIS</TD><TD>254</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1,IL7,AZGP1</TD></TR>
<TR><TD>3.711e-02</TD><TD>-3.29</TD><TD>NMYC_01</TD><TD>MSigDB lists</TD><TD>NMYC_01</TD><TD>254</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,RNF128,USP2</TD></TR>
<TR><TD>3.723e-02</TD><TD>-3.29</TD><TD>GAPDH (glyceraldehyde-3-phosphate dehydrogenase)</TD><TD>protein interactions</TD><TD>2597</TD><TD>257</TD><TD>3</TD><TD>17456</TD><TD>50</TD>
<TD>GRIA2,CDKN2A,ZIC1</TD></TR>
<TR><TD>3.737e-02</TD><TD>-3.29</TD><TD>PTX</TD><TD>smart domains</TD><TD>SM00159</TD><TD>10</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>NPTX2</TD></TR>
<TR><TD>3.738e-02</TD><TD>-3.29</TD><TD>aminoglycan biosynthetic process</TD><TD>biological process</TD><TD>GO:0006023</TD><TD>108</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>HS3ST3B1,GPC5</TD></TR>
<TR><TD>3.747e-02</TD><TD>-3.28</TD><TD>neurotransmitter receptor activity</TD><TD>molecular function</TD><TD>GO:0030594</TD><TD>115</TD><TD>2</TD><TD>17306</TD><TD>46</TD>
<TD>GABRB2,GRIA2</TD></TR>
<TR><TD>3.752e-02</TD><TD>-3.28</TD><TD>calcium ion binding</TD><TD>molecular function</TD><TD>GO:0005509</TD><TD>701</TD><TD>5</TD><TD>17306</TD><TD>46</TD>
<TD>PLCH1,PCDH17,CRB1,PCDH20,PCDH11X</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>Ephrin_rcpt_lig-bd_dom</TD><TD>interpro domains</TD><TD>IPR001090</TD><TD>14</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>Eph_TM</TD><TD>interpro domains</TD><TD>IPR027936</TD><TD>14</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>Tyr_kinase_rcpt_V_CS</TD><TD>interpro domains</TD><TD>IPR001426</TD><TD>14</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.769e-02</TD><TD>-3.28</TD><TD>Tyr_kinase_ephrin_rcpt</TD><TD>interpro domains</TD><TD>IPR016257</TD><TD>14</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.773e-02</TD><TD>-3.28</TD><TD>GO_NEUROGENESIS</TD><TD>MSigDB lists</TD><TD>GO_NEUROGENESIS</TD><TD>1343</TD><TD>8</TD><TD>17275</TD><TD>50</TD>
<TD>FOXA2,EPHA3,GABRB2,BMPR1B,PLAG1,CRB1,SATB2,DCDC2</TD></TR>
<TR><TD>3.775e-02</TD><TD>-3.28</TD><TD>GO_NEURON_MIGRATION</TD><TD>MSigDB lists</TD><TD>GO_NEURON_MIGRATION</TD><TD>106</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,DCDC2</TD></TR>
<TR><TD>3.775e-02</TD><TD>-3.28</TD><TD>ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_DN</TD><TD>106</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,HEY1</TD></TR>
<TR><TD>3.781e-02</TD><TD>-3.28</TD><TD>cell migration</TD><TD>biological process</TD><TD>GO:0016477</TD><TD>886</TD><TD>6</TD><TD>18054</TD><TD>51</TD>
<TD>EPHA3,SATB2,CXCL14,ALX1,GPC5,DCDC2</TD></TR>
<TR><TD>3.784e-02</TD><TD>-3.27</TD><TD>MORF_FSHR</TD><TD>MSigDB lists</TD><TD>MORF_FSHR</TD><TD>256</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,STAC,IL7</TD></TR>
<TR><TD>3.785e-02</TD><TD>-3.27</TD><TD>skin-leg-malignant_melanoma-nodular</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-malignant_melanoma-nodular</TD><TD>261</TD><TD>3</TD><TD>17255</TD><TD>49</TD>
<TD>MTSS1,SATB2,CDKN2A</TD></TR>
<TR><TD>3.794e-02</TD><TD>-3.27</TD><TD>neuron part</TD><TD>cellular component</TD><TD>GO:0097458</TD><TD>1720</TD><TD>9</TD><TD>18985</TD><TD>51</TD>
<TD>DCDC2,EPHA3,BMPR1B,CPEB2,GABRB2,NPTX2,PCDH17,GRIA2,CRB1</TD></TR>
<TR><TD>3.832e-02</TD><TD>-3.26</TD><TD>SKIL (SKI like proto-oncogene)</TD><TD>protein interactions</TD><TD>6498</TD><TD>108</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>PAPPA,HEY1</TD></TR>
<TR><TD>3.840e-02</TD><TD>-3.26</TD><TD>REACTOME_GLYCOSAMINOGLYCAN_METABOLISM</TD><TD>MSigDB lists</TD><TD>REACTOME_GLYCOSAMINOGLYCAN_METABOLISM</TD><TD>107</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>GPC5,HS3ST3B1</TD></TR>
<TR><TD>3.840e-02</TD><TD>-3.26</TD><TD>GO_CELLULAR_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>107</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>3.840e-02</TD><TD>-3.26</TD><TD>DOANE_BREAST_CANCER_ESR1_UP</TD><TD>MSigDB lists</TD><TD>DOANE_BREAST_CANCER_ESR1_UP</TD><TD>107</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,AZGP1</TD></TR>
<TR><TD>3.868e-02</TD><TD>-3.25</TD><TD>transcription regulator activity</TD><TD>molecular function</TD><TD>GO:0140110</TD><TD>2038</TD><TD>10</TD><TD>17306</TD><TD>46</TD>
<TD>HEY1,SATB2,PLAG1,ZIC4,PAX9,ZIC1,MEIS2,ZFHX4,FOXA2,ALX1</TD></TR>
<TR><TD>3.876e-02</TD><TD>-3.25</TD><TD>EphA2_TM</TD><TD>pfam domains</TD><TD>PF14575</TD><TD>14</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.876e-02</TD><TD>-3.25</TD><TD>Ephrin_lbd</TD><TD>pfam domains</TD><TD>PF01404</TD><TD>14</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>EPHA3</TD></TR>
<TR><TD>3.876e-02</TD><TD>-3.25</TD><TD>WH2</TD><TD>pfam domains</TD><TD>PF02205</TD><TD>14</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>MTSS1</TD></TR>
<TR><TD>3.884e-02</TD><TD>-3.25</TD><TD>regulation of vasculogenesis</TD><TD>biological process</TD><TD>GO:2001212</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.884e-02</TD><TD>-3.25</TD><TD>synaptic transmission, GABAergic</TD><TD>biological process</TD><TD>GO:0051932</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>GABRB2</TD></TR>
<TR><TD>3.884e-02</TD><TD>-3.25</TD><TD>dicarboxylic acid biosynthetic process</TD><TD>biological process</TD><TD>GO:0043650</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.884e-02</TD><TD>-3.25</TD><TD>positive regulation of extrinsic apoptotic signaling pathway via death domain receptors</TD><TD>biological process</TD><TD>GO:1902043</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.884e-02</TD><TD>-3.25</TD><TD>establishment of endothelial intestinal barrier</TD><TD>biological process</TD><TD>GO:0090557</TD><TD>14</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>3.887e-02</TD><TD>-3.25</TD><TD>TTANTCA_UNKNOWN</TD><TD>MSigDB lists</TD><TD>TTANTCA_UNKNOWN</TD><TD>871</TD><TD>6</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,NPTX2,USP2,ZFHX4,PCDH11X,PAX9</TD></TR>
<TR><TD>3.896e-02</TD><TD>-3.25</TD><TD>KRAS.600_UP.V1_UP</TD><TD>MSigDB lists</TD><TD>KRAS.600_UP.V1_UP</TD><TD>259</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,HS3ST3B1,HEY1</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_II</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>pituitary-adenoma-non_functioning</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-non_functioning</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>pituitary-adenoma-ACTH</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-ACTH</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>chondroid</TD><TD>COSMIC cancer mutations</TD><TD>chondroid</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>ovary-sex_cord-stromal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-sex_cord-stromal_tumour</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>ACTH</TD><TD>COSMIC cancer mutations</TD><TD>ACTH</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>penis</TD><TD>COSMIC cancer mutations</TD><TD>penis</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>bone-calcaneus-chondrosarcoma</TD><TD>COSMIC cancer mutations</TD><TD>bone-calcaneus-chondrosarcoma</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH20</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>in_situ_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>in_situ_neoplasm</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>bone-vertebrae-chordoma-chondroid</TD><TD>COSMIC cancer mutations</TD><TD>bone-vertebrae-chordoma-chondroid</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>autonomic_ganglia-paraganglioma</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-paraganglioma</TD><TD>14</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.905e-02</TD><TD>-3.24</TD><TD>ATAAGCT_MIR21</TD><TD>MSigDB lists</TD><TD>ATAAGCT_MIR21</TD><TD>108</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,PCDH17</TD></TR>
<TR><TD>3.915e-02</TD><TD>-3.24</TD><TD>heparan sulfate sulfotransferase activity</TD><TD>molecular function</TD><TD>GO:0034483</TD><TD>15</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>HS3ST3B1</TD></TR>
<TR><TD>3.915e-02</TD><TD>-3.24</TD><TD>transforming growth factor beta-activated receptor activity</TD><TD>molecular function</TD><TD>GO:0005024</TD><TD>15</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>OTX2 (orthodenticle homeobox 2)</TD><TD>protein interactions</TD><TD>5015</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>AMHR2 (anti-Mullerian hormone receptor type 2)</TD><TD>protein interactions</TD><TD>269</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>SLC25A15 (solute carrier family 25 member 15)</TD><TD>protein interactions</TD><TD>10166</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EYA4</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>MTSS1 (MTSS I-BAR domain containing 1)</TD><TD>protein interactions</TD><TD>9788</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MTSS1</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>RHEBL1 (RHEB like 1)</TD><TD>protein interactions</TD><TD>121268</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>SOX3 (SRY-box transcription factor 3)</TD><TD>protein interactions</TD><TD>6658</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>UBI4 (ubiquitin)</TD><TD>protein interactions</TD><TD>850620</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>3.938e-02</TD><TD>-3.23</TD><TD>Sqstm1 (sequestosome 1)</TD><TD>protein interactions</TD><TD>18412</TD><TD>14</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>3.947e-02</TD><TD>-3.23</TD><TD>integral component of postsynaptic membrane</TD><TD>cellular component</TD><TD>GO:0099055</TD><TD>117</TD><TD>2</TD><TD>18985</TD><TD>51</TD>
<TD>GABRB2,PCDH17</TD></TR>
<TR><TD>3.956e-02</TD><TD>-3.23</TD><TD>low-density lipoprotein particle</TD><TD>cellular component</TD><TD>GO:0034362</TD><TD>15</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>LSR</TD></TR>
<TR><TD>3.972e-02</TD><TD>-3.23</TD><TD>YKACATTT_UNKNOWN</TD><TD>MSigDB lists</TD><TD>YKACATTT_UNKNOWN</TD><TD>261</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZFHX4,PCDH11X,PLAG1</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>GO_CELLULAR_RESPONSE_TO_ARSENIC_CONTAINING_SUBSTANCE</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_RESPONSE_TO_ARSENIC_CONTAINING_SUBSTANCE</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>GO_GTPASE_INHIBITOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_GTPASE_INHIBITOR_ACTIVITY</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>GO_TRANSCRIPTION_FACTOR_ACTIVITY_RNA_POLYMERASE_II_CORE_PROMOTER_SEQUENCE_SPECIFIC</TD><TD>MSigDB lists</TD><TD>GO_TRANSCRIPTION_FACTOR_ACTIVITY_RNA_POLYMERASE_II_CORE_PROMOTER_SEQUENCE_SPECIFIC</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>CASTELLANO_NRAS_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>CASTELLANO_NRAS_TARGETS_DN</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>GO_PYRIDINE_NUCLEOTIDE_BIOSYNTHETIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_PYRIDINE_NUCLEOTIDE_BIOSYNTHETIC_PROCESS</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>AHRARNT_02</TD><TD>MSigDB lists</TD><TD>AHRARNT_02</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>GO_HEART_TRABECULA_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_HEART_TRABECULA_FORMATION</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>SA_G1_AND_S_PHASES</TD><TD>MSigDB lists</TD><TD>SA_G1_AND_S_PHASES</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>BIOCARTA_STEM_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_STEM_PATHWAY</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>IL7</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>GO_LIGASE_REGULATOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_LIGASE_REGULATOR_ACTIVITY</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>3.978e-02</TD><TD>-3.22</TD><TD>chr13q21</TD><TD>MSigDB lists</TD><TD>chr13q21</TD><TD>14</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.000e-02</TD><TD>-3.22</TD><TD>ORANGE</TD><TD>prosite domains</TD><TD>PS51054</TD><TD>12</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.012e-02</TD><TD>-3.22</TD><TD>skin-extremity-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-extremity-malignant_melanoma</TD><TD>1914</TD><TD>10</TD><TD>17255</TD><TD>49</TD>
<TD>SLC6A15,EPHA3,EDA2R,KYNU,ZFHX4,CDKN2A,PCDH17,CPEB2,RBM11,PAPPA</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>human chr13q31.3</TD><TD>chromosome location</TD><TD>human chr13q31.3</TD><TD>21</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>human chr3q26.33</TD><TD>chromosome location</TD><TD>human chr3q26.33</TD><TD>21</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>PEX5L</TD></TR>
<TR><TD>4.015e-02</TD><TD>-3.22</TD><TD>human chr3q28</TD><TD>chromosome location</TD><TD>human chr3q28</TD><TD>21</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>CLDN1</TD></TR>
<TR><TD>4.025e-02</TD><TD>-3.21</TD><TD>extremity</TD><TD>COSMIC cancer mutations</TD><TD>extremity</TD><TD>1915</TD><TD>10</TD><TD>17255</TD><TD>49</TD>
<TD>KYNU,EDA2R,SLC6A15,EPHA3,RBM11,PAPPA,CPEB2,PCDH17,CDKN2A,ZFHX4</TD></TR>
<TR><TD>4.033e-02</TD><TD>-3.21</TD><TD>PLipase_C_Pinositol-sp_Y</TD><TD>interpro domains</TD><TD>IPR001711</TD><TD>15</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.033e-02</TD><TD>-3.21</TD><TD>PI-PLC_fam</TD><TD>interpro domains</TD><TD>IPR001192</TD><TD>15</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.037e-02</TD><TD>-3.21</TD><TD>GSE37532_VISCERAL_ADIPOSE_TISSUE_VS_LN_DERIVED_TCONV_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE37532_VISCERAL_ADIPOSE_TISSUE_VS_LN_DERIVED_TCONV_CD4_TCELL_UP</TD><TD>110</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A,ZIC1</TD></TR>
<TR><TD>4.037e-02</TD><TD>-3.21</TD><TD>DAIRKEE_TERT_TARGETS_DN</TD><TD>MSigDB lists</TD><TD>DAIRKEE_TERT_TARGETS_DN</TD><TD>110</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PLEKHM3,PAPPA</TD></TR>
<TR><TD>4.089e-02</TD><TD>-3.20</TD><TD>regulation of cellular localization</TD><TD>biological process</TD><TD>GO:0060341</TD><TD>903</TD><TD>6</TD><TD>18054</TD><TD>51</TD>
<TD>GPC5,STAC,ZIC1,EPHA3,PCDH17,FOXA2</TD></TR>
<TR><TD>4.108e-02</TD><TD>-3.19</TD><TD>aging</TD><TD>biological process</TD><TD>GO:0007568</TD><TD>271</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>CLDN1,KYNU,CDKN2A</TD></TR>
<TR><TD>4.125e-02</TD><TD>-3.19</TD><TD>USF_C</TD><TD>MSigDB lists</TD><TD>USF_C</TD><TD>265</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,SLC6A15,USP2</TD></TR>
<TR><TD>4.147e-02</TD><TD>-3.18</TD><TD>OAR</TD><TD>pfam domains</TD><TD>PF03826</TD><TD>15</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>ALX1</TD></TR>
<TR><TD>4.147e-02</TD><TD>-3.18</TD><TD>CRAL_TRIO</TD><TD>pfam domains</TD><TD>PF00650</TD><TD>15</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>CLVS2</TD></TR>
<TR><TD>4.147e-02</TD><TD>-3.18</TD><TD>PI-PLC-Y</TD><TD>pfam domains</TD><TD>PF00387</TD><TD>15</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.158e-02</TD><TD>-3.18</TD><TD>Glycosaminoglycan metabolism</TD><TD>REACTOME pathways</TD><TD>R-HSA-1630316</TD><TD>124</TD><TD>2</TD><TD>10287</TD><TD>27</TD>
<TD>GPC5,HS3ST3B1</TD></TR>
<TR><TD>4.160e-02</TD><TD>-3.18</TD><TD>skin-chest-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-chest-malignant_melanoma</TD><TD>114</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,PLCH1</TD></TR>
<TR><TD>4.171e-02</TD><TD>-3.18</TD><TD>GSE36095_WT_VS_HDAC9_KO_TREG_DN</TD><TD>MSigDB lists</TD><TD>GSE36095_WT_VS_HDAC9_KO_TREG_DN</TD><TD>112</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,NPTX2</TD></TR>
<TR><TD>4.171e-02</TD><TD>-3.18</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP</TD><TD>MSigDB lists</TD><TD>SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP</TD><TD>112</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,EPHA3</TD></TR>
<TR><TD>4.171e-02</TD><TD>-3.18</TD><TD>heparan sulfate proteoglycan binding</TD><TD>molecular function</TD><TD>GO:0043395</TD><TD>16</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>FST</TD></TR>
<TR><TD>4.171e-02</TD><TD>-3.18</TD><TD>inhibitory extracellular ligand-gated ion channel activity</TD><TD>molecular function</TD><TD>GO:0005237</TD><TD>16</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>ureter</TD><TD>COSMIC cancer mutations</TD><TD>ureter</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>adrenal_gland-adrenal_gland-pheochromocytoma</TD><TD>COSMIC cancer mutations</TD><TD>adrenal_gland-adrenal_gland-pheochromocytoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>transitional</TD><TD>COSMIC cancer mutations</TD><TD>transitional</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>meninges-meningioma-anaplastic</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-anaplastic</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>choriocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>choriocarcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>ovary-germ_cell_tumour-yolk_sac_tumour</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-yolk_sac_tumour</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>dysgerminoma</TD><TD>COSMIC cancer mutations</TD><TD>dysgerminoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>meninges-meningioma-transitional</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-transitional</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>pituitary-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>salivary_gland-parotid-carcinoma-acinic_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_gland-parotid-carcinoma-acinic_cell_carcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>meninges-meningioma-atypical</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-atypical</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-gastrointestinal_stromal_tumour-epithelioid</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-fibrous_tissue_and_uncertain_origin-gastrointestinal_stromal_tumour-epithelioid</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>pituitary-adenoma-GH</TD><TD>COSMIC cancer mutations</TD><TD>pituitary-adenoma-GH</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>thymus-thymic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thymus-thymic_carcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>soft_tissue-nerve_sheath-neurofibroma</TD><TD>COSMIC cancer mutations</TD><TD>soft_tissue-nerve_sheath-neurofibroma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>ovary-germ_cell_tumour-dysgerminoma</TD><TD>COSMIC cancer mutations</TD><TD>ovary-germ_cell_tumour-dysgerminoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>central_nervous_system-brain-other-ganglioglioma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-other-ganglioglioma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>right</TD><TD>COSMIC cancer mutations</TD><TD>right</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>GH</TD><TD>COSMIC cancer mutations</TD><TD>GH</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>meninges-meningioma-fibroblastic</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-fibroblastic</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>biliary_tract-bile_duct-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>biliary_tract-bile_duct-carcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>testis-germ_cell_tumour-mixed</TD><TD>COSMIC cancer mutations</TD><TD>testis-germ_cell_tumour-mixed</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>testis-germ_cell_tumour-embryonal_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>testis-germ_cell_tumour-embryonal_carcinoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>lipoma</TD><TD>COSMIC cancer mutations</TD><TD>lipoma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.178e-02</TD><TD>-3.18</TD><TD>autonomic_ganglia-head_neck-paraganglioma</TD><TD>COSMIC cancer mutations</TD><TD>autonomic_ganglia-head_neck-paraganglioma</TD><TD>15</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.188e-02</TD><TD>-3.17</TD><TD>regulation of protein localization to cell periphery</TD><TD>biological process</TD><TD>GO:1904375</TD><TD>115</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>EPHA3,STAC</TD></TR>
<TR><TD>4.203e-02</TD><TD>-3.17</TD><TD>GO_CALCIUM_ION_BINDING</TD><TD>MSigDB lists</TD><TD>GO_CALCIUM_ION_BINDING</TD><TD>663</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,CRB1,PCDH11X,PCDH20,PLCH1</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>CLDN1 (claudin 1)</TD><TD>protein interactions</TD><TD>9076</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CLDN1</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>ZNF440 (zinc finger protein 440)</TD><TD>protein interactions</TD><TD>126070</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PAX9</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>WNK4 (WNK lysine deficient protein kinase 4)</TD><TD>protein interactions</TD><TD>65266</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CLDN1</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>PAPPA (pappalysin 1)</TD><TD>protein interactions</TD><TD>5069</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PAPPA</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>CRELD2 (cysteine rich with EGF like domains 2)</TD><TD>protein interactions</TD><TD>79174</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>RNF128 (ring finger protein 128)</TD><TD>protein interactions</TD><TD>79589</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>RNF128</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>ASPRV1 (aspartic peptidase retroviral like 1)</TD><TD>protein interactions</TD><TD>151516</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>Tubb5 (tubulin, beta 5 class I)</TD><TD>protein interactions</TD><TD>22154</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1)</TD><TD>protein interactions</TD><TD>5167</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>TRIM74 (tripartite motif containing 74)</TD><TD>protein interactions</TD><TD>378108</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>MAB21L2 (mab-21 like 2)</TD><TD>protein interactions</TD><TD>10586</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>MEIS2</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>CYB5D2 (cytochrome b5 domain containing 2)</TD><TD>protein interactions</TD><TD>124936</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>NPTX2</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>MMRN1 (multimerin 1)</TD><TD>protein interactions</TD><TD>22915</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>GABBR1 (gamma-aminobutyric acid type B receptor subunit 1)</TD><TD>protein interactions</TD><TD>2550</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>GSDMA (gasdermin A)</TD><TD>protein interactions</TD><TD>284110</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>EFNA5 (ephrin A5)</TD><TD>protein interactions</TD><TD>1946</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.213e-02</TD><TD>-3.17</TD><TD>AGAP2 (ArfGAP with GTPase domain, ankyrin repeat and PH domain 2)</TD><TD>protein interactions</TD><TD>116986</TD><TD>15</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.214e-02</TD><TD>-3.17</TD><TD>Bone Morphogenic Protein (BMP) Signalling and Regulation</TD><TD>WikiPathways</TD><TD>WP1425</TD><TD>12</TD><TD>1</TD><TD>5311</TD><TD>19</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.238e-02</TD><TD>-3.16</TD><TD>GSE1925_CTRL_VS_IFNG_PRIMED_MACROPHAGE_3H_IFNG_STIM_DN</TD><TD>MSigDB lists</TD><TD>GSE1925_CTRL_VS_IFNG_PRIMED_MACROPHAGE_3H_IFNG_STIM_DN</TD><TD>113</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>IDO2,EDA2R</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>GO_ENDOCARDIAL_CUSHION_FORMATION</TD><TD>MSigDB lists</TD><TD>GO_ENDOCARDIAL_CUSHION_FORMATION</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS</TD><TD>MSigDB lists</TD><TD>REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>MODULE_215</TD><TD>MSigDB lists</TD><TD>MODULE_215</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>GO_REGULATION_OF_HAIR_FOLLICLE_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_HAIR_FOLLICLE_DEVELOPMENT</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>RODRIGUES_NTN1_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>RODRIGUES_NTN1_TARGETS_UP</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>CAIRO_PML_TARGETS_BOUND_BY_MYC_DN</TD><TD>MSigDB lists</TD><TD>CAIRO_PML_TARGETS_BOUND_BY_MYC_DN</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>GO_SUMO_TRANSFERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_SUMO_TRANSFERASE_ACTIVITY</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>GO_POLYPEPTIDE_N_ACETYLGALACTOSAMINYLTRANSFERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_POLYPEPTIDE_N_ACETYLGALACTOSAMINYLTRANSFERASE_ACTIVITY</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>GALNT13</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>GO_HEPARAN_SULFATE_SULFOTRANSFERASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_HEPARAN_SULFATE_SULFOTRANSFERASE_ACTIVITY</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HS3ST3B1</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>GO_ATRIOVENTRICULAR_VALVE_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_ATRIOVENTRICULAR_VALVE_MORPHOGENESIS</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>GO_NEGATIVE_REGULATION_OF_B_CELL_PROLIFERATION</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_B_CELL_PROLIFERATION</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION</TD><TD>MSigDB lists</TD><TD>REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>ZHANG_GATA6_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>ZHANG_GATA6_TARGETS_UP</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>GALNT13</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>GO_T_CELL_LINEAGE_COMMITMENT</TD><TD>MSigDB lists</TD><TD>GO_T_CELL_LINEAGE_COMMITMENT</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>IL7</TD></TR>
<TR><TD>4.256e-02</TD><TD>-3.16</TD><TD>chr2q22</TD><TD>MSigDB lists</TD><TD>chr2q22</TD><TD>15</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU</TD></TR>
<TR><TD>4.257e-02</TD><TD>-3.16</TD><TD>intrinsic component of postsynaptic membrane</TD><TD>cellular component</TD><TD>GO:0098936</TD><TD>122</TD><TD>2</TD><TD>18985</TD><TD>51</TD>
<TD>GABRB2,PCDH17</TD></TR>
<TR><TD>4.257e-02</TD><TD>-3.16</TD><TD>axoneme</TD><TD>cellular component</TD><TD>GO:0005930</TD><TD>122</TD><TD>2</TD><TD>18985</TD><TD>51</TD>
<TD>DCDC2,SPAG6</TD></TR>
<TR><TD>4.296e-02</TD><TD>-3.15</TD><TD>OAR_dom</TD><TD>interpro domains</TD><TD>IPR003654</TD><TD>16</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>ALX1</TD></TR>
<TR><TD>4.306e-02</TD><TD>-3.15</TD><TD>KIM_WT1_TARGETS_8HR_DN</TD><TD>MSigDB lists</TD><TD>KIM_WT1_TARGETS_8HR_DN</TD><TD>114</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,FST</TD></TR>
<TR><TD>4.320e-02</TD><TD>-3.14</TD><TD>ciliary plasm</TD><TD>cellular component</TD><TD>GO:0097014</TD><TD>123</TD><TD>2</TD><TD>18985</TD><TD>51</TD>
<TD>SPAG6,DCDC2</TD></TR>
<TR><TD>4.341e-02</TD><TD>-3.14</TD><TD>SENESE_HDAC3_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>SENESE_HDAC3_TARGETS_UP</TD><TD>459</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15,CPEB2,KYNU,PAPPA</TD></TR>
<TR><TD>4.366e-02</TD><TD>-3.13</TD><TD>L-tryptophan degradation III (eukaryotic)</TD><TD>BIOCYC pathways</TD><TD>META_TRYPTOPHAN-DEGRADATION-1</TD><TD>8</TD><TD>1</TD><TD>902</TD><TD>5</TD>
<TD>KYNU</TD></TR>
<TR><TD>4.373e-02</TD><TD>-3.13</TD><TD>SUMOylation of transcription factors</TD><TD>REACTOME pathways</TD><TD>R-HSA-3232118</TD><TD>17</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.373e-02</TD><TD>-3.13</TD><TD>Unblocking of NMDA receptor, glutamate binding and activation</TD><TD>REACTOME pathways</TD><TD>R-HSA-438066</TD><TD>17</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.373e-02</TD><TD>-3.13</TD><TD>Trafficking of GluR2-containing AMPA receptors</TD><TD>REACTOME pathways</TD><TD>R-HSA-416993</TD><TD>17</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.374e-02</TD><TD>-3.13</TD><TD>GSE12707_AT16L1_HYPOMORPH_VS_WT_THYMUS_UP</TD><TD>MSigDB lists</TD><TD>GSE12707_AT16L1_HYPOMORPH_VS_WT_THYMUS_UP</TD><TD>115</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B,CLDN1</TD></TR>
<TR><TD>4.374e-02</TD><TD>-3.13</TD><TD>GSE25677_MPL_VS_MPL_AND_R848_STIM_BCELL_DN</TD><TD>MSigDB lists</TD><TD>GSE25677_MPL_VS_MPL_AND_R848_STIM_BCELL_DN</TD><TD>115</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU,CRB1</TD></TR>
<TR><TD>4.374e-02</TD><TD>-3.13</TD><TD>GSE32901_NAIVE_VS_TH1_CD4_TCELL_UP</TD><TD>MSigDB lists</TD><TD>GSE32901_NAIVE_VS_TH1_CD4_TCELL_UP</TD><TD>115</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128,PCDH20</TD></TR>
<TR><TD>4.400e-02</TD><TD>-3.12</TD><TD>TATTATA_MIR374</TD><TD>MSigDB lists</TD><TD>TATTATA_MIR374</TD><TD>272</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,NPTX2,PAPPA</TD></TR>
<TR><TD>4.401e-02</TD><TD>-3.12</TD><TD>positive regulation of developmental process</TD><TD>biological process</TD><TD>GO:0051094</TD><TD>1418</TD><TD>8</TD><TD>18054</TD><TD>51</TD>
<TD>FST,EPHA3,BMPR1B,IL7,FOXA2,CDKN2A,PLAG1,ALX1</TD></TR>
<TR><TD>4.417e-02</TD><TD>-3.12</TD><TD>PI-PLC-X</TD><TD>pfam domains</TD><TD>PF00388</TD><TD>16</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.426e-02</TD><TD>-3.12</TD><TD>ribosomal small subunit binding</TD><TD>molecular function</TD><TD>GO:0043024</TD><TD>17</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>CPEB2</TD></TR>
<TR><TD>4.426e-02</TD><TD>-3.12</TD><TD>amino acid:cation symporter activity</TD><TD>molecular function</TD><TD>GO:0005416</TD><TD>17</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.426e-02</TD><TD>-3.12</TD><TD>transmembrane receptor protein serine/threonine kinase activity</TD><TD>molecular function</TD><TD>GO:0004675</TD><TD>17</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.426e-02</TD><TD>-3.12</TD><TD>transmembrane-ephrin receptor activity</TD><TD>molecular function</TD><TD>GO:0005005</TD><TD>17</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.427e-02</TD><TD>-3.12</TD><TD>central_nervous_system-brain-glioma-oligoastrocytoma_Grade_III</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-oligoastrocytoma_Grade_III</TD><TD>118</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,PCDH20</TD></TR>
<TR><TD>4.427e-02</TD><TD>-3.12</TD><TD>sulfation</TD><TD>biological process</TD><TD>GO:0051923</TD><TD>16</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HS3ST3B1</TD></TR>
<TR><TD>4.427e-02</TD><TD>-3.12</TD><TD>response to follicle-stimulating hormone</TD><TD>biological process</TD><TD>GO:0032354</TD><TD>16</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PAPPA</TD></TR>
<TR><TD>4.427e-02</TD><TD>-3.12</TD><TD>inositol trisphosphate biosynthetic process</TD><TD>biological process</TD><TD>GO:0032959</TD><TD>16</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.443e-02</TD><TD>-3.11</TD><TD>GGCACTT_MIR519E</TD><TD>MSigDB lists</TD><TD>GGCACTT_MIR519E</TD><TD>116</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ZFHX4,ZIC4</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>eye-uveal_tract-malignant_melanoma-epithelioid</TD><TD>COSMIC cancer mutations</TD><TD>eye-uveal_tract-malignant_melanoma-epithelioid</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>normal</TD><TD>COSMIC cancer mutations</TD><TD>normal</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>embryonal_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>embryonal_carcinoma</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-precursor_T_cell_lymphoblastic_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-precursor_T_cell_lymphoblastic_lymphoma</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>flank</TD><TD>COSMIC cancer mutations</TD><TD>flank</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>urinary_tract-carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>urinary_tract-carcinoma</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_III-IV</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-brain-glioma-ependymoma_Grade_III-IV</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>skin-leg-adnexal_tumour-malignant_adnexal_tumour</TD><TD>COSMIC cancer mutations</TD><TD>skin-leg-adnexal_tumour-malignant_adnexal_tumour</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.450e-02</TD><TD>-3.11</TD><TD>renal_pelvis</TD><TD>COSMIC cancer mutations</TD><TD>renal_pelvis</TD><TD>16</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.454e-02</TD><TD>-3.11</TD><TD>neuron migration</TD><TD>biological process</TD><TD>GO:0001764</TD><TD>119</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,DCDC2</TD></TR>
<TR><TD>4.454e-02</TD><TD>-3.11</TD><TD>regulation of cell-matrix adhesion</TD><TD>biological process</TD><TD>GO:0001952</TD><TD>119</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A,EPHA3</TD></TR>
<TR><TD>4.467e-02</TD><TD>-3.11</TD><TD>CRAL_TRIO_N</TD><TD>smart domains</TD><TD>SM01100</TD><TD>12</TD><TD>1</TD><TD>9476</TD><TD>36</TD>
<TD>CLVS2</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>FLRT1 (fibronectin leucine rich transmembrane protein 1)</TD><TD>protein interactions</TD><TD>23769</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH17</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>INHBA (inhibin subunit beta A)</TD><TD>protein interactions</TD><TD>3624</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>MTMR11 (myotubularin related protein 11)</TD><TD>protein interactions</TD><TD>10903</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>CAPNS2 (calpain small subunit 2)</TD><TD>protein interactions</TD><TD>84290</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>NMU (neuromedin U)</TD><TD>protein interactions</TD><TD>10874</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>HOXB13 (homeobox B13)</TD><TD>protein interactions</TD><TD>10481</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FOXA2</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>CHN1 (chimerin 1)</TD><TD>protein interactions</TD><TD>1123</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>Stub1 (STIP1 homology and U-Box containing protein 1)</TD><TD>protein interactions</TD><TD>56424</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>FRG1 (FSHD region gene 1)</TD><TD>protein interactions</TD><TD>2483</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>INHBE (inhibin subunit beta E)</TD><TD>protein interactions</TD><TD>83729</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>CACNA2D2 (calcium voltage-gated channel auxiliary subunit alpha2delta 2)</TD><TD>protein interactions</TD><TD>9254</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>4.488e-02</TD><TD>-3.10</TD><TD>ULBP2 (UL16 binding protein 2)</TD><TD>protein interactions</TD><TD>80328</TD><TD>16</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>IDO2</TD></TR>
<TR><TD>4.497e-02</TD><TD>-3.10</TD><TD>BMPR1A (bone morphogenetic protein receptor type 1A)</TD><TD>protein interactions</TD><TD>657</TD><TD>118</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>FST,BMPR1B</TD></TR>
<TR><TD>4.512e-02</TD><TD>-3.10</TD><TD>YEGNASUBRAMANIAN_PROSTATE_CANCER</TD><TD>MSigDB lists</TD><TD>YEGNASUBRAMANIAN_PROSTATE_CANCER</TD><TD>117</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,EPHA3</TD></TR>
<TR><TD>4.512e-02</TD><TD>-3.10</TD><TD>KAN_RESPONSE_TO_ARSENIC_TRIOXIDE</TD><TD>MSigDB lists</TD><TD>KAN_RESPONSE_TO_ARSENIC_TRIOXIDE</TD><TD>117</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>CXCL14,HEY1</TD></TR>
<TR><TD>4.512e-02</TD><TD>-3.10</TD><TD>AAAGGAT_MIR501</TD><TD>MSigDB lists</TD><TD>AAAGGAT_MIR501</TD><TD>117</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC4,SATB2</TD></TR>
<TR><TD>4.530e-02</TD><TD>-3.09</TD><TD>WONG_ADULT_TISSUE_STEM_MODULE</TD><TD>MSigDB lists</TD><TD>WONG_ADULT_TISSUE_STEM_MODULE</TD><TD>677</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>USP2,STAC,CXCL14,SLC6A15,GRIA2</TD></TR>
<TR><TD>4.531e-02</TD><TD>-3.09</TD><TD>non_small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>non_small_cell_carcinoma</TD><TD>5266</TD><TD>21</TD><TD>17255</TD><TD>49</TD>
<TD>SPAG6,PLEKHM3,EDA2R,GRIA2,USP2,PCDH11X,RNF128,PLAG1,ZFHX4,HEY1,PEX5L,PCDH20,IL7,BMPR1B,EPHA3,FOXA2,SATB2,PAX9,CXCL14,CDKN2A,EYA4</TD></TR>
<TR><TD>4.531e-02</TD><TD>-3.09</TD><TD>lung-carcinoma-non_small_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>lung-carcinoma-non_small_cell_carcinoma</TD><TD>5266</TD><TD>21</TD><TD>17255</TD><TD>49</TD>
<TD>SATB2,CXCL14,PAX9,EYA4,CDKN2A,PCDH20,IL7,PEX5L,BMPR1B,EPHA3,FOXA2,USP2,GRIA2,PCDH11X,RNF128,PLAG1,ZFHX4,HEY1,SPAG6,EDA2R,PLEKHM3</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>PID_HIF1A_PATHWAY</TD><TD>MSigDB lists</TD><TD>PID_HIF1A_PATHWAY</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>chr4q23</TD><TD>MSigDB lists</TD><TD>chr4q23</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>FUKUSHIMA_TNFSF11_TARGETS</TD><TD>MSigDB lists</TD><TD>FUKUSHIMA_TNFSF11_TARGETS</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>GO_CELLULAR_MODIFIED_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>MSigDB lists</TD><TD>GO_CELLULAR_MODIFIED_AMINO_ACID_CATABOLIC_PROCESS</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>KYNU</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>GO_CELL_SURFACE_RECEPTOR_SIGNALING_PATHWAY_INVOLVED_IN_HEART_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_CELL_SURFACE_RECEPTOR_SIGNALING_PATHWAY_INVOLVED_IN_HEART_DEVELOPMENT</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>GO_CATION_AMINO_ACID_SYMPORTER_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_CATION_AMINO_ACID_SYMPORTER_ACTIVITY</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS</TD><TD>MSigDB lists</TD><TD>REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA</TD></TR>
<TR><TD>4.534e-02</TD><TD>-3.09</TD><TD>GO_POSITIVE_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_VIA_DEATH_DOMAIN_RECEPTORS</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_VIA_DEATH_DOMAIN_RECEPTORS</TD><TD>16</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>BMPR1B</TD></TR>
<TR><TD>4.547e-02</TD><TD>-3.09</TD><TD>skin-back-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-back-malignant_melanoma</TD><TD>281</TD><TD>3</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1,PLAG1,CDKN2A</TD></TR>
<TR><TD>4.548e-02</TD><TD>-3.09</TD><TD>extraskeletal</TD><TD>COSMIC cancer mutations</TD><TD>extraskeletal</TD><TD>923</TD><TD>6</TD><TD>17255</TD><TD>49</TD>
<TD>MTSS1,PLEKHM3,EYA4,CDKN2A,ZFHX4,HEY1</TD></TR>
<TR><TD>4.553e-02</TD><TD>-3.09</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic</TD><TD>15095</TD><TD>47</TD><TD>17255</TD><TD>49</TD>
<TD>GALNT13,CRB1,SPAG6,MTSS1,STAC,SCGB3A2,GPC5,SATB2,PAX9,AZGP1,MEIS2,FST,ENPP5,CDKN2A,EYA4,ZIC4,HS3ST3B1,CLDN1,CLVS2,PCDH20,PEX5L,BMPR1B,EPHA3,IDO2,NPTX2,FOXA2,GABRB2,GRIA2,USP2,PCDH11X,PLCH1,RNF128,PLAG1,ZFHX4,HEY1,EDA2R,PLEKHM3,KYNU,PCDH17,CPEB2,CXCL14,LSR,ZIC1,ALX1,IL7,SLC6A15,DCDC2</TD></TR>
<TR><TD>4.553e-02</TD><TD>-3.09</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell</TD><TD>15095</TD><TD>47</TD><TD>17255</TD><TD>49</TD>
<TD>KYNU,PLEKHM3,EDA2R,PLCH1,RNF128,PLAG1,GRIA2,USP2,PCDH11X,HEY1,ZFHX4,ALX1,IL7,DCDC2,SLC6A15,PCDH17,CPEB2,CXCL14,LSR,ZIC1,MTSS1,SPAG6,STAC,SCGB3A2,GPC5,CRB1,GALNT13,PCDH20,PEX5L,CLVS2,CLDN1,FOXA2,NPTX2,GABRB2,EPHA3,BMPR1B,IDO2,MEIS2,AZGP1,FST,ENPP5,SATB2,PAX9,ZIC4,CDKN2A,HS3ST3B1,EYA4</TD></TR>
<TR><TD>4.553e-02</TD><TD>-3.09</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic</TD><TD>15095</TD><TD>47</TD><TD>17255</TD><TD>49</TD>
<TD>HEY1,ZFHX4,PLAG1,RNF128,PLCH1,PCDH11X,GRIA2,USP2,KYNU,EDA2R,PLEKHM3,LSR,ZIC1,CPEB2,CXCL14,PCDH17,DCDC2,SLC6A15,IL7,ALX1,CRB1,GALNT13,GPC5,SCGB3A2,STAC,SPAG6,MTSS1,EYA4,HS3ST3B1,CDKN2A,ZIC4,ENPP5,FST,MEIS2,AZGP1,PAX9,SATB2,GABRB2,FOXA2,NPTX2,EPHA3,BMPR1B,IDO2,PCDH20,PEX5L,CLVS2,CLDN1</TD></TR>
<TR><TD>4.553e-02</TD><TD>-3.09</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma</TD><TD>15095</TD><TD>47</TD><TD>17255</TD><TD>49</TD>
<TD>PLAG1,PLCH1,RNF128,PCDH11X,USP2,GRIA2,HEY1,ZFHX4,KYNU,PLEKHM3,EDA2R,CXCL14,CPEB2,PCDH17,LSR,ZIC1,IL7,ALX1,DCDC2,SLC6A15,CRB1,GALNT13,STAC,MTSS1,SPAG6,GPC5,SCGB3A2,ENPP5,FST,AZGP1,MEIS2,PAX9,SATB2,CDKN2A,ZIC4,EYA4,HS3ST3B1,PCDH20,CLVS2,PEX5L,CLDN1,NPTX2,FOXA2,GABRB2,IDO2,EPHA3,BMPR1B</TD></TR>
<TR><TD>4.559e-02</TD><TD>-3.09</TD><TD>PA_domain</TD><TD>interpro domains</TD><TD>IPR003137</TD><TD>17</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>RNF128</TD></TR>
<TR><TD>4.564e-02</TD><TD>-3.09</TD><TD>classic</TD><TD>COSMIC cancer mutations</TD><TD>classic</TD><TD>15096</TD><TD>47</TD><TD>17255</TD><TD>49</TD>
<TD>SCGB3A2,GPC5,SPAG6,MTSS1,STAC,GALNT13,CRB1,BMPR1B,IDO2,EPHA3,NPTX2,FOXA2,GABRB2,CLDN1,PEX5L,PCDH20,CLVS2,ZIC4,HS3ST3B1,CDKN2A,EYA4,SATB2,PAX9,AZGP1,MEIS2,FST,ENPP5,EDA2R,PLEKHM3,KYNU,HEY1,ZFHX4,GRIA2,USP2,PCDH11X,RNF128,PLCH1,PLAG1,SLC6A15,DCDC2,ALX1,IL7,ZIC1,LSR,PCDH17,CXCL14,CPEB2</TD></TR>
<TR><TD>4.572e-02</TD><TD>-3.09</TD><TD>GO_NUCLEIC_ACID_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY</TD><TD>MSigDB lists</TD><TD>GO_NUCLEIC_ACID_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY</TD><TD>1146</TD><TD>7</TD><TD>17275</TD><TD>50</TD>
<TD>PLAG1,PAX9,ALX1,HEY1,FOXA2,ZIC1,MEIS2</TD></TR>
<TR><TD>4.582e-02</TD><TD>-3.08</TD><TD>NKX25_01</TD><TD>MSigDB lists</TD><TD>NKX25_01</TD><TD>118</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>PCDH17,ZIC4</TD></TR>
<TR><TD>4.602e-02</TD><TD>-3.08</TD><TD>GO_EMBRYONIC_ORGAN_MORPHOGENESIS</TD><TD>MSigDB lists</TD><TD>GO_EMBRYONIC_ORGAN_MORPHOGENESIS</TD><TD>277</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,ALX1,SATB2</TD></TR>
<TR><TD>4.607e-02</TD><TD>-3.08</TD><TD>medulla</TD><TD>COSMIC cancer mutations</TD><TD>medulla</TD><TD>15100</TD><TD>47</TD><TD>17255</TD><TD>49</TD>
<TD>HEY1,ZFHX4,RNF128,PLCH1,PLAG1,USP2,GRIA2,PCDH11X,KYNU,EDA2R,PLEKHM3,LSR,ZIC1,PCDH17,CPEB2,CXCL14,DCDC2,SLC6A15,ALX1,IL7,CRB1,GALNT13,SCGB3A2,GPC5,SPAG6,MTSS1,STAC,ZIC4,CDKN2A,HS3ST3B1,EYA4,MEIS2,AZGP1,ENPP5,FST,SATB2,PAX9,NPTX2,FOXA2,GABRB2,EPHA3,BMPR1B,IDO2,PCDH20,CLVS2,PEX5L,CLDN1</TD></TR>
<TR><TD>4.618e-02</TD><TD>-3.08</TD><TD>desmoplastic</TD><TD>COSMIC cancer mutations</TD><TD>desmoplastic</TD><TD>15101</TD><TD>47</TD><TD>17255</TD><TD>49</TD>
<TD>CPEB2,CXCL14,PCDH17,ZIC1,LSR,IL7,ALX1,DCDC2,SLC6A15,PLAG1,RNF128,PLCH1,PCDH11X,GRIA2,USP2,HEY1,ZFHX4,KYNU,EDA2R,PLEKHM3,ENPP5,FST,AZGP1,MEIS2,PAX9,SATB2,EYA4,HS3ST3B1,ZIC4,CDKN2A,PCDH20,CLVS2,PEX5L,CLDN1,NPTX2,GABRB2,FOXA2,BMPR1B,IDO2,EPHA3,CRB1,GALNT13,STAC,SPAG6,MTSS1,GPC5,SCGB3A2</TD></TR>
<TR><TD>4.634e-02</TD><TD>-3.07</TD><TD>positive regulation of cellular biosynthetic process</TD><TD>biological process</TD><TD>GO:0031328</TD><TD>1969</TD><TD>10</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,HEY1,PLAG1,ALX1,ZFHX4,MEIS2,BMPR1B,PAX9,FOXA2,ZIC1</TD></TR>
<TR><TD>4.640e-02</TD><TD>-3.07</TD><TD>tight junction</TD><TD>cellular component</TD><TD>GO:0070160</TD><TD>128</TD><TD>2</TD><TD>18985</TD><TD>51</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>4.651e-02</TD><TD>-3.07</TD><TD>RECEPTOR_TYR_KIN_V_2</TD><TD>prosite domains</TD><TD>PS00791</TD><TD>14</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.651e-02</TD><TD>-3.07</TD><TD>EPH_LBD</TD><TD>prosite domains</TD><TD>PS51550</TD><TD>14</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.651e-02</TD><TD>-3.07</TD><TD>RECEPTOR_TYR_KIN_V_1</TD><TD>prosite domains</TD><TD>PS00790</TD><TD>14</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.651e-02</TD><TD>-3.07</TD><TD>GO_EMBRYONIC_SKELETAL_SYSTEM_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_EMBRYONIC_SKELETAL_SYSTEM_DEVELOPMENT</TD><TD>119</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>SATB2,ALX1</TD></TR>
<TR><TD>4.651e-02</TD><TD>-3.07</TD><TD>PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_UP</TD><TD>MSigDB lists</TD><TD>PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_UP</TD><TD>119</TD><TD>2</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,MEIS2</TD></TR>
<TR><TD>4.658e-02</TD><TD>-3.07</TD><TD>positive regulation of protein localization to membrane</TD><TD>biological process</TD><TD>GO:1905477</TD><TD>122</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>STAC,EPHA3</TD></TR>
<TR><TD>4.684e-02</TD><TD>-3.06</TD><TD>ACATTCC_MIR1_MIR206</TD><TD>MSigDB lists</TD><TD>ACATTCC_MIR1_MIR206</TD><TD>279</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>EYA4,ZIC4,HS3ST3B1</TD></TR>
<TR><TD>4.687e-02</TD><TD>-3.06</TD><TD>PA</TD><TD>pfam domains</TD><TD>PF02225</TD><TD>17</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>RNF128</TD></TR>
<TR><TD>4.688e-02</TD><TD>-3.06</TD><TD>TUBA1A (tubulin alpha 1a)</TD><TD>protein interactions</TD><TD>7846</TD><TD>282</TD><TD>3</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A,HEY1,CPEB2</TD></TR>
<TR><TD>4.693e-02</TD><TD>-3.06</TD><TD>embryonic organ morphogenesis</TD><TD>biological process</TD><TD>GO:0048562</TD><TD>286</TD><TD>3</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,ZIC1,SATB2</TD></TR>
<TR><TD>4.697e-02</TD><TD>-3.06</TD><TD>pulmonary valve morphogenesis</TD><TD>biological process</TD><TD>GO:0003184</TD><TD>17</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-adult_T_cell_lymphoma-leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-adult_T_cell_lymphoma-leukaemia</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>pineal_gland</TD><TD>COSMIC cancer mutations</TD><TD>pineal_gland</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>upper_extremity</TD><TD>COSMIC cancer mutations</TD><TD>upper_extremity</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>extranodal</TD><TD>COSMIC cancer mutations</TD><TD>extranodal</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>thymic_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>thymic_carcinoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>lower_extremity</TD><TD>COSMIC cancer mutations</TD><TD>lower_extremity</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>hypothalamus</TD><TD>COSMIC cancer mutations</TD><TD>hypothalamus</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>liver-other-adenoma</TD><TD>COSMIC cancer mutations</TD><TD>liver-other-adenoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>thymoma</TD><TD>COSMIC cancer mutations</TD><TD>thymoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>jejunum</TD><TD>COSMIC cancer mutations</TD><TD>jejunum</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>anaplastic</TD><TD>COSMIC cancer mutations</TD><TD>anaplastic</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>neurofibroma</TD><TD>COSMIC cancer mutations</TD><TD>neurofibroma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I</TD><TD>COSMIC cancer mutations</TD><TD>central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>small_intestine-jejunum-carcinoma-adenocarcinoma</TD><TD>COSMIC cancer mutations</TD><TD>small_intestine-jejunum-carcinoma-adenocarcinoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>optic_nerve</TD><TD>COSMIC cancer mutations</TD><TD>optic_nerve</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>thymus-thymoma</TD><TD>COSMIC cancer mutations</TD><TD>thymus-thymoma</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.722e-02</TD><TD>-3.05</TD><TD>adult_T_cell_lymphoma-leukaemia</TD><TD>COSMIC cancer mutations</TD><TD>adult_T_cell_lymphoma-leukaemia</TD><TD>17</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.726e-02</TD><TD>-3.05</TD><TD>CHANDRAN_METASTASIS_DN</TD><TD>MSigDB lists</TD><TD>CHANDRAN_METASTASIS_DN</TD><TD>280</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>AZGP1,EYA4,EPHA3</TD></TR>
<TR><TD>4.726e-02</TD><TD>-3.05</TD><TD>HORIUCHI_WTAP_TARGETS_UP</TD><TD>MSigDB lists</TD><TD>HORIUCHI_WTAP_TARGETS_UP</TD><TD>280</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>PAPPA,PCDH17,HEY1</TD></TR>
<TR><TD>4.727e-02</TD><TD>-3.05</TD><TD>cellular amino acid catabolic process</TD><TD>biological process</TD><TD>GO:0009063</TD><TD>123</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>IDO2,KYNU</TD></TR>
<TR><TD>4.739e-02</TD><TD>-3.05</TD><TD>Growth_fac_rcpt_cys_sf</TD><TD>interpro domains</TD><TD>IPR009030</TD><TD>127</TD><TD>2</TD><TD>18616</TD><TD>51</TD>
<TD>EPHA3,CRB1</TD></TR>
<TR><TD>4.742e-02</TD><TD>-3.05</TD><TD>endocytic vesicle</TD><TD>cellular component</TD><TD>GO:0030139</TD><TD>302</TD><TD>3</TD><TD>18985</TD><TD>51</TD>
<TD>SCGB3A2,GRIA2,MTSS1</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>ANKRD12 (ankyrin repeat domain 12)</TD><TD>protein interactions</TD><TD>23253</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>SLC4A1 (solute carrier family 4 member 1 (Diego blood group))</TD><TD>protein interactions</TD><TD>6521</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>TTC33 (tetratricopeptide repeat domain 33)</TD><TD>protein interactions</TD><TD>23548</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>RBM11</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>PCDH12 (protocadherin 12)</TD><TD>protein interactions</TD><TD>51294</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH17</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>RNF144B (ring finger protein 144B)</TD><TD>protein interactions</TD><TD>255488</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>ALX4 (ALX homeobox 4)</TD><TD>protein interactions</TD><TD>60529</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>ALX1</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>ATG2A (autophagy related 2A)</TD><TD>protein interactions</TD><TD>23130</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CPEB2</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>GLI2 (GLI family zinc finger 2)</TD><TD>protein interactions</TD><TD>2736</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>ZIC1</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>AZIN1 (antizyme inhibitor 1)</TD><TD>protein interactions</TD><TD>51582</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>SPPL3 (signal peptide peptidase like 3)</TD><TD>protein interactions</TD><TD>121665</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>KCNQ1 (potassium voltage-gated channel subfamily Q member 1)</TD><TD>protein interactions</TD><TD>3784</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>Shcbp1 (Shc SH2-domain binding protein 1)</TD><TD>protein interactions</TD><TD>20419</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>SCNN1G (sodium channel epithelial 1 gamma subunit)</TD><TD>protein interactions</TD><TD>6340</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>USP2</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>CNTNAP3B (contactin associated protein like 3B)</TD><TD>protein interactions</TD><TD>728577</TD><TD>17</TD><TD>1</TD><TD>17456</TD><TD>50</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.762e-02</TD><TD>-3.04</TD><TD>human chr5q34</TD><TD>chromosome location</TD><TD>human chr5q34</TD><TD>25</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.775e-02</TD><TD>-3.04</TD><TD>side of membrane</TD><TD>cellular component</TD><TD>GO:0098552</TD><TD>510</TD><TD>4</TD><TD>18985</TD><TD>51</TD>
<TD>AZGP1,GRIA2,NPTX2,STAC</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>BIOCARTA_IL7_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_IL7_PATHWAY</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>IL7</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>GO_POLY_PYRIMIDINE_TRACT_BINDING</TD><TD>MSigDB lists</TD><TD>GO_POLY_PYRIMIDINE_TRACT_BINDING</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>RBM11</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>GO_LABYRINTHINE_LAYER_BLOOD_VESSEL_DEVELOPMENT</TD><TD>MSigDB lists</TD><TD>GO_LABYRINTHINE_LAYER_BLOOD_VESSEL_DEVELOPMENT</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP</TD><TD>MSigDB lists</TD><TD>GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>GO_POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR</TD><TD>MSigDB lists</TD><TD>GO_POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>GO_REGULATION_OF_WATER_LOSS_VIA_SKIN</TD><TD>MSigDB lists</TD><TD>GO_REGULATION_OF_WATER_LOSS_VIA_SKIN</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CLDN1</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>BIOCARTA_ARF_PATHWAY</TD><TD>MSigDB lists</TD><TD>BIOCARTA_ARF_PATHWAY</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>GO_PROTEIN_LOCALIZATION_TO_LYSOSOME</TD><TD>MSigDB lists</TD><TD>GO_PROTEIN_LOCALIZATION_TO_LYSOSOME</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>RNF128</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS</TD><TD>MSigDB lists</TD><TD>REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>TGCACGA_MIR517A_MIR517C</TD><TD>MSigDB lists</TD><TD>TGCACGA_MIR517A_MIR517C</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_REGULATORY_REGION_DNA_BINDING</TD><TD>MSigDB lists</TD><TD>GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_REGULATORY_REGION_DNA_BINDING</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>HEY1</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>YAO_HOXA10_TARGETS_VIA_PROGESTERONE_DN</TD><TD>MSigDB lists</TD><TD>YAO_HOXA10_TARGETS_VIA_PROGESTERONE_DN</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>FST</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>GO_ENDOCYTIC_VESICLE_LUMEN</TD><TD>MSigDB lists</TD><TD>GO_ENDOCYTIC_VESICLE_LUMEN</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>SCGB3A2</TD></TR>
<TR><TD>4.810e-02</TD><TD>-3.03</TD><TD>PLASARI_NFIC_TARGETS_BASAL_DN</TD><TD>MSigDB lists</TD><TD>PLASARI_NFIC_TARGETS_BASAL_DN</TD><TD>17</TD><TD>1</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.820e-02</TD><TD>-3.03</TD><TD>PLipase_C_PInositol-sp_X_dom</TD><TD>interpro domains</TD><TD>IPR000909</TD><TD>18</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.820e-02</TD><TD>-3.03</TD><TD>Glu/Gly-bd</TD><TD>interpro domains</TD><TD>IPR019594</TD><TD>18</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.820e-02</TD><TD>-3.03</TD><TD>Iono_rcpt_met</TD><TD>interpro domains</TD><TD>IPR001508</TD><TD>18</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.820e-02</TD><TD>-3.03</TD><TD>Iontro_rcpt</TD><TD>interpro domains</TD><TD>IPR001320</TD><TD>18</TD><TD>1</TD><TD>18616</TD><TD>51</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.826e-02</TD><TD>-3.03</TD><TD>regulation of nucleobase-containing compound metabolic process</TD><TD>biological process</TD><TD>GO:0019219</TD><TD>4043</TD><TD>17</TD><TD>18054</TD><TD>51</TD>
<TD>SATB2,BMPR1B,PAX9,RBM11,FOXA2,ALX1,ZIC4,EYA4,USP2,PLAG1,HEY1,EDA2R,ZIC1,CDKN2A,ZFHX4,MEIS2,FST</TD></TR>
<TR><TD>4.839e-02</TD><TD>-3.03</TD><TD>skin-ear-malignant_melanoma</TD><TD>COSMIC cancer mutations</TD><TD>skin-ear-malignant_melanoma</TD><TD>124</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>PLCH1,CDKN2A</TD></TR>
<TR><TD>4.844e-02</TD><TD>-3.03</TD><TD>CCND1 (cyclin D1)</TD><TD>protein interactions</TD><TD>595</TD><TD>123</TD><TD>2</TD><TD>17456</TD><TD>50</TD>
<TD>USP2,CDKN2A</TD></TR>
<TR><TD>4.851e-02</TD><TD>-3.03</TD><TD>GCTNWTTGK_UNKNOWN</TD><TD>MSigDB lists</TD><TD>GCTNWTTGK_UNKNOWN</TD><TD>283</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>ZIC1,ZIC4,EPHA3</TD></TR>
<TR><TD>4.865e-02</TD><TD>-3.02</TD><TD>liver development</TD><TD>biological process</TD><TD>GO:0001889</TD><TD>125</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>LSR,CLDN1</TD></TR>
<TR><TD>4.870e-02</TD><TD>-3.02</TD><TD>parathyroid</TD><TD>COSMIC cancer mutations</TD><TD>parathyroid</TD><TD>486</TD><TD>4</TD><TD>17255</TD><TD>49</TD>
<TD>ZIC1,GPC5,CDKN2A,MTSS1</TD></TR>
<TR><TD>4.875e-02</TD><TD>-3.02</TD><TD>Defective B3GAT3 causes JDSSDHD</TD><TD>REACTOME pathways</TD><TD>R-HSA-3560801</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.875e-02</TD><TD>-3.02</TD><TD>Defective B4GALT7 causes EDS, progeroid type</TD><TD>REACTOME pathways</TD><TD>R-HSA-3560783</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.875e-02</TD><TD>-3.02</TD><TD>Defective B3GALT6 causes EDSP2 and SEMDJL1</TD><TD>REACTOME pathways</TD><TD>R-HSA-4420332</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>GPC5</TD></TR>
<TR><TD>4.875e-02</TD><TD>-3.02</TD><TD>Na+/Cl- dependent neurotransmitter transporters</TD><TD>REACTOME pathways</TD><TD>R-HSA-442660</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>SLC6A15</TD></TR>
<TR><TD>4.875e-02</TD><TD>-3.02</TD><TD>Miscellaneous transport and binding events</TD><TD>REACTOME pathways</TD><TD>R-HSA-5223345</TD><TD>19</TD><TD>1</TD><TD>10287</TD><TD>27</TD>
<TD>AZGP1</TD></TR>
<TR><TD>4.893e-02</TD><TD>-3.02</TD><TD>MORF_ARL3</TD><TD>MSigDB lists</TD><TD>MORF_ARL3</TD><TD>284</TD><TD>3</TD><TD>17275</TD><TD>50</TD>
<TD>GABRB2,STAC,PAX9</TD></TR>
<TR><TD>4.901e-02</TD><TD>-3.02</TD><TD>L-tryptophan degradation XI (mammalian, via kynurenine)</TD><TD>BIOCYC pathways</TD><TD>META_PWY-6309</TD><TD>9</TD><TD>1</TD><TD>902</TD><TD>5</TD>
<TD>KYNU</TD></TR>
<TR><TD>4.901e-02</TD><TD>-3.02</TD><TD>NAD biosynthesis II (from tryptophan)</TD><TD>BIOCYC pathways</TD><TD>META_NADSYN-PWY</TD><TD>9</TD><TD>1</TD><TD>902</TD><TD>5</TD>
<TD>KYNU</TD></TR>
<TR><TD>4.909e-02</TD><TD>-3.01</TD><TD>knee</TD><TD>COSMIC cancer mutations</TD><TD>knee</TD><TD>125</TD><TD>2</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A,PLCH1</TD></TR>
<TR><TD>4.929e-02</TD><TD>-3.01</TD><TD>negative regulation of gene expression</TD><TD>biological process</TD><TD>GO:0010629</TD><TD>2270</TD><TD>11</TD><TD>18054</TD><TD>51</TD>
<TD>CPEB2,SATB2,PLAG1,HEY1,ALX1,USP2,ZFHX4,MEIS2,FST,PAX9,CDKN2A</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>GABA-A receptor activity</TD><TD>molecular function</TD><TD>GO:0004890</TD><TD>19</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>ionotropic glutamate receptor activity</TD><TD>molecular function</TD><TD>GO:0004970</TD><TD>19</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>ephrin receptor activity</TD><TD>molecular function</TD><TD>GO:0005003</TD><TD>19</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>EPHA3</TD></TR>
<TR><TD>4.934e-02</TD><TD>-3.01</TD><TD>polypeptide N-acetylgalactosaminyltransferase activity</TD><TD>molecular function</TD><TD>GO:0004653</TD><TD>19</TD><TD>1</TD><TD>17306</TD><TD>46</TD>
<TD>GALNT13</TD></TR>
<TR><TD>4.935e-02</TD><TD>-3.01</TD><TD>embryonic skeletal system development</TD><TD>biological process</TD><TD>GO:0048706</TD><TD>126</TD><TD>2</TD><TD>18054</TD><TD>51</TD>
<TD>ALX1,SATB2</TD></TR>
<TR><TD>4.942e-02</TD><TD>-3.01</TD><TD>TGGTGCT_MIR29A_MIR29B_MIR29C</TD><TD>MSigDB lists</TD><TD>TGGTGCT_MIR29A_MIR29B_MIR29C</TD><TD>479</TD><TD>4</TD><TD>17275</TD><TD>50</TD>
<TD>EPHA3,CLDN1,PLAG1,HS3ST3B1</TD></TR>
<TR><TD>4.948e-02</TD><TD>-3.01</TD><TD>human chr4q32.1</TD><TD>chromosome location</TD><TD>human chr4q32.1</TD><TD>26</TD><TD>1</TD><TD>26169</TD><TD>51</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.956e-02</TD><TD>-3.00</TD><TD>Lig_chan</TD><TD>pfam domains</TD><TD>PF00060</TD><TD>18</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.956e-02</TD><TD>-3.00</TD><TD>MHC_I</TD><TD>pfam domains</TD><TD>PF00129</TD><TD>18</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>AZGP1</TD></TR>
<TR><TD>4.956e-02</TD><TD>-3.00</TD><TD>Lig_chan-Glu_bd</TD><TD>pfam domains</TD><TD>PF10613</TD><TD>18</TD><TD>1</TD><TD>17385</TD><TD>49</TD>
<TD>GRIA2</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>heterochromatin organization</TD><TD>biological process</TD><TD>GO:0070828</TD><TD>18</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>peroxisomal membrane transport</TD><TD>biological process</TD><TD>GO:0015919</TD><TD>18</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>PEX5L</TD></TR>
<TR><TD>4.967e-02</TD><TD>-3.00</TD><TD>regulation of cell-cell adhesion mediated by cadherin</TD><TD>biological process</TD><TD>GO:2000047</TD><TD>18</TD><TD>1</TD><TD>18054</TD><TD>51</TD>
<TD>FOXA2</TD></TR>
<TR><TD>4.972e-02</TD><TD>-3.00</TD><TD>GO_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>MSigDB lists</TD><TD>GO_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER</TD><TD>695</TD><TD>5</TD><TD>17275</TD><TD>50</TD>
<TD>MEIS2,ZIC1,PAX9,ALX1,PLAG1</TD></TR>
<TR><TD>4.975e-02</TD><TD>-3.00</TD><TD>PIPLC_Y_DOMAIN</TD><TD>prosite domains</TD><TD>PS50008</TD><TD>15</TD><TD>1</TD><TD>12079</TD><TD>41</TD>
<TD>PLCH1</TD></TR>
<TR><TD>4.985e-02</TD><TD>-3.00</TD><TD>GABA-A receptor complex</TD><TD>cellular component</TD><TD>GO:1902711</TD><TD>19</TD><TD>1</TD><TD>18985</TD><TD>51</TD>
<TD>GABRB2</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>salivary_duct_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>salivary_duct_carcinoma</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>calcaneus</TD><TD>COSMIC cancer mutations</TD><TD>calcaneus</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>PCDH20</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>dysplasia</TD><TD>COSMIC cancer mutations</TD><TD>dysplasia</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>meninges-meningioma-meningothelial</TD><TD>COSMIC cancer mutations</TD><TD>meninges-meningioma-meningothelial</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-anaplastic_large_cell_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-anaplastic_large_cell_lymphoma</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>endometrium-carcinoma-clear_cell_carcinoma</TD><TD>COSMIC cancer mutations</TD><TD>endometrium-carcinoma-clear_cell_carcinoma</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>fibroblastic</TD><TD>COSMIC cancer mutations</TD><TD>fibroblastic</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>COSMIC cancer mutations</TD><TD>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-marginal_zone_lymphoma</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
<TR><TD>4.992e-02</TD><TD>-3.00</TD><TD>meningothelial</TD><TD>COSMIC cancer mutations</TD><TD>meningothelial</TD><TD>18</TD><TD>1</TD><TD>17255</TD><TD>49</TD>
<TD>CDKN2A</TD></TR>
</TABLE>
</BODY></HTML>
